UID,Searchword,API,URL,Title,Summary,Article,Title_Sentiment,Title_Positive,Title_Neutral,Title_Negative,Article_Sentiment,Article_Positive,Article_Neutral,Article_Negative,Verified,Language,Topics,Date,Load_Date,Source
16114,Deutsche Boerse,Twitter API,Twitter,Retweet selected by the https://t.co/kmOCQTFIJb team |  Deutsche Boerse  Swisscom Settle Securities with Corda and‚Ä¶ https://t.co/smaQ3QsmgU,nan,Retweet selected by the https://t.co/kmOCQTFIJb team |  Deutsche Boerse  Swisscom Settle Securities with Corda and‚Ä¶ https://t.co/smaQ3QsmgU,neutral,0.15,0.83,0.02,neutral,0.15,0.83,0.02,True,English,"['kmOCQTFIJb team', 'Deutsche Boerse', 'Retweet', 'Swisscom', 'Securities', 'Corda', 'kmOCQTFIJb team', 'Deutsche Boerse', 'Retweet', 'Swisscom', 'Securities', 'Corda']",2023-01-09,2023-01-16,Unknown
16115,Deutsche Boerse,Twitter API,Twitter,Given¬†that¬†Crypto¬†Finance¬†Group¬†is¬†a¬†FINMA-regulated¬†service¬†provider¬†and¬†a¬†member¬†of¬†Deutsche¬†B√∂rse¬†Group ,nan,Given¬†that¬†Crypto¬†Finance¬†Group¬†is¬†a¬†FINMA-regulated¬†service¬†provider¬†and¬†a¬†member¬†of¬†Deutsche¬†B√∂rse¬†Group ,neutral,0.0,1.0,0.0,neutral,0.0,1.0,0.0,True,English,"['Deutsche\xa0B√∂rse\xa0Group', 'Crypto\xa0Finance\xa0Group', 'FINMA-regulated\xa0service\xa0provider', 'member', 'Deutsche\xa0B√∂rse\xa0Group', 'Crypto\xa0Finance\xa0Group', 'FINMA-regulated\xa0service\xa0provider', 'member']",2023-01-08,2023-01-16,Unknown
16214,Deutsche Boerse,Twitter API,Twitter,üçøüç©üç™üçíüçàü•ëüç≥ü•öüç§üçíüçäüçØüçûü•êü•ñü•ûüçØüçûü•êü•ñüçéüçêüçäü•´üç≥ü•öüçãüçåüçâü•¶Action taken by New York Stock Exchange  Deutsche B√∂rse  Euronext and Borsa Italia #‚Ä¶ https://t.co/dZSOJaM6cH,nan,üçøüç©üç™üçíüçàü•ëüç≥ü•öüç§üçíüçäüçØüçûü•êü•ñü•ûüçØüçûü•êü•ñüçéüçêüçäü•´üç≥ü•öüçãüçåüçâü•¶Action taken by New York Stock Exchange  Deutsche B√∂rse  Euronext and Borsa Italia #‚Ä¶ https://t.co/dZSOJaM6cH,neutral,0.07,0.91,0.02,neutral,0.07,0.91,0.02,True,English,"['New York Stock Exchange', 'Deutsche B√∂rse', 'Borsa Italia', 'Action', 'Euronext', 'New York Stock Exchange', 'Deutsche B√∂rse', 'Borsa Italia', 'Action', 'Euronext']",2023-01-10,2023-01-16,Unknown
16443,Deutsche Boerse,Twitter API,Twitter,@Clearstream (Deutsche B√∂rse Group) is officially a member of ABSL Czech Republic.We are delighted to collaborate‚Ä¶ https://t.co/tphHUj1FAE,nan,@Clearstream (Deutsche B√∂rse Group) is officially a member of ABSL Czech Republic.We are delighted to collaborate‚Ä¶ https://t.co/tphHUj1FAE,positive,0.99,0.01,0.0,positive,0.99,0.01,0.0,True,English,"['Deutsche B√∂rse Group', 'ABSL Czech Republic', 'member', 'Deutsche B√∂rse Group', 'ABSL Czech Republic', 'member']",2023-01-13,2023-01-16,Unknown
16507,EuroNext,NewsApi.org,https://www.independent.ie/business/irish/belgian-nursing-home-group-care-property-buys-cork-centre-for-75m-and-aspires-for-more-42285347.html,Belgian nursing home group Care Property buys Cork centre for ‚Ç¨7.5m and ‚Äòaspires for more‚Äô,Belgian-listed Care Property Invest has agreed to buy a residential care facility in Skibbereen in a deal worth around ‚Ç¨7.5m as it shares hopes to acquire more properties in Ireland in the &ldquo;near future&rdquo;.,Belgian-listed Care Property Invest has agreed to buy a residential care facility in Skibbereen in a deal worth around ‚Ç¨7.5m as it shares hopes to acquire more properties in Ireland in the ‚Äúnear future‚Äù.The agreement  subject to conditions  to acquire the 51-resident Skibbereen Residential Care Centre was agreed last week.who will operate the centre under a 25-year leasehold agreement.Peter Van Heukelom  chief executive of Care Property  said the deal was the company‚Äôs latest move in its Irish expansion plan.‚ÄúSigning the agreement to acquire this up-and-running residential care centre marks another step forward in Care Property Invest's Irish growth trajectory ‚Äù he said. ‚ÄúAdditionally  we are pleased to partner with experienced healthcare operator Brookhaven Healthcare for the second time.Expand Close It is the second time Care Property has entered into a partnership with Irish healthcare operator Brookhaven Healthcare / FacebookTwitterEmailWhatsapp It is the second time Care Property has entered into a partnership with Irish healthcare operator Brookhaven Healthcare‚ÄúWe currently have seven effectively acquired residential care projects on Irish soil and aspire to further increase this number in the near future.‚ÄùBrookhaven currently operates six residential care centres throughout Ireland  totalling 472 beds  offering both premium long-term and convalescence care. The company is led by chairman and CEO Tim Murphy and is headquartered in Malahide  Co Dublin.With the addition of Skibbereen Residential Care Centre to its growing portfolio  Brookhaven Healthcare will increase its capacity to 523 beds across seven residential care centres.Care Property has developed an international portfolio of 146 healthcare projects  spread across Belgium  The Netherlands  Spain and Ireland. It had a market capitalisation on Euronext Brussels of approximately ‚Ç¨459m.In December  Care acquired a yet-to-be-developed Irish residential care centre called the 'Sugarloaf Care Centre' in Co WicklowThe Belgian company first entered the Irish market last February when it acquired Ballincurrig Care Centre in Co Cork for ‚Ç¨6.2m.In December  Care acquired a yet-to-be-developed Irish residential care centre called the 'Sugarloaf Care Centre' in Kilmacanogue  Co Wicklow. The project is set to accommodate 119 residents and has a total investment value of around ‚Ç¨23.4m. Its planned delivery date is in the fourth quarter of 2024.,neutral,0.0,1.0,0.0,positive,0.95,0.05,0.0,True,English,"['Belgian nursing home group Care Property', 'Cork centre', 'aspires', '51-resident Skibbereen Residential Care Centre', 'six residential care centres', 'seven residential care centres', 'Belgian-listed Care Property Invest', 'Irish residential care centre', 'second time Care Property', 'residential care facility', 'Ballincurrig Care Centre', 'residential care projects', 'Peter Van Heukelom', 'Irish expansion plan', 'Irish growth trajectory', 'CEO Tim Murphy', 'total investment value', 'experienced healthcare operator', 'Irish healthcare operator', '25-year leasehold agreement', 'convalescence care', 'Irish soil', 'Irish market', '146 healthcare projects', 'Brookhaven Healthcare', 'near future', 'chief executive', 'latest move', 'premium long-term', 'Co Dublin', 'growing portfolio', 'international portfolio', 'The Netherlands', 'market capitalisation', 'Euronext Brussels', 'Co Wicklow', 'Co Cork', 'delivery date', 'fourth quarter', 'Belgian company', 'deal', 'hopes', 'properties', 'Ireland', 'conditions', 'running', 'step', 'partnership', 'Facebook', 'Twitter', 'Email', 'Whatsapp', 'number', '472 beds', 'chairman', 'Malahide', 'addition', 'capacity', '523 beds', 'Belgium', 'Spain', 'December', 'Kilmacanogue', '119 residents']",2023-01-15,2023-01-16,independent.ie
16511,Deutsche Boerse,Bing API,https://artlyst.com/news/deutsche-borse-photography-foundation-announce-2023-prize-and-exhibition/,Deutsche BoÃàrse Photography Foundation Announce 2023 Shortlist And Exhibition,The Photographers‚Äô Gallery London has revealed exhibition details of the 2023 edition of the Deutsche B√∂rse Photography Foundation Prize.,The Photographers‚Äô Gallery London has revealed exhibition details of the 2023 edition and the shortlist for the Deutsche BoÃàrse Photography Foundation Prize.The 2023 exhibition will feature work by the four international shortlisted artists: Bieke Depoorter  Samuel Fosso  Arthur Jafa and Frida Orupabo  at The Photographers‚Äô Gallery  London  from 3 March until 11 June 2023. The exhibition will tour to the Muzeum Fotografii w Krakowie  Krakow  Poland (30 June to 17 September 2023).The winner of the ¬£30 000 prize will be announced at a special evening award ceremony on 11 May 2023  with the other finalists each receiving ¬£5 000.Originally established in 1996 and organised in partnership with the Deutsche B√∂rse Photography Foundation in Frankfurt/Main since 2016  this long-standing and influential annual Prize identifies and rewards artists and their projects considered to have made the most significant contribution to photography over the previous 12 months.Over its 27-year history  the Prize has become renowned as one of the most important international awards for photographers  as well as a barometer of photographic development  foregrounding outstanding  innovative and thought-provoking work. This year‚Äôs shortlisted artists all push the boundaries of photography and exemplify its resonance and relevance as a cultural force today.The complex ethical relationship and boundaries which have rarely been explored between the photographer and their subject provide the focus for Bieke Depoorter‚Äôs intense scrutiny of her relationship with her subjects. Drawing upon the West African tradition of studio portraiture  Samuel Fosso repurposes this genre through self portraiture by creating startling new identities  based on social archetypes as well as real historical figures. Drawing from a rich collection of images  film footage and music  Arthur Jafa uncompromisingly articulates Black experience  providing us with an exercise in visual literacy  confronting us with a new Black aesthetic which avoids fixed hierarchies and linear storytelling. Giving sculptural form to photo collage  Frida Orupabo reimagines the historical Black female body through her extraordinary multilayered collages and Instagram posts using material circulated online.The Deutsche B√∂rse Photography Foundation Prize exhibition will feature a selection of work from the nominated projects of the four 2023 shortlisted artists. Their nominated projects areBieke Depoorter ‚Äì for her exhibition A Chance Encounter at C/O Berlin (30 April ‚Äì7 September 2022). Top PhotoBieke Depoorter (b. 1986  Kortrijk  Belgium) blurs the traditional relationship between photographer and subject. She questions the role and responsibilities of the photographer  the possibility or impossibility of truth in representation and grapples with personal and professional boundaries. Her nominated project presents two unfolding  ongoing  bodies of work  Michael and Agata. In both  a chance encounter develops into an enduring personal relationship and  thereafter  into an interrogation of the medium. A selection of work from the Michael project will be on display at The Photographers‚Äô Gallery.In Michael  Depoorter examines the life and the disappearance of a man she met on the streets of Portland  Oregon in 2015. Gifted three suitcases of Michael‚Äôs personal items  sketchbooks and essays  his subsequent disappearance turns Depoorter detective. Depoorter‚Äôs work documents her immersive  perhaps obsessive  quest to find Michael and to understand his life. In Agata  a first meeting in a Parisian strip-club in 2017 evolves with complex tension into an intricate  changing narrative. The project explores questions of collaboration  the limits of a creative friendship  performance  boundaries and authorship.Samuel Fosso ‚Äì for his exhibition Samuel Fosso at the Maison Europ√©enne de la Photographie  Paris  (10 November 2021 ‚Äì 13 March 2022). Top PhotoSince the mid-1970s  Samuel Fosso (b. 1962  Kumba  Cameroon) has dedicated his artistic practice to self-portraits and performative photography. Fosso‚Äôs retrospective exhibition traces a career of almost 50 years  bringing together iconic series  lesser known works  archival material and previously unpublished images.Raised in Nigeria  Fosso fled the Biafran War as a young boy  and in 1972 was taken in by an uncle in Bangui in the Central African Republic. In 1975  at the age of thirteen  Fosso opened his Studio Photo Nationale. Alongside commercial work  Fosso immediately began a series of self-portraits ‚Äì a mode of representation he has never abandoned. Playing the role of key historical figures and social archetypes in front of the camera  Fosso embodies a powerful way of existing in the world  and a vivid demonstration of photography‚Äôs role in the construction of myths.Arthur Jafa ‚Äì for his exhibition Live Evil at Luma  Arles (14 April ‚Äì 13 November 2022).Arthur Jafa (b. 1960  Tupelo  Mississippi  United States) is an artist and filmmaker. Nominated for the largest and most comprehensive exhibition of his work to date  Jafa draws upon a substantial collection of film and still images  creating visceral  dynamic films and room-sized installations. In the gallery space and on the screen  Jafa derives power from astute juxtaposition and lyrical  syncopated editing. Since the 1980s  Jafa has been accumulating and assembling pictures from books and magazines  arranging this imagery in new constellations within notebooks and latterly within dynamic artworks. For ready-made moving images  YouTube remains a favourite resource  alongside news footage and home video. By placing one resonant cultural artefact next to another Jafa references and questions the universal and specific articulations of Black experience. Eschewing a linear narrative  Jafa organises his material through formal and affective associations  linking his images through visual resemblance or thematic resonance. In this way Jafa aspires to an art that harnesses ‚Äúthe power  beauty  and alienation of black music.‚ÄùFrida Orupabo ‚Äì for her exhibition I have seen a million pictures of my face and still I have no idea  Fotomuseum Winterthur (26 February ‚Äì 29 May 2022).The sculptural collages and digital works of Frida Orupabo (b. 1986  Sarpsborg  Norway) are multi-layered formations  exploring questions of race  sexuality and identity. Orupabo  a Norwegian Nigerian artist and sociologist  grounds her inquiry in her own experience of cultural belonging. Utilising visual material circulating online  spanning colonial-era photographs and ethnographic relics to contemporary imagery  Orupabo‚Äôs hand-wrought works re-arrange and re-make the archive. The resulting images take the shape of fragmented Black  mostly female-bodied  figures. These figures  first dislocated  are reassembled layer by layer in a complex and poetic manoeuvre that simultaneously denounces one-dimensional depictions of Black lives. Her collaged cut-outs hold our gaze and invite various readings of the stories and lives of the people depicted  many of whom are entirely absent from the archives. In this way Orupabo invites a consideration of how photography significantly contributes to the formation and perpetuation of colonial power relations and violence.A fully illustrated catalogue with newly commissioned essays on the shortlisted artists and their nominated projects will be on sale in The Photographers‚Äô Gallery shop and online. Writer and curator Awa Konat√©  founder of the interdisciplinary research platform Culture Art Society  writes on the work of Frida Orupabo. Gideon Jacobs  writer  artist and former Creative Director of Magnum Photos  writes on Bieke Depoorter. Curator and cultural historian Mark Sealy  Director of Autograph APB  explores the work of Samuel Fosso. New York-based American DJ  writer and interdisciplinary artist Jace Clayton considers Arthur Jafa‚Äôs work.A programme of talks and events will take place during the exhibition about the artists and their work. On 1 February  ‚ÄòOn Photography‚Äô ‚Äì an online roundtable talk ‚Äì will explore the role of photography and the most urgent issues facing photographers today.Read MoreVisitRelated Posts[jetpack-related-posts],neutral,0.0,1.0,0.0,mixed,0.35,0.21,0.44,True,English,"['Deutsche BoÃàrse Photography Foundation', '2023 Shortlist', 'Exhibition', 'The Deutsche B√∂rse Photography Foundation Prize exhibition', 'Maison Europ√©enne de la Photographie', 'Deutsche BoÃàrse Photography Foundation Prize', 'special evening award ceremony', 'two unfolding, ongoing, bodies', 'historical Black female body', 'The Photographers‚Äô Gallery London', 'four international shortlisted artists', 'influential annual Prize', 'important international awards', 'real historical figures', 'key historical figures', 'four 2023 shortlisted artists', 'Muzeum Fotografii w', 'West African tradition', 'startling new identities', 'new Black aesthetic', 'extraordinary multilayered collages', 'intricate, changing narrative', 'lesser known works', 'Central African Republic', 'A Chance Encounter', 'complex ethical relationship', 'enduring personal relationship', 'performative photography', 'Black experience', 'complex tension', 'traditional relationship', 'exhibition details', 'retrospective exhibition', 'comprehensive exhibition', 'Frida Orupabo', 'other finalists', 'significant contribution', 'previous 12 months', '27-year history', 'photographic development', 'cultural force', 'intense scrutiny', 'self portraiture', 'social archetypes', 'rich collection', 'film footage', 'visual literacy', 'fixed hierarchies', 'linear storytelling', 'sculptural form', 'photo collage', 'Instagram posts', 'C/O Berlin', 'Top Photo', 'three suitcases', 'personal items', 'first meeting', 'Parisian strip-club', 'creative friendship', 'artistic practice', 'Biafran War', 'young boy', 'Photo Nationale', 'powerful way', 'vivid demonstration', 'United States', 'Arthur Jafa', '¬£30,000 prize', 'Bieke Depoorter', 'Depoorter detective', 'Samuel Fosso', 'studio portraiture', 'subsequent disappearance', 'iconic series', 'unpublished images', 'nominated projects', 'thought-provoking work', 'professional boundaries', 'commercial work', 'Michael project', '2023 exhibition', '2023 edition', '3 March', '11 June', 'Krakowie', 'Poland', '17 September', 'winner', '11 May', 'partnership', 'Frankfurt/Main', 'long-standing', 'barometer', 'innovative', 'resonance', 'relevance', 'subject', 'focus', 'genre', 'music', 'exercise', 'material', 'selection', 'Kortrijk', 'Belgium', 'role', 'possibility', 'truth', 'representation', 'Agata', 'medium', 'display', 'life', 'man', 'streets', 'Portland', 'Oregon', 'sketchbooks', 'essays', 'quest', 'collaboration', 'limits', 'authorship', 'mid-1970s', 'Kumba', 'Cameroon', 'self-portraits', 'career', '50 years', 'Nigeria', 'uncle', 'Bangui', 'mode', 'front', 'camera', 'world', 'construction', 'myths', 'Luma', 'Arles', 'April', '13 November', 'Tupelo', 'Mississippi', 'filmmaker', 'largest', 'date']",2023-01-16,2023-01-16,artlyst.com
16512,EuroNext,NewsApi.org,https://biztoc.com/x/ae350f7101c35312,Euronext to switch derivatives clearing to Italy in 2024,Exchanges group prepares to move financial and commodity derivatives away from French capital to Milan #milan,Exchanges group prepares to move financial and commodity derivatives away from French capital to Milan #milan This story appeared on ft.com  2023-01-16.,neutral,0.01,0.99,0.0,neutral,0.0,1.0,0.0,True,English,"['Euronext', 'derivatives', 'Italy', 'Exchanges group', 'commodity derivatives', 'French capital', 'financial', 'Milan', 'story']",2023-01-16,2023-01-16,biztoc.com
16513,EuroNext,NewsApi.org,https://finance.yahoo.com/news/veon-ceo-letter-2023-noteholders-063000785.html,VEON CEO letter to 2023 Noteholders,Amsterdam  16 January 2023 ‚Äì VEON Ltd. (NASDAQ: VEON  Euronext Amsterdam: VEON)  a global digital operator that provides converged connectivity and online...,VEON Ltd.Amsterdam  16 January 2023 ‚Äì VEON Ltd. (NASDAQ: VEON  Euronext Amsterdam: VEON)  a global digital operator that provides converged connectivity and online services  has today contacted holders (the ‚Äú2023 Noteholders‚Äù) of interests in the 5.95% notes due February 2023 and the 7.25% notes due April 2023 (together  the ‚Äú2023 Notes‚Äù) issued by VEON Holdings BV (‚ÄúVEON Holdings‚Äù) in relation to the English Scheme of Arrangement (the ‚ÄúScheme‚Äù) that aims to extend the maturities of the 2023 Notes by eight months from their respective maturity dates.In the letter  VEON‚Äôs Chief Executive Officer Kaan Terzioƒülu requested the assistance and cooperation of 2023 Noteholders in connection with the Scheme  and specifically requested them to vote in favour of the Scheme at the forthcoming scheme meeting taking place on 24 January 2023. The deadline by which 2023 Noteholders must submit their Voting and Proxy Forms (or  if the 2023 Noteholder holds their 2023 Notes through DTC  procure that their DTC participant submits on their behalf) is 5.00 p.m. (London time) on 20 January 2023. The letter further explained:‚ÄúWe understand the significance of what we are asking and take our obligations to our stakeholders  including the repayment of our debts in full and on time  very seriously.However  despite strong operational results and a strong balance sheet  given the current circumstances  we must consider the repayment of the 2023 Notes within the context of our future debt obligations beyond 2023 and the difficulties VEON currently faces in raising debt or equity on the international capital markets on commercially acceptable terms. It is this which has led us to take the decision to launch the Scheme  as we believe it would provide the best route to us repaying you in advance of VEON Holdings‚Äô other future debt obligations.Your support and the resultant implementation of the proposal set out in the Scheme will enable us to avoid the near-term inefficient use of cash that would result from a significant portion of the principal repayment (relating to 2023 Notes held via the Russian National Settlement Depository (‚ÄúNSD‚Äù)) being trapped in international clearing systems (with no clear prospect of such monies being returned to VEON). VEON and its legal advisors have spent significant time and efforts exploring potential options to avoid having cash trapped in the international clearing systems  but at present there does not appear to be a clearly viable path to avoid this unattractive outcome. At a time that  due to Russian Decree 430  the Group potentially can no longer rely on payments to the international clearing systems effectively being recognised by its Russian noteholders as a full discharge of the underlying liability  the proposed maturity extension will provide additional time for the impact of Decree 430 on VimpelCom and the Group (as set out in the Scheme documentation) to become clearer and for the Group to mitigate  where possible  the associated risk of double payments. The Scheme proposal would also provide time to progress our asset monetization strategy anchored by the sale of our Russian business (the ‚ÄúVimpelCom Disposal‚Äù)  as announced on 24 November 2022. We believe that the VimpelCom Disposal represents the single-most material deleveraging action available to VEON Holdings and increases the prospects of VEON regaining access to the international capital markets  and thereby refinancing its indebtedness  on commercially acceptable terms.Story continuesAs set out more fully in the Scheme documents  in return for granting us with a modest extension  we have sought to compensate the 2023 Noteholders with the benefit of an amendment fee and a put right. As announced on 11 January 2023  the Company has further amended the terms of the proposal set out in the Scheme and entered into undertakings to vote in favour of the Scheme with certain 2023 Noteholders holding approximately 10.4% of the principal amount of the 2023 Notes. Each of these amendments improves the terms of the proposal for the benefit of the 2023 Noteholders.If the Scheme fails  the directors of VEON Holdings will need to continue to assess the Company‚Äôs solvency and liquidity position up to the original maturity date of the February 2023 Notes. Whilst VEON Holdings will have sufficient cash to pay the 2023 Notes on their original maturity dates  we cannot exclude the possibility that the directors may determine that the best action for VEON Holdings to take is not to pay on maturity while the double-payment risk continues. We consider that  by providing further runway to allow the sale of VimpelCom to complete  the Scheme will greatly reduce the risks of non-payment and impact on our stakeholders.We are pleased that good progress has already been made in respect of the implementation of the Scheme (and strive to continue this progress). In particular  on 26 December  we announced that VEON Holdings was granted an OFAC License (if you would like to see a copy of the OFAC License  you can request a copy by email to bonds@veon.com). Following receipt of this license  VEON Holdings believes that no further licenses are required in order to permit eligible noteholders to vote on the Scheme. In addition  we are in active dialogue with the Netherlands Ministry of Finance and the UK Office of Financial Sanctions Implementation in respect of the licenses we have sought from those regulators  which will be required to implement the amendments contemplated by the Scheme.Therefore in consideration of the steps taken above  we request your support and encourage you to vote in favour of the Scheme at the forthcoming scheme meeting. By doing so  you will provide us with crucial time to mitigate the risks of trapped cash and potential double-payment and to undertake the VimpelCom Disposal and our wider asset monetization programme  thus allowing VEON to deleverage and provide the best-available route for the repayment of your notes.For all relevant information in relation to the Scheme please visit https://is.kroll.com/veon  and any further questions on the voting process can be addressed to Kroll Issuer Services Limited (as the Company‚Äôs information agent) by email to veon@is.kroll.com or by telephone on + 44 20 7704 0880.Finally  we acknowledge the questions which have been raised by several of you to us and to our advisors and hope that we have been able to address them. However should you have any questions on the Scheme  other topics covered in this letter  or other matters related to VEON Group  please contact bonds@veon.com .Thank you for your continued trust in and support of our company.‚ÄùDisclaimerThis press release contains ‚Äúforward-looking statements‚Äù  as the phrase is defined in Section 27A of the U.S. Securities Act of 1933  as amended  and Section 21E of the U.S. Securities Exchange Act of 1934  as amended. Forward-looking statements are not historical facts  and include statements relating to  among other things  the Scheme  expectations regarding management plans and the ability to successfully execute operating model  governance  strategic and development plans. Forward-looking statements are inherently subject to risks and uncertainties  many of which VEON cannot predict with accuracy and some of which VEON might not even anticipate. The forward-looking statements contained in this release speak only as of the date of this release. VEON does not undertake to publicly update  except as required by U.S. federal securities laws  any forward-looking statement to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.About VEONVEON is a global digital operator that currently provides converged connectivity and online services to over 200 million customers in seven high-growth markets. We are transforming people‚Äôs lives  empowering individuals  creating opportunities for greater digital inclusion and driving economic growth across countries that are home to more than 8% of the world‚Äôs population. Headquartered in Amsterdam  VEON is listed on NASDAQ and Euronext.For more information visit: https://www.veon.com .Contact InformationVEONInvestor RelationsNik Kershawbonds@veon.com,neutral,0.01,0.99,0.0,mixed,0.4,0.12,0.47,True,English,"['VEON CEO letter', '2023 Noteholders', 'Chief Executive Officer Kaan Terzioƒülu', 'VEON Holdings‚Äô other future debt obligations', 'single-most material deleveraging action', 'Russian National Settlement Depository', 'global digital operator', 'strong operational results', 'strong balance sheet', 'international capital markets', 'near-term inefficient use', 'international clearing systems', 'asset monetization strategy', 'respective maturity dates', 'original maturity date', 'forthcoming scheme meeting', 'VEON Holdings BV', 'The Scheme proposal', 'best action', 'Russian business', 'maturity extension', 'converged connectivity', 'online services', 'eight months', 'Proxy Forms', 'current circumstances', 'best route', 'significant portion', 'clear prospect', 'legal advisors', 'potential options', 'viable path', 'unattractive outcome', 'Russian Decree', 'underlying liability', 'associated risk', 'modest extension', 'amendment fee', 'principal amount', 'liquidity position', 'double-payment risk', 'OFAC License', 'VEON Ltd', 'Russian noteholders', 'Euronext Amsterdam', 'DTC participant', 'London time', 'acceptable terms', 'resultant implementation', 'significant time', 'full discharge', 'additional time', 'double payments', 'VimpelCom Disposal', 'good progress', 'English Scheme', 'Scheme documentation', 'Scheme documents', 'principal repayment', 'sufficient cash', 'February 2023 Notes', '2023 Noteholders', '5.95% notes', '7.25% notes', 'January', 'NASDAQ', 'interests', 'April', 'relation', 'maturities', 'letter', 'assistance', 'cooperation', 'connection', 'favour', 'place', 'deadline', 'Voting', 'behalf', 'significance', 'stakeholders', 'debts', 'context', 'difficulties', 'equity', 'decision', 'advance', 'support', 'NSD', 'monies', 'efforts', 'present', 'Group', 'impact', 'sale', '24 November', 'prospects', 'access', 'indebtedness', 'Story', 'return', 'benefit', 'put', 'right', 'Company', 'undertakings', 'amendments', 'directors', 'solvency', 'possibility', 'runway', 'risks', '26 December', 'copy', 'email', 'bonds']",2023-01-16,2023-01-16,finance.yahoo.com
16514,EuroNext,NewsApi.org,https://finance.yahoo.com/news/onward-announces-participation-upcoming-events-063000214.html,ONWARD Announces Participation at Upcoming Events,EINDHOVEN  the Netherlands  LAUSANNE  Switzerland  and BOSTON  MA USA  Jan. 16  2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD)  the medical...,ONWARD MedicalEINDHOVEN  the Netherlands  LAUSANNE  Switzerland  and BOSTON  MA USA  Jan. 16  2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD)  the medical technology company creating innovative therapies to restore movement  independence  and health in people with spinal cord injury  today announced that management will participate in the following events in the upcoming weeks:Degroof Petercam Healthcare ConferenceJanuary 26  2023Brussels  BelgiumDave Marver  CEO  will participate in 1:1 meetings.TechShare by EuronextJanuary 27  2023Rotterdam  NetherlandsDave Marver will deliver the keynote address at the annual IPO educational program organized by Euronext.Sachs 4th Annual European HealthTech CEO ForumFebruary 28  2023Zurich  SwitzerlandDave Marver will participate in the panel discussion  ‚ÄúNextGen Medtech & Devices‚Äù.BioCapital EuropeMarch 9  2023Amsterdam  NetherlandsDave Marver will give a company presentation.Oppenheimer 33rd Annual Healthcare ConferenceMarch 13-15  2023Virtual eventDave Marver or Lara Smith Weber  CFO  will give a company presentation.VFB Happening (Flemish Federation of Investors)March 25  2023Ghent  BelgiumDave Marver will give a company presentation.Information on upcoming conferences is available in the Investor section of the ONWARD website at https://ir.onwd.com/news-events.About ONWARD MedicalONWARD is a medical technology company creating innovative therapies to restore movement  independence  and health in people with spinal cord injuries. ONWARD‚Äôs work builds on more than a decade of basic science and preclinical research conducted at the world‚Äôs leading neuroscience laboratories. ONWARD‚Äôs ARC Therapy  which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems  is designed to deliver targeted  programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury  ultimately improving their quality of life.Story continuesONWARD has received five Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external  non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company‚Äôs first pivotal study  called Up-LIFT  evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022.ONWARD is headquartered in Eindhoven  the Netherlands. It maintains a Science and Engineering Center in Lausanne  Switzerland  and has a growing U.S. presence in Boston  Massachusetts. The company has an academic partnership with .NeuroRestore  a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). For additional information about the company  please visit ONWD.com. To access our 2023 Financial Calendar  please visit IR.ONWD.com.For Company Enquiries:info@onwd.comFor Media Enquiries:MC Services AGUS: Laurie Doyle  P: +1 339 832 0752Europe: Dr. Johanna Kobler  Katja Arnold  Kaja Skorka  P: +49 89 210 228 0media@onwd.comFor Investor Enquiries:investors@onwd.comDisclaimerCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company or  as appropriate  the Company directors‚Äô current expectations and projections about future events. By their nature  forward-looking statements involve several risks  uncertainties  and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors  including  but not limited to  changes in demand  competition  and technology  can cause actual events  performance  or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result  the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions  or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person‚Äôs officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.,neutral,0.02,0.97,0.0,negative,0.0,0.08,0.91,True,English,"['Upcoming Events', 'ONWARD', 'Participation', '4th Annual European HealthTech CEO Forum', 'Oppenheimer 33rd Annual Healthcare Conference', 'targeted, programmed spinal cord stimulation', 'Degroof Petercam Healthcare Conference', 'annual IPO educational program', 'five Breakthrough Device Designations', 'growing U.S. presence', 'ONWARD Medical N.V.', 'spinal cord injury', 'spinal cord injuries', 'Lara Smith Weber', 'leading neuroscience laboratories', 'U.S. FDA', 'external, non-invasive platform', 'Positive top-line data', 'first pivotal study', 'upper extremity strength', 'marketing approval submissions', 'Swiss Federal Institute', 'MC Services AG', 'Dr. Johanna Kobler', 'transcutaneous ARC Therapy', 'implantable pulse generator', 'external (ARC-EX) systems', 'Lausanne University Hospital', 'medical technology company', 'MA USA', 'GLOBE NEWSWIRE', 'innovative therapies', 'upcoming weeks', 'Dave Marver', 'keynote address', 'panel discussion', 'NextGen Medtech', 'Virtual event', 'VFB Happening', 'Flemish Federation', 'upcoming conferences', 'Investor section', 'a decade', 'preclinical research', 'other functions', 'wearable stimulator', 'wireless programmer', 'human use', 'Engineering Center', 'academic partnership', '2023 Financial Calendar', 'Media Enquiries', 'Laurie Doyle', 'Katja Arnold', 'Kaja Skorka', 'Investor Enquiries', 'press release', 'financial effects', 'subsidiary undertakings', 'forward-looking statement', 'ONWARD website', 'future accuracy', 'company presentation', 'Company Enquiries', 'following events', 'basic science', 'additional information', 'current expectations', 'several risks', 'actual results', 'actual events', 'past trends', 'BioCapital Europe', 'ARC-IM neurostimulator', 'future events', 'statements', 'ARC-EX.', 'EINDHOVEN', 'Netherlands', 'Switzerland', 'BOSTON', 'Jan', 'Euronext', 'ONWD', 'movement', 'independence', 'people', 'management', 'Brussels', 'Belgium', '1:1 meetings', 'TechShare', 'Rotterdam', 'Sachs', 'February', 'Zurich', 'Devices', 'March', 'Amsterdam', 'CFO', 'Investors', 'Ghent', 'news-events', 'work', 'world', 'quality', 'life', 'Story', 'September', 'ability', 'May', 'Massachusetts', 'NeuroRestore', 'collaboration', 'EPFL', 'CHUV', 'Disclaimer', 'beliefs', 'opinions', 'projections', 'nature', 'uncertainties', 'assumptions', 'outcome', 'plans', 'multitude', 'factors', 'changes', 'demand', 'competition', 'performance', 'development', 'activities', 'representation', 'obligation', 'update', 'revisions', 'conditions', 'circumstances', 'advisers', 'representatives', 'person', 'officers', 'employees', 'errors', 'responsibility']",2023-01-16,2023-01-16,finance.yahoo.com
16515,EuroNext,NewsApi.org,https://finance.yahoo.com/news/argenx-announces-extraordinary-general-meeting-183000850.html,argenx Announces Extraordinary General Meeting of Shareholders on February 27  2023 to Appoint Steve Krognes as Non-Executive Director,January 16  2023 Amsterdam  the Netherlands ‚Äì argenx SE (Euronext & Nasdaq: ARGX)  a global immunology company committed to improving the lives of people...,argenx SEJanuary 16  2023Amsterdam  the Netherlands ‚Äì argenx SE (Euronext & Nasdaq: ARGX)  a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases  today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday  February 27  2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701  1118 BN Schiphol  the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy  requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.AgendaThe sole voting item on the agenda will be the proposed appointment of Mr. Steve Krognes as non-executive director and Chair of the Audit and Compliance Committee of the Company‚Äôs Board of Directors.The full agenda for the meeting  as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.Resignation Werner LanthalerUpon appointment of Mr. Krognes  Werner Lanthaler will resign as non-executive director of the Board and Chair of the Audit and Compliance Committee to enable this important step in the long term succession planning for the board of directors and the audit and compliance committee chairperson role. The Company would like to express its gratitude towards Werner Lanthaler for his substantial contributions over the last eight years. Werner's entrepreneurial nature combined with broad experience in finance  executive leadership  and life sciences has helped guide argenx from a research-focused company to a fully integrated commercial-stage global immunology company.Story continuesAbout argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP)  argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S.  Japan  and the EU. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information  visit www.argenx.com and follow us on LinkedIn  Twitter  and Instagram.For further information  please contact:Media:Kelsey Kirkkkirk@argenx.comInvestors:Beth DelGiaccobdelgiacco@argenx.com,neutral,0.0,1.0,0.0,positive,0.95,0.05,0.0,True,English,"['Extraordinary General Meeting', 'Steve Krognes', 'Non-Executive Director', 'argenx', 'Shareholders', 'February', 'several earlier stage experimental medicines', 'long term succession planning', 'multiple serious autoimmune diseases', 'compliance committee chairperson role', 'commercial-stage global immunology company', 'novel antibody-based medicines', 'severe autoimmune diseases', 'last eight years', 'leading academic researchers', 'Immunology Innovation Program', 'neonatal Fc receptor', 'sole voting item', 'Mr. Steve Krognes', 'electronic) proxy option', 'extraordinary general meeting', 'Hilton Amsterdam Schiphol', 'Mr. Krognes', 'immunology breakthroughs', 'The Company', 'research-focused company', 'Schiphol Boulevard', 'BN Schiphol', 'other persons', 'formal notice', 'voting system', 'executive director', 'ancillary documents', 'free copy', 'important step', 'substantial contributions', 'broad experience', 'executive leadership', 'life sciences', 'world-class portfolio', 'FcRn) blocker', 'U.S.', 'therapeutic franchises', 'Kelsey Kirk', 'Beth DelGiacco', 'Werner Lanthaler', 'meeting rights', 'argenx SE', 'argenx website', 'full agenda', 'argenx offices', 'January', 'Netherlands', 'Euronext', 'Nasdaq', 'ARGX', 'lives', 'people', 'shareholders', 'Monday', 'February', 'convocation', 'information', 'requirements', 'notification', 'registration', 'abnamro', 'appointment', 'Audit', 'Board', 'Directors', 'inspection', 'Resignation', 'gratitude', 'nature', 'finance', 'integrated', 'Story', 'IIP', 'Japan', 'efgartigimod', 'LinkedIn', 'Twitter', 'Instagram', 'Media', 'Investors', 'bdelgiacco', '12:00']",2023-01-16,2023-01-16,finance.yahoo.com
16516,EuroNext,NewsApi.org,https://www.businesswire.com/news/home/20230115005037/en/Innate-Pharma-Announces-Publication-of-Preclinical-Data-with-a-Trifunctional-NK-Cell-Engager-in-Acute-Myeloid-Leukemia-in-Nature-Biotechnology,Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology,MARSEILLE  France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (‚ÄúInnate‚Äù or the ‚ÄúCompany‚Äù) announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a tri‚Ä¶,"MARSEILLE  France--(BUSINESS WIRE)--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (‚ÄúInnate‚Äù or the ‚ÄúCompany‚Äù) announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123. The studies were conducted by Innate and Sanofi and published in Nature Biotechnology on January 12  2023.The study shows that expression of CD64 on AML blasts confers resistance to anti-CD123 antibody-dependent cell cytotoxicity (ADCC) and redirecting NK cells against cancer targets through binding to CD16a and NKp46 circumvents this resistance. Moreover  through their binding to NKp46  CD123-NKCE specifically target NK cells and has potent antitumor activity against primary AML blasts; it induces NK cell activation and cytokine secretion only in the presence of AML cells. In vivo  its antitumor activity in a mouse tumor model exceeds that of the comparator anti-CD123 antibody. The efficacy of CD123-NKCE in vitro in human peripheral blood mononuclear cells and in vivo in nonhuman primates was associated with the induction of low pro-inflammatory cytokine release and no signs of toxicity.These results support clinical development of CD123-NKCE. A Phase 1/2 clinical trial by Sanofi is ongoing  evaluating IPH6101/SAR‚Äô579 (SAR443579)  the first NKp46/CD16-based CD123-targeted ANKETTM NK cell engager  in patients with relapsed or refractory acute myeloid leukemia (R/R AML)  B-cell acute lymphoblastic leukemia (B-ALL) or high-risk myelodysplastic syndrome (HR-MDS).Eric Vivier  DVM  PhD  Chief Scientific Officer of Innate Pharma:‚ÄúThe activity  safety  pharmacokinetic and pharmacodynamics data provided here demonstrate the superiority of CD123-NKCEs over comparator cytotoxic antibodies in terms of antitumor activity  and their favorable safety profiles relative to T cell therapies for the treatment of AML. IPH6101/SAR‚Äô579 is a multi-specific NKCE targeting CD123 currently in a Phase 1 trial in AML sponsored by Sanofi. At Innate Pharma  we are developing a broad portfolio of NK Cell Engager programs via our proprietary platform ANKETTM that can address different types of cancer.‚ÄùValeria Fantin  Ph.D.  Global Head of Oncology Research at Sanofi:‚ÄúAt Sanofi  we are building a diverse oncology portfolio including next-generation NK-based assets and bringing new approaches to fighting cancer. We're pleased with our productive collaboration with Innate Pharma  and data like this reinforce our confidence in proceeding to clinical evaluation of this novel NK cell engager.""About ANKETTMANKETTM (Antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation  multi-specific natural killer (NK) cell engagers to treat certain types of cancer.This versatile  fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic immunity against cancer. It leverages the advantages of harnessing NK cell effector functions against cancer cells and also provides proliferation and activation signals targeted to NK cells.Our latest innovation  the tetra-specific ANKET molecule  is the first NK cell engager technology to engage activating receptors (NKp46 and CD16)  a tumor antigen and an interleukin-2 receptor (via an IL-2 variant  IL-2v) via a single molecule.About Innate PharmaInnate Pharma S.A. is a global  clinical-stage oncology-focused biotech company dedicated to improving treatment and clinical outcomes for patients through therapeutic antibodies that harness the immune system to fight cancer.Innate Pharma‚Äôs broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.Innate is a pioneer in the understanding of Natural Killer cell biology and has expanded its expertise in the tumor microenvironment and tumor-antigens  as well as antibody engineering. This innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry including Bristol-Myers Squibb  Novo Nordisk A/S  Sanofi  and a multi-products collaboration with AstraZeneca.Headquartered in Marseille  France with a US office in Rockville  MD  Innate Pharma is listed on Euronext Paris and Nasdaq in the US.Learn more about Innate Pharma at www.innate-pharma.comInformation about Innate Pharma shares:ISIN code FR0010331421 Ticker code Euronext: IPH Nasdaq: IPHA LEI 9695002Y8420ZB8HJE29Disclaimer on forward-looking information and risk factors:This press release contains certain forward-looking statements  including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words  including ‚Äúbelieve ‚Äù ‚Äúpotential ‚Äù ‚Äúexpect‚Äù and ‚Äúwill‚Äù and similar expressions  is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions  these forward-looking statements are subject to numerous risks and uncertainties  which could cause actual results to differ materially from those anticipated. These risks and uncertainties include  among other things  the uncertainties inherent in research and development  including related to safety  progression of and results from its ongoing and planned clinical trials and preclinical studies  review and approvals by regulatory authorities of its product candidates  the Company‚Äôs commercialization efforts  the Company‚Äôs continued ability to raise capital to fund its development and the overall impact of the COVID-19 outbreak on the global healthcare system as well as the Company‚Äôs business  financial condition and results of operations. For an additional discussion of risks and uncertainties which could cause the company's actual results  financial condition  performance or achievements to differ from those contained in the forward-looking statements  please refer to the Risk Factors (‚ÄúFacteurs de Risque"") section of the Universal Registration Document filed with the French Financial Markets Authority (‚ÄúAMF‚Äù)  which is available on the AMF website http://www.amf-france.org or on Innate Pharma‚Äôs website  and public filings and reports filed with the U.S. Securities and Exchange Commission (‚ÄúSEC‚Äù)  including the Company‚Äôs Annual Report on Form 20-F for the year ended December 31  2021  and subsequent filings and reports filed with the AMF or SEC  or otherwise made public  by the Company.This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country.",neutral,0.0,0.99,0.01,mixed,0.55,0.19,0.25,True,English,"['Trifunctional NK Cell Engager', 'Acute Myeloid Leukemia', 'Innate Pharma', 'Preclinical Data', 'Nature Biotechnology', 'Publication', 'first NKp46/CD16-based CD123-targeted ANKETTM NK cell engager', 'Private Securities Litigation Reform Act', 'Antibody-based NK cell Engager Therapeutics', 'human peripheral blood mononuclear cells', 'first NK cell engager technology', 'global, clinical-stage oncology-focused biotech company', 'trifunctional NKp46-CD16a-NK cell engager', 'NK Cell Engager programs', 'novel NK cell engager', 'Natural Killer cell biology', 'high unmet medical need', 'NK cell effector functions', 'anti-CD123 antibody-dependent cell cytotoxicity', 'B-cell acute lymphoblastic leukemia', 'next-generation, multi-specific natural killer', 'refractory acute myeloid leukemia', 'low pro-inflammatory cytokine release', 'Phase 1/2 clinical trial', 'Innate Pharma S.A.', 'NK) cell engagers', 'NK cell activation', 'T cell therapies', 'next-generation NK-based assets', 'comparator anti-CD123 antibody', 'high-risk myelodysplastic syndrome', 'Chief Scientific Officer', 'Novo Nordisk A/S', 'multi-specific NKCE targeting', 'tetra-specific ANKET molecule', 'mouse tumor model', 'diverse oncology portfolio', 'comparator cytotoxic antibodies', 'favorable safety profiles', 'diversified proprietary portfolio', 'Ticker code Euronext', 'primary AML blasts', 'potent antitumor activity', 'Innate Pharma SA', 'Innate Pharma shares', 'NK cells', 'Phase 1 trial', 'Global Head', 'purpose technology', 'cytokine secretion', 'press release', 'broad portfolio', 'Oncology Research', 'activation signals', 'single molecule', 'antibody engineering', 'ISIN code', 'clinical development', 'clinical evaluation', 'clinical outcomes', 'class clinical', 'Euronext Paris', 'proprietary platform', 'tumor antigen', 'tumor microenvironment', 'AML) cells', 'AML cells', 'BUSINESS WIRE', 'Nature Biotechnology', 'nonhuman primates', 'Eric Vivier', 'Valeria Fantin', 'Ph.D.', 'new approaches', 'productive collaboration', 'new class', 'synthetic immunity', 'latest innovation', 'activating receptors', 'interleukin-2 receptor', 'IL-2 variant', 'therapeutic antibodies', 'immune system', 'broad pipeline', 'preclinical candidates', 'innovative approach', 'major alliances', 'biopharmaceutical industry', 'Bristol-Myers Squibb', 'multi-products collaboration', 'risk factors', 'forward-looking statements', 'similar expressions', 'reasonable assumptions', 'numerous risks', 'R/R AML', 'cancer cells', 'preclinical data', 'pharmacodynamics data', 'different types', 'US office', 'IPHA LEI', 'forward-looking information', 'cancer targets', 'IPH Nasdaq', 'MARSEILLE', 'France', 'publication', 'control', 'studies', 'Sanofi', 'January', 'study', 'CD64', 'resistance', 'ADCC', 'binding', 'CD123-NKCE', 'presence', 'vivo', 'efficacy', 'vitro', 'induction', 'signs', 'results', 'IPH6101/SAR', 'patients', 'relapsed', 'B-ALL', 'HR-MDS', 'DVM', 'PhD', 'pharmacokinetic', 'superiority', 'terms', 'treatment', 'confidence', 'molecules', 'advantages', 'proliferation', 'several', 'cancers', 'pioneer', 'understanding', 'expertise', 'tumor-antigens', 'leaders', 'AstraZeneca', 'Rockville', 'Disclaimer', 'meaning', 'words', 'believe', 'expect', 'will', 'uncertainties']",2023-01-16,2023-01-16,businesswire.com
16517,EuroNext,NewsApi.org,https://finance.yahoo.com/news/exor-n-v-periodic-report-071000996.html,Exor N.V.: Periodic Report on the Buyback Program,EXOR N.V. (AMS: EXO) (‚ÄúExor‚Äù or the ‚ÄúCompany‚Äù) announces that  under the second tranche of the share buyback program of up to ‚Ç¨250 million announced on 29...,EXOR N.V. (AMS: EXO) (‚ÄúExor‚Äù or the ‚ÄúCompany‚Äù) announces that  under the second tranche of the share buyback program of up to ‚Ç¨250 million announced on 29 July 2022 (the ‚Äúsecond tranche‚Äù)  the Company has completed the following transactions on Euronext Amsterdam:Trading Date Number of ordinary shares purchased Average price per share excluding fees (‚Ç¨) Total consideration excluding fees (‚Ç¨) 9 January 2023 41 935 72.7754 3 051 836.40 10 January 2023 37 277 72.6132 2 706 802.26 11 January 2023 31 829 72.6205 2 311 437.89 12 January 2023 42 048 72.7275 3 058 045.92 13 January 2023 27 582 72.2800 1 993 626.96 TOTAL 180 671 13 121 749.43After these purchases  the total invested amount under the second tranche is approximately ‚Ç¨181.8 million for a total amount of 2 676 492 ordinary shares purchased.As of 13 January 2023  the Company held in total 13 464 590 ordinary shares in treasury (5.59% of total ordinary issued share capital).A comprehensive overview of the transactions carried out under the share buyback program  as well as the details of the above transactions  are available on Exor‚Äôs corporate website under the Share Buyback section.Attachment,neutral,0.01,0.99,0.0,neutral,0.0,0.99,0.0,True,English,"['Exor N.V.', 'Periodic Report', 'Buyback Program', 'total ordinary issued share capital', 'share buyback program', 'Share Buyback section', 'EXOR N.V.', 'ordinary shares', 'second tranche', 'Euronext Amsterdam', 'Trading Date', 'Average price', 'Total consideration', 'comprehensive overview', 'corporate website', 'total amount', 'following transactions', 'Company', '29 July', 'Number', 'fees', '9 January', 'purchases', '13 January', 'treasury', 'details', 'Attachment']",2023-01-16,2023-01-16,finance.yahoo.com
16518,EuroNext,NewsApi.org,https://finance.yahoo.com/news/fl-entertainment-weekly-share-transaction-171100333.html,FL Entertainment: Weekly share transaction,Press Release Paris ‚Äì January 16th  2023 Share Transactions Disclosure FL Entertainment N.V. (894500G73K46H93RF180) declares the following transactions made ...,FL EntertainmentPress ReleaseParis ‚Äì January 16th  2023Share Transactions DisclosureFL Entertainment N.V. (894500G73K46H93RF180) declares the following transactions made on its own shares (NL0015000X07) from January 09th to January 13th  2023 in accordance with the authorization given by the shareholder‚Äôs annual meeting on June 30  2022.Trade Date Side Total Daily Volume (Number of Shares) Average Price Amount of Transactions Market Identification Code 2023-01-09 BUY 7 9.000000 63.00 XAMS 2023-01-09 SELL 100 9.100000 910.00 XAMS 2023-01-11 BUY 793 9.081967 7 202.00 XAMS 2023-01-12 BUY 200 8.925000 1 785.00 XAMS 2023-01-13 SELL 152 8.984868 1 365.70 XAMSThe disclosure of all share transactions was made publicly available and can be consulted on the company‚Äôs website (https://fl-entertainment.com/) under the section ¬´Investor Relations¬ª.AgendaFY 2022 results: 16 March 2023Investor RelationsCaroline Cohen ‚Äì Phone: +33 1 44 95 23 34 ‚Äì c.cohen@flentertainment.comPress RelationsAnne-France Malrieu - afmalrieu@image7.frAbout FL EntertainmentFounded by St√©phane Courbit  a 30-year entertainment industry pioneer and entrepreneur  FL Entertainment Group is a global leader in multimedia content and gambling  combining the strengths of Banijay  the world‚Äôs largest independent producer distributor  with Betclic Everest Group  the fastest-growing online sports betting platform in Europe. In 2021  FL Entertainment recorded through Banijay and Betclic Everest Group  a combined revenue  and adjusted EBITDA  of ‚Ç¨3.5bn and ‚Ç¨609m respectively. FL Entertainment listed on Euronext Amsterdam in July 2022.ISIN: NL0015000X07 - Bloomberg: FLE NA - Reuters: FLE.ASAttachment,neutral,0.04,0.96,0.0,positive,0.82,0.17,0.01,True,English,"['FL Entertainment', 'transaction', 'Trade Date Side Total Daily Volume', 'growing online sports betting platform', 'largest independent producer distributor', 'Transactions Market Identification Code', '30-year entertainment industry pioneer', 'FL Entertainment N.V.', 'Average Price Amount', 'St√©phane Courbit', 'Betclic Everest Group', 'FLE.AS Attachment', 'FL Entertainment Group', 'Share Transactions Disclosure', 'following transactions', 'FLE NA', 'Press Release', 'annual meeting', 'Investor Relations', 'FY 2022 results', 'Press Relations', 'Anne-France Malrieu', 'global leader', 'multimedia content', 'combined revenue', 'adjusted EBITDA', 'Euronext Amsterdam', 'Caroline Cohen', 'Paris', 'January', 'shares', 'accordance', 'authorization', 'shareholder', 'June', 'Number', 'BUY', 'XAMS', 'SELL', 'company', 'website', 'section', 'Agenda', '16 March', 'Phone', 'image', 'strengths', 'Banijay', 'world', 'Europe', 'July', 'ISIN', 'Bloomberg', 'Reuters']",2023-01-16,2023-01-16,finance.yahoo.com
16519,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/01/16/2589395/0/en/Euronext-confirms-the-expansion-of-Euronext-Clearing-to-derivatives-markets-for-Q3-2024.html,Euronext confirms the expansion of Euronext Clearing to derivatives markets for Q3 2024,Contacts Media  Contact Investor Relations  Amsterdam  +31 20 721 4133  Brussels  +32 2 620 15 50  +33 1 70 48 24 27  Dublin  +33 1 70 48 24 45  Lisbon...,"Contacts Media Contact Investor Relations Amsterdam +31 20 721 4133 Brussels +32 2 620 15 50 +33 1 70 48 24 27 Dublin +33 1 70 48 24 45 Lisbon +351 210 600 614 Milan +39 02 72 42 62 12 Oslo +47 41 69 59 10 Paris +33 1 70 48 24 45Euronext confirms the expansion of Euronext Clearing to derivatives markets for Q3 2024Amsterdam  Brussels  Dublin  Lisbon  Milan  Oslo and Paris ‚Äì 16 January 2023 ‚Äì Euronext  the leading pan-European market infrastructure  today announces that the European expansion of Euronext Clearing to Euronext derivatives markets is planned for Q3 2024.Since April 2021  Euronext has been the owner of a multi-asset clearing house  Euronext Clearing (formerly CC&G)  and is thus in a position to directly manage its clearing activities to complete its value chain. In November 2021  Euronext announced its ambition to internalise the clearing activity of its cash and derivatives flows  today operated by third-party providers. As a result Euronext Clearing will become Euronext‚Äôs clearing house (‚ÄúCCP‚Äù) of choice for cash equity1  listed derivatives and commodities markets.Combined with the successful migration of its Core Data Centre in June 2022 from Basildon (United Kingdom) to Bergamo (Italy) and the planned migration of the Borsa Italiana capital markets to Optiq¬Æ  Euronext‚Äôs proprietary trading platform  the expansion of Euronext Clearing will allow Euronext to manage the entire trading value chain of its markets by the end of 2024. Euronext will directly operate clearing activities for its cash  listed derivatives and commodities markets  and create value through a harmonised clearing framework across Euronext venues. It will provide one single platform for clients to access information on collateral  risk  and clearing. Euronext Clearing will bring margin efficiencies to clients with the implementation of a new Value-at-Risk methodology  offering the financial ecosystem with increasingly efficient and resilient solutions for risk capture and allocation within the system. This move will also bring efficiencies across all asset classes  with transparency on data  particularly on settlement  leveraging Euronext Securities to access the Target-2-Securities (T2S) settlement platform. Euronext Clearing will allow Euronext to significantly increase its footprint in the post-trade space and align strategic priorities between trading and clearing. Euronext will be in an ideal position to innovate and improve time-to-market  notably on derivatives products  to serve the evolving needs of its clients.Positioning of Euronext Clearing as the CCP of choice across its cash equity markets1As announced on 3 November 2022  Euronext confirms the first phase of the expansion of Euronext Clearing with the expected positioning of Euronext Clearing as the Euronext CCP of choice for its cash equity markets1 by the end of Q4 2023. Euronext will continue to offer an open access CCP model for cash equity clearing.Migration2 of Euronext listed derivatives and commodities markets to Euronext Clearing expected in Q3 2024Euronext confirms it expects to migrate the listed financial derivatives and commodities markets of Euronext Amsterdam  Euronext Brussels  Euronext Lisbon  Oslo B√∏rs and Euronext Paris from LCH SA to Euronext Clearing by Q3 2024. As a reminder  Euronext Clearing already clears Euronext Milan listed derivatives.The migration of Euronext listed derivatives and commodities markets is the final step of the European expansion of Euronext Clearing set up as part of Euronext ‚ÄòGrowth for Impact 2024‚Äô strategic plan. It will unlock innovation capabilities  notably on derivatives products. Furthermore  the migration will maximise value extraction through a harmonised clearing framework across Euronext venues and deliver on the announced targeted run-rate annual synergies for 2024.Euronext and LCH SA are committed to working together to ensure an orderly migration of clearing flows from LCH SA to Euronext Clearing.Notification of early termination of the derivatives clearing agreement (the ‚ÄúAgreement‚Äù) with LCH SAAs Euronext Clearing undertakes derivatives clearing services in Europe  Euronext has decided to terminate the existing Agreement with LCH SA  under the terms of the Agreement. Therefore  on 16 January 2023  Euronext served LCH SA notice of termination for the purposes of the Agreement.As set up in the Agreement  Euronext will pay a termination fee of approximately ‚Ç¨36.03 million toLCH SA  to be provisioned in its income statement as non-underlying expenses in Q1 2023  and payable in 2024. It is reminded that this amount is included in the ‚Ç¨150 million of implementation costs related to the ‚ÄòGrowth for Impact 2024‚Äô strategic plan and already announced in November 2021.Following the notification of the early termination of the Agreement  LCH Group has the option to buy back Euronext's 11.1% stake in LCH SA. Further communications on the stake owned by Euronext in LCH SA will be made when appropriate.The termination of the Agreement does not impact the existing clearing agreement signed between MTS S.p.A and LCH SA nor the existing agreement related to the interoperability link on Italian Government Bonds between Euronext Clearing and LCH SA4.St√©phane Boujnah  Chief Executive Officer and Chairman of the Managing Board of Euronext  said:‚ÄúWe are pleased to announce that the migration of Euronext derivatives clearing activities to Euronext Clearing is planned for Q3 2024  a few months after the migration of Euronext cash clearing activities. Combined with the successful migration of the Core Data Centre to Bergamo in June 2022 and the planned migration of the Borsa Italiana capital markets to Optiq¬Æ in 2023  the expansion of our clearing activities is a major step towards the delivery our ‚ÄúGrowth for Impact 2024‚Äù strategic plan. This will significantly contribute to achieve the ‚Ç¨100 million 2024 targeted run-rate annual synergies related to the Borsa Italiana Group acquisition.Euronext has profoundly transformed itself over the past five years and is uniquely positioned to become the leading European market infrastructure. Euronext is now the leading listing venue and the largest liquidity pool in Europe  thanks to its single trading platform. The expansion of Euronext Clearing to Euronext markets is another significant transformational milestone  allowing Euronext to manage the entire trading value chain  and become a major player in the post-trade space.We look forward to completing these strategic milestones in the coming months. I would like to thank all the Euronext teams that have already been working on these key projects for more than a year and that will be critical to the delivery of these projects. I would like to thank LCH SA for the great collaboration during the past years.‚ÄùCONTACT ANALYSTS & INVESTORS ‚Äì ir@euronext.com Aur√©lie Cohen +33 1 70 48 24 27 ir@euronext.com Cl√©ment Kubiak +33 1 70 48 26 33 ir@euronext.comCONTACTS MEDIA ‚Äì mediateam@euronext.com Aur√©lie Cohen (Europe) +33 1 70 48 24 45 parispressoffice@euronext.com Marianne Aalders (Amsterdam) +31 20 721 41 33 maalders@euronext.com Pascal Brabant (Brussels) +32 2 620 15 50 pbrabant@euronext.com Sandra Machado (Lisbon) +351 210 600 614 smachado@euronext.com Andrea Monzani (Europe/Milan/Rome) +39 02 72 42 62 13 Italypressoffice@euronext.com Cathrine Lorvik Segerlund (Oslo) +47 41 69 59 10 clsegerlund@euronext.com Sarah Mound (Paris/Dublin) +33 1 70 48 24 45 parispressoffice@euronext.comAbout EuronextEuronext is the leading pan-European market infrastructure  connecting European economies to global capital markets  to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium  France  Ireland  Italy  the Netherlands  Norway and Portugal. With close to 1 930 listed equity issuers and around ‚Ç¨6.3 trillion in market capitalisation as of end December 2022  it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets  one of Europe‚Äôs leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities  FX  Exchange Traded Funds  Warrants & Certificates  Bonds  Derivatives  Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing  and custody and settlement services through Euronext Securities central securities depositories in Denmark  Italy  Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market  it also operates a number of junior markets  simplifying access to listing for SMEs.For the latest news  go to euronext.com or follow us on Twitter ( twitter.com/ euronext ) and LinkedIn ( linkedin.com/ euronex t ).DisclaimerThis press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided ‚Äúas is‚Äù  without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content  Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using  trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext‚Äôs subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use.¬© 2023  Euronext N.V. - All rights reserved.The Euronext Group processes your personal data in order to provide you with information about Euronext (the ""Purpose""). With regard to the processing of this personal data  Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation  ‚ÄúGDPR‚Äù)  and any applicable national laws  rules and regulations implementing the GDPR  as provided in its privacy statement available at: www.euronext.com/privacy-policy. In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights  please refer to: www.euronext.com/data_subjects_rights_request_information. To make a request regarding the processing of your data or to unsubscribe from this press release service  please use our data subject request form at connect2.euronext.com/form/data-subjects-rights-request or email our Data Protection Officer at dpo@euronext.com.1 Excluding Oslo B√∏rs cash markets2 Migrations are subject to the declaration of non-objection of relevant regulators3 Of which ‚Ç¨6 million to be adjusted for inflation impact4 For more information  please refer to Euronext 2021 Universal Registration Document ‚Äì Section 7.2.1  Material ContractsAttachment",neutral,0.0,1.0,0.0,neutral,0.02,0.96,0.02,True,English,"['derivatives markets', 'Euronext Clearing', 'expansion', 'Q3', 'Contacts Media Contact Investor Relations', 'leading pan-European market infrastructure', 'Borsa Italiana capital markets', 'open access CCP model', 'entire trading value chain', 'one single platform', 'run-rate annual synergies', 'proprietary trading platform', 'Impact 2024‚Äô strategic plan', 'cash equity markets1', 'harmonised clearing framework', 'Core Data Centre', 'T2S) settlement platform', 'Oslo B√∏rs', 'multi-asset clearing house', 'cash equity clearing', 'LCH SA notice', 'derivatives clearing services', 'existing clearing agreement', 'Euronext derivatives markets', 'derivatives clearing agreement', 'strategic priorities', 'commodities markets', 'new Value', 'value extraction', 'clearing activities', 'clearing activity', 'clearing flows', 'LCH Group', 'existing Agreement', 'CC&G', 'derivatives flows', 'third-party providers', 'listed derivatives', 'United Kingdom', 'margin efficiencies', 'financial ecosystem', 'resilient solutions', 'asset classes', 'post-trade space', 'derivatives products', 'evolving needs', 'first phase', 'financial derivatives', 'final step', 'innovation capabilities', 'income statement', 'underlying expenses', 'Further communications', 'Euronext Clearing', 'Risk methodology', 'risk capture', 'early termination', 'termination fee', 'Euronext venues', 'Euronext Securities', 'Euronext CCP', 'ideal position', 'expected positioning', 'implementation costs', 'European expansion', 'successful migration', 'orderly migration', 'Euronext ‚ÄòGrowth', 'Euronext Amsterdam', 'Euronext Brussels', 'Euronext Lisbon', 'Euronext Paris', 'Euronext Milan', 'Dublin', 'Q3', '16 January', 'April', 'owner', 'November', 'ambition', 'result', 'choice', 'June', 'Basildon', 'Bergamo', 'Italy', 'planned', 'Optiq¬Æ', 'end', 'clients', 'information', 'collateral', 'efficient', 'allocation', 'move', 'transparency', 'Target-2-Securities', 'footprint', 'time', 'Q4', 'Migration2', 'reminder', 'Notification', 'terms', 'purposes', 'Q1', 'amount', 'option', '11.1% stake', 'MTS']",2023-01-16,2023-01-16,globenewswire.com
16520,EuroNext,NewsApi.org,https://finance.yahoo.com/news/press-release-biocartis-group-nv-164000400.html,Press release Biocartis Group NV: Completion of Comprehensive Recapitalization Transactions,PRESS RELEASE: REGULATED INFORMATION16 January 2023  17:40 CET Completion of Comprehensive Recapitalization Transactions Mechelen  Belgium  16 January 2023 ‚Äì...,"PRESS RELEASE: REGULATED INFORMATION16 January 2023  17:40 CETCompletion of Comprehensive Recapitalization TransactionsMechelen  Belgium  16 January 2023 ‚ÄìBiocartis Group NV (the ""Company"" or ""Biocartis"")  an innovative molecular diagnostics company (Euronext Brussels: BCART) is pleased to announce that the final steps in the previously announced comprehensive recapitalization transactions have been completed today.The initial holders of the Company's 4.50% new second lien secured convertible bonds due 2026 (the ""New Convertible Bonds"") have subscribed for additional New Convertible Bonds in an aggregate amount equal to EUR 25 000 200 (such additional New Convertible Bonds  the ""New Money Bonds""). From their issuance up until the next interest payment date of 15 March 2023  the New Money Bonds will trade under ISIN number BE6340726304. On 15 March 2023  the ISIN of the New Money Bonds will be merged with the ISIN of the New Convertible Bonds  as a result of which both the New Money Bonds and the previously issued New Convertible Bonds will trade under ISIN BE6338582206 and will be fully fungible.Following the issuance of the New Money Bonds and as part of the bond buyback transactions that took place on 19 October 2022 (as referred to in the press releases of the Company dated 1 September 2022 and 20 October 2022)  certain holders of the Company's New Convertible Bonds delivered an additional EUR 306 000 in New Convertible Bonds to the Company for no consideration. The New Convertible Bonds so delivered have been cancelled.As a result of the aforementioned issuance of New Money Bonds and cancellation of New Convertible Bonds  the total outstanding principal amount of New Convertible Bonds (including New Money Bonds) is equal to EUR 116 764 200.Furthermore  the completion of the issuance of the New Money Bonds  has enabled the Company to make another drawdown of approximately EUR 11 million under the Company's senior secured term loan (‚ÄúConvertible Term Loans‚Äù) provided by certain holders of the Company's New Convertible Bonds  resulting in the EUR 30 million available under the Convertible Term Loans being fully drawn.Story continuesThis completes the comprehensive recapitalization that was announced on 1 September 2022 and that will support the Company's growth for the foreseeable future with EUR 66 million of gross proceeds.--- END ---More information:Renate DegraveHead of Corporate Communications & Investor Relations Biocartise-mail rdegrave@biocartis.comtel +32 15 631 729mobile +32 471 53 60 64About BiocartisWith its revolutionary and proprietary Idylla‚Ñ¢ platform  Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing  by making molecular testing actionable  convenient  fast and suitable for any lab. The Idylla‚Ñ¢ platform is a fully automated sample-to-result  real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster  informed treatment decisions. Idylla‚Ñ¢'s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs  with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today  Biocartis offers tests supporting melanoma  colorectal  lung and liver cancer  as well as for COVID-19  Flu  RSV and sepsis. For more information  visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_   Facebook or LinkedIn.Biocartis and Idylla‚Ñ¢ are registered trademarks in Europe  the United States and other countries. The Biocartis and Idylla‚Ñ¢ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.This press release is not for distribution  directly or indirectly  in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933  as amended.Important informationThis announcement is not a prospectus for the purposes of Regulation 2017/1129  as amended (together with any applicable implementing measures in any Member State of the European Economic Area  the ‚ÄúProspectus Regulation‚Äù) or the Prospectus Regulation as it forms part of UK domestic law by virtue of the UK European Union (Withdrawal) Act 2018 and as amended by The Prospectus (Amendment etc.) (EU Exit) Regulations 2019 (each as amended) (the ""UK Prospectus Regulation"").THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION  DIRECTLY OR INDIRECTLY  IN THE UNITED STATES OF AMERICA  AUSTRALIA  CANADA  JAPAN  SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW.THIS ANNOUNCEMENT IS FOR GENERAL INFORMATION ONLY AND DOES NOT FORM PART OF ANY OFFER TO SELL OR PURCHASE  OR THE SOLICITATION OF ANY OFFER TO SELL OR PURCHASE  ANY NEW BONDS  OUTSTANDING BONDS OR OTHER SECURITIES. THE DISTRIBUTION OF THIS ANNOUNCEMENT AND THE OFFER  SALE AND PURCHASE OF THE NEW BONDS  NEW TERM LOANS OR THE OUTSTANDING BONDS DESCRIBED IN THIS ANNOUNCEMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW. ANY PERSONS READING THIS ANNOUNCEMENT SHOULD INFORM THEMSELVES OF AND OBSERVE ANY SUCH RESTRICTIONS.There shall be no offer  solicitation  sale or purchase or exchange of the New Convertible Bonds in any jurisdiction in which such offer  solicitation  sale  or purchase would be unlawful prior to registration  exemption from registration or qualification under the securities laws of any such jurisdiction. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933  as amended from time to time (the ""U.S. Securities Act"") or the securities laws of any state of the United States  and may not be offered or sold in the United States unless these securities are registered under the U.S. Securities Act  or an exemption from the registration requirements of the U.S. Securities Act is available.Biocartis has not registered  and does not intend to register  any portion of the offering of the securities concerned in the United States  and does not intend to conduct a public offering of securities in the United States. This communication is only addressed to and directed at persons in member states of the European Economic Area (each a ""Member States"") and in the United Kingdom who are ""qualified investors"" within the meaning of Article 2(e) of the Prospectus Regulation and of the UK Prospectus Regulation  respectively (""Qualified Investors""). This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ""Order"") or (iii) high net worth companies  and other persons to whom it may lawfully be communicated  falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as ""relevant persons""). The securities referred to herein are only available to  and any invitation  offer or agreement to subscribe  purchase or otherwise acquire such securities will be engaged in only with  relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. This announcement cannot be used as a basis for any investment agreement or decision. Biocartis is not liable if the aforementioned restrictions are not complied with by any person.",neutral,0.0,1.0,0.0,negative,0.0,0.04,0.96,True,English,"['Biocartis Group NV', 'Comprehensive Recapitalization Transactions', 'Press release', 'Completion', 'next interest payment date', 'faster, informed treatment decisions', 'key unmet clinical needs', 'senior secured term loan', 'total outstanding principal amount', 'U.S. Securities Act', 'additional New Convertible Bonds', 'The New Convertible Bonds', 'innovative molecular diagnostics company', 'Convertible Term Loans', 'molecular diagnostics market', 'New Money Bonds', '4.50% new second lien', 'bond buyback transactions', 'Polymerase Chain Reaction', 'fastest growing segment', 'European Economic Area', 'UK domestic law', 'UK European Union', 'Comprehensive Recapitalization Transactions', 'proprietary Idylla‚Ñ¢ platform', 'applicable implementing measures', 'accurate molecular information', 'molecular diagnostic tests', 'The Idylla‚Ñ¢ platform', 'Biocartis Group NV', 'Investor Relations Biocartis', 'individual Biocartis product', 'UK Prospectus Regulation', 'United States Securities', 'molecular testing', 'The Prospectus', 'aggregate amount', 'minimum amount', 'product labeling', 'The Biocartis', 'PRESS RELEASE', 'REGULATED INFORMATION', 'Euronext Brussels', 'final steps', 'foreseeable future', 'gross proceeds', 'More information', 'Renate Degrave', 'Corporate Communications', 'personalized medicine', 'real-time PCR', 'based system', 'expanding menu', 'liver cancer', 'other countries', 'Idylla‚Ñ¢ trademark', 'Exchange Commission', 'Important information', 'Member State', 'EU Exit', 'universal access', 'initial holders', 'ISIN number', 'January', 'CET', 'Completion', 'Mechelen', 'Belgium', 'BCART', 'issuance', '15 March', 'result', 'part', 'place', '19 October', '1 September', '20 October', 'consideration', 'cancellation', 'drawdown', 'Story', 'growth', 'Head', 'mail', 'revolutionary', 'patients', 'world', 'house', 'focus', 'oncology', 'melanoma', 'colorectal', 'lung', 'COVID', 'Flu', 'RSV', 'sepsis', 'Twitter', 'Facebook', 'LinkedIn', 'trademarks', 'logo', 'uses', 'distribution', 'jurisdiction', 'persons', 'restrictions', 'responsibility', 'violation', 'offer', 'invitation', 'sale', 'purchase', 'America', 'registration', 'exemption', 'announcement', 'purposes', 'virtue', 'Amendment', 'Regulations']",2023-01-16,2023-01-16,finance.yahoo.com
16521,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/DEUTSCHE-BORSE-AG-449617/news/Euronext-to-switch-derivatives-clearing-to-Italy-in-2024-42743233/?utm_medium=RSS&utm_content=20230116,Euronext to switch derivatives clearing to Italy in 2024,(marketscreener.com) Pan-European stock exchange Euronext will shift clearing of derivatives trading to its new clearing arm in Italy by the third quarter of next year  it said on Monday  to compete directly with London Stock Exchange Group and Cboe.https://w‚Ä¶,"Euronext currently clears its derivatives transactions at LCH SA  owned by London Stock Exchange Group (LSEG)  but wants to build up its own in-house clearing operation  in tune with European Union efforts to deepen the bloc's capital market after Brexit.""Euronext confirms it expects to migrate the listed financial derivatives and commodities markets of Euronext Amsterdam  Euronext Brussels  Euronext Lisbon  Oslo Bors and Euronext Paris from LCH SA to Euronext Clearing by Q3 2024 "" the exchange said in a statement.It had already announced that Italy would become the default centre for clearing its stock transactions by the end of this year. Under EU 'open access' rules  customers can continue to clear their Euronext share trades at rivals such as LCH or Cboe if they want to.""We are very confident we will capture the bulk of our cash equities clearing "" Anthony Attia  Euronext global head of primary markets and post trade  told Reuters.Clearing equities and derivatives in one centre will build ""critical mass"" to allow customers to net across positions  Attia said.Euronext  which obtained its own clearing house as part of its acquisition of Borsa Italiana in Milan  owns just over 11% of LCH SA  a stake LSEG now has an option to buy.Attia said the stake was worth around 66.8 million euros ($72.2 million).LSEG had no comment on whether it would buy the stake.Separately  LSEG confirmed its agreement with Euronext on clearing financial and commodity derivatives would terminate next year but said LCH SA would remain ""strategically important"".LCH SA clears the majority of the Eurozone repo market and Euro credit derivatives market in addition to many European equity market venues  LSEG said.""We look forward to continuing to provide clearing services to our global customers  who benefit from access to our multi-asset offering "" LSEG added.($1 = 0.9249 euros)(Reporting by Huw Jones; Editing by David Goodman and Mark Potter)By Huw Jones",neutral,0.01,0.99,0.0,neutral,0.01,0.98,0.01,True,English,"['Euronext', 'derivatives', 'Italy', 'many European equity market venues', ""EU 'open access' rules"", 'Euro credit derivatives market', 'London Stock Exchange Group', 'European Union efforts', 'Eurozone repo market', 'house clearing operation', 'cash equities clearing', 'Euronext share trades', 'Euronext global head', 'capital market', 'stock transactions', 'Clearing equities', 'clearing house', 'clearing services', 'derivatives transactions', 'commodity derivatives', 'commodities markets', 'Oslo Bors', 'default centre', 'primary markets', 'post trade', 'one centre', 'critical mass', 'Borsa Italiana', 'multi-asset offering', 'Huw Jones', 'David Goodman', 'Mark Potter', 'LCH SA', 'global customers', 'Euronext Amsterdam', 'Euronext Brussels', 'Euronext Lisbon', 'Euronext Paris', 'financial derivatives', 'Anthony Attia', 'LSEG', 'tune', 'bloc', 'Brexit', 'Q3', 'statement', 'Italy', 'end', 'year', 'rivals', 'Cboe', 'bulk', 'Reuters', 'positions', 'part', 'acquisition', 'Milan', 'stake', 'option', 'comment', 'agreement', 'majority', 'addition', '0.9249 euros', 'Editing', '66.8']",2023-01-16,2023-01-16,marketscreener.com
16522,EuroNext,NewsApi.org,https://finance.yahoo.com/news/dsm-delivery-shares-203000487.html,DSM - delivery of shares,Following the Offering Circular published on 22 November 2022  Royal DSM is required to announce transactions relating to the ordinary shares in its capital ...,This is a press release by Koninklijke DSM N.V. (Royal DSM)  pursuant to the provisions of Sections 13 paragraphs 1 and 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the Decree) in connection with the public offer by Danube AG (to be renamed DSM-Firmenich AG) for all the issued and outstanding ordinary shares in the capital of DSM (the Exchange Offer). This press release does not constitute an offer  or any solicitation of any offer  to buy or subscribe for any securities. This press release is not for general release  publication or distribution  in whole or in part  in or into  directly or indirectly  the United States or any other jurisdiction where such release  publication or distribution would violate applicable laws or regulations.HEERLEN  Netherlands  Jan. 16  2023 /PRNewswire/ -- Following the Offering Circular published on 22 November 2022  Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.DSM Logo.Pursuant to commitments entered into prior to issuing the Offering Circular  DSM has on 16 January 2023  delivered 420 ordinary shares to employees in view of settling the exercise of an equivalent number of stock options granted under the respective DSM Incentive Plan (average exercise price ‚Ç¨97.36). On the date hereof  the total number of issued and outstanding DSM ordinary shares is 173 080 990. As a consequence of the delivery included herein  the number of outstanding DSM ordinary shares increased by 0.0002%.DSMRoyal DSM is a global  purpose-led company in Health  Nutrition & Bioscience  applying science to improve the health of people  animals and the planet. DSM's purpose is to create brighter lives for all. DSM's products and solutions address some of the world's biggest challenges while simultaneously creating economic  environmental and societal value for all its stakeholders ‚Äì customers  employees  shareholders  and society at large. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.Story continuesOr find us on:LinkedIn: http://www.linkedin.com/company/3108Twitter: http://www.twitter.com/DSMFacebook: http://www.facebook.com/DSMcompanyYouTube: http://www.youtube.com/user/dsmcompanyFor more informationDSM Media Relations Gareth Mead tel. +31 (0) 45 5782420 email media.contacts@dsm.com DSM Investor Relations Dave Huizing tel. +31 (0) 45 5782864 email investor.relations@dsm.comForward-looking statementsThis press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations  estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release  unless required by law. The English language version of the press release is leading.Logo - https://mma.prnewswire.com/media/329419/dsm_logo.jpgCisionView original content:https://www.prnewswire.co.uk/news-releases/dsm---delivery-of-shares-301722621.html,neutral,0.02,0.98,0.0,mixed,0.39,0.21,0.4,True,English,"['DSM', 'delivery', 'shares', 'DSM Media Relations Gareth Mead', 'DSM Investor Relations Dave Huizing', 'Koninklijke DSM N.V.', 'respective DSM Incentive Plan', 'Dutch public offer rules', 'outstanding DSM ordinary shares', 'outstanding ordinary shares', 'Public Takeover Bids', 'English language version', 'future (financial) performance', 'average exercise price', 'global, purpose-led company', '420 ordinary shares', 'treasury shares', 'Dutch Decree', 'actual performance', 'Royal DSM', 'Sections 13 paragraphs', 'biedingen Wft', 'Danube AG', 'Exchange Offer', 'United States', 'other jurisdiction', 'applicable laws', 'Offering Circular', 'share units', 'stock options', 'brighter lives', 'biggest challenges', 'economic, environmental', 'societal value', 'Euronext Amsterdam', 'current expectations', 'many factors', 'original content', 'press release', 'general release', 'DSM Logo', 'equivalent number', 'total number', 'Forward-looking statements', 'Such statements', 'More information', 'provisions', 'connection', 'capital', 'solicitation', 'securities', 'publication', 'distribution', 'part', 'regulations', 'HEERLEN', 'Netherlands', 'Jan.', '22 November', 'transactions', 'accordance', 'delivery', 'employees', 'view', 'vesting', 'commitments', '16 January', 'date', 'consequence', 'Health', 'Nutrition', 'Bioscience', 'people', 'animals', 'planet', 'products', 'solutions', 'world', 'stakeholders', 'customers', 'shareholders', 'society', 'Story', 'LinkedIn', 'Twitter', 'Facebook', 'DSMcompany', 'YouTube', 'position', 'estimates', 'projections', 'readers', 'risks', 'uncertainties', 'obligation', 'Cision', 'prnewswire', 'news-releases']",2023-01-16,2023-01-16,finance.yahoo.com
16523,EuroNext,NewsApi.org,https://finance.yahoo.com/news/share-repurchase-program-kbc-ancora-164000446.html,Update on share repurchase program KBC Ancora until 13 January 2023,Regulated information  inside information  Leuven  16 January 2023 (17:40 CET) Update on share repurchase program KBC Ancora until 13 January 2023 As part of...,KBC AncoraRegulated information  inside information  Leuven  16 January 2023 (17:40 CET)Update on share repurchase program KBC Ancora until 13 January 2023As part of the EUR 50 million share repurchase program  as confirmed on 20 May 2022  KBC Ancora has announced that it bought back a total of 27 700 shares in the period from 09 January 2023 to 13 January 2023.The following transactions were carried out during the period in question:Transaction date Number of shares Average price (EUR) Lowest price (EUR) Highest price (EUR) Total amount (EUR) Mon 9 January 2023 7 000 44.93 44.64 45.30 314 486.90 Tue 10 January 2023 4 500 44.79 44.50 44.92 201 564.90 Wed 11 January 2023 5 000 45.17 44.86 45.28 225 831.50 Thu 12 January 2023 5 000 45.92 45.18 46.26 229 594.00 Fri 13 January 2023 6 200 46.11 45.86 46.36 285 857.20 TOTAL(period concerned) 27 700 45.39 44.50 46.36 1 257 334.50 TOTAL (overall repurchase program) 1 006 055 36.41 31.68 46.36 36 631 505.19All transactions were carried out in the central order book of Euronext Brussels.Since the start of the share repurchase program on 10 June 2022  KBC Ancora has bought back 1 006 055 of its own shares  or 1.28% of the total number of shares issued (i.e. 78 301 314)  for an average price of 36.41 euros per share and for a total amount of 36 631 505 euros. KBC Ancora has currently implemented 73.26% of the repurchase program.The repurchase program runs within the limits of the share repurchase authorization granted by the Extraordinary General Meeting of Shareholders on 30 October 2020.---------------------------------KBC Ancora is a listed company that holds 18.6% of the shares in KBC Group. Together with Cera  MRBB and the Other Permanent Shareholders  it ensures shareholder stability and the ongoing development of the KBC Group. As core shareholders of KBC Group  they have concluded a shareholders‚Äô agreement to this end.Financial calendar:27 January 2023 Interim financial report (1H)1 September 2023 Annual press release for the financial year 2022/202327 October 2023 Annual General Meeting of ShareholdersStory continuesThis press release is available in Dutch  French and English on the website www.kbcancora.be.KBC Ancora Investor Relations & Press contact: Jan BergmansTel. +32 (0)16 27 96 72email: jan.bergmans@kbcancora.be or mailbox@kbcancora.beAttachment,neutral,0.0,1.0,0.0,neutral,0.01,0.97,0.02,True,English,"['share repurchase program', 'KBC Ancora', 'Update', '13 January', 'EUR 50 million share repurchase program', 'KBC Ancora Investor Relations', 'central order book', 'Extraordinary General Meeting', 'Annual General Meeting', 'share repurchase authorization', 'Interim financial report', 'Annual press release', 'Other Permanent Shareholders', 'Financial calendar', 'financial year', 'Press contact', 'KBC Group', 'Transaction date', 'Average price', 'Lowest price', 'Highest price', 'Euronext Brussels', 'listed company', 'shareholder stability', 'ongoing development', 'core shareholders', 'shareholders‚Äô agreement', 'Total amount', 'Regulated information', 'following transactions', 'total number', 'Mon 9 January', 'Jan Bergmans', '16 January', '13 January', '09 January', '27 January', 'Leuven', 'Update', 'part', '20 May', '27,700 shares', 'period', 'question', 'Tue', 'Wed', 'start', '10 June', '36.41 euros', '36,631,505 euros', 'limits', '30 October', 'Cera', 'MRBB', '1 September', '27 October', 'Story', 'Dutch', 'French', 'English', 'website', 'Tel.', 'email', 'kbcancora', 'Attachment']",2023-01-16,2023-01-16,finance.yahoo.com
16524,EuroNext,NewsApi.org,https://finance.yahoo.com/news/bghl-gbp-nav-063000147.html,BGHL (GBP): NAV(s),BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for...,"BOUSSARD AND GAVAUDAN HOLDING LIMITED (GBP)BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 13 Jan 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 27.1859 ¬£ 23.9220 Estimated MTD return -2.09 % -2.05 % Estimated YTD return -2.09 % -2.05 % Estimated ITD return 171.86 % 139.22 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 22.00 N/A Premium/discount to estimated NAV -19.08 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 1 900.00 Premium/discount to estimated NAV N/A -20.58 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 302 469 126 294 Held in treasury 5 000 N/A Shares Issued 12 307 469 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 238.0429 Class GBP A Shares (estimated) ¬£ 127.6163The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comStory continuesThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.16,0.84,True,English,"['BGHL', 'GBP', 'NAV', 'A Liquidity Enhancement Agreement Euro Shares Sterling Shares Number', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'GAVAUDAN HOLDING LIMITED Ordinary Shares', 'Class GBP A Shares', 'A N/A Average Price', 'N/A Sterling Shares Amsterdam', 'London Stock Exchange plc', 'Guernsey Financial Services Commission', 'Dutch Financial Supervision Act', 'Sterling Shares Shares', 'Euro Shares Amsterdam', 'US Investment Company Act', 'A N/A Range', 'expert financial advice', 'Guernsey Policy Council', 'collective investment scheme', 'UK Listing Authority', 'other professional advice', 'BG Fund ICAV', 'Gavaudan Investment Management', 'closed-ended investment company', 'US Securities Act', 'investment manager fees', '5,000 N/A Shares', 'BG Fund NAV', 'The Shares', 'A Premium/discount', 'Dutch Authority', 'Emmanuel Gavaudan', 'N/A GBX', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'The Company', 'investment performance', 'original investment', 'investment decision', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'main market', 'United States', 'following information', 'information purposes', 'necessary approval', 'future results', 'listed securities', 'Market information', 'LSE) Market', 'BOUSSARD', 'business', 'returns', 'AEX', 'Transactions', 'treasury', 'respect', 'role', 'LLP.', 'Email', 'Story', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-01-16,2023-01-16,finance.yahoo.com
16525,EuroNext,NewsApi.org,https://finance.yahoo.com/news/guerbet-2023-strategic-priorities-174000731.html,Guerbet: 2023 Strategic Priorities,2023 Strategic Priorities Diagnostic Imaging: increase EluciremTM sales and strengthen international positionsInterventional Imaging: prioritise Lipiodol...,GUERBET2023 Strategic PrioritiesDiagnostic Imaging : increase Elucirem TM sales and strengthen international positionsInterventional Imaging : prioritise Lipiodol sales with the development of innovative indicationsArtificial Intelligence: execution of the roadmap for the emergence of a major AI player dedicated to medical imaging in oncologyVillepinte  16 January 2023: Guerbet (FR0000032526 GBT)  a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.For several quarters  the Group has operated in an environment marked by a favorable trend in the contrast agent market  where structural volume growth seems to be accompanied by positive price effects over time  particularly in the face of difficult purchasing conditions (notably for iodine).In this demanding yet promising context  Guerbet intends to capitalise on its core target activities and established positions  allocate its resources to developing recognised products adapted to the immediate needs of professionals  and mobilising its teams around three main ambitions:Diagnostic Imaging: strategic reinforcementIn this market where Guerbet generates nearly 90% of its revenue  2023 will mark an important milestone with the market release in the United States of the first batches of the brand new EluciremTM  which is attracting strong interest from the scientific community and ordering parties. In Europe  the European Medicines Agency (EMA) review is expected in the second half of the year. In addition to ElucirmTM  the Group intends to strengthen its solid positions in diagnostic imaging (world‚Äôs number 2 in the MRI  number 4 in X-Rays) by supporting customer needs as close as possible with its comprehensive  interconnected offering  including contrast agents  injection systems  and digital solutions.Story continuesInterventional Imaging: resources allocated to the growth of established productsCommercial development and expansion of applications of LipiodolEstablished for 40 years as a standard in the treatment of liver cancer  Lipiodol also has a strong foothold in other areas ‚Äì including vascular embolization  lymphography  and hysterosalpingography (HSG) ‚Äì which now account for a significant portion of sales volumes and future growth. The potential for development of new innovative indications appears to be significant  particularly in the treatment of musculoskeletal disorders  venous diseases  and post-surgery and cancer disorders. Research and development efforts will thus be accelerated in order to explore new applications for Lipiodol.Microcatheter activity divestment planIn connection with the evolution of its strategy aimed at leveraging key assets  Guerbet is planning the gradual divestment of its microcatheter activities historically housed within Accurate Medical Therapeutics. Since its acquisition in 2018  the microcatheters portfolio has been significantly expanded  now containing 38 references across the two SeQure¬Æ and DraKon‚Ñ¢ microcatheter ranges for peripheral embolization procedures. This activity has is not significant revenue contributor at the Group level and currently requires specialised  reinforced sales teams and significant investments to achieve its full commercial potential. These necessities are no longer in line with the Group‚Äôs development strategy.Guerbet also plans to divest the Occlugel technology acquired in 2018  including several ranges of microspheres for use in embolization.Artificial Intelligence: acceleration of the roadmapFollowing the termination of its collaboration with Merative (formerly IBM Watson Health) announced in October 2022  Guerbet has regained all the necessary latitude to roll out the commercial strategy while maintaining full ownership of the developed assets (application software source codes and algorithms) and their intellectual property. Very promising results were already obtained in 2022 in the detection of liver damage and prostate cancer. The commercial development of the solutions will benefit from the licensing agreement expected to be signed in the first half of 2023 with Intrasense following Guerbet‚Äôs acquisition of a stake in the company announced on 11 January. Guerbet ultimately aims to enable the development of a major player in artificial intelligence applied to medical imaging in oncology.Upcoming events:Publication of 2022 full-year revenueFebruary 9  2023  after tradingAbout GuerbetAt Guerbet  we build lasting relationships so that we enable people to live better. That is our purpose. We are a global leader in medical imaging  offering a comprehensive range of pharmaceutical products  medical devices  and digital and AI solutions for diagnostic and interventional imaging. As pioneers in contrast products for 95 years  with more than 2 600 employees worldwide  we continuously innovate and devote 8%-10% of our revenue to research and development in five centers in France  Israel  and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B ‚Äì mid caps) and generated ‚Ç¨732 million in revenue in 2021. For more information  please visit www.guerbet.com .About GadopiclenolGadopiclenol  initially invented by Guerbet with subsequent contribution of Bracco intellectual property  is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity. The efficacy and safety of Gadopiclenol have been evaluated in MRI of the Central Nervous System  head and neck  thorax  abdomen  pelvis and musculoskeletal system (refer to the approved USPI for full information).Details on Phase III clinical trials are available on www.ClinicalTrials.gov :‚Ä¢ Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) Full Text View - ClinicalTrials.gov‚Ä¢ Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) - Full Text View - ClinicalTrials.govGadopiclenol is currently in the process of examination by the European Medicines Agency.Forward-looking statementsThis press release may contain statements of a forward-looking nature  based on assumptions and predictions made by the management of the Guerbet group. Various known and unknown risks  uncertainties and other factors could lead to marked differences between the future results  financial situation  development and performances of the company  and the estimates made here. These factors include those mentioned in the public reports of Guerbet  available on its website www.guerbet.com .The company assumes no responsibility whatsoever in relation to the updating of these forward-looking statements  or how they correspond to future events or developments.Contacts:GuerbetJ√©r√¥me Estampes  Chief Financial Officer +33.1.45.91.50.00 / jerome.estampes@guerbet.comClaire Lauvernier  Communications Director +33.6.79.52.11.88 / claire.lauvernier@guerbet.comActifinMarianne Py  Financial Communications + 33.1.56.88.11.25 / mpy@actifin.frJennifer Jullia  Press +33.1.56.88.11.19 / jjullia@actifin.frAttachment,neutral,0.01,0.99,0.0,mixed,0.22,0.18,0.61,True,English,"['2023 Strategic Priorities', 'Guerbet', 'application software source codes', 'Microcatheter activity divestment plan', 'international positions Interventional Imaging', '2023 Strategic Priorities Diagnostic Imaging', 'persistent inflationary pressures', 'positive price effects', 'difficult purchasing conditions', 'three main ambitions', 'European Medicines Agency', 'IBM Watson Health', 'new business opportunities', 'brand new EluciremTM', 'complex international environment', 'core target activities', 'comprehensive, interconnected offering', 'DraKon‚Ñ¢ microcatheter ranges', 'Very promising results', 'Elucirem TM sales', 'Accurate Medical Therapeutics', 'structural volume growth', 'peripheral embolization procedures', 'new innovative indications', 'major AI player', 'significant revenue contributor', 'contrast agent market', 'full commercial potential', 'microcatheter activities', 'gradual divestment', 'major player', 'strategic reinforcement', 'medical imaging', 'promising context', 'several ranges', 'full ownership', 'comprehensive range', 'solid positions', 'significant portion', 'significant investments', 'contrast agents', 'sales volumes', 'new applications', 'medical devices', 'Artificial Intelligence', 'FR0000032526 GBT', 'global specialist', 'developing markets', 'several quarters', 'favorable trend', 'demanding yet', 'immediate needs', 'important milestone', 'market release', 'United States', 'first batches', 'strong interest', 'scientific community', 'ordering parties', 'EMA) review', 'second half', 'customer needs', 'injection systems', 'liver cancer', 'strong foothold', 'other areas', 'vascular embolization', 'future growth', 'musculoskeletal disorders', 'venous diseases', 'cancer disorders', 'microcatheters portfolio', 'two SeQure¬Æ', 'Occlugel technology', 'necessary latitude', 'intellectual property', 'liver damage', 'prostate cancer', 'licensing agreement', 'first half', 'Upcoming events', '2022 full-year revenue', 'lasting relationships', 'global leader', 'AI solutions', 'commercial strategy', 'contrast products', 'Commercial development', 'sales teams', 'recognised products', 'pharmaceutical products', 'development efforts', 'Lipiodol sales', 'oncology Villepinte', 'key assets', 'Group level', 'development strategy', 'digital solutions', 'GUERBET', 'execution', 'roadmap', 'emergence', 'revelation', 'time', 'face', 'iodine', 'resources', 'professionals', 'addition', 'ElucirmTM', 'world', 'MRI', 'X-Rays', 'Story', 'expansion', '40 years', 'standard', 'treatment', 'lymphography', 'hysterosalpingography', 'HSG', 'post-surgery', 'Research', 'connection', 'evolution', 'acquisition', '38 references', 'necessities', 'line', 'microspheres', 'use', 'acceleration', 'termination', 'collaboration', 'Merative', 'October', 'algorithms', 'detection', 'Intrasense', 'stake', 'company', '11 January', 'Publication', 'February', 'people', 'purpose', 'pioneers', '95 years', '2,600 employees']",2023-01-16,2023-01-16,finance.yahoo.com
16526,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/01/16/2588939/0/en/ONWARD-Announces-Participation-at-Upcoming-Events.html,ONWARD Announces Participation at Upcoming Events,EINDHOVEN  the Netherlands  LAUSANNE  Switzerland  and BOSTON  MA USA  Jan. 16  2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD)  the medical technology company creating innovative therapies to restore movement  independence  and health in people‚Ä¶,English Dutch FrenchEINDHOVEN  the Netherlands  LAUSANNE  Switzerland  and BOSTON  MA USA  Jan. 16  2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD)  the medical technology company creating innovative therapies to restore movement  independence  and health in people with spinal cord injury  today announced that management will participate in the following events in the upcoming weeks:Degroof Petercam Healthcare ConferenceJanuary 26  2023Brussels  BelgiumDave Marver  CEO  will participate in 1:1 meetings.TechShare by EuronextJanuary 27  2023Rotterdam  NetherlandsDave Marver will deliver the keynote address at the annual IPO educational program organized by Euronext.Sachs 4th Annual European HealthTech CEO ForumFebruary 28  2023Zurich  SwitzerlandDave Marver will participate in the panel discussion  ‚ÄúNextGen Medtech & Devices‚Äù.BioCapital EuropeMarch 9  2023Amsterdam  NetherlandsDave Marver will give a company presentation.Oppenheimer 33rd Annual Healthcare ConferenceMarch 13-15  2023Virtual eventDave Marver or Lara Smith Weber  CFO  will give a company presentation.VFB Happening (Flemish Federation of Investors)March 25  2023Ghent  BelgiumDave Marver will give a company presentation.Information on upcoming conferences is available in the Investor section of the ONWARD website at https://ir.onwd.com/news-events.About ONWARD MedicalONWARD is a medical technology company creating innovative therapies to restore movement  independence  and health in people with spinal cord injuries. ONWARD‚Äôs work builds on more than a decade of basic science and preclinical research conducted at the world‚Äôs leading neuroscience laboratories. ONWARD‚Äôs ARC Therapy  which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems  is designed to deliver targeted  programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury  ultimately improving their quality of life.ONWARD has received five Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external  non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company‚Äôs first pivotal study  called Up-LIFT  evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022.ONWARD is headquartered in Eindhoven  the Netherlands. It maintains a Science and Engineering Center in Lausanne  Switzerland  and has a growing U.S. presence in Boston  Massachusetts. The company has an academic partnership with .NeuroRestore  a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). For additional information about the company  please visit ONWD.com. To access our 2023 Financial Calendar  please visit IR.ONWD.com.For Company Enquiries:info@onwd.comFor Media Enquiries:MC Services AGUS: Laurie Doyle  P: +1 339 832 0752Europe: Dr. Johanna Kobler  Katja Arnold  Kaja Skorka  P: +49 89 210 228 0media@onwd.comFor Investor Enquiries:investors@onwd.comDisclaimerCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company or  as appropriate  the Company directors‚Äô current expectations and projections about future events. By their nature  forward-looking statements involve several risks  uncertainties  and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors  including  but not limited to  changes in demand  competition  and technology  can cause actual events  performance  or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result  the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions  or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person‚Äôs officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.,neutral,0.02,0.97,0.0,negative,0.0,0.16,0.84,True,English,"['Upcoming Events', 'ONWARD', 'Participation', '4th Annual European HealthTech CEO Forum', 'Oppenheimer 33rd Annual Healthcare Conference', 'targeted, programmed spinal cord stimulation', 'Degroof Petercam Healthcare Conference', 'annual IPO educational program', 'five Breakthrough Device Designations', 'growing U.S. presence', 'ONWARD Medical N.V.', 'spinal cord injury', 'spinal cord injuries', 'English Dutch French', 'Lara Smith Weber', 'leading neuroscience laboratories', 'U.S. FDA', 'external, non-invasive platform', 'Positive top-line data', 'first pivotal study', 'upper extremity strength', 'marketing approval submissions', 'Swiss Federal Institute', 'MC Services AG', 'Dr. Johanna Kobler', 'transcutaneous ARC Therapy', 'implantable pulse generator', 'external (ARC-EX) systems', 'Lausanne University Hospital', 'medical technology company', 'MA USA', 'GLOBE NEWSWIRE', 'innovative therapies', 'upcoming weeks', 'Dave Marver', 'keynote address', 'panel discussion', 'NextGen Medtech', 'Virtual event', 'VFB Happening', 'Flemish Federation', 'upcoming conferences', 'Investor section', 'a decade', 'preclinical research', 'other functions', 'wearable stimulator', 'wireless programmer', 'human use', 'Engineering Center', 'academic partnership', '2023 Financial Calendar', 'Media Enquiries', 'Laurie Doyle', 'Katja Arnold', 'Kaja Skorka', 'Investor Enquiries', 'press release', 'financial effects', 'subsidiary undertakings', 'forward-looking statements', 'future accuracy', 'ONWARD website', 'company presentation', 'Company Enquiries', 'following events', 'basic science', 'additional information', 'current expectations', 'several risks', 'actual results', 'actual events', 'past trends', 'BioCapital Europe', 'ARC-IM neurostimulator', 'future events', 'ARC-EX.', 'EINDHOVEN', 'Netherlands', 'Switzerland', 'BOSTON', 'Euronext', 'ONWD', 'movement', 'independence', 'people', 'management', 'January', 'Brussels', 'Belgium', '1:1 meetings', 'TechShare', 'Rotterdam', 'Sachs', 'February', 'Zurich', 'Devices', 'March', 'Amsterdam', 'CFO', 'Investors', 'Ghent', 'news-events', 'work', 'world', 'quality', 'life', 'September', 'ability', 'May', 'Massachusetts', 'NeuroRestore', 'collaboration', 'EPFL', 'CHUV', 'Disclaimer', 'beliefs', 'opinions', 'projections', 'nature', 'uncertainties', 'assumptions', 'outcome', 'plans', 'multitude', 'factors', 'changes', 'demand', 'competition', 'performance', 'development', 'activities', 'representation', 'obligation', 'update', 'revisions', 'conditions', 'circumstances', 'advisers', 'representatives', 'person', 'officers', 'employees', 'errors', 'responsibility']",2023-01-16,2023-01-16,globenewswire.com
16527,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/GROUPE-BRUXELLES-LAMBERT-5953/news/Groupe-Bruxelles-Lambert-Transactions-on-GBL-shares-from-January-9-2023-until-January-13-2023-i-42742905/?utm_medium=RSS&utm_content=20230116,Groupe Bruxelles Lambert : Transactions on GBL shares from January 9  2023 until January 13  2023 (included),(marketscreener.com)   January 16  2023 - After 5:45pm CET   Regulated information   Delivering meaningful growth   Transactions on GBL Shares   Disclosure of transaction on GBL shares from January 9  2023 until January 13  2023    Implementa‚Ä¶,January 16  2023 - After 5:45pm CET Regulated information Delivering meaningful growth Transactions on GBL Shares Disclosure of transaction on GBL shares from January 9  2023 until January 13  2023 (included) Implementation of the authorization of the Extraordinary General Shareholders' Meeting of April 28  2020 Purchases GBL  directly and through its subsidiaries  acquired during the period from January 9  2023 until January 13  2023 included  as part of: The share buyback program: 0 GBL shareThe share buyback program (by an independent financial institution on the basis of a discretionary mandate until March 31  2023): 132 479 GBL shares Number of Average Lowest Highest Amount Trade date price price Negotiation method / market shares price (EUR) (EUR) (EUR) (EUR) Stock Exchange 01/09/2023 26 007 77.52 77.12 78.02 2 016 078 Euronext  CBOE  Turquoise  Acquis Stock Exchange 01/10/2023 28 669 76.77 76.40 77.90 2 200 954 Euronext  CBOE  Turquoise  Acquis Stock Exchange 01/11/2023 25 425 78.02 76.66 78.52 1 983 552 Euronext  CBOE  Turquoise  Acquis Stock Exchange 01/12/2023 29 525 78.45 77.94 78.74 2 316 230 Euronext  CBOE  Turquoise  Acquis Stock Exchange 01/13/2023 22 853 78.84 78.38 79.38 1 801 737 Euronext  CBOE  Turquoise  Acquis Total 132 479 77.89 10 318 549 Regulated information of January 16  2023 // Page 1 / 3 // For more information: www.gbl.beThe liquidity agreement: 51 000 GBL shares Number of Average Lowest Highest Amount Trade date price price Negotiation method / market shares price (EUR) (EUR) (EUR) (EUR) 01/09/2023 11 525 77.50 77.12 78.02 893 145 Stock Exchange Euronext 01/10/2023 11 475 76.77 76.40 77.90 880 979 Stock Exchange Euronext 01/11/2023 8 525 77.53 76.66 78.52 660 953 Stock Exchange Euronext 01/12/2023 14 975 78.44 77.94 78.74 1 174 609 Stock Exchange Euronext 01/13/2023 4 500 78.84 78.38 79.38 354 802 Stock Exchange Euronext Total 51 000 77.74 3 964 488 Sales GBL  directly and through its subsidiaries  sold during the period from January 9  2023 until January 13  2023 included  as part of: The liquidity agreement: 48 750 GBL shares Number of Average Lowest Highest Amount Trade date price price Negotiation method / market shares price (EUR) (EUR) (EUR) (EUR) 01/09/2023 11 500 77.53 77.12 78.02 891 618 Stock Exchange Euronext 01/10/2023 11 500 76.81 76.40 77.90 883 268 Stock Exchange Euronext 01/11/2023 8 500 77.57 76.66 78.52 659 354 Stock Exchange Euronext 01/12/2023 14 750 78.50 77.94 78.74 1 157 903 Stock Exchange Euronext 01/13/2023 2 500 78.85 78.38 79.38 197 135 Stock Exchange Euronext Total 48 750 77.73 3 789 278 As of January 13  2023  GBL holds directly and through its subsidiaries 12 461 039 GBL shares representing 8.1% of the issued capital  and holds 2 250 shares under the liquidity agreement. On that date  66.6% of the fifth share buyback program is executed1. 1 cf. http://www.gbl.be/en/transactions-gbl-shares Regulated information of January 16  2023 // Page 2 / 3 // For more information: www.gbl.be,neutral,0.0,1.0,0.0,neutral,0.04,0.92,0.05,True,English,"['Groupe Bruxelles Lambert', 'GBL shares', 'Transactions', 'January', 'Average Lowest Highest Amount Trade date price price Negotiation method', ""Extraordinary General Shareholders' Meeting"", 'fifth share buyback program', 'market shares price', '197,135 Stock Exchange Euronext Total', 'meaningful growth Transactions', 'independent financial institution', 'Acquis Stock Exchange', '609 Stock Exchange Euronext', '4,802 Stock Exchange Euronext', '1,618 Stock Exchange Euronext', '51,000 GBL shares Number', '132,479 GBL shares', '48,750 GBL shares', '12,461,039 GBL shares', 'discretionary mandate', 'liquidity agreement', '4,488 Sales GBL', 'gbl.be', '52 Euronext', '2,250 shares', 'January', '5:45pm', 'information', 'Disclosure', 'Implementation', 'authorization', 'April', 'subsidiaries', 'period', 'part', 'basis', 'March', 'CBOE', 'Turquoise', 'Page', 'The', 'capital', 'transactions-gbl-shares']",2023-01-16,2023-01-16,marketscreener.com
16528,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/MERLIN-PROPERTIES-SOCIMI-16796079/news/Merlin-Properties-SOCIMI-S-A-Liquidity-contract-December-2022-42740288/?utm_medium=RSS&utm_content=20230116,Merlin Properties SOCIMI S A : - Liquidity contract December 2022,(marketscreener.com)   Lisbon  9 January 2023   Monthly report on the transactions carried out under the liquidity contract    As previously disclosed to the market  MERLIN Properties  SOCIMI  S.A. has executed  on 14 January 2020  a liquidity contrac‚Ä¶,"Lisbon  9 January 2023Monthly report on the transactions carried out under the liquidity contract (December 2022)As previously disclosed to the market  MERLIN Properties  SOCIMI  S.A. (""MERLIN"") has executed  on 14 January 2020  a liquidity contract with JB Capital Markets  Sociedad de Valores  S.A.U. (""JB Capital Markets"")  aiming at favouring the liquidity and regularity of trading of MERLIN's shares in the regulated market of Euronext Lisbon  operated by Euronext Lisbon - Sociedade Gestora de Mercados Regulamentados  S.A. (""Liquidity Contract"") under the regime set forth in the Accepted Market Practice of the Portuguese Securities and Market Commission on liquidity contracts of 10 November 2017 (""Accepted Market Practice"").Within this context  under the terms and for the purposes of the Accepted Market Practice  MERLIN hereby informs that  during the period from 1 December to 31 December 2022  the following transactions on shares representing the share capital of MERLIN have been executed by JB Capital Markets under the Liquidity Contract (aggregated daily information):",neutral,0.0,1.0,0.0,neutral,0.0,1.0,0.0,True,English,"['Merlin Properties SOCIMI S A', 'Liquidity contract', 'Sociedade Gestora de Mercados Regulamentados', 'Sociedad de Valores', 'JB Capital Markets', 'Accepted Market Practice', 'S.A.U.', 'share capital', 'regulated market', 'Market Commission', 'Portuguese Securities', 'daily information', 'liquidity contract', 'Euronext Lisbon', 'following transactions', '9 January', 'report', 'December', 'Properties', 'SOCIMI', 'MERLIN', '14 January', 'regularity', 'trading', 'shares', 'regime', '10 November', 'context', 'terms', 'purposes', 'period']",2023-01-16,2023-01-16,marketscreener.com
16529,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/01/16/2589428/0/en/DEINOVE-Update-on-the-receivership-proceedings.html,DEINOVE - Update on the receivership proceedings,DEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent  global challenge of antibiotic resistance  announces that  in the context of the receivership procee‚Ä¶,English FrenchDEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent  global challenge of antibiotic resistance  announces that  in the context of the receivership proceedings (‚Äúproc√©dure de redressement judiciaire‚Äù) opened on November 7  2022  the Montpellier Commercial Court met on January 13  2023 to examine the case and reserved its decision until January 23  2023.The listing of the Company's shares (ISIN: FR0010879056)  which has been suspended since January 11  2023  will remain suspended.ABOUT DEINOVEDEINOVE is a French biotechnology company pioneering the exploration of a new domain of life  unexplored at 99.9%: the ‚Äúmicrobial dark matter‚Äù. By revealing the metabolic potential of rare bacteria or still classified as uncultivable  it tackles a global health and economic challenge: antimicrobial resistance.The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.This breakthrough approach gave rise to one of the world‚Äôs first specialized micro-biotechnology platforms and a unique collection of nearly 10 000 rare strains and thousands of bacterial extracts. Today  DEINOVE is conducting several development programs  of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infection  one of the world‚Äôs first emergencies. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis.Located at the heart of the Euromedecine park in Montpellier  DEINOVE has been listed on EURONEXT GROWTH¬Æ (ALDEI ‚Äì code ISIN FR0010879056) since 2010. The Company has 45 employees and relies on a network of world-class academic  technological  industrial and institutional partners.CONTACTSInvestorsMario AlcarazChief Financial and Administrative Officer+33 (0)4 48 19 01 00ir@deinove.comMediaATCG Partners+33 (0)9 81 87 46 72communication@deinove.comAttachment,neutral,0.09,0.91,0.01,mixed,0.24,0.15,0.61,True,English,"['receivership proceedings', 'DEINOVE', 'Update', 'proc√©dure de redressement judiciaire', 'Phase II clinical trial', 'severe Clostridioides difficile infection', 'first specialized micro-biotechnology platforms', 'world-class academic, technological, industrial', 'microbial dark matter', 'several development programs', 'low concentrated compounds', 'first antibiotic candidate', 'complex chemical structures', 'Euronext Growth Paris', 'urgent, global challenge', 'Montpellier Commercial Court', 'French biotech company', 'French biotechnology company', 'new bacterial micro-factories', 'first emergencies', 'industrial production', 'EURONEXT GROWTH¬Æ', 'English French', 'antibiotic resistance', 'global health', 'economic challenge', 'chemical synthesis', 'bacterial biodiversity', 'new domain', 'new therapies', 'bacterial extracts', 'The Company', 'receivership proceedings', 'metabolic potential', 'antimicrobial resistance', 'life-threatening infections', 'high speed', 'breakthrough approach', 'unique collection', 'other issue', 'Euromedecine park', 'institutional partners', 'Mario Alcaraz', 'Chief Financial', 'Administrative Officer', 'ATCG Partners', 'rare bacteria', '10,000 rare strains', 'DEINOVE', 'ALDEI', 'pioneer', 'exploration', 'exploitation', 'context', 'November', 'January', 'case', 'decision', 'listing', 'shares', 'superbugs', 'microbes', 'antimicrobials', 'rise', 'thousands', 'race', 'heart', 'code', 'ISIN', '45 employees', 'network', 'CONTACTS', 'Investors', 'Media', 'communication', 'Attachment', '9']",2023-01-16,2023-01-16,globenewswire.com
16530,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/EXOR-N-V-142350737/news/Exor-N-V-Periodic-Report-on-the-Buyback-Program-42739417/?utm_medium=RSS&utm_content=20230116,Exor N.V.: Periodic Report on the Buyback Program,(marketscreener.com)  EXOR N.V. announces that  under the second tranche of the share buyback program of up to ‚Ç¨250 million announced on 29 July 2022   the Company has completed the following transactions on Euronext Amsterdam: Trading DateNumber of ordinary‚Ä¶,EXOR N.V. (AMS: EXO) (‚ÄúExor‚Äù or the ‚ÄúCompany‚Äù) announces that  under the second tranche of the share buyback program of up to ‚Ç¨250 million announced on 29 July 2022 (the ‚Äúsecond tranche‚Äù)  the Company has completed the following transactions on Euronext Amsterdam:Trading Date Number of ordinary shares purchased Average price per share excluding fees (‚Ç¨) Total consideration excluding fees (‚Ç¨) 9 January 2023 41 935 72.7754 3 051 836.40 10 January 2023 37 277 72.6132 2 706 802.26 11 January 2023 31 829 72.6205 2 311 437.89 12 January 2023 42 048 72.7275 3 058 045.92 13 January 2023 27 582 72.2800 1 993 626.96 TOTAL 180 671 13 121 749.43After these purchases  the total invested amount under the second tranche is approximately ‚Ç¨181.8 million for a total amount of 2 676 492 ordinary shares purchased.As of 13 January 2023  the Company held in total 13 464 590 ordinary shares in treasury (5.59% of total ordinary issued share capital).A comprehensive overview of the transactions carried out under the share buyback program  as well as the details of the above transactions  are available on Exor‚Äôs corporate website under the Share Buyback section.Attachment,neutral,0.01,0.99,0.0,neutral,0.0,0.99,0.0,True,English,"['Exor N.V.', 'Periodic Report', 'Buyback Program', 'total ordinary issued share capital', 'share buyback program', 'Share Buyback section', 'EXOR N.V.', 'ordinary shares', 'second tranche', 'Euronext Amsterdam', 'Trading Date', 'Average price', 'Total consideration', 'comprehensive overview', 'corporate website', 'total amount', 'following transactions', 'Company', '29 July', 'Number', 'fees', '9 January', 'purchases', '13 January', 'treasury', 'details', 'Attachment']",2023-01-16,2023-01-16,marketscreener.com
16531,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/DEINOVE-6130009/news/DEINOVE-Update-on-the-receivership-proceedings-42743201/?utm_medium=RSS&utm_content=20230116,DEINOVE - Update on the receivership proceedings,(marketscreener.com) DEINOVE   a French biotech company  pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent  global challenge of antibiotic resistance  announces that  in the context of the receivership proceedings ope‚Ä¶,DEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent  global challenge of antibiotic resistance  announces that  in the context of the receivership proceedings (‚Äúproc√©dure de redressement judiciaire‚Äù) opened on November 7  2022  the Montpellier Commercial Court met on January 13  2023 to examine the case and reserved its decision until January 23  2023.The listing of the Company's shares (ISIN: FR0010879056)  which has been suspended since January 11  2023  will remain suspended.ABOUT DEINOVEDEINOVE is a French biotechnology company pioneering the exploration of a new domain of life  unexplored at 99.9%: the ‚Äúmicrobial dark matter‚Äù. By revealing the metabolic potential of rare bacteria or still classified as uncultivable  it tackles a global health and economic challenge: antimicrobial resistance.The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.This breakthrough approach gave rise to one of the world‚Äôs first specialized micro-biotechnology platforms and a unique collection of nearly 10 000 rare strains and thousands of bacterial extracts. Today  DEINOVE is conducting several development programs  of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infection  one of the world‚Äôs first emergencies. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis.Located at the heart of the Euromedecine park in Montpellier  DEINOVE has been listed on EURONEXT GROWTH¬Æ (ALDEI ‚Äì code ISIN FR0010879056) since 2010. The Company has 45 employees and relies on a network of world-class academic  technological  industrial and institutional partners.CONTACTSInvestorsMario AlcarazChief Financial and Administrative Officer+33 (0)4 48 19 01 00ir@deinove.comMediaATCG Partners+33 (0)9 81 87 46 72communication@deinove.comAttachment,neutral,0.09,0.91,0.01,negative,0.0,0.12,0.88,True,English,"['receivership proceedings', 'DEINOVE', 'Update', 'proc√©dure de redressement judiciaire', 'Phase II clinical trial', 'severe Clostridioides difficile infection', 'first specialized micro-biotechnology platforms', 'world-class academic, technological, industrial', 'microbial dark matter', 'several development programs', 'low concentrated compounds', 'first antibiotic candidate', 'complex chemical structures', 'French biotech company', 'French biotechnology company', 'Euronext Growth Paris', 'urgent, global challenge', 'Montpellier Commercial Court', 'new bacterial micro-factories', 'first emergencies', 'industrial production', 'EURONEXT GROWTH¬Æ', 'antibiotic resistance', 'global health', 'economic challenge', 'chemical synthesis', 'bacterial biodiversity', 'new domain', 'new therapies', 'bacterial extracts', 'The Company', 'receivership proceedings', 'metabolic potential', 'antimicrobial resistance', 'life-threatening infections', 'high speed', 'breakthrough approach', 'unique collection', 'other issue', 'Euromedecine park', 'institutional partners', 'Mario Alcaraz', 'Chief Financial', 'Administrative Officer', 'ATCG Partners', 'rare bacteria', '10,000 rare strains', 'DEINOVE', 'ALDEI', 'pioneer', 'exploration', 'exploitation', 'context', 'November', 'January', 'case', 'decision', 'listing', 'shares', 'superbugs', 'microbes', 'antimicrobials', 'rise', 'thousands', 'race', 'heart', 'code', 'ISIN', '45 employees', 'network', 'CONTACTS', 'Investors', 'Media', 'communication', 'Attachment']",2023-01-16,2023-01-16,marketscreener.com
16532,EuroNext,NewsApi.org,https://fortune.com/recommends/article/what-is-the-new-york-stock-exchange/,What is the New York Stock Exchange?,The New York Stock Exchange (NYSE) is the world‚Äôs largest stock exchange.,This article was originally published on Bankrate.com.The New York Stock Exchange (NYSE) is the world‚Äôs largest stock exchange. It‚Äôs headquartered on 11 Wall Street and 18 Broad Street in New York City and is arguably the world‚Äôs most famous and recognizable stock exchange. Established in 1792  the organization became a publicly-traded company in 2006; from 1971 until 2006  it was a not-for-profit corporation.What is a stock exchange?A stock exchange is where shares of publicly-traded companies are bought and sold. While at one time  the trading floor at the NYSE was one of the busiest ‚Äî imagine scurrying stockbrokers  yelling and hundreds of phones ‚Äî trading action has moved primarily online. That said  the iconic image of someone ringing the opening and closing bells still remains one of the hallmarks of the NYSE.NYSE trading hoursThe core trading session runs from 9:30 a.m. to 4:00 p.m. Eastern time  Monday through Friday. The pre-opening session starts at 6:30 a.m. Eastern.NYSE holidaysThe stock exchange is closed on a number of federal holidays ‚Äî but not all. Here are the NYSE days off:New Year‚Äôs DayMartin Luther King  Jr. DayWashington‚Äôs BirthdayGood FridayMemorial DayJuneteenthIndependence DayLabor DayThanksgiving DayChristmas DayHistory of the New York Stock ExchangeIn New York City on May 17  1792  two dozen stock brokers and merchants signed the ‚ÄúButtonwood Agreement ‚Äù supposedly named for the type of tree under which the earliest transactions took place. The short document outlined the basic rules for trading securities  such as commissions  hours and a non-compete agreement among the brokers. The agreement was in response to the financial panic in March and April of the same year.Trading was informal at first  and took place primarily in nearby coffeehouses. In 1817  however  the organization adopted a constitution and created the New York Stock & Exchange Board. It later adopted the name we know today. In 1865 the New York Stock Exchange moved to Broad Street  where it‚Äôs still partially located  although it has expanded in the interim years.The stock ticker debuted in 1867  and in 1878  telephones were installed on the trading floor. The exchange continued to change and grow  and in 1903 moved into its current building  designed by George B. Post. The Classical Revival building  complete with columns and portico  is a National Historic Landmark and a popular tourist attraction. It was also the first place in North America to be air-conditioned. Computers were first introduced in the 1960s to help process data.While technology and online trading have played major roles in the NYSE for decades  it wasn‚Äôt until the COVID-19 pandemic that the exchange moved purely to electronic trading and operated without a trading floor. It didn‚Äôt last long  however. After closing in March 2020  the floor reopened in late May.Who owns the NYSE?In 2013  Intercontinental Exchange (NYSE: ICE) acquired the NYSE and remains the parent organization. ICE is an American company that was founded in 2000.Over its 200-year existence  the NYSE has acquired and merged with various companies  including the American Stock Exchange.What is the oldest stock exchange?There‚Äôs debate over the origin of the first stock exchange. Some scholars point to the founding of the Dutch East India Company in 1602 as the start of easily transferable shares. By 1680  the public engaged in transactions you‚Äôd recognize today  such as futures and options trading. The company eventually became the Amsterdam Stock Exchange. After a merger with a few other exchanges in 2000  it became Euronext.Another contender is the Frankfurt Stock Exchange  also known as Borse Frankfurt. The exchange claims it was established in 1585. At a city fair that year  merchants met to establish uniform exchange rates. Additionally  the Frankfurt Stock Exchange traces its roots back to medieval fairs in the 11th and 12th centuries that hosted commercial and monetary transactions  eventually leading to Frankfurt becoming a banking and trading hub in the early 1500s.What is the largest stock exchange?The NYSE is the largest equities-based exchange in the world by market capitalization. As of late 2022  Nasdaq and the Shanghai Stock Exchange are the second and third largest  respectively.NYSE vs. NasdaqTo start  Nasdaq is much younger than the NYSE. Founded in 1971  it was the world‚Äôs first electronic stock market. More importantly  Nasdaq doesn‚Äôt have a trading floor  unlike the NYSE. Instead  all trades are electronic and its physical location in Times Square  MarketSite  is a broadcast studio. Nasdaq has lower listing fees and minimum earning requirements than the NYSE  which makes it more accessible to smaller companies. With this comes the potential of hosting more high-growth and volatile stocks than the NYSE.Bottom lineFor now  the NYSE is the largest stock exchange in the world  but that may not last as other exchanges close the gap. Regardless  its influence on the U.S. economy is enormous.,neutral,0.0,1.0,0.0,mixed,0.56,0.16,0.29,True,English,"['New York Stock Exchange', 'The New York Stock Exchange', 'The Classical Revival building', 'Dutch East India Company', 'two dozen stock brokers', 'Labor Day Thanksgiving Day', 'Good Friday Memorial Day', 'first electronic stock market', 'New York City', 'Martin Luther King', 'George B. Post', 'National Historic Landmark', 'popular tourist attraction', 'lower listing fees', 'minimum earning requirements', 'U.S. economy', 'largest stock exchange', 'recognizable stock exchange', 'oldest stock exchange', 'first stock exchange', 'Amsterdam Stock Exchange', 'Shanghai Stock Exchange', 'uniform exchange rates', 'largest equities-based exchange', 'American Stock Exchange', 'Frankfurt Stock Exchange', 'core trading session', 'New Year', 'NYSE trading hours', 'stock ticker', 'electronic trading', 'current building', 'market capitalization', 'The NYSE', 'Jr. Day', 'Independence Day', 'Christmas Day', 'Exchange Board', 'Intercontinental Exchange', 'city fair', 'pre-opening session', 'American company', 'first place', 'Borse Frankfurt', 'trading action', 'trading securities', 'online trading', 'options trading', 'trading hub', 'Bankrate.com', '11 Wall Street', '18 Broad Street', 'profit corporation', 'one time', 'iconic image', 'Eastern time', 'federal holidays', 'short document', 'basic rules', 'financial panic', 'same year', 'nearby coffeehouses', 'interim years', 'North America', 'major roles', 'COVID-19 pandemic', '200-year existence', 'other exchanges', 'medieval fairs', '12th centuries', 'early 1500s', 'physical location', 'Times Square', 'broadcast studio', 'volatile stocks', 'Bottom line', 'trading floor', 'Buttonwood Agreement', 'earliest transactions', 'compete agreement', 'various companies', 'monetary transactions', 'smaller companies', 'transferable shares', 'parent organization', 'NYSE holidays', 'late May', 'article', 'world', 'famous', 'stockbrokers', 'hundreds', 'phones', 'someone', 'closing', 'bells', 'hallmarks', '9:30 a', '6:30 a', 'number', 'Washington', 'Birthday', 'History', 'merchants', 'type', 'commissions', 'response', 'March', 'April', 'constitution', 'name', 'columns', 'portico', 'Computers', '1960s', 'process', 'data', 'technology', 'decades', 'ICE', 'debate', 'origin', 'scholars', 'founding', 'start', 'public', 'futures', 'merger', 'contender', 'roots', '11th', 'commercial', 'banking', 'Nasdaq', 'trades', 'MarketSite', 'potential', 'high-growth', 'gap', 'influence', '4:00']",2023-01-16,2023-01-16,fortune.com
16533,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/HOMIZY-S-P-A-131014705/news/Homizy-loss-as-of-Sept-30-of-nearly-EUR400-000-42743096/?utm_medium=RSS&utm_content=20230116,Homizy  loss as of Sept. 30 of nearly EUR400 000,(marketscreener.com) Homizy Spa on Monday approved its financial statements as of September 30  2022  which closed with a loss of EUR385 951. As for the Homizy Group's consolidated financial statements as of Sept. 30  2022  the company reported a net loss of ‚Ä¶,"(Alliance News) - Homizy Spa on Monday approved its financial statements as of September 30  2022  which closed with a loss of EUR385 951.As for the Homizy Group's consolidated financial statements as of Sept. 30  2022  the company reported a net loss of EUR584 000  a value of production of EUR3.2 million  and a negative EBITT of EUR692 000.The consolidated value of production consists mainly of the increase in fixed assets due to the progress of work on the two properties on Via Tucidide and Via Bistolfi  as specified by the company in a note: ""The group is proceeding with the activities for the realization of the two projects  which  also in light of the new timelines envisaged for the issuance of the relevant authorizations by the competent authorities  will be completed for the commissioning of income during the first half of 2024.""Consolidated EBIT is negatively impacted  by EUR 273 000  by the amortization of the costs of listing the company on the Euronext Growth Pro market. Consolidated shareholders' equity is EUR 13.6 million. Consolidated net financial debt is negative EUR7.3 million  due to proceeds from the IPO raising.In addition  the company has appointed BDO Italy to audit the accounts until the approval of the financial statements ending September 30  2025.Homizy on Monday closed flat at EUR4.40 per share.By Chiara Bruschi  Alliance News reporterComments and questions to redazione@alliancenews.comCopyright 2023 Alliance News IS Italian Service Ltd. All rights reserved.",negative,0.0,0.04,0.96,negative,0.0,0.03,0.97,True,English,"['Homizy', 'loss', 'Sept.', 'Alliance News IS Italian Service Ltd', 'Euronext Growth Pro market', 'Consolidated net financial debt', 'Alliance News reporter', ""Consolidated shareholders' equity"", 'Consolidated EBIT', 'financial statements', 'net loss', 'consolidated value', 'negative EBITT', 'fixed assets', 'two properties', 'Via Tucidide', 'Via Bistolfi', 'two projects', 'new timelines', 'relevant authorizations', 'competent authorities', 'first half', 'IPO raising', 'BDO Italy', 'Chiara Bruschi', 'Homizy Spa', 'Homizy Group', 'Monday', 'September', 'Sept.', 'company', 'production', 'increase', 'progress', 'work', 'note', 'activities', 'realization', 'light', 'issuance', 'commissioning', 'income', 'amortization', 'costs', 'proceeds', 'addition', 'accounts', 'approval', 'Comments', 'questions', 'redazione', 'Copyright', 'rights']",2023-01-16,2023-01-16,marketscreener.com
16534,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/COCA-COLA-EUROPACIFIC-PAR-27862553/news/Coca-Cola-Europacific-Partners-Oferta-P-blica-de-Distribuicao-de-acoes-reservada-a-trabalhadores-d-42740441/?utm_medium=RSS&utm_content=20230116,Coca Cola Europacific Partners : Oferta P√∫blica de Distribui√ß√£o de a√ß√µes reservada a trabalhadores da Coca-Cola Europacific Partners PLC - Resultados da Oferta,(marketscreener.com)   13 January 2023   Coca-Cola Europacific Partners plc   a company incorporated in the UK  registered with nr. 9717350 and with head-office in   Pemberton House  Bakers Road  Uxbridge  United Kingdom  UB8 1EZ   Employee shar‚Ä¶,"13 January 2023Coca-Cola Europacific Partners plca company incorporated in the UK  registered with nr. 9717350 and with head-office inPemberton House  Bakers Road  Uxbridge  United Kingdom  UB8 1EZEmployee share purchase plan (""ESPP"") information document for certain employees of Coca-Cola Europacific Partners plc certain subsidiaries under the ESPP International sub-planResults of the Offer in PortugalPursuant to article 127 of the Portuguese Securities Code and regarding the above offer  the offering results in Portugal between 5 September 2022 and 16 September 2022 were the following and are hereby disclosed:ISIN Code Number of shares Share price (average) Total shares price GB00BDCPN049 534.681995 USD 56.077501 USD 29 983.63Coca-Cola Europacific Partners plc share capital is listed on the NASDAQ  the Euronext Amsterdam  the London Stock Exchange (standard listing)  and the Barcelona  Bilbao  Madrid and Valencia stock exchanges.",neutral,0.0,1.0,0.0,neutral,0.0,1.0,0.0,True,English,"['Coca Cola Europacific Partners', 'Coca-Cola Europacific Partners PLC', 'Oferta P√∫blica', 'Distribui√ß√£o', 'a√ß√µes', 'trabalhadores', 'Resultados', 'Coca-Cola Europacific Partners plc share capital', 'Employee share purchase plan', 'shares Share price', 'ESPP"") information document', 'ESPP International sub-plan', 'Portuguese Securities Code', 'ISIN Code Number', 'Total shares price', 'London Stock Exchange', 'Valencia stock exchanges', 'Pemberton House', 'Bakers Road', 'United Kingdom', 'UB8 1EZ', 'Euronext Amsterdam', 'standard listing', 'offering results', 'January', 'company', 'UK', 'nr', 'head-office', 'Uxbridge', 'employees', 'subsidiaries', 'Portugal', 'article', '5 September', '16 September', 'average', 'NASDAQ', 'Barcelona', 'Bilbao', 'Madrid']",2023-01-16,2023-01-16,marketscreener.com
16535,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/ARGAN-53235/news/ARGAN-has-regained-its-100-occupancy-rate-with-a-major-signing-DISNEYLAND-PARIS-on-26-000-sq-m-in-42742852/?utm_medium=RSS&utm_content=20230116,ARGAN has regained its 100% occupancy rate  with a major signing: DISNEYLAND PARIS on 26 000 sq.m in Ferri√®res-en-Brie (77),(marketscreener.com) Press release ‚Äì16¬†January 2023 ‚Äì 17h45 ARGAN has regained its 100% occupancy rate  with a major signing: DISNEYLAND PARIS on 26 000 sq.m in Ferri√®res-en-Brie Located in Ferri√®res-en-Brie   along the A4 Highway  close to the theme parks an‚Ä¶,Press release ‚Äì16 January 2023 ‚Äì 17h45ARGAN has regained its 100% occupancy rate with a major signing: DISNEYLAND PARIS on 26 000 sq.min Ferri√®res-en-Brie (77)Located in Ferri√®res-en-Brie (77)  along the A4 Highway  close to the theme parks and in the heart of the Marne-la-Vall√©e area  this class A warehouse is rented to DISNEYLAND PARIS under a 10-year long-term lease.Ideally located in front of the A4 highway  the ARGAN logistics park in Ferri√®res-en-Brie consists of two class A sites of 47 000 sq.m and 32 000 sq.m. DISNEYLAND PARIS is leasing four cells of the latter building  i.e. 24 500 sq.m  plus 1 500 sq.m of office space.With more than 375 million visits since 1992 and 16 000 employees  DISNEYLAND PARIS has become Europe's leading tourist destination and a major economic and employment hub  playing an important role in the development of the Val d'Europe region.ARGAN and DISNEYLAND PARIS are mutually committed to a long-term lease of 10 years.With this new high-profile signing  all of ARGAN's platforms are now leased for a total of 3.5 million square meters.This transaction was completed with the support of CBRE's teams.Financial calendar 2023 (Publication of the press release after closing of the stock exchange)19 th January 2023: 2022 Results presentationJanuary 2023: 2022 Results presentation 3rd April 2023: Q1 2023 SalesAbout ARGANARGAN is the only French real estate company specialising in the DEVELOPMENT & RENTAL OF PREMIUM WAREHOUSES listed on EURONEXT.As at 31 December 2022  ARGAN‚Äôs portfolio amounted to 3.5 million sq.m  comprising approximately 100 warehouses located exclusively in France  valued at ‚Ç¨4.0 billion. ARGAN is listed on Compartment A of Euronext Paris (ISIN FR0010481960 - ARG) and is included in the CAC All-Share and IEIF SIIC France indices. The company opted for the listed real estate investment companies (SIICs) tax regime on 01 July 2007.www.ARGAN.frFrancis Albertinelli - Directeur Administratif et FinancierT√©l : 01 47 47 05 46E-mail : contact@ARGAN.frwww.ARGAN.fr Aude Vayre ‚Äì Relations presseT√©l : 06 14 64 15 65E-mail : ARGAN@citigatedewerogerson.comAttachment,neutral,0.0,1.0,0.0,positive,0.95,0.05,0.0,True,English,"['100% occupancy rate', 'major signing', 'DISNEYLAND PARIS', 'ARGAN', '26,000 sq', 'Brie', 'real estate investment companies', 'French real estate company', 'IEIF SIIC France indices', 'two class A sites', 'Marne-la-Vall√©e area', 'leading tourist destination', 'SIICs) tax regime', 'new high-profile signing', '3.5 million square meters', '10-year long-term lease', 'ARGAN logistics park', 'Compartment A', 'major signing', '375 million visits', 'Press release', '100% occupancy rate', 'DISNEYLAND PARIS', 'A4 Highway', 'theme parks', 'Ferri√®res-en-Brie', 'four cells', 'latter building', 'office space', 'major economic', 'employment hub', 'important role', 'Financial calendar', 'stock exchange', '2022 Results presentation', 'CAC All-Share', 'Francis Albertinelli', 'Directeur Administratif', 'T√©l', 'Aude Vayre', 'Relations presse', 'PREMIUM WAREHOUSES', 'Euronext Paris', 'th January', 'ARGAN.fr', '100 warehouses', '26,000 sq', '47,000 sq', '32,000 sq', '1,500 sq', 'heart', 'front', '16,000 employees', 'Europe', 'development', '10 years', 'platforms', 'total', 'transaction', 'support', 'CBRE', 'teams', 'Publication', 'closing', 'April', 'Q1', 'Sales', 'RENTAL', '31 December', 'portfolio', 'ISIN', '01 July', 'Financier', 'mail', 'Attachment', '24,500', '1992']",2023-01-16,2023-01-16,marketscreener.com
16536,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/01/16/2589399/0/en/FL-Entertainment-Weekly-share-transaction.html,FL Entertainment: Weekly share transaction,Press Release  Paris ‚Äì January 16th  2023  Share Transactions Disclosure  FL Entertainment N.V. (894500G73K46H93RF180) declares the following...,Press ReleaseParis ‚Äì January 16th  2023Share Transactions DisclosureFL Entertainment N.V. (894500G73K46H93RF180) declares the following transactions made on its own shares (NL0015000X07) from January 09th to January 13th  2023 in accordance with the authorization given by the shareholder‚Äôs annual meeting on June 30  2022.Trade Date Side Total Daily Volume (Number of Shares) Average Price Amount of Transactions Market Identification Code 2023-01-09 BUY 7 9.000000 63.00 XAMS 2023-01-09 SELL 100 9.100000 910.00 XAMS 2023-01-11 BUY 793 9.081967 7 202.00 XAMS 2023-01-12 BUY 200 8.925000 1 785.00 XAMS 2023-01-13 SELL 152 8.984868 1 365.70 XAMSThe disclosure of all share transactions was made publicly available and can be consulted on the company‚Äôs website (https://fl-entertainment.com/) under the section ¬´Investor Relations¬ª.AgendaFY 2022 results: 16 March 2023Investor RelationsCaroline Cohen ‚Äì Phone: +33 1 44 95 23 34 ‚Äì c.cohen@flentertainment.comPress RelationsAnne-France Malrieu - afmalrieu@image7.frAbout FL EntertainmentFounded by St√©phane Courbit  a 30-year entertainment industry pioneer and entrepreneur  FL Entertainment Group is a global leader in multimedia content and gambling  combining the strengths of Banijay  the world‚Äôs largest independent producer distributor  with Betclic Everest Group  the fastest-growing online sports betting platform in Europe. In 2021  FL Entertainment recorded through Banijay and Betclic Everest Group  a combined revenue  and adjusted EBITDA  of ‚Ç¨3.5bn and ‚Ç¨609m respectively. FL Entertainment listed on Euronext Amsterdam in July 2022.ISIN: NL0015000X07 - Bloomberg: FLE NA - Reuters: FLE.ASAttachment,neutral,0.04,0.96,0.0,neutral,0.02,0.98,0.0,True,English,"['FL Entertainment', 'transaction', 'Trade Date Side Total Daily Volume', 'growing online sports betting platform', 'largest independent producer distributor', 'Transactions Market Identification Code', '30-year entertainment industry pioneer', 'FL Entertainment N.V.', 'Average Price Amount', 'St√©phane Courbit', 'Betclic Everest Group', 'FLE.AS Attachment', 'FL Entertainment Group', 'Share Transactions Disclosure', 'following transactions', 'FLE NA', 'Press Release', 'annual meeting', 'Investor Relations', 'FY 2022 results', 'Press Relations', 'Anne-France Malrieu', 'global leader', 'multimedia content', 'combined revenue', 'adjusted EBITDA', 'Euronext Amsterdam', 'Caroline Cohen', 'Paris', 'January', 'shares', 'accordance', 'authorization', 'shareholder', 'June', 'Number', 'BUY', 'XAMS', 'SELL', 'company', 'website', 'section', 'Agenda', '16 March', 'Phone', 'image', 'strengths', 'Banijay', 'world', 'Europe', 'July', 'ISIN', 'Bloomberg', 'Reuters']",2023-01-16,2023-01-16,globenewswire.com
16537,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/01/16/2589384/0/en/ARGAN-has-regained-its-100-occupancy-rate-with-a-major-signing-DISNEYLAND-PARIS-on-26-000-sq-m-in-Ferri%C3%A8res-en-Brie-77.html,ARGAN has regained its 100% occupancy rate  with a major signing: DISNEYLAND PARIS on 26 000 sq.m in Ferri√®res-en-Brie (77),Press release ‚Äì16¬†January 2023 ‚Äì 17h45  ARGAN has regained its 100% occupancy rate  with a major signing: DISNEYLAND PARIS on 26 000 sq.m in......,French EnglishPress release ‚Äì16 January 2023 ‚Äì 17h45ARGAN has regained its 100% occupancy rate with a major signing: DISNEYLAND PARIS on 26 000 sq.min Ferri√®res-en-Brie (77)Located in Ferri√®res-en-Brie (77)  along the A4 Highway  close to the theme parks and in the heart of the Marne-la-Vall√©e area  this class A warehouse is rented to DISNEYLAND PARIS under a 10-year long-term lease.Ideally located in front of the A4 highway  the ARGAN logistics park in Ferri√®res-en-Brie consists of two class A sites of 47 000 sq.m and 32 000 sq.m. DISNEYLAND PARIS is leasing four cells of the latter building  i.e. 24 500 sq.m  plus 1 500 sq.m of office space.With more than 375 million visits since 1992 and 16 000 employees  DISNEYLAND PARIS has become Europe's leading tourist destination and a major economic and employment hub  playing an important role in the development of the Val d'Europe region.ARGAN and DISNEYLAND PARIS are mutually committed to a long-term lease of 10 years.With this new high-profile signing  all of ARGAN's platforms are now leased for a total of 3.5 million square meters.This transaction was completed with the support of CBRE's teams.Financial calendar 2023 (Publication of the press release after closing of the stock exchange)19 th January 2023: 2022 Results presentationJanuary 2023: 2022 Results presentation 3rd April 2023: Q1 2023 SalesAbout ARGANARGAN is the only French real estate company specialising in the DEVELOPMENT & RENTAL OF PREMIUM WAREHOUSES listed on EURONEXT.As at 31 December 2022  ARGAN‚Äôs portfolio amounted to 3.5 million sq.m  comprising approximately 100 warehouses located exclusively in France  valued at ‚Ç¨4.0 billion. ARGAN is listed on Compartment A of Euronext Paris (ISIN FR0010481960 - ARG) and is included in the CAC All-Share and IEIF SIIC France indices. The company opted for the listed real estate investment companies (SIICs) tax regime on 01 July 2007.www.ARGAN.frFrancis Albertinelli - Directeur Administratif et FinancierT√©l : 01 47 47 05 46E-mail : contact@ARGAN.frwww.ARGAN.fr Aude Vayre ‚Äì Relations presseT√©l : 06 14 64 15 65E-mail : ARGAN@citigatedewerogerson.comAttachment,neutral,0.0,1.0,0.0,positive,0.7,0.29,0.01,True,English,"['100% occupancy rate', 'major signing', 'DISNEYLAND PARIS', 'ARGAN', '26,000 sq', 'Brie', 'real estate investment companies', 'IEIF SIIC France indices', 'two class A sites', 'French real estate company', 'Marne-la-Vall√©e area', 'leading tourist destination', 'SIICs) tax regime', 'new high-profile signing', '3.5 million square meters', '10-year long-term lease', 'ARGAN logistics park', 'French English', 'Compartment A', 'major signing', '375 million visits', 'Press release', '100% occupancy rate', 'DISNEYLAND PARIS', 'A4 Highway', 'theme parks', 'Ferri√®res-en-Brie', 'four cells', 'latter building', 'office space', 'major economic', 'employment hub', 'important role', 'Financial calendar', 'stock exchange', '2022 Results presentation', 'CAC All-Share', 'Francis Albertinelli', 'Directeur Administratif', 'T√©l', 'Aude Vayre', 'Relations presse', 'Europe region', 'PREMIUM WAREHOUSES', 'Euronext Paris', '19 th January', '100 warehouses', '26,000 sq', '47,000 sq', '32,000 sq', '1,500 sq', 'heart', 'front', '16,000 employees', 'development', '10 years', 'platforms', 'total', 'transaction', 'support', 'CBRE', 'teams', 'Publication', 'closing', 'April', 'Q1', 'Sales', 'RENTAL', '31 December', 'portfolio', 'ISIN', '01 July', 'Financier', 'mail', 'Attachment', '24,500', '1992']",2023-01-16,2023-01-16,globenewswire.com
16538,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/PORTOBELLO-S-P-A-44954066/news/Portobello-S-p-A-BECOMES-THE-ITALIAN-NET-ZERO-RETAIL-CHAIN-42739692/?utm_medium=RSS&utm_content=20230116,Portobello S p A : BECOMES THE ITALIAN NET ZERO RETAIL CHAIN,(marketscreener.com)   PRESS RELEASE   PORTOBELLO BECOMES THE ITALIAN NET ZERO RETAIL CHAIN   Partnership strengthened with Forever Bamb√π to offset 600 tons of CO2 per year   with bamboo forests entirely in Italy   Rome  16 January 2023   Por‚Ä¶,"PRESS RELEASEPORTOBELLO BECOMES THE ITALIAN NET ZERO RETAIL CHAINPartnership strengthened with Forever Bamb√π to offset 600 tons of CO2 per yearwith bamboo forests entirely in ItalyRome  16 January 2023Portobello S.p.A. (""Portobello"" or the ""Company"")  holding company listed on the Euronext Growth Milan which operates through bartering in the publishing and advertising sector and owns the homonymous retail chain and the ePrice portal  announces that it has strengthened its commitment to environmental sustainability through the Forever Zero CO2 project  the carbon offset program of Forever Bamb√π  a leader in the planting of giant bamboo with biodynamic and symbiotic agriculture  for industrial  food and energy purposes.Thanks to this ambitious project  Portobello has offset the polluting emissions of the entire retail chain  31 stores open to date  through the absorption of approximately 600 tons of CO2 per year. In 2022 approximately 23 000 sqm of bamboo forest have already been planted in Civitella Paganico (GR) and this year the Company will arrange a further 23 700 sqm  of which 16 600 sqm in Civitella Paganico and 7 100 sqm in Portomaggiore (FE) to compensate a total of 1 200 tons of CO2 per year  corresponding to 24 000 tons of CO2 by 2043.Pietro Peligra  Chairman of Portobello  explains: ""Sustainable development today is no longer a choice but a duty that must be promoted through concrete  effective and measurable actions. Thanks to the partnership with Forever Bamb√π we have offset the CO2 emissions of all Portobello stores  through the planting of giant bamboo entirely in Italy. Our commitment will continue in the future by offsetting all the stores that we open every year in order to proudly continue to be the zero impact Italian chain!""""Forever Bamb√π is pleased to continue with Portobello the important path undertaken in 2022 for the zeroing of their carbon footprint. To all intents and purposes  Portobello represents Italian excellence as a low-impact distribution chain. I am sure that the decision to integrate a twenty-year sustainability project like Forever Zero CO2 into the business plan will be rewarded by consumers  who are increasingly attentive to green issues""  comments Emanuele Rissone  Forever Bamb√π President and Founder.Portobello's carbon neutrality  the result of an accurate scientific study by Forever Bamb√π technicians  is related to all the Company's stores open to date. The program was born from the desire to implement the company's carbon offset parallel to the increase in number of the stores on the national territory foreseen by the Industrial Plan. A bamboo forest - thanks to Forever Bamb√π's exclusive method of cultivation  management and pruning - can absorb up to 265 tons of CO2 per year  36 times more than a mixed forest under the same conditions.To find out more about the project: www.foreverzeroco2.it",neutral,0.0,0.99,0.0,positive,0.64,0.35,0.01,True,English,"['NET ZERO RETAIL CHAIN', 'Portobello S', 'NET ZERO RETAIL CHAIN', 'zero impact Italian chain', 'Portobello S.p.A.', 'Forever Zero CO2 project', 'homonymous retail chain', 'entire retail chain', 'low-impact distribution chain', 'Euronext Growth Milan', 'accurate scientific study', 'twenty-year sustainability project', 'Forever Bamb√π President', 'Forever Bamb√π technicians', 'carbon offset program', 'Italian excellence', 'environmental sustainability', 'ambitious project', 'carbon footprint', 'carbon neutrality', 'PRESS RELEASE', 'bamboo forests', 'advertising sector', 'ePrice portal', 'giant bamboo', 'symbiotic agriculture', 'industrial, food', 'polluting emissions', 'Civitella Paganico', 'Pietro Peligra', 'Sustainable development', 'concrete, effective', 'measurable actions', 'important path', 'business plan', 'green issues', 'Emanuele Rissone', 'national territory', 'Industrial Plan', 'exclusive method', 'mixed forest', 'same conditions', 'CO2 emissions', 'energy purposes', 'holding company', 'Portobello stores', '31 stores', 'Partnership', '600 tons', 'Italy', 'Rome', 'January', 'bartering', 'publishing', 'commitment', 'leader', 'planting', 'biodynamic', 'date', '23,000 sqm', '23,700 sqm', '16,600 sqm', '7,100 sqm', 'Portomaggiore', 'total', '1,200 tons', '24,000 tons', 'Chairman', 'choice', 'duty', 'future', 'order', 'zeroing', 'intents', 'decision', 'consumers', 'Founder', 'result', 'desire', 'increase', 'number', 'cultivation', 'management', 'pruning', '265 tons']",2023-01-16,2023-01-16,marketscreener.com
16539,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/ONWARD-MEDICAL-N-V-128192407/news/ONWARD-Announces-Participation-at-Upcoming-Events-42739163/?utm_medium=RSS&utm_content=20230116,ONWARD Announces Participation at Upcoming Events,(marketscreener.com) EINDHOVEN  the Netherlands  LAUSANNE  Switzerland  and BOSTON  MA USA  Jan. 16  2023 -- ONWARD Medical N.V.   the medical technology company creating innovative therapies to restore movement  independence  and health in people with spinal‚Ä¶,EINDHOVEN  the Netherlands  LAUSANNE  Switzerland  and BOSTON  MA USA  Jan. 16  2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD)  the medical technology company creating innovative therapies to restore movement  independence  and health in people with spinal cord injury  today announced that management will participate in the following events in the upcoming weeks:Degroof Petercam Healthcare ConferenceJanuary 26  2023Brussels  BelgiumDave Marver  CEO  will participate in 1:1 meetings.TechShare by EuronextJanuary 27  2023Rotterdam  NetherlandsDave Marver will deliver the keynote address at the annual IPO educational program organized by Euronext.Sachs 4th Annual European HealthTech CEO ForumFebruary 28  2023Zurich  SwitzerlandDave Marver will participate in the panel discussion  ‚ÄúNextGen Medtech & Devices‚Äù.BioCapital EuropeMarch 9  2023Amsterdam  NetherlandsDave Marver will give a company presentation.Oppenheimer 33rd Annual Healthcare ConferenceMarch 13-15  2023Virtual eventDave Marver or Lara Smith Weber  CFO  will give a company presentation.VFB Happening (Flemish Federation of Investors)March 25  2023Ghent  BelgiumDave Marver will give a company presentation.Information on upcoming conferences is available in the Investor section of the ONWARD website at https://ir.onwd.com/news-events.About ONWARD MedicalONWARD is a medical technology company creating innovative therapies to restore movement  independence  and health in people with spinal cord injuries. ONWARD‚Äôs work builds on more than a decade of basic science and preclinical research conducted at the world‚Äôs leading neuroscience laboratories. ONWARD‚Äôs ARC Therapy  which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems  is designed to deliver targeted  programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury  ultimately improving their quality of life.ONWARD has received five Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external  non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company‚Äôs first pivotal study  called Up-LIFT  evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022.ONWARD is headquartered in Eindhoven  the Netherlands. It maintains a Science and Engineering Center in Lausanne  Switzerland  and has a growing U.S. presence in Boston  Massachusetts. The company has an academic partnership with .NeuroRestore  a collaboration between the Swiss Federal Institute of Technology (EPFL) and Lausanne University Hospital (CHUV). For additional information about the company  please visit ONWD.com. To access our 2023 Financial Calendar  please visit IR.ONWD.com.For Company Enquiries:info@onwd.comFor Media Enquiries:MC Services AGUS: Laurie Doyle  P: +1 339 832 0752Europe: Dr. Johanna Kobler  Katja Arnold  Kaja Skorka  P: +49 89 210 228 0media@onwd.comFor Investor Enquiries:investors@onwd.comDisclaimerCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company or  as appropriate  the Company directors‚Äô current expectations and projections about future events. By their nature  forward-looking statements involve several risks  uncertainties  and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors  including  but not limited to  changes in demand  competition  and technology  can cause actual events  performance  or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result  the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions  or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person‚Äôs officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.,neutral,0.02,0.97,0.0,negative,0.0,0.09,0.91,True,English,"['Upcoming Events', 'ONWARD', 'Participation', '4th Annual European HealthTech CEO Forum', 'Oppenheimer 33rd Annual Healthcare Conference', 'targeted, programmed spinal cord stimulation', 'Degroof Petercam Healthcare Conference', 'annual IPO educational program', 'five Breakthrough Device Designations', 'MC Services AG US', 'growing U.S. presence', 'ONWARD Medical N.V.', 'spinal cord injury', 'spinal cord injuries', 'Lara Smith Weber', 'leading neuroscience laboratories', 'U.S. FDA', 'external, non-invasive platform', 'Positive top-line data', 'first pivotal study', 'upper extremity strength', 'marketing approval submissions', 'Swiss Federal Institute', 'Dr. Johanna Kobler', 'transcutaneous ARC Therapy', 'implantable pulse generator', 'external (ARC-EX) systems', 'Lausanne University Hospital', 'medical technology company', 'MA USA', 'GLOBE NEWSWIRE', 'innovative therapies', 'upcoming weeks', 'Dave Marver', 'keynote address', 'panel discussion', 'NextGen Medtech', 'Virtual event', 'VFB Happening', 'Flemish Federation', 'upcoming conferences', 'Investor section', 'a decade', 'preclinical research', 'other functions', 'wearable stimulator', 'wireless programmer', 'human use', 'Engineering Center', 'academic partnership', '2023 Financial Calendar', 'Media Enquiries', 'Laurie Doyle', 'Katja Arnold', 'Kaja Skorka', 'Investor Enquiries', 'press release', 'financial effects', 'subsidiary undertakings', 'forward-looking statements', 'future accuracy', 'ONWARD website', 'company presentation', 'Company Enquiries', 'following events', 'basic science', 'additional information', 'current expectations', 'several risks', 'actual results', 'actual events', 'past trends', 'BioCapital Europe', 'ARC-IM neurostimulator', 'future events', 'ARC-EX.', 'EINDHOVEN', 'Netherlands', 'Switzerland', 'BOSTON', 'Jan', 'Euronext', 'ONWD', 'movement', 'independence', 'people', 'management', 'Brussels', 'Belgium', '1:1 meetings', 'TechShare', 'Rotterdam', 'Sachs', 'February', 'Zurich', 'Devices', 'March', 'Amsterdam', 'CFO', 'Investors', 'Ghent', 'work', 'world', 'quality', 'life', 'September', 'ability', 'May', 'Massachusetts', 'NeuroRestore', 'collaboration', 'EPFL', 'CHUV', 'Disclaimer', 'beliefs', 'opinions', 'projections', 'nature', 'uncertainties', 'assumptions', 'outcome', 'plans', 'multitude', 'factors', 'changes', 'demand', 'competition', 'performance', 'development', 'activities', 'representation', 'obligation', 'update', 'revisions', 'conditions', 'circumstances', 'advisers', 'representatives', 'person', 'officers', 'employees', 'errors', 'responsibility']",2023-01-16,2023-01-16,marketscreener.com
16540,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/SOCIETE-GENERALE-4702/news/Societe-Generale-Information-regarding-executed-transactions-within-the-framework-of-a-share-buybac-42742830/?utm_medium=RSS&utm_content=20230116,Societe Generale: Information regarding executed transactions within the framework of a share buyback program (outside the liquidity agreement),(marketscreener.com) INFORMATION REGARDING EXECUTED TRANSACTIONS WITHIN THE FRAMEWORK OF A SHARE BUYBACK PROGRAM Regulated Information Paris  16th January 2023 No 596/2014 on Market Abuse Regulation and Article 3 of Delegated Regulation 2016/1052 supplementin‚Ä¶,INFORMATION REGARDING EXECUTED TRANSACTIONS WITHIN THE FRAMEWORK OF A SHARE BUYBACK PROGRAM (OUTSIDE THE LIQUIDITY AGREEMENT)Regulated InformationParis  16th January 2023(In accordance with Article 5 of Regulation (EU) No 596/2014 on Market Abuse Regulation and Article 3(3) of Delegated Regulation (EU) 2016/1052 supplementing Regulation (EU) No 596/2014 through regulatory technical standards concerning the conditions applicable to buyback programs and stabilization measures)Societe Generale launched  on 16 December 2022  an additional share buyback program of 2 707 207 Societe Generale shares in order to cover and honor the free shares allocation for the benefit of employees and Group executive directors.Societe Generale received all necessary authorizations from supervisory authorities. These buybacks will be carried out in compliance with the authorizations provided by the General Meeting of 17th May 2022  in particular regarding the maximum price  as well as in accordance with the Market Abuse Regulation. They will be performed on the trading platforms on which Societe Generale shares are listed for trading or are traded  including the regulated market of Euronext Paris.The liquidity contract concluded with Rothschild has also temporarily been suspended throughout the buyback period.Issuer name: Societe Generale - LEI O2RNE8IBXP4R0TD8PU41Reference of the financial instrument: ISIN FR0000130809Period: From 09 to 13 January 2023Purchases performed by Societe Generale during the periodAggregated presentation by day and marketIssuer name Issuer code (LEI) Transaction date ISIN Code Daily total volume (in number of shares) Daily weighted average price of shares acquired Platform SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41 09/01/2023 FR0000130809 71 000 25 2045 XPAR SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41 10/01/2023 FR0000130809 81 136 24 6398 XPAR SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41 10/01/2023 FR0000130809 61 182 24 5461 CEUX SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41 10/01/2023 FR0000130809 25 682 24 4865 TQEX SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41 11/01/2023 FR0000130809 91 000 24 2212 XPAR SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41 11/01/2023 FR0000130809 60 000 24 1945 CEUX SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41 11/01/2023 FR0000130809 20 000 24 2127 TQEX SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41 12/01/2023 FR0000130809 3 900 24 3197 XPAR SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41 13/01/2023 FR0000130809 62 117 24 3736 XPAR TOTAL 476 017 24 5122Detailed presentation by transactionThe detailed presentation by transaction is available within the Chapter 6 Description of the buyback programs  reports on share buyback and statements on the liquidity agreement:Regulated Information - Societe Generale (societegenerale.com)Press contact:Jean-Baptiste Froville_+33 1 58 98 68 00_ jean-baptiste.froville@socgen.comFanny Rouby_+33 1 57 29 11 12_ fanny.rouby@socgen.comSociete GeneraleSociete Generale is one of the leading European financial services groups. Based on a diversified and integrated banking model  the Group combines financial strength and proven expertise in innovation with a strategy of sustainable growth. Committed to the positive transformations of the world‚Äôs societies and economies  Societe Generale and its teams seek to build  day after day  together with its clients  a better and sustainable future through responsible and innovative financial solutions.Active in the real economy for over 150 years  with a solid position in Europe and connected to the rest of the world  Societe Generale has over 117 000 members of staff in 66 countries and supports on a daily basis 25 million individual clients  businesses and institutional investors around the world by offering a wide range of advisory services and tailored financial solutions. The Group is built on three complementary core businesses:French Retail Banking with the SG bank  resulting from the merger of the two Societe Generale and Cr√©dit du Nord networks  and Boursorama. Each offers a full range of financial services with omnichannel products at the cutting edge of digital innovation;International Retail Banking  Insurance and Financial Services  with networks in Africa  Central and Eastern Europe and specialised businesses that are leaders in their markets;with networks in Africa  Central and Eastern Europe and specialised businesses that are leaders in their markets; Global Banking and Investor Solutions  which offers recognised expertise  key international locations and integrated solutions.Societe Generale is included in the principal socially responsible investment indices: DJSI (Europe)  FTSE4Good (Global and Europe)  Bloomberg Gender-Equality Index  Refinitiv Diversity and Inclusion Index  Euronext Vigeo (Europe and Eurozone)  STOXX Global ESG Leaders indexes  and the MSCI Low Carbon Leaders Index (World and Europe).In case of doubt regarding the authenticity of this press release  please go to the end of Societe Generale‚Äôs newsroom page where official Press Releases sent by Societe Generale can be certified using blockchain technology. A link will allow you to check the document‚Äôs legitimacy directly on the web page.For more information  you can follow us on Twitter @societegenerale or visit our website societegenerale.com.Attachment,neutral,0.0,1.0,0.0,negative,0.01,0.27,0.72,True,English,"['share buyback program', 'Societe Generale', 'liquidity agreement', 'Information', 'transactions', 'framework', 'Cr√©dit du Nord networks', 'MSCI Low Carbon Leaders Index', 'leading European financial services groups', 'three complementary core businesses', 'Daily weighted average price', 'Platform SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41', 'CEUX SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41', 'TQEX SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41', 'XPAR SOCIETE GENERALE O2RNE8IBXP4R0TD8PU41', 'Global ESG Leaders indexes', 'additional share buyback program', 'Issuer name Issuer code', 'Bloomberg Gender-Equality Index', 'regulatory technical standards', 'key international locations', 'French Retail Banking', 'two Societe Generale', 'International Retail Banking', 'Daily total volume', 'official Press Releases', 'integrated banking model', 'innovative financial solutions', 'tailored financial solutions', 'free shares allocation', 'Group executive directors', '25 million individual clients', 'responsible investment indices', '2,707,207 Societe Generale shares', 'Market Abuse Regulation', 'XPAR TOTAL', 'Inclusion Index', 'LEI O2RNE8IBXP4R0TD8PU41', 'Global Banking', 'maximum price', 'daily basis', 'integrated solutions', 'advisory services', 'financial instrument', 'financial strength', 'buyback programs', 'ISIN Code', 'Investor Solutions', 'Press contact', 'specialised businesses', 'Delegated Regulation', 'supplementing Regulation', 'EXECUTED TRANSACTIONS', 'LIQUIDITY AGREEMENT', 'stabilization measures', 'supervisory authorities', 'General Meeting', '17th May', 'liquidity contract', 'proven expertise', 'sustainable growth', 'positive transformations', 'sustainable future', 'real economy', 'solid position', 'institutional investors', 'wide range', 'SG bank', 'full range', 'omnichannel products', 'cutting edge', 'recognised expertise', 'Refinitiv Diversity', 'Euronext Vigeo', 'newsroom page', 'buyback period', 'Regulated Information', 'Detailed presentation', 'necessary authorizations', 'trading platforms', 'Euronext Paris', 'Jean-Baptiste Froville', 'Fanny Rouby', 'digital innovation', 'Transaction date', 'The Group', 'Eastern Europe', 'FRAMEWORK', '16th', 'Article', 'conditions', '16 December', 'order', 'benefit', 'employees', 'buybacks', 'compliance', 'accordance', 'Rothschild', 'Reference', '13 January', 'Purchases', 'day', 'number', 'Chapter', 'Description', 'reports', 'statements', 'socgen', 'diversified', 'strategy', 'world', 'societies', 'economies', 'teams', '150 years', 'rest', '117,000 members', 'staff', '66 countries', 'merger', 'Boursorama', 'Insurance', 'Africa', 'Central', 'markets', 'DJSI', 'FTSE4Good', 'Eurozone', 'case', 'doubt', 'authenticity', 'blockch', '09']",2023-01-16,2023-01-16,marketscreener.com
16541,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/ARGENX-SE-16911676/news/argenx-Announces-Extraordinary-General-Meeting-of-Shareholders-on-February-27-2023-to-Appoint-Steve-42743268/?utm_medium=RSS&utm_content=20230116,argenx Announces Extraordinary General Meeting of Shareholders on February 27  2023 to Appoint Steve Krognes as Non-Executive Director,(marketscreener.com) January 16  2023 Amsterdam  the Netherlands ‚Äì argenx SE   a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases  today announced an extraordinary general meeting of shareholders w‚Ä¶,January 16  2023Amsterdam  the Netherlands ‚Äì argenx SE (Euronext & Nasdaq: ARGX)  a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases  today announced an extraordinary general meeting of shareholders will be held at 12:00 PM CET on Monday  February 27  2023 at the Hilton Amsterdam Schiphol at Schiphol Boulevard 701  1118 BN Schiphol  the Netherlands.The shareholders and all other persons with meeting rights are invited to attend the extraordinary general meeting of shareholders. The formal notice of convocation (including information on attending the meeting in person or by proxy  requirements for notification and registration for the meeting and regarding the e-voting system) is available on the argenx website www.argenx.com and on www.abnamro.com/evoting.AgendaThe sole voting item on the agenda will be the proposed appointment of Mr. Steve Krognes as non-executive director and Chair of the Audit and Compliance Committee of the Company‚Äôs Board of Directors.The full agenda for the meeting  as well as all ancillary documents relevant for the meeting are available via the argenx website and are also available for inspection at the argenx offices. A free copy thereof may also be obtained by e-mailing legal@argenx.com. argenx would like to encourage shareholders to use the voting by (electronic) proxy option as referred to in the convocation.Resignation Werner LanthalerUpon appointment of Mr. Krognes  Werner Lanthaler will resign as non-executive director of the Board and Chair of the Audit and Compliance Committee to enable this important step in the long term succession planning for the board of directors and the audit and compliance committee chairperson role. The Company would like to express its gratitude towards Werner Lanthaler for his substantial contributions over the last eight years. Werner's entrepreneurial nature combined with broad experience in finance  executive leadership  and life sciences has helped guide argenx from a research-focused company to a fully integrated commercial-stage global immunology company.About argenxargenx is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases. Partnering with leading academic researchers through its Immunology Innovation Program (IIP)  argenx aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx developed and is commercializing the first-and-only approved neonatal Fc receptor (FcRn) blocker in the U.S.  Japan  and the EU. The Company is evaluating efgartigimod in multiple serious autoimmune diseases and advancing several earlier stage experimental medicines within its therapeutic franchises. For more information  visit www.argenx.com and follow us on LinkedIn  Twitter  and Instagram.For further information  please contact:Media:Kelsey Kirkkkirk@argenx.comInvestors:Beth DelGiaccobdelgiacco@argenx.com,neutral,0.0,1.0,0.0,mixed,0.66,0.09,0.26,True,English,"['Extraordinary General Meeting', 'Steve Krognes', 'Non-Executive Director', 'argenx', 'Shareholders', 'February', 'several earlier stage experimental medicines', 'long term succession planning', 'multiple serious autoimmune diseases', 'compliance committee chairperson role', 'commercial-stage global immunology company', 'novel antibody-based medicines', 'severe autoimmune diseases', 'last eight years', 'leading academic researchers', 'Immunology Innovation Program', 'neonatal Fc receptor', 'sole voting item', 'Mr. Steve Krognes', 'electronic) proxy option', 'extraordinary general meeting', 'Hilton Amsterdam Schiphol', 'Mr. Krognes', 'immunology breakthroughs', 'The Company', 'research-focused company', 'Schiphol Boulevard', 'BN Schiphol', 'other persons', 'formal notice', 'voting system', 'non-executive director', 'ancillary documents', 'free copy', 'important step', 'substantial contributions', 'broad experience', 'executive leadership', 'life sciences', 'world-class portfolio', 'FcRn) blocker', 'U.S.', 'therapeutic franchises', 'Kelsey Kirk', 'Beth DelGiacco', 'Werner Lanthaler', 'meeting rights', 'full agenda', 'argenx SE', 'argenx website', 'argenx offices', 'January', 'Netherlands', 'Euronext', 'Nasdaq', 'ARGX', 'lives', 'people', 'shareholders', 'Monday', 'February', 'convocation', 'information', 'requirements', 'notification', 'registration', 'abnamro', 'appointment', 'Audit', 'Board', 'Directors', 'inspection', 'Resignation', 'gratitude', 'nature', 'finance', 'integrated', 'IIP', 'Japan', 'efgartigimod', 'LinkedIn', 'Twitter', 'Instagram', 'Media', 'Investors', 'bdelgiacco', '12:00']",2023-01-16,2023-01-16,marketscreener.com
16542,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/FERRARI-N-V-25600249/news/Ferrari-N-v-Periodic-Report-on-the-Buyback-Program-42742642/?utm_medium=RSS&utm_content=20230116,Ferrari N.v.: Periodic Report on the Buyback Program,(marketscreener.com) Maranello   January 16  2023 ‚Äì Ferrari N.V. informs that the Company has purchased  under the Euro 200 million share buyback program announced on December 1  2022  as the second tranche of the multi-year share buyback program of approxima‚Ä¶,Maranello (Italy)  January 16  2023 ‚Äì Ferrari N.V. (NYSE/EXM: RACE) (‚ÄúFerrari‚Äù or the ‚ÄúCompany‚Äù) informs that the Company has purchased  under the Euro 200 million share buyback program announced on December 1  2022  as the second tranche of the multi-year share buyback program of approximately Euro 2 billion expected to be executed by 2026 in line with the disclosure made during the 2022 Capital Markets Day (the ‚ÄúSecond Tranche‚Äù)  the additional common shares - reported in aggregate form  on a daily basis - on the Euronext Milan (EXM) as follows:TradingDate(dd/mm/yyyy)Stock ExchangeNumber of common shares purchasedAverage price per shareexcluding fees(‚Ç¨)Consideration excluding fees(‚Ç¨)09/01/2023 EXM 5 200 214.6976 1 116 427.52 10/01/2023 EXM 5 150 214.6407 1 105 399.61 11/01/2023 EXM 5 120 215.9513 1 105 670.66 12/01/2023 EXM 5 100 217.3482 1 108 475.82 13/01/2023 EXM 5 090 217.4830 1 106 988.47Total- 25 660 216.0157 5 542 962.07(*) translated at the European Central Bank EUR/USD exchange reference rate as of the date of each purchaseSince the announcement of such Second Tranche till January 13  2023  the total invested consideration has been:Euro 34 880 796.71 for No. 166 708 common shares purchased on the EXMUSD 8 757 853.08 (Euro 8 271 632.62*) for No. 40 049 common shares purchased on the NYSE.As of January 13  2023  the Company held in treasury No. 12 034 386 common shares equal to 4.68% of the total issued share capital including the common shares and the special voting shares  net of shares assigned under the Company‚Äôs equity incentive plan.Since July 1  2022 until January 13  2023  the Company has purchased a total of 980 494 own common shares on EXM and NYSE  including transactions for Sell to Cover  for a total consideration of Euro 193 878 109.04.A comprehensive overview of the transactions carried out under the buyback program  as well as the details of the above transactions  are available on Ferrari‚Äôs corporate website under the Buyback Programs section ( https://www.ferrari.com/en-EN/corporate/buyback-programs ).Attachment,neutral,0.0,1.0,0.0,neutral,0.02,0.97,0.02,True,English,"['Ferrari N.v.', 'Periodic Report', 'Buyback Program', 'EUR/USD exchange reference rate', '200 million share buyback program', 'multi-year share buyback program', 'Buyback Programs section', 'European Central Bank', 'equity incentive plan', '2022 Capital Markets Day', 'special voting shares', 'additional common shares', 'Ferrari N.V.', 'No. 166,708 common shares', 'No. 40,049 common shares', 'share capital', 'Stock Exchange', '12,034,386 common shares', 'treasury No.', 'second tranche', 'aggregate form', 'daily basis', 'Euronext Milan', 'Average price', 'comprehensive overview', 'corporate website', 'Trading Date', 'total consideration', 'Maranello', 'Italy', 'NYSE/EXM', 'RACE', 'Company', 'December', 'line', 'disclosure', 'Number', 'fees', 'purchase', 'announcement', 'January', 'July', 'transactions', 'Sell', 'details', 'buyback-programs', 'Attachment', '980,494']",2023-01-16,2023-01-16,marketscreener.com
16543,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BIOCARTIS-GROUP-NV-22033639/news/Press-release-Biocartis-Group-NV-Completion-of-Comprehensive-Recapitalization-Transactions-42742806/?utm_medium=RSS&utm_content=20230116,Press release Biocartis Group NV: Completion of Comprehensive Recapitalization Transactions,(marketscreener.com) PRESS RELEASE:¬†REGULATED INFORMATION16 January 2023  17:40 CET Completion of Comprehensive Recapitalization Transactions Mechelen  Belgium  16 January 2023 ‚ÄìBiocartis Group NV   an innovative molecular diagnostics company is pleased to an‚Ä¶,"PRESS RELEASE: REGULATED INFORMATION16 January 2023  17:40 CETCompletion of Comprehensive Recapitalization TransactionsMechelen  Belgium  16 January 2023 ‚ÄìBiocartis Group NV (the ""Company"" or ""Biocartis"")  an innovative molecular diagnostics company (Euronext Brussels: BCART) is pleased to announce that the final steps in the previously announced comprehensive recapitalization transactions have been completed today.The initial holders of the Company's 4.50% new second lien secured convertible bonds due 2026 (the ""New Convertible Bonds"") have subscribed for additional New Convertible Bonds in an aggregate amount equal to EUR 25 000 200 (such additional New Convertible Bonds  the ""New Money Bonds""). From their issuance up until the next interest payment date of 15 March 2023  the New Money Bonds will trade under ISIN number BE6340726304. On 15 March 2023  the ISIN of the New Money Bonds will be merged with the ISIN of the New Convertible Bonds  as a result of which both the New Money Bonds and the previously issued New Convertible Bonds will trade under ISIN BE6338582206 and will be fully fungible.Following the issuance of the New Money Bonds and as part of the bond buyback transactions that took place on 19 October 2022 (as referred to in the press releases of the Company dated 1 September 2022 and 20 October 2022)  certain holders of the Company's New Convertible Bonds delivered an additional EUR 306 000 in New Convertible Bonds to the Company for no consideration. The New Convertible Bonds so delivered have been cancelled.As a result of the aforementioned issuance of New Money Bonds and cancellation of New Convertible Bonds  the total outstanding principal amount of New Convertible Bonds (including New Money Bonds) is equal to EUR 116 764 200.Furthermore  the completion of the issuance of the New Money Bonds  has enabled the Company to make another drawdown of approximately EUR 11 million under the Company's senior secured term loan (‚ÄúConvertible Term Loans‚Äù) provided by certain holders of the Company's New Convertible Bonds  resulting in the EUR 30 million available under the Convertible Term Loans being fully drawn.This completes the comprehensive recapitalization that was announced on 1 September 2022 and that will support the Company's growth for the foreseeable future with EUR 66 million of gross proceeds.--- END ---More information:Renate DegraveHead of Corporate Communications & Investor Relations Biocartise-mail rdegrave@biocartis.comtel +32 15 631 729mobile +32 471 53 60 64About BiocartisWith its revolutionary and proprietary Idylla‚Ñ¢ platform  Biocartis (Euronext Brussels: BCART) aspires to enable personalized medicine for patients around the world through universal access to molecular testing  by making molecular testing actionable  convenient  fast and suitable for any lab. The Idylla‚Ñ¢ platform is a fully automated sample-to-result  real-time PCR (Polymerase Chain Reaction) based system designed to offer in-house access to accurate molecular information in a minimum amount of time for faster  informed treatment decisions. Idylla‚Ñ¢'s continuously expanding menu of molecular diagnostic tests address key unmet clinical needs  with a focus in oncology. This is the fastest growing segment of the molecular diagnostics market worldwide. Today  Biocartis offers tests supporting melanoma  colorectal  lung and liver cancer  as well as for COVID-19  Flu  RSV and sepsis. For more information  visit www.biocartis.com or follow Biocartis on Twitter @Biocartis_   Facebook or LinkedIn.Biocartis and Idylla‚Ñ¢ are registered trademarks in Europe  the United States and other countries. The Biocartis and Idylla‚Ñ¢ trademark and logo are used trademarks owned by Biocartis. Please refer to the product labeling for applicable intended uses for each individual Biocartis product.This press release is not for distribution  directly or indirectly  in any jurisdiction where to do so would be unlawful. Any persons reading this press release should inform themselves of and observe any such restrictions. Biocartis takes no responsibility for any violation of any such restrictions by any person. This press release does not constitute an offer or invitation for the sale or purchase of securities in any jurisdiction. No securities of Biocartis may be offered or sold in the United States of America absent registration with the United States Securities and Exchange Commission or an exemption from registration under the U.S. Securities Act of 1933  as amended.Important informationThis announcement is not a prospectus for the purposes of Regulation 2017/1129  as amended (together with any applicable implementing measures in any Member State of the European Economic Area  the ‚ÄúProspectus Regulation‚Äù) or the Prospectus Regulation as it forms part of UK domestic law by virtue of the UK European Union (Withdrawal) Act 2018 and as amended by The Prospectus (Amendment etc.) (EU Exit) Regulations 2019 (each as amended) (the ""UK Prospectus Regulation"").THIS ANNOUNCEMENT IS NOT FOR DISTRIBUTION  DIRECTLY OR INDIRECTLY  IN THE UNITED STATES OF AMERICA  AUSTRALIA  CANADA  JAPAN  SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE TO DO SO WOULD BE PROHIBITED BY APPLICABLE LAW.THIS ANNOUNCEMENT IS FOR GENERAL INFORMATION ONLY AND DOES NOT FORM PART OF ANY OFFER TO SELL OR PURCHASE  OR THE SOLICITATION OF ANY OFFER TO SELL OR PURCHASE  ANY NEW BONDS  OUTSTANDING BONDS OR OTHER SECURITIES. THE DISTRIBUTION OF THIS ANNOUNCEMENT AND THE OFFER  SALE AND PURCHASE OF THE NEW BONDS  NEW TERM LOANS OR THE OUTSTANDING BONDS DESCRIBED IN THIS ANNOUNCEMENT IN CERTAIN JURISDICTIONS MAY BE RESTRICTED BY LAW. ANY PERSONS READING THIS ANNOUNCEMENT SHOULD INFORM THEMSELVES OF AND OBSERVE ANY SUCH RESTRICTIONS.There shall be no offer  solicitation  sale or purchase or exchange of the New Convertible Bonds in any jurisdiction in which such offer  solicitation  sale  or purchase would be unlawful prior to registration  exemption from registration or qualification under the securities laws of any such jurisdiction. The securities referred to herein have not been and will not be registered under the U.S. Securities Act of 1933  as amended from time to time (the ""U.S. Securities Act"") or the securities laws of any state of the United States  and may not be offered or sold in the United States unless these securities are registered under the U.S. Securities Act  or an exemption from the registration requirements of the U.S. Securities Act is available.Biocartis has not registered  and does not intend to register  any portion of the offering of the securities concerned in the United States  and does not intend to conduct a public offering of securities in the United States. This communication is only addressed to and directed at persons in member states of the European Economic Area (each a ""Member States"") and in the United Kingdom who are ""qualified investors"" within the meaning of Article 2(e) of the Prospectus Regulation and of the UK Prospectus Regulation  respectively (""Qualified Investors""). This communication is only being distributed to and is only directed at (i) persons who are outside the United Kingdom or (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the ""Order"") or (iii) high net worth companies  and other persons to whom it may lawfully be communicated  falling within Article 49(2)(a) to (d) of the Order (all such persons together being referred to as ""relevant persons""). The securities referred to herein are only available to  and any invitation  offer or agreement to subscribe  purchase or otherwise acquire such securities will be engaged in only with  relevant persons. Any person who is not a relevant person should not act or rely on this document or any of its contents. This announcement cannot be used as a basis for any investment agreement or decision. Biocartis is not liable if the aforementioned restrictions are not complied with by any person.",neutral,0.0,1.0,0.0,mixed,0.17,0.11,0.71,True,English,"['Biocartis Group NV', 'Comprehensive Recapitalization Transactions', 'Press release', 'Completion', 'next interest payment date', 'faster, informed treatment decisions', 'key unmet clinical needs', 'senior secured term loan', 'total outstanding principal amount', 'U.S. Securities Act', 'additional New Convertible Bonds', 'The New Convertible Bonds', 'innovative molecular diagnostics company', 'Convertible Term Loans', 'molecular diagnostics market', 'New Money Bonds', '4.50% new second lien', 'bond buyback transactions', 'Polymerase Chain Reaction', 'fastest growing segment', 'European Economic Area', 'UK domestic law', 'UK European Union', 'Comprehensive Recapitalization Transactions', 'proprietary Idylla‚Ñ¢ platform', 'applicable implementing measures', 'accurate molecular information', 'molecular diagnostic tests', 'The Idylla‚Ñ¢ platform', 'Biocartis Group NV', 'Investor Relations Biocartis', 'individual Biocartis product', 'UK Prospectus Regulation', 'United States Securities', 'molecular testing', 'The Prospectus', 'aggregate amount', 'minimum amount', 'product labeling', 'The Biocartis', 'PRESS RELEASE', 'REGULATED INFORMATION', 'Euronext Brussels', 'final steps', 'foreseeable future', 'gross proceeds', 'More information', 'Renate Degrave', 'Corporate Communications', 'personalized medicine', 'real-time PCR', 'based system', 'expanding menu', 'liver cancer', 'other countries', 'Idylla‚Ñ¢ trademark', 'Exchange Commission', 'Important information', 'Member State', 'EU Exit', 'universal access', 'initial holders', 'ISIN number', 'January', 'CET', 'Completion', 'Mechelen', 'Belgium', 'BCART', 'issuance', '15 March', 'result', 'part', 'place', '19 October', '1 September', '20 October', 'consideration', 'cancellation', 'drawdown', 'growth', 'Head', 'mail', 'revolutionary', 'patients', 'world', 'sample', 'house', 'focus', 'oncology', 'melanoma', 'colorectal', 'lung', 'COVID', 'Flu', 'RSV', 'sepsis', 'Twitter', 'Facebook', 'LinkedIn', 'trademarks', 'logo', 'uses', 'distribution', 'jurisdiction', 'persons', 'restrictions', 'responsibility', 'violation', 'offer', 'invitation', 'sale', 'purchase', 'America', 'registration', 'exemption', 'announcement', 'purposes', 'virtue', 'Amendment', 'Regulations']",2023-01-16,2023-01-16,marketscreener.com
16544,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/VEON-LTD-121357098/news/VEON-CEO-letter-to-2023-Noteholders-42739162/?utm_medium=RSS&utm_content=20230116,VEON CEO letter to 2023 Noteholders,(marketscreener.com) Amsterdam  16 January 2023 ‚Äì VEON Ltd.   a global digital operator that provides converged connectivity and online services  has today contacted holders of interests in the 5.95% notes due February 2023 and the 7.25% notes due April 2023 ‚Ä¶,Amsterdam  16 January 2023 ‚Äì VEON Ltd. (NASDAQ: VEON  Euronext Amsterdam: VEON)  a global digital operator that provides converged connectivity and online services  has today contacted holders (the ‚Äú2023 Noteholders‚Äù) of interests in the 5.95% notes due February 2023 and the 7.25% notes due April 2023 (together  the ‚Äú2023 Notes‚Äù) issued by VEON Holdings BV (‚ÄúVEON Holdings‚Äù) in relation to the English Scheme of Arrangement (the ‚ÄúScheme‚Äù) that aims to extend the maturities of the 2023 Notes by eight months from their respective maturity dates.In the letter  VEON‚Äôs Chief Executive Officer Kaan Terzioƒülu requested the assistance and cooperation of 2023 Noteholders in connection with the Scheme  and specifically requested them to vote in favour of the Scheme at the forthcoming scheme meeting taking place on 24 January 2023. The deadline by which 2023 Noteholders must submit their Voting and Proxy Forms (or  if the 2023 Noteholder holds their 2023 Notes through DTC  procure that their DTC participant submits on their behalf) is 5.00 p.m. (London time) on 20 January 2023. The letter further explained:‚ÄúWe understand the significance of what we are asking and take our obligations to our stakeholders  including the repayment of our debts in full and on time  very seriously.However  despite strong operational results and a strong balance sheet  given the current circumstances  we must consider the repayment of the 2023 Notes within the context of our future debt obligations beyond 2023 and the difficulties VEON currently faces in raising debt or equity on the international capital markets on commercially acceptable terms. It is this which has led us to take the decision to launch the Scheme  as we believe it would provide the best route to us repaying you in advance of VEON Holdings‚Äô other future debt obligations.Your support and the resultant implementation of the proposal set out in the Scheme will enable us to avoid the near-term inefficient use of cash that would result from a significant portion of the principal repayment (relating to 2023 Notes held via the Russian National Settlement Depository (‚ÄúNSD‚Äù)) being trapped in international clearing systems (with no clear prospect of such monies being returned to VEON). VEON and its legal advisors have spent significant time and efforts exploring potential options to avoid having cash trapped in the international clearing systems  but at present there does not appear to be a clearly viable path to avoid this unattractive outcome. At a time that  due to Russian Decree 430  the Group potentially can no longer rely on payments to the international clearing systems effectively being recognised by its Russian noteholders as a full discharge of the underlying liability  the proposed maturity extension will provide additional time for the impact of Decree 430 on VimpelCom and the Group (as set out in the Scheme documentation) to become clearer and for the Group to mitigate  where possible  the associated risk of double payments. The Scheme proposal would also provide time to progress our asset monetization strategy anchored by the sale of our Russian business (the ‚ÄúVimpelCom Disposal‚Äù)  as announced on 24 November 2022. We believe that the VimpelCom Disposal represents the single-most material deleveraging action available to VEON Holdings and increases the prospects of VEON regaining access to the international capital markets  and thereby refinancing its indebtedness  on commercially acceptable terms.As set out more fully in the Scheme documents  in return for granting us with a modest extension  we have sought to compensate the 2023 Noteholders with the benefit of an amendment fee and a put right. As announced on 11 January 2023  the Company has further amended the terms of the proposal set out in the Scheme and entered into undertakings to vote in favour of the Scheme with certain 2023 Noteholders holding approximately 10.4% of the principal amount of the 2023 Notes. Each of these amendments improves the terms of the proposal for the benefit of the 2023 Noteholders.If the Scheme fails  the directors of VEON Holdings will need to continue to assess the Company‚Äôs solvency and liquidity position up to the original maturity date of the February 2023 Notes. Whilst VEON Holdings will have sufficient cash to pay the 2023 Notes on their original maturity dates  we cannot exclude the possibility that the directors may determine that the best action for VEON Holdings to take is not to pay on maturity while the double-payment risk continues. We consider that  by providing further runway to allow the sale of VimpelCom to complete  the Scheme will greatly reduce the risks of non-payment and impact on our stakeholders.We are pleased that good progress has already been made in respect of the implementation of the Scheme (and strive to continue this progress). In particular  on 26 December  we announced that VEON Holdings was granted an OFAC License (if you would like to see a copy of the OFAC License  you can request a copy by email to bonds@veon.com). Following receipt of this license  VEON Holdings believes that no further licenses are required in order to permit eligible noteholders to vote on the Scheme. In addition  we are in active dialogue with the Netherlands Ministry of Finance and the UK Office of Financial Sanctions Implementation in respect of the licenses we have sought from those regulators  which will be required to implement the amendments contemplated by the Scheme.Therefore in consideration of the steps taken above  we request your support and encourage you to vote in favour of the Scheme at the forthcoming scheme meeting. By doing so  you will provide us with crucial time to mitigate the risks of trapped cash and potential double-payment and to undertake the VimpelCom Disposal and our wider asset monetization programme  thus allowing VEON to deleverage and provide the best-available route for the repayment of your notes.For all relevant information in relation to the Scheme please visit https://is.kroll.com/veon  and any further questions on the voting process can be addressed to Kroll Issuer Services Limited (as the Company‚Äôs information agent) by email to veon@is.kroll.com or by telephone on + 44 20 7704 0880.Finally  we acknowledge the questions which have been raised by several of you to us and to our advisors and hope that we have been able to address them. However should you have any questions on the Scheme  other topics covered in this letter  or other matters related to VEON Group  please contact bonds@veon.com .Thank you for your continued trust in and support of our company.‚ÄùDisclaimerThis press release contains ‚Äúforward-looking statements‚Äù  as the phrase is defined in Section 27A of the U.S. Securities Act of 1933  as amended  and Section 21E of the U.S. Securities Exchange Act of 1934  as amended. Forward-looking statements are not historical facts  and include statements relating to  among other things  the Scheme  expectations regarding management plans and the ability to successfully execute operating model  governance  strategic and development plans. Forward-looking statements are inherently subject to risks and uncertainties  many of which VEON cannot predict with accuracy and some of which VEON might not even anticipate. The forward-looking statements contained in this release speak only as of the date of this release. VEON does not undertake to publicly update  except as required by U.S. federal securities laws  any forward-looking statement to reflect events or circumstances after such date or to reflect the occurrence of unanticipated events.About VEONVEON is a global digital operator that currently provides converged connectivity and online services to over 200 million customers in seven high-growth markets. We are transforming people‚Äôs lives  empowering individuals  creating opportunities for greater digital inclusion and driving economic growth across countries that are home to more than 8% of the world‚Äôs population. Headquartered in Amsterdam  VEON is listed on NASDAQ and Euronext.For more information visit: https://www.veon.com .,neutral,0.01,0.99,0.0,mixed,0.43,0.03,0.54,True,English,"['VEON CEO letter', '2023 Noteholders', 'Chief Executive Officer Kaan Terzioƒülu', 'single-most material deleveraging action', 'Russian National Settlement Depository', 'other future debt obligations', 'global digital operator', 'strong operational results', 'strong balance sheet', 'international capital markets', 'near-term inefficient use', 'international clearing systems', 'asset monetization strategy', 'respective maturity dates', 'original maturity date', 'forthcoming scheme meeting', 'VEON Holdings BV', 'The Scheme proposal', 'best action', 'Russian business', 'maturity extension', 'converged connectivity', 'online services', 'eight months', 'Proxy Forms', 'current circumstances', 'best route', 'significant portion', 'clear prospect', 'legal advisors', 'potential options', 'viable path', 'unattractive outcome', 'Russian Decree', 'underlying liability', 'associated risk', 'modest extension', 'amendment fee', 'principal amount', 'liquidity position', 'double-payment risk', 'OFAC License', 'Russian noteholders', 'VEON Ltd', 'Euronext Amsterdam', 'DTC participant', 'London time', 'acceptable terms', 'resultant implementation', 'significant time', 'full discharge', 'additional time', 'double payments', 'VimpelCom Disposal', 'good progress', 'English Scheme', 'Scheme documentation', 'Scheme documents', 'principal repayment', 'sufficient cash', 'February 2023 Notes', '2023 Noteholders', '5.95% notes', '7.25% notes', 'NASDAQ', 'interests', 'April', 'relation', 'maturities', 'letter', 'assistance', 'cooperation', 'connection', 'favour', 'place', '24 January', 'deadline', 'Voting', 'behalf', '20 January', 'significance', 'stakeholders', 'debts', 'context', 'difficulties', 'equity', 'decision', 'advance', 'support', 'NSD', 'monies', 'efforts', 'present', 'Group', 'impact', 'sale', '24 November', 'prospects', 'access', 'indebtedness', 'return', 'benefit', 'put', 'right', '11 January', 'Company', 'undertakings', 'amendments', 'directors', 'solvency', 'possibility', 'runway', 'risks', '26 December', 'copy', 'email', 'bonds', 'receipt']",2023-01-16,2023-01-16,marketscreener.com
16545,EuroNext,NewsApi.org,https://finance.yahoo.com/news/sic-power-semiconductor-market-experience-083000528.html,SiC Power Semiconductor Market to Experience Substantial CAGR Growth of 26.0% by 2030  Size  Share  Trends  Industry Growth  Key Drivers and Opportunity Analysis,"Recent study report released by Data Bridge Market research with titled ""SiC Power Semiconductor Market"" guarantees you will remain better informed than your...","SEOUL  South Korea  Jan. 16  2023 /PRNewswire/ -- Recent study report released by Data Bridge Market research with titled ""SiC Power Semiconductor Market"" guarantees you will remain better informed than your competition. Highly in-depth data collection and results analysis has been conducted to generate the world class SiC Power Semiconductor market report. The report effectively communicates research findings such as consumer trends  market trends  and competitor behaviour that surround the target audience. This market research report contains a summary of research findings and insights uncovered during the data collection and analysis processes. It has information about a company's competition  industry trends/opportunities  and recommendations for next steps based on the research questions being addressed. SiC Power Semiconductor market research report helps guide decision-making and highlight market opportunities.Data_Bridge_Market_Research_LogoSiC Power Semiconductor report is not only clear and concise but also detailed and comprehensive prepared by keeping in mind that stakeholders must be able to interpret the research findings with ease. As market research reports are presented to many stakeholders  not all of them will have a strong understanding of market research terms  so this report is written in clear and simple language. Moreover  all diagrams are clearly labelled and accurately described what they are displaying. While creating SiC Power Semiconductor report  it has been imagined that a reader has no prior knowledge on the topic to ensure and hence the findings are explained comprehensively.Data Bridge Market Research analyses that the global SiC power semiconductor market is expected to reach a value of USD 7 030 515.23 thousand by 2030  at a CAGR of 26.0% during the forecast period. The global SiC power semiconductor market report also comprehensively covers pricing analysis  patent analysis  and technological advancements.Download Sample Copy of SiC Power Semiconductor Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sic-power-semiconductor-marketMarket DefinitionSiC power semiconductor refers to the type of semiconductor that contains carbon and silicon and operates at very high voltage and temperature. SiC power semiconductors can be used in producing a strong as well as a very hard material. SiC power semiconductors can be implemented in various sectors such as telecommunication  energy and power  automotive  renewable power generation  and in different other areas. They are basically considered due to higher maximum thermal conductive properties that have widened the area of application. SiC power semiconductors are devices that are considered high-frequency power devices that are majorly applicable in wireless communications. SiC semiconductor offers ten times the dielectric breakdown field strength  three times the thermal conductivity  and three times the bandgap as compared to a silicon semiconductor. The SiC semiconductor has taken over the market because of its high performance and efficiency. The SiC power semiconductor offers to work at high voltage and current and offers low on-resistance in addition to being efficient at high temperatures. The combination of silicon carbide has thus proved to be a better and optimum choice of semiconductor.Market DriversAdvent Of SiC Power SemiconductorsThere are very useful properties of SiC as a semiconductor material. In applications such as inverters  motor drives  and battery chargers  silicon carbide (SiC) devices offer many advantages  such as improved power density  reduced cooling requirements  and reduced overall system cost. These advantages are enough to make SiC power semiconductors at the high efficient stage.The energy lost by SiC during the reverse recovery phase is only 1% of the energy lost by silicon which creates a huge difference in the efficiency of the material. The virtual absence of a tail current allows a faster turn‚Äìoff  and it makes lower losses. Since there is less energy to dissipate  a SiC device able to switch at higher frequencies and improve efficiency. The more efficient  small size  and lower weight of SiC as compared to other materials can create a higher-rated solution or a smaller design with reduced cooling requirements. Thus  the advent of SiC power semiconductors is a major factor expected to drive the growth of the Global SiC power semiconductor market.Rising Penetration of Electronic VehiclesThe world is changing so fast  and it is turning towards renewable energy. All sectors  market players  and government institutes are making more focus to build electric vehicle infrastructure and generate more demand for electric vehicles.As per the information from International Energy Agency (IEA)  16.5 million electric cars were on the road in 2021  a tripling in just three years  and this is a big number as compared to 2020. Electric car sales increased and doubled in China  continued to increase in Europe  and picked up in the U.S. in 2021. This data shows that there is a tremendous increase in the penetration of EVs in the market  which may positively affect the environment as well as the Global SiC power semiconductor market. SiC is highly efficient at high voltages  enabling fast battery charging times that are comparable to filling the tank of conventional vehicles. Silicon carbide power electronics are enabling a surge in 800-volt drive systems  paving the way for lighter EVs with greater range.Some of the major players operating in the SiC Power Semiconductor market are:WOLFSPEED  INC. STMicroelectronics ROHM CO.  LTD. Fuji Electric Co.  Ltd. Mitsubishi Electric Corporation Texas Instruments Incorporated Infineon Technologies AG Semikron Danfoss Xiamen Powerway Advanced Material Co.  Ltd. Renesas Electronics Corporation TOSHIBA ELECTRONIC DEVICES & STORAGE CORPORATION Microchip Technology Inc. Semiconductor Components Industries  LLC NXP Semiconductors UnitedSiC SemiQ Inc. Littlefuse  Inc. Allegro MicroSystems  Inc. Hitachi Power Semiconductor Device  Ltd. (A Subsidiary of Hitachi Group)  andGeneSiC SemiconductorGet Full PDF Research Report to Understand More @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-sic-power-semiconductor-marketRecent DevelopmentsIn December 2022  STMicroelectronics and Soitec (Euronext Paris)  in designing and manufacturing innovative semiconductor materials  announced the next stage of their cooperation on Silicon Carbide (SiC) substrates  with the qualification of Soitec's SiC substrate technology by ST planned over the next 18 months. The goal of this cooperation is the adoption by ST of Soitec's SmartSiC technology for its future 200mm substrate manufacturing  feeding its devices and modules manufacturing business  with volume production expected in the midterm. This collaboration will help the company to boost its financials as well as the growth of the Global SiC power semiconductor market.In July 2022  Semikron Danfoss and the Kyoto-based company ROHM Semiconductor have been collaborating for more than ten years with regard to the implementation of silicon carbide (SiC) inside power modules. Recently  ROHM's latest 4th generation of SiC MOSFETs has been fully qualified in SEMIKRON's eMPack modules for automotive use. Hence  both companies serve worldwide customers' needs. This collaboration enhanced the company's financials and made a positive impact on the growth of the Global SiC power semiconductor market.The report provides insights on the following pointers:Market Penetration: Comprehensive information on the product portfolios of the top players in the SiC Power Semiconductor marketProduct Development/Innovation: Detailed insights on upcoming technologies  R&D activities  and product launches in the marketCompetitive Assessment: In-depth assessment of the market strategies  and geographic and business segments of the leading players in the marketMarket Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographiesMarket Diversification: Exhaustive information about new products  untapped geographies  recent developments  and investments in the SiC Power Semiconductor MarketKey Industry Segmentation: SiC Power Semiconductor MarketBy TypeMOSFETSHybrid ModulesSchottky Barrier Diodes (SBDS)IGBTBipolar Junction Transistor (BJT)Pin DiodeJunction FET (JFET)By Voltage Range301-900 V901-1700 VAbove 1701 VBy Wafer Size6 Inch4 Inch2 InchAbove 6 InchBy Wafer TypeSiC epitaxial wafersBlank SiC wafersBy ApplicationElectric Vehicles (EV)PhotovoltaicsPower suppliesIndustrial motor drivesEV charging infrastructureRF DevicesBy VerticalAutomotiveUtilities and energyIndustrialTransportationIT and telecommunicationConsumer electronicsAerospace and defenseCommercialTo Gain More Insights about this Research  Visit @ https://www.databridgemarketresearch.com/reports/global-sic-power-semiconductor-marketA comprehensive analysis will be provided covering the following points in the report:Executive Market SummaryScope of the SiC Power Semiconductor ReportKey Finding and RecommendationsGrowth and Investment OpportunitiesSiC Power Semiconductor Market Value Chain/Supply Chain AnalysisSiC Power Semiconductor Market Attractive Investment PropositionCompetitive landscape and SWOT AnalysisSiC Power Semiconductor Market Segmentation OutlookRegional OutlookCompany Profiles of Key PlayersRegional Analysis/Insights: SiC Power Semiconductor MarketThe countries covered in the SiC power semiconductor market report are U.S.  Canada  Mexico  Germany  U.K.  Italy  France  Spain  Switzerland  Netherlands  Belgium  Russia  Turkey  Poland  Sweden  Denmark  Rest of Europe  Japan  China  South Korea  India  Australia and New Zealand  Hong Kong  Taiwan  Singapore  Thailand  Indonesia  Malaysia  Philippines  Vietnam  and Rest of Asia-Pacific  South Africa  UAE.  Israel  Egypt  Qatar  Saudi Arabia  Kuwait  Rest of the Middle East and Africa  Brazil  Argentina  and Rest of South America.In 2023  the Asia-Pacific region is expected to dominate the global SiC power semiconductor market due to the high demand for SiC power semiconductors. Additionally  the high demand for power modules and related devices is expected to act as a driving factor for the market's growth.Table of Contents:Introduction Market Segmentation Executive Summary Premium Insights Global SiC Power Semiconductor Market: Regulations Market Overview Global SiC Power Semiconductor Market  By Type Global SiC Power Semiconductor Market  By Voltage Range Global SiC Power Semiconductor Market  By Wafer Size Global SiC Power Semiconductor Market  By Wafer Type Global SiC Power Semiconductor Market  By Application Global SiC Power Semiconductor Market  By Vertical Global SiC Power Semiconductor Market  By Region Global SiC Power Semiconductor Market: Company Landscape SWOT Analyses Company Profile Questionnaires Related ReportsTo Check the Complete Table of contents  click here @ https://www.databridgemarketresearch.com/toc/?dbmr=global-sic-power-semiconductor-marketExplore More Reports:GaN and SiC Power Semiconductor Market  By Product (Sic Power Module  GaN Power Module  Discrete SiC  Dicrete GaN)  Application (Power Supplies  Industrial Motor Drives  H/EV  PV Inverters  Traction  Others)  Country (U.S.  Canada  Mexico  Brazil  Argentina  Rest of South America  Germany  Italy  U.K.  France  Spain  Netherlands  Belgium  Switzerland  Turkey  Russia  Rest of Europe  Japan  China  India  South Korea  Australia  Singapore  Malaysia  Thailand  Indonesia  Philippines  Rest of Asia-Pacific  Saudi Arabia  U.A.E  South Africa  Egypt  Israel  Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-gan-and-sic-power-semiconductor-marketAsia-Pacific SiC Power Semiconductor Market  By Type (MOSFETS  Hybrid Modules  Schottky Barrier Diodes (SBDS)  IGBT  Bipolar Junction Transistor (BJT)  Pin Diode  Junction FET (JFET)  and Others)  Voltage Range (301-900 V  901-1700 V  Above 1701 V)  Wafer size (6 Inch  4 Inch  2 Inch  Above 6 Inch)  Wafer type (SiC Epitaxial Wafers  Blank SiC Wafers)  Application (Electric Vehicles (EV)  Photovoltaics  Power Supplies  Industrial Motor Drives  EV Charging Infrastructure  RF Devices  and Others)  Vertical (Automotive  Utilities and Energy  Industrial  Transportation  IT and Telecommunication  Consumer Electronics  Aerospace and Defense  Commercial  and Others) https://www.databridgemarketresearch.com/reports/asia-pacific-sic-power-semiconductor-marketEurope SiC Power Semiconductor Market  By Type (MOSFETS  Hybrid Modules  Schottky Barrier Diodes (SBDS)  IGBT  Bipolar Junction Transistor (BJT)  Pin Diode  Junction FET (JFET)  and Others)  Voltage Range (301-900 V  901-1700 V  Above 1701 V)  Wafer size (6 Inch  4 Inch  2 Inch  Above 6 Inch)  Wafer type (SiC Epitaxial Wafers  Blank SiC Wafers)  Application (Electric Vehicles (EV)  Photovoltaics  Power Supplies  Industrial Motor Drives  EV Charging Infrastructure  RF Devices  and Others)  Vertical (Automotive  Utilities and Energy  Industrial  Transportation  IT and Telecommunication  Consumer Electronics  Aerospace and Defense  Commercial  and Others) https://www.databridgemarketresearch.com/reports/europe-sic-power-semiconductor-marketMiddle East and Africa SiC Power Semiconductor Market  By Type (MOSFETS  Hybrid Modules  Schottky Barrier Diodes (SBDS)  IGBT  Bipolar Junction Transistor (BJT)  Pin Diode  Junction FET (JFET)  and Others)  Voltage Range (301-900 V  901-1700 V  Above 1701 V)  Wafer size (6 Inch  4 Inch  2 Inch  Above 6 Inch)  Wafer type (SiC Epitaxial Wafers  Blank SiC Wafers)  Application (Electric Vehicles (EV)  Photovoltaics  Power Supplies  Industrial Motor Drives  EV Charging Infrastructure  RF Devices  and Others)  Vertical (Automotive  Utilities and Energy  Industrial  Transportation  IT and Telecommunication  Consumer Electronics  Aerospace and Defense  Commercial  and Others) https://www.databridgemarketresearch.com/reports/middle-east-and-africa-sic-power-semiconductor-marketNorth America SiC Power Semiconductor Market  By Type (MOSFETS  Hybrid Modules  Schottky Barrier Diodes (SBDS)  IGBT  Bipolar Junction Transistor (BJT)  Pin Diode  Junction FET (JFET)  and Others)  Voltage Range (301-900 V  901-1700 V  Above 1701 V)  Wafer size (6 Inch  4 Inch  2 Inch  Above 6 Inch)  Wafer type (SiC Epitaxial Wafers  Blank SiC Wafers)  Application (Electric Vehicles (EV)  Photovoltaics  Power Supplies  Industrial Motor Drives  EV Charging Infrastructure  RF Devices  and Others)  Vertical (Automotive  Utilities and Energy  Industrial  Transportation  IT and Telecommunication  Consumer Electronics  Aerospace and Defense  Commercial  and Others) https://www.databridgemarketresearch.com/reports/north-america-sic-power-semiconductor-marketPin Fin Heat Sink for Integrated Gate Bipolar Transistor (IGBT) Market  By Material Type (Copper  Aluminium)  Application (Consumer Electronics  Automotive Field  Others)  Country (U.S.  Canada  Mexico  Brazil  Argentina  Rest of South America  Germany  France  Italy  U.K.  Belgium  Spain  Russia  Turkey  Netherlands  Switzerland  Rest of Europe  Japan  China  India  South Korea  Australia  Singapore  Malaysia  Thailand  Indonesia  Philippines  Rest of Asia-Pacific  U.A.E  Saudi Arabia  Egypt  South Africa  Israel  Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-pin-fin-heat-sink-for-igbt-marketInsulated Gate Bipolar Transistor (IGBT) Discrete Semiconductor Market  By Type (Discrete IGBT  Modular IGBT)  Power Rating (High- Power  Medium- Power  Low- Power)  End- User (Automotive  Consumer Electronics  Communication  Industrial  Other End-Use Verticals) https://www.databridgemarketresearch.com/reports/global-igbt-discrete-semiconductor-marketInsulated Gate Bipolar Transistor (IGBT) Market  By Type (Discrete  Modular)  Power Rating (High-Power  Medium-Power  Low-Power)  End-user Industry (EV/HEV  Renewables  UPS  Rail  Motor Drives  Industrial  Commercial)  Country (U.S.  Canada  Mexico  Brazil  Argentina  Rest of South America  Germany  Italy  U.K.  France  Spain  Netherlands  Belgium  Switzerland  Turkey  Russia  Rest of Europe  Japan  China  India  South Korea  Australia  Singapore  Malaysia  Thailand  Indonesia  Philippines  Rest of Asia-Pacific  Saudi Arabia  U.A.E  South Africa  Egypt  Israel  Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-insulated-gate-bipolar-transistor-igbt-marketAbout Data Bridge Market Research:An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.Contact Us:-Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:- corporatesales@databridgemarketresearch.comLogo: https://mma.prnewswire.com/media/1011053/Data_Bridge_Market_Research_Logo.jpgCisionView original content:https://www.prnewswire.com/news-releases/sic-power-semiconductor-market-to-experience-substantial-cagr-growth-of-26-0-by-2030--size-share-trends-industry-growth-key-drivers-and-opportunity-analysis-301721242.htmlSOURCE Data Bridge Market Research",neutral,0.0,1.0,0.0,mixed,0.47,0.21,0.32,True,English,"['SiC Power Semiconductor Market', 'Substantial CAGR Growth', 'Industry Growth', 'Key Drivers', 'Opportunity Analysis', 'Size', 'Share', 'Trends', 'world class SiC Power Semiconductor market report', 'global SiC power semiconductor market report', 'SiC Power Semiconductor market research report', 'higher maximum thermal conductive properties', 'Data Bridge Market Research analyses', 'dielectric breakdown field strength', 'SiC Power Semiconductor report', 'The SiC power semiconductor', 'SiC power semiconductors', 'Recent study report', 'market research reports', 'market research terms', 'The SiC semiconductor', 'renewable power generation', 'overall system cost', 'reverse recovery phase', 'frequency power devices', 'electric vehicle infrastructure', '16.5 million electric cars', 'Electric car sales', 'depth data collection', 'different other areas', 'high efficient stage', 'International Energy Agency', 'reduced cooling requirements', 'power density', 'market trends', 'market opportunities', 'Market Definition', 'Market Drivers', 'market players', 'thermal conductivity', 'useful properties', 'higher frequencies', 'SiC) devices', 'SiC device', 'semiconductor material', 'silicon semiconductor', 'research questions', 'research findings', 'electric vehicles', 'other materials', 'high voltage', 'high performance', 'high temperatures', 'renewable energy', 'South Korea', 'results analysis', 'consumer trends', 'competitor behaviour', 'target audience', 'analysis processes', 'industry trends/opportunities', 'next steps', 'simple language', 'prior knowledge', 'forecast period', 'pricing analysis', 'patent analysis', 'technological advancements', 'wireless communications', 'optimum choice', 'motor drives', 'battery chargers', 'huge difference', 'virtual absence', 'lower losses', 'lower weight', 'higher-rated solution', 'smaller design', 'major factor', 'Rising Penetration', 'Electronic Vehicles', 'government institutes', 'three years', 'big number', 'U.S.', 'hard material', 'less energy', 'silicon carbide', 'many stakeholders', 'strong understanding', 'Sample Copy', 'various sectors', 'many advantages', 'tail current', 'SEOUL', 'Jan.', 'PRNewswire', 'competition', 'summary', 'insights', 'information', 'company', 'recommendations', 'decision-making', 'Data_Bridge_Market_Research_Logo', 'mind', 'ease', 'clear', 'diagrams', 'reader', 'topic', 'value', 'CAGR', 'Download', 'databridgemarketresearch', 'type', 'carbon', 'telecommunication', 'automotive', 'application', 'bandgap', 'efficiency', 'resistance', 'addition', 'combination', 'Advent', 'inverters', 'growth', 'focus', 'demand', 'IEA', 'road', 'China', 'Europe']",2023-01-16,2023-01-16,finance.yahoo.com
16546,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/KBC-ANCORA-SA-53036/news/Update-on-share-repurchase-program-KBC-Ancora-until-13-January-2023-42742800/?utm_medium=RSS&utm_content=20230116,Update on share repurchase program KBC Ancora until 13 January 2023,(marketscreener.com) Regulated information  inside information  Leuven  16 January 2023 Update on share repurchase program KBC Ancora until 13 January 2023 As part of the EUR 50 million share repurchase program  as confirmed on 20 May 2022  KBC Ancora has ann‚Ä¶,Regulated information  inside information  Leuven  16 January 2023 (17:40 CET)Update on share repurchase program KBC Ancora until 13 January 2023As part of the EUR 50 million share repurchase program  as confirmed on 20 May 2022  KBC Ancora has announced that it bought back a total of 27 700 shares in the period from 09 January 2023 to 13 January 2023.The following transactions were carried out during the period in question:Transaction date Number of shares Average price (EUR) Lowest price (EUR) Highest price (EUR) Total amount (EUR) Mon 9 January 2023 7 000 44.93 44.64 45.30 314 486.90 Tue 10 January 2023 4 500 44.79 44.50 44.92 201 564.90 Wed 11 January 2023 5 000 45.17 44.86 45.28 225 831.50 Thu 12 January 2023 5 000 45.92 45.18 46.26 229 594.00 Fri 13 January 2023 6 200 46.11 45.86 46.36 285 857.20 TOTAL(period concerned) 27 700 45.39 44.50 46.36 1 257 334.50 TOTAL (overall repurchase program) 1 006 055 36.41 31.68 46.36 36 631 505.19All transactions were carried out in the central order book of Euronext Brussels.Since the start of the share repurchase program on 10 June 2022  KBC Ancora has bought back 1 006 055 of its own shares  or 1.28% of the total number of shares issued (i.e. 78 301 314)  for an average price of 36.41 euros per share and for a total amount of 36 631 505 euros. KBC Ancora has currently implemented 73.26% of the repurchase program.The repurchase program runs within the limits of the share repurchase authorization granted by the Extraordinary General Meeting of Shareholders on 30 October 2020.---------------------------------KBC Ancora is a listed company that holds 18.6% of the shares in KBC Group. Together with Cera  MRBB and the Other Permanent Shareholders  it ensures shareholder stability and the ongoing development of the KBC Group. As core shareholders of KBC Group  they have concluded a shareholders‚Äô agreement to this end.Financial calendar:27 January 2023 Interim financial report (1H)1 September 2023 Annual press release for the financial year 2022/202327 October 2023 Annual General Meeting of ShareholdersThis press release is available in Dutch  French and English on the website www.kbcancora.be.KBC Ancora Investor Relations & Press contact: Jan BergmansTel. +32 (0)16 27 96 72email: jan.bergmans@kbcancora.be or mailbox@kbcancora.beAttachment,neutral,0.0,1.0,0.0,neutral,0.01,0.99,0.0,True,English,"['share repurchase program', 'KBC Ancora', 'Update', '13 January', 'EUR 50 million share repurchase program', 'KBC Ancora Investor Relations', 'central order book', 'Extraordinary General Meeting', 'Annual General Meeting', 'share repurchase authorization', 'Interim financial report', 'Annual press release', 'Other Permanent Shareholders', 'Financial calendar', 'financial year', 'Press contact', 'KBC Group', 'Transaction date', 'Average price', 'Lowest price', 'Highest price', 'Euronext Brussels', 'listed company', 'shareholder stability', 'ongoing development', 'core shareholders', 'shareholders‚Äô agreement', 'Total amount', 'Regulated information', 'following transactions', 'total number', 'Jan Bergmans', 'Leuven', '16 January', 'Update', '13 January', 'part', '20 May', '27,700 shares', 'period', '09 January', 'question', 'Mon', 'Tue', 'Wed', 'start', '10 June', '36.41 euros', '36,631,505 euros', 'limits', '30 October', 'Cera', 'MRBB', '27 January', '1 September', '27 October', 'Dutch', 'English', 'website', 'Tel.', 'email', 'kbcancora', 'Attachment']",2023-01-16,2023-01-16,marketscreener.com
16547,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/01/16/2589401/0/fr/SII-SII-acquires-Metanext.html,SII : SII acquires Metanext,Paris  January 16  2023 ‚Äì 6 p.m.  SII acquires Metanext  SII Group  specialist in engineering services  confirms the acquisition of 100% of the capital...,French EnglishParis  January 16  2023 ‚Äì 6 p.m.SII acquires MetanextSII Group  specialist in engineering services  confirms the acquisition of 100% of the capital of METANEXT. As announced on November 21  2022  the parties signed the final closing of the operation.SII strengthens its cloud services by the acquisition of METANEXTA digital services company specialized in Cloud services  METANEXT achieved a turnover of nearly 18 M‚Ç¨ in 2021. With a team of around 160 consultants  located in Ile-de-France and Lyon  METANEXT addresses the functional and technological issues of blue-chip and mid-sized clients thanks to an offer structured around three main divisions: Cloud Solutions  Integration of Private and/or Public Cloud Solutions and Operation Support (Expertise Centers & Managed Services). METANEXT is mainly present in the Banking & Finance  Insurance  and Manufacturing & Services sectors.This industrial project represents an important step for METANEXT  which benefiting from new opportunities and new capacities for its teams and clients. ‚ÄúThis project represents a decisive step in METANEXT‚Äôs development. In close cooperation with SII Group  our teams are becoming a national reference in terms of support towards the Cloud‚Äù  states Tristan Monroe  President of METANEXT.An operation of technological diversification in France for SII GroupThis operation is in line with the strategic orientation aiming at a technological diversification for SII Group. Through this acquisition  SII accelerates its development on the Cloud expertise and reinforces its proximity with a group of strategic blue-chip clients.This operation brings forward commercial  geographic & skill-related synergies  being a source of profitable growth for SII Group.The transaction  which covers the entire operational scope of METANEXT  is financed in cash.Advisors for Acquirer: KPMG  KPMG Avocats and CJ Astorg***Next Appointment:Fiscal 2022-2023 third quarter revenue  Tuesday  February 7  2023 after the close of the trading-Contacts:SII - Eric Matteucci - : 01.42.84.82.22-Receive our press releases by subscribing to our website: www.sii-group.comCompartment B - Euronext ParisLEI: 96950044FWV7YEJCKR65About SII GROUPThe SII Group is an engineering and technology consulting company and a digital services firm  founded in 1979 by Bernard HUV√â  a trained engineer.Currently  SII Group employs nearly 11 000 employees in 18 countries over four continents through 80 local establishments. The Group recruits an average of 4 000 consultants and engineers each year who work on a daily basis towards integrating and developing new technologies as well as improving information systems.Always concerned about coming up with innovative and value-adding solutions  SII operates at the service of blue-chip clients in a variety of sectors such as Aerospace & Defense  Banking & Insurance  Telecommunications  Energy  Retail  and Transport & Industry. Certified by both EcoVadis Platinum and Great Place to Work  SII Group stands out thanks to its social policy in favor of a sustainable and numerical world as well as its strong corporate culture in favor of work-life quality and inclusion.SII Group recorded a turnover of 828.9 M‚Ç¨ in fiscal year 2021/2022  closed in March 31st.About METANEXTFounded and chaired by Tristan MONROE since 2002  METANEXT is an independent consulting firm  specialized in Cloud transformation consulting. Being a partner of big technological actors in the Cloud  METANEXT supports clients  big and mid-sized companies and institutions in their transformation thanks to a complete approach where it acts as a Cloud Advisor  Cloud Builder and Managed Services Provider.METANEXT is part of the Top 120 of French Digital Services companies. Its consultants operate in France at the service of blue-chip clients‚Äô ISDs in the sectors of Banking & Finance  Insurance and Services & Manufacturing.METANEXT realized a turnover of nearly 18 M‚Ç¨ in 2021.Pi√®ce jointe,neutral,0.15,0.84,0.01,neutral,0.05,0.95,0.0,True,English,"['SII', 'Metanext', 'French Digital Services companies', 'three main divisions', 'entire operational scope', '23 third quarter revenue', 'technology consulting company', 'strong corporate culture', 'independent consulting firm', 'Pi√®ce jointe', 'digital services company', 'digital services firm', 'Euronext Paris LEI', 'Managed Services Provider', 'Public Cloud Solutions', 'big technological actors', 'blue-chip clients‚Äô ISDs', 'Cloud transformation consulting', 'strategic blue-chip clients', 'The SII Group', 'French English', 'mid-sized companies', 'strategic orientation', 'The Group', 'cloud services', 'value-adding solutions', 'technological issues', 'technological diversification', 'final closing', 'mid-sized clients', 'Expertise Centers', 'important step', 'new opportunities', 'new capacities', 'decisive step', 'national reference', 'Tristan Monroe', 'Cloud expertise', 'commercial, geographic', 'skill-related synergies', 'profitable growth', 'CJ Astorg', 'Next Appointment', 'Eric Matteucci', 'press releases', 'Compartment B', 'Bernard HUV√â', 'four continents', '80 local establishments', 'daily basis', 'new technologies', 'information systems', 'EcoVadis Platinum', 'Great Place', 'social policy', 'numerical world', 'work-life quality', 'complete approach', 'Cloud Advisor', 'Cloud Builder', 'engineering services', 'Services sectors', 'industrial project', 'close cooperation', 'KPMG Avocats', 'fiscal year', 'Operation Support', 'January', 'Metanext', 'specialist', 'acquisition', 'capital', 'November', 'parties', 'turnover', '18 M', 'team', '160 consultants', 'France', 'Lyon', 'functional', 'offer', 'Integration', 'Private', 'Banking', 'Finance', 'Insurance', 'Manufacturing', 'development', 'terms', 'President', 'line', 'proximity', 'source', 'transaction', 'cash', 'Advisors', 'Acquirer', 'Tuesday', 'February', 'trading', 'Contacts', 'website', '11,000 employees', '18 countries', 'average', '4,000 consultants', 'engineers', 'innovative', 'variety', 'Aerospace', 'Defense', 'Telecommunications', 'Energy', 'Retail', 'Transport', 'Industry', 'favor', 'sustainable', 'inclusion', '828.9 M', 'March', 'partner', 'institutions', 'Top']",2023-01-16,2023-01-16,globenewswire.com
16548,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/ALGOWATT-S-P-A-3822461/news/algoWatt-S-p-A-Project-funded-to-develop-innovative-thermal-energy-storage-solutions-for-smart-bui-42739050/?utm_medium=RSS&utm_content=20230116,algoWatt S p A : Project funded to develop innovative thermal energy storage solutions for smart buildings,(marketscreener.com)    The company will play the role of digital energy solution provider and system integrator in the THUMBS UP project  receiving funding of Euro 275 000 under the Horizon Europe programme   algoWatt will implement a Smart Building En‚Ä¶,"The company will play the role of digital energy solution provider and system integrator in the THUMBS UP project  receiving funding of Euro 275 000 under the Horizon Europe programmealgoWatt will implement a Smart Building Energy Management System  in a complex project that will include the development of innovative thermal energy storage technologies  with the integration also of a digital twin of the building that will be used for experimentationalgoWatt  a GreenTech Company listed on the Euronext Milan market of Borsa Italiana  announces that it has received funding of approximately Euro 275 000 for activities as Digital Energy solution provider and system integrator within the project THUMBS UP ""Thermal energy storage solUtions to optimally Manage BuildingS and Unlock their grid balancing and flexibility Potential""  financed with funds from the Horizon Europe programme to achieve high-performance results that will significantly contribute to the development of a sustainable economy in the European Union. THUMBS UP aims to develop innovative technologies and uses of daily and weekly thermal energy storage systems that can be easily integrated into buildings to increase their energy efficiency and harness the Power-to-Heat (PtH) paradigm  to make buildings key players in the flexibility of the global energy grid. THUMBS UP aims  in this sense  to overcome the limitations of state-of-the-art building-integrated technologies  increasing energy density and reducing the intesity factors of capital investment in this sector. To capitalise on know-how already available within the consortium  THUMBS UP will promote complementary digital innovations aimed at simulating  optimising and maximising the technical  operational and economic benefits of the proposed solutions  through:the Smart Building Energy Management System (under algoWatt) to integrate  control and manage building-level design solutions  maximise the use of local RES  optimise the efficiency of H&C - Heating & Cooling systems and coordinate operation with other building assets and energy demand;the Digital Twin to (i) optimise and maximise the energy flexibility and load-shifting benefits that building-integrated solutions provide to the electricity grid (through supply services for heating/cooling and grid in aggregation) and (ii) (for buildings connected to DHN) to coordinate the operation of the solutions with the supply of thermal energy from DHN  reduce peak thermal power and enable a more flexible use of heat.The THUMBS UP project  with a total duration of 48 months and an investment of approximately Euro 7.6 million (with funding of approximately Euro 6.4 million)  is coordinated by Veolia Servicios Lecam Sociedad Anonima Unipersonal (ES) and involves 18 companies  universities and research centres  including the University of Genoa  the University of Messina and the Polytechnic of Turin. The THUMBS UP project received funding from the European Union's Horizon Europe research and innovation programme under Grant Agreement No. 101096921.",neutral,0.06,0.93,0.0,neutral,0.01,0.99,0.0,True,English,"['innovative thermal energy storage solutions', 'algoWatt S', 'smart buildings', 'Veolia Servicios Lecam Sociedad Anonima Unipersonal', 'Smart Building Energy Management System', 'weekly thermal energy storage systems', 'innovative thermal energy storage technologies', 'digital energy solution provider', 'Thermal energy storage solUtions', 'The THUMBS UP project', 'other building assets', 'Euronext Milan market', 'complementary digital innovations', 'peak thermal power', 'Horizon Europe programme', 'Horizon Europe research', 'global energy grid', 'building-level design solutions', 'innovative technologies', 'system integrator', 'Cooling systems', 'energy density', 'energy demand', 'energy flexibility', 'digital twin', 'building-integrated technologies', 'energy efficiency', 'complex project', 'innovation programme', 'research centres', 'building-integrated solutions', 'Borsa Italiana', 'grid balancing', 'high-performance results', 'sustainable economy', 'European Union', 'PtH) paradigm', 'key players', 'intesity factors', 'technical, operational', 'economic benefits', 'local RES', 'H&C', 'load-shifting benefits', 'electricity grid', 'total duration', 'Grant Agreement', 'flexibility Potential', 'GreenTech Company', 'capital investment', 'supply services', 'flexible use', 'role', 'funding', 'algoWatt', 'development', 'integration', 'experimentation', 'activities', 'BuildingS', 'funds', 'uses', 'daily', 'Heat', 'sense', 'limitations', 'state', 'sector', 'know', 'consortium', 'aggregation', 'DHN', '48 months', '18 companies', 'universities', 'University', 'Genoa', 'Messina', 'Polytechnic', 'Turin']",2023-01-16,2023-01-16,marketscreener.com
16549,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/PIQUADRO-S-P-A-373104/news/Piquadro-S-p-A-316CS-Piquadro-buy-back-purchase-week-January-9-13-2023-42740831/?utm_medium=RSS&utm_content=20230116,Piquadro S p A : 316CS Piquadro buy back purchase week January 9 13 2023,(marketscreener.com)   Press release   REPORT ON THE TREASURY SHARES BUY-BACK PLAN OF   PIQUADRO S.P.A.   Silla di Gaggio Montano   January 16  2023. With reference to treasury shares buy-backplan  Piquadro S.p.A. hereby announces that  during the ‚Ä¶,Press releaseREPORT ON THE TREASURY SHARES BUY-BACK PLAN OFPIQUADRO S.P.A.Silla di Gaggio Montano (BO)  January 16  2023. With reference to treasury shares buy-backplan  Piquadro S.p.A. hereby announces that  during the period from January 9th to January 13th  2023  it purchased no. 3 986 treasury shares for a total consideration of 7 976.06 Euro  as authorized by the shareholders' meeting on July 25th  2022  already disclosed pursuant to Art. 144-bisof Consob Regulation no. 11971/1999.Details of the daily transactions on the Euronext Milan are as follows:Number of ordinary Average price (Euro) Consideration Date shares purchased (Euro) 01/09/2023 266 1.9450 517.37 01/10/2023 815 1.9434 1 583.87 01/11/2023 720 1.9900 1 432.80 01/12/2023 935 2.0833 1 947.89 01/13/2023 1 250 1.9953 2 494.13 Total 3 986 2.0010 7 976.06Following the above purchases and considering the treasury shares already in portfolio  as of January 13th  2023 Piquadro S.p.A. holds no. 1 794 432 treasury shares  equal to 3.5889% of the share capital.Piquadro GroupThe Piquadro Group operates in the sector of leather accessories through the Piquadro  The Bridge and Lancel brands. Cornerstones for the three brands is attention to details and the quality of the workmanship as well as the leather but the Piquadro product stands out for its innovative design and technological content  while The Bridge emphasizes the vintage flavor of Tuscan craftsmanship and finally the Lancel collections embody the Parisian allure of a fashion house founded in 1876.The origins of the Group date back to 1987 when Marco Palmieri  now President and Chief Executive Officer  founded his company near Bologna  where it is still headquartered. The distribution network extends over 50 countries around the world and counts 176 outlets including 81 Piquadro boutiques (53 in Italy and 28 abroad including 48 DOS directly operated stores and 33 franchised stores)  13 The Bridge boutiques (13 in Italy including 11 DOS directly operated stores and 2 franchised) and 82 Lancel boutiques (61 in France and 21 abroad  of which 75 DOS directly operated stores and 7 franchised). The Group's consolidated turnover for the year 2021/2022 ended on March 31  2022  is ‚Ç¨ 149 4 million. Piquadro S.p.A. has been listed on the Italian Stock Exchange since October 2007.,neutral,0.0,1.0,0.0,neutral,0.02,0.96,0.02,True,English,"['Piquadro S', '316CS Piquadro', 'purchase', 'January', 'PIQUADRO S.P.A.', 'ordinary Average price', 'Chief Executive Officer', 'Italian Stock Exchange', 'Consideration Date shares', 'TREASURY SHARES BUY', 'The Piquadro Group', 'The Bridge boutiques', '81 Piquadro boutiques', 'Piquadro product', '3,986 treasury shares', '1,794,432 treasury shares', 'total consideration', '82 Lancel boutiques', 'The Group', 'Press release', 'BACK PLAN', 'Gaggio Montano', ""shareholders' meeting"", 'Consob Regulation', 'daily transactions', 'Euronext Milan', 'share capital', 'Lancel brands', 'three brands', 'innovative design', 'technological content', 'vintage flavor', 'Tuscan craftsmanship', 'Lancel collections', 'Parisian allure', 'fashion house', 'Marco Palmieri', 'distribution network', 'leather accessories', '33 franchised stores', 'REPORT', 'Silla', 'January', 'reference', 'backplan', 'period', '7,976.06 Euro', 'July', 'Art.', 'Details', 'Number', 'purchases', 'portfolio', 'sector', 'Cornerstones', 'attention', 'quality', 'workmanship', 'origins', 'President', 'company', 'Bologna', '50 countries', 'world', '176 outlets', 'Italy', '48 DOS', '11 DOS', 'France', '75 DOS', 'turnover', 'year', 'March', 'October', '13']",2023-01-16,2023-01-16,marketscreener.com
16550,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/STMICROELECTRONICS-N-V-4710/news/STMicroelectronics-Announces-Status-of-Common-Share-Repurchase-Program-42741656/?utm_medium=RSS&utm_content=20230116,STMicroelectronics Announces Status of Common Share Repurchase Program,(marketscreener.com) STMicroelectronics Announces Status ofCommon Share Repurchase Program Disclosure of Transactions in Own Shares ‚Äì Period from Jan 09  2023 to Jan 13  2023 AMSTERDAM ‚Äì January 16  2023 -- STMicroelectronics N.V.   a global semiconductor lea‚Ä¶,STMicroelectronics Announces Status ofCommon Share Repurchase ProgramDisclosure of Transactions in Own Shares ‚Äì Period from Jan 09  2023 to Jan 13  2023AMSTERDAM ‚Äì January 16  2023 -- STMicroelectronics N.V. (the ‚ÄúCompany‚Äù or ‚ÄúSTMicroelectronics‚Äù)  a global semiconductor leader serving customers across the spectrum of electronics applications  announces full details of its common share repurchase program (the ‚ÄúProgram‚Äù) disclosed via a press release dated July 1  2021. The Program was approved by a shareholder resolution dated May 27  2021 and by the supervisory board.STMicroelectronics N.V. (registered with the trade register under number 33194537) (LEI: 213800Z8NOHIKRI42W10) (Ticker: ‚ÄúSTM‚Äù) announces the repurchase (by a broker acting for the Company) on the regulated market of Euronext Paris  in the period between Jan 09  2023 to Jan 13  2023 (the ‚ÄúPeriod‚Äù)  of 171 529 ordinary shares (equal to 0.02% of its issued share capital) at the weighted average purchase price per share of EUR 37.0815 and for an overall price of EUR 6 360 559.01.The purpose of these transactions under article 5(2) of Regulation (EU) 596/2014 (the Market Abuse Regulation) was to meet obligations arising from share option programmes  or other allocations of shares  to employees or to members of the administrative  management or supervisory bodies of the issuer or of an associate company.The shares may be held in treasury prior to being used for such purpose and  to the extent that they are not ultimately needed for such purpose  they may be used for any other lawful purpose under article 5(2) of the Market Abuse Regulation.Below is a summary of the repurchase transactions made in the course of the Period in relation to the ordinary shares of STM (ISIN: NL0000226223)  in detailed form.Transactions in PeriodDates of transaction Number of shares purchased Weighted average purchase price per share (EUR) Total amount paid (EUR) Market on which the shares were bought (MIC code) 09-Jan-23 35 260 36.3454 1 281 538.80 XPAR 10-Jan-23 34 436 37.0163 1 274 693.31 XPAR 11-Jan-23 34 343 37.0556 1 272 600.47 XPAR 12-Jan-23 33 882 37.5042 1 270 717.30 XPAR 13-Jan-23 33 608 37.5211 1 261 009.13 XPAR Total for Period 171 529 37.0815 6 360 559.01Following the share buybacks detailed above  the Company holds in total 7 787 505 treasury shares  which represents approximately 0.9% of the Company‚Äôs issued share capital.In accordance with Article 5(1)(b) of the Market Abuse Regulation and Article 2(3) of Commission Delegated Regulation (EU) 2016/1052  a full breakdown of the individual trades in the Program are disclosed on the ST website (https://investors.st.com/stock-and-bond-information/share-buyback).About STMicroelectronicsAt ST  we are 48 000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer  we work with more than 200 000 customers and thousands of partners to design and build products  solutions  and ecosystems that address their challenges and opportunities  and the need to support a more sustainable world. Our technologies enable smarter mobility  more efficient power and energy management  and the wide-scale deployment of the Internet of Things and connectivity. ST is committed to becoming carbon neutral by 2027. Further information can be found at www.st.com.For further information  please contact:INVESTOR RELATIONS:C√©line BerthierGroup VP  Investor RelationsTel: +41.22.929.58.12celine.berthier@st.comMEDIA RELATIONS:Alexis BretonCorporate External CommunicationsTel: + 33.6.59.16.79.08alexis.breton@st.comAttachment,neutral,0.0,1.0,0.0,negative,0.0,0.29,0.71,True,English,"['Common Share Repurchase Program', 'STMicroelectronics', 'Status', 'C√©line Berthier Group VP', 'Common Share Repurchase Program', 'art manufacturing facilities', 'integrated device manufacturer', 'Corporate External Communications', 'global semiconductor leader', 'average purchase price', 'semiconductor supply chain', 'Commission Delegated Regulation', 'share option programmes', 'Market Abuse Regulation', 'STMicroelectronics N.V.', 'other lawful purpose', 'overall price', 'other allocations', 'regulated market', 'share capital', 'share buybacks', 'semiconductor technologies', 'electronics applications', 'full details', 'press release', 'shareholder resolution', 'supervisory board', 'trade register', 'Euronext Paris', 'administrative, management', 'supervisory bodies', 'repurchase transactions', 'detailed form', 'MIC code', 'full breakdown', 'individual trades', 'sustainable world', 'smarter mobility', 'efficient power', 'energy management', 'wide-scale deployment', 'INVESTOR RELATIONS', 'MEDIA RELATIONS', 'Total amount', 'Own Shares', '171,529 ordinary shares', 'ST website', 'investors.st', 'Alexis Breton', 'Further information', 'associate company', 'Period Dates', '7,787,505 treasury shares', 'XPAR Total', 'Status', 'Disclosure', 'Jan', 'AMSTERDAM', 'customers', 'spectrum', 'May', 'number', 'Ticker', 'broker', 'article', 'obligations', 'employees', 'members', 'issuer', 'extent', 'summary', 'course', 'ISIN', 'accordance', 'bond', '48,000 creators', 'makers', 'state', 'thousands', 'partners', 'products', 'solutions', 'ecosystems', 'challenges', 'opportunities', 'need', 'Internet', 'Things', 'connectivity', 'Tel', 'Attachment']",2023-01-16,2023-01-16,marketscreener.com
16551,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/INVIBES-ADVERTISING-N-V-44658586/news/Invibes-Advertising-N-v-Half-yearly-report-on-the-liquidity-contract-42742844/?utm_medium=RSS&utm_content=20230116,Invibes Advertising N.v. :  Half-yearly report on the liquidity contract,(marketscreener.com)  Press releaseHalf-yearly report on the liquidity contractLondon   16 Januray 2023 ‚Äì Under the liquidity contract for the shares of InvibesAdvertising entrusted to TP ICAP SA  thefollowing resources were included in the liquidity ac‚Ä¶,"Press releaseHalf-yearly report on the liquidity contractLondon   16 Januray 2023 ‚Äì Under the liquidity contract for the shares of InvibesAdvertising (BE0974299316 - ALINV FP) entrusted to TP ICAP (Europe) SA  thefollowing resources were included in the liquidity account on 31/12/2022:‚Ä¢ 8 656 shares‚Ä¢ 16 218.02 Euros in cashIn the 2nd half of 2022  a total of:Purchase 21 942 shares 231 081.35 EUR 516 transactions Sale 19 972 shares 207 417.97 EUR 296 transactionsIt recalled that at the time of the half-yearly report at 30/06/2022  the following resources were included in the liquidity account:6 686 shares40 742.04 Euros in cashIt is recalled that when the new liquidity contract was set up on 17/11/2021  the following means were made available:‚Ä¢ 6 000 shares‚Ä¢ 50 000.00 Euros in cashTP ICAP (Europe) SA is authorised and regulated by the Autorit√© de Contr√¥le Prudentielet de R√©solution (ACPR) and the Autorit√© des March√©s Financiers (AMF).About Invibes AdvertisingInvibes Advertising is an international technology company specializing in digital advertising innovation. Founded in 2011 by co-CEOs Kris Vlaemynck and Nicolas Pollet  Invibes Advertising has developed an integrated technology platform designed to strengthen the relationship between brands and consumers through in-feed ads.At Invibes Advertising we believe in the power of connections.The power of connecting brands directly with consumers to enable more meaningful interactions.The power of connecting big data  innovative in-feed formats  wide reach and extensive intelligence services in a single  holistic platform to bring brands and consumers together seamlessly and efficiently.The power of connecting a unique pull of passionate  dynamic and knowledgeable in-feed specialists from across the globe to make up the extraordinary team that is Invibes Advertising.In order to partner with some of the greatest brands in the world  like Amazon  Bacardi  Volkswagen  Dell  IKEA and Toyota  we rely on even greater people to share our innovations with the world. Along with our unwavering belief in technological potential  more fundamentally  we believe in the potential of our people. At Invibes Advertising we actively strive to maintain an energetic  open environment that fosters a culture of ideation  growth and #GoodVibes  that shines straight through to our clients.Want to hear more about Invibes Advertising? Visit: www.invibes.comInvibes Advertising is listed on the Euronext Stock Exchange (Ticker: ALINV ‚Äì ISIN: BE0974299316)For our latest press releases  go to:https://www.invibes.com/uk/en/investors.htmlKeep up with all the latest news on Invibes Advertising:LinkedIn @Invibes Advertising Twitter @Invibes_advFinancial & Corporate Contacts:Kris Vlaemynck  co-CEOkris.vlaemynck@invibes.comThis publication embed ""üîí Actusnews SECURITY MASTER "".- SECURITY MASTER Key: mJpqlZZuaWfIyJ6akstob5VnbW+Sx2WYmmmVyGluZsrJap+VlZxnnMqeZnBplWpp- Check this key: https://www.security-master-key.com.Regulated information:Acquisition or disposal of the issuer's own shares:- Information relating to the liquidity contract Full and original press release in PDF: https://www.actusnews.com/news/78053-2023-01-16-pr-invibes-advertising-en.pdfReceive by email the next press releases of the company by registering on www.actusnews.com  it's free¬© 2023 ActusNews",neutral,0.0,1.0,0.0,neutral,0.03,0.97,0.0,True,English,"['Invibes Advertising N.v.', 'Half-yearly report', 'liquidity contract', 'de Contr√¥le Prudentiel', 'Press release Half-yearly report', 'original press release', 'next press releases', 'March√©s Financiers', 'integrated technology platform', 'extensive intelligence services', 'single, holistic platform', 'energetic, open environment', 'Euronext Stock Exchange', 'latest press releases', 'digital advertising innovation', 'international technology company', 'SECURITY MASTER Key', 'CEOs Kris Vlaemynck', 'Actusnews SECURITY MASTER', 'new liquidity contract', 'Invibes Advertising Twitter', 'latest news', 'liquidity account', 'TP ICAP', 'Europe) SA', 'following resources', '2nd half', 'following means', 'R√©solution', 'Nicolas Pollet', 'feed ads', 'meaningful interactions', 'big data', 'feed formats', 'wide reach', 'unique pull', 'passionate, dynamic', 'feed specialists', 'extraordinary team', 'unwavering belief', 'Corporate Contacts', 'ALINV FP', 'greater people', 'technological potential', 'Regulated information', 'greatest brands', 'London', 'Januray', 'shares', '31/12', '8.02 Euros', 'cash', 'total', 'Purchase', '516 transactions', '296 transactions', 'time', '30/06', '2.04 Euros', '17/11', '50,000.00 Euros', 'ACPR', 'AMF', 'relationship', 'consumers', 'power', 'connections', 'knowledgeable', 'globe', 'order', 'world', 'Amazon', 'Bacardi', 'Volkswagen', 'Dell', 'IKEA', 'Toyota', 'innovations', 'culture', 'ideation', 'growth', 'clients', 'Visit', 'Ticker', 'investors', 'LinkedIn', 'Financial', 'publication', 'Acquisition', 'disposal', 'issuer', 'Full', 'PDF', 'email']",2023-01-16,2023-01-16,marketscreener.com
16552,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/INVIBES-ADVERTISING-N-V-44658586/news/Invibes-Advertising-NV-Half-yearly-report-on-the-liquidity-contract-42742841/?utm_medium=RSS&utm_content=20230116,Invibes Advertising NV: Half-yearly report on the liquidity contract,(marketscreener.com) Invibes Advertising NV / Key word: Liquidity ProblemInvibes Advertising NV: Half-yearly report on the liquidity contract 16.01.2023 / 17:45 CET/CESTPress release¬†Half-yearly report on the liquidity contractLon‚Ä¶,Invibes Advertising NV / Key word(s): Liquidity ProblemInvibes Advertising NV: Half-yearly report on the liquidity contract16.01.2023 / 17:45 CET/CESTPress releaseHalf-yearly report on the liquidity contractLondon  16 Januray 2023 ‚Äì Under the liquidity contract for the shares of InvibesAdvertising (BE0974299316 - ALINV FP) entrusted to TP ICAP (Europe) SA  thefollowing resources were included in the liquidity account on 31/12/2022:‚Ä¢ 8 656 shares‚Ä¢ 16 218.02 Euros in cashIn the 2nd half of 2022  a total of:Purchase 21 942 shares 231 081.35 EUR 516 transactions Sale 19 972 shares 207 417.97 EUR 296 transactionsIt recalled that at the time of the half-yearly report at 30/06/2022  the following resources were included in the liquidity account:6 686 shares40 742.04 Euros in cashIt is recalled that when the new liquidity contract was set up on 17/11/2021  the following means were made available:‚Ä¢ 6 000 shares‚Ä¢ 50 000.00 Euros in cashTP ICAP (Europe) SA is authorised and regulated by the Autorit√© de Contr√¥le Prudentielet de R√©solution (ACPR) and the Autorit√© des March√©s Financiers (AMF).About Invibes AdvertisingInvibes Advertising is an international technology company specializing in digital advertising innovation. Founded in 2011 by co-CEOs Kris Vlaemynck and Nicolas Pollet  Invibes Advertising has developed an integrated technology platform designed to strengthen the relationship between brands and consumers through in-feed ads.At Invibes Advertising we believe in the power of connections.The power of connecting brands directly with consumers to enable more meaningful interactions.The power of connecting big data  innovative in-feed formats  wide reach and extensive intelligence services in a single  holistic platform to bring brands and consumers together seamlessly and efficiently.The power of connecting a unique pull of passionate  dynamic and knowledgeable in-feed specialists from across the globe to make up the extraordinary team that is Invibes Advertising.In order to partner with some of the greatest brands in the world  like Amazon  Bacardi  Volkswagen  Dell  IKEA and Toyota  we rely on even greater people to share our innovations with the world. Along with our unwavering belief in technological potential  more fundamentally  we believe in the potential of our people. At Invibes Advertising we actively strive to maintain an energetic  open environment that fosters a culture of ideation  growth and #GoodVibes  that shines straight through to our clients.Want to hear more about Invibes Advertising? Visit: www.invibes.comInvibes Advertising is listed on the Euronext Stock Exchange (Ticker: ALINV ‚Äì ISIN: BE0974299316)For our latest press releases  go to:https://www.invibes.com/uk/en/investors.htmlKeep up with all the latest news on Invibes Advertising:LinkedIn @Invibes Advertising Twitter @Invibes_advFinancial & Corporate Contacts:Kris Vlaemynck  co-CEO,neutral,0.01,0.99,0.0,positive,0.67,0.33,0.0,True,English,"['Invibes Advertising NV', 'Half-yearly report', 'liquidity contract', 'de Contr√¥le Prudentiel', 'Press release Half-yearly report', 'March√©s Financiers', 'international technology company', 'integrated technology platform', 'extensive intelligence services', 'single, holistic platform', 'energetic, open environment', 'Euronext Stock Exchange', 'latest press releases', 'digital advertising innovation', 'CEOs Kris Vlaemynck', 'new liquidity contract', 'Invibes Advertising NV', 'Invibes Advertising Twitter', 'latest news', 'Liquidity Problem', 'liquidity account', 'TP ICAP', 'Europe) SA', 'following resources', '2nd half', 'following means', 'R√©solution', 'Nicolas Pollet', 'feed ads', 'meaningful interactions', 'big data', 'feed formats', 'wide reach', 'unique pull', 'passionate, dynamic', 'feed specialists', 'extraordinary team', 'unwavering belief', 'Corporate Contacts', 'ALINV FP', 'greater people', 'technological potential', 'greatest brands', 'CET', 'CEST', 'London', 'Januray', 'shares', '31/12', '8.02 Euros', 'cash', 'total', 'Purchase', '516 transactions', '296 transactions', 'time', '2.04 Euros', '17/11', '50,000.00 Euros', 'ACPR', 'AMF', 'relationship', 'consumers', 'power', 'connections', 'innovative', 'knowledgeable', 'globe', 'order', 'world', 'Amazon', 'Bacardi', 'Volkswagen', 'Dell', 'IKEA', 'Toyota', 'innovations', 'culture', 'ideation', 'growth', 'clients', 'Visit', 'Ticker', 'investors', 'LinkedIn', 'Financial']",2023-01-16,2023-01-16,marketscreener.com
16553,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/FACEPHI-BIOMETR-A-S-A-111615266/news/FacePhi-Biometr-a-S-A-Half-year-report-on-the-implementation-of-Facephi-s-liquidity-contract-as-of-42743143/?utm_medium=RSS&utm_content=20230116,FacePhi Biometr√≠a S A : Half year report on the implementation of Facephi¬¥s liquidity contract as of 31.12.2022,(marketscreener.com)   Alicante  16th January 2023   Report on the implementation of the liquidity contract of   FacePhi for the second half of 2022   Dear Sirs    In accordance with the provisions of the Financial Markets Authority n¬∫ 2021-01 o‚Ä¶,"Alicante  16th January 2023Report on the implementation of the liquidity contract ofFacePhi for the second half of 2022Dear Sirs In accordance with the provisions of the Financial Markets Authority (AMF) n¬∫ 2021-01 of 22 June 2021 renewing the introduction of liquidity contracts on equity securities as an accepted market practice  FACEPHI BIOMETRIA  S.A. (hereinafter ""Facephi"" or ""the Company"")  an Euronext Growth Paris listed and traded firm (ticker: ALPHI) informs the public of the results of the implementation of the liquidity contract entered into with TSAF - Tradition Securities And Futures - for the second half of the year 2022.The following means were included in the account as of 31/12/2022:2 570 shares135 716.82 ‚Ç¨In the second half of the year 2022  the liquidity contract negotiated:BUY SELL Number of Shares 2 004 4 234 Number of transactions 11 15 Amount 4 712.05 ‚Ç¨ 10 277.75 ‚Ç¨ Transaction for each day Date Company B/S Number Price Amount in ‚Ç¨ 04/07/2022 FacePhi B 100 2.3 230 05/07/2022 FacePhi B 100 2.2 220 06/07/2022 FacePhi B 100 2.1 210 06/07/2022 FacePhi S 10 2.2 22 08/07/2022 FacePhi S 90 2.2 198 11/07/2022 FacePhi S 100 2.3 230 13/07/2022 FacePhi S 100 2.4 240 1www.facephi.com",neutral,0.0,1.0,0.0,neutral,0.01,0.98,0.0,True,English,"['FacePhi Biometr√≠a S A', 'Half year report', 'liquidity contract', 'implementation', '31.', 'Company B/S Number Price Amount', 'Financial Markets Authority', 'Euronext Growth Paris', 'BUY SELL Number', 'second half', 'Dear Sirs', 'equity securities', 'market practice', 'S.A.', 'Tradition Securities', 'following means', 'liquidity contract', 'FacePhi B', 'FacePhi S', 'Alicante', '16th', 'Report', 'implementation', 'accordance', 'provisions', 'AMF', '22 June', 'introduction', 'BIOMETRIA', 'firm', 'ticker', 'ALPHI', 'public', 'results', 'TSAF', 'Futures', 'year', 'account', '31/12', '2,570 shares', 'transactions', 'day', 'Date', '2022']",2023-01-16,2023-01-16,marketscreener.com
16554,EuroNext,NewsApi.org,https://www.prnewswire.co.uk/news-releases/dsm---delivery-of-shares-301722621.html,DSM - delivery of shares,This is a press release by Koninklijke DSM N.V. (Royal DSM)  pursuant to the provisions of Sections 13 paragraphs 1 and 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the Decree) in connection with the public offer by Danube A‚Ä¶,This is a press release by Koninklijke DSM N.V. (Royal DSM)  pursuant to the provisions of Sections 13 paragraphs 1 and 2 of the Dutch Decree on Public Takeover Bids (Besluit openbare biedingen Wft) (the Decree) in connection with the public offer by Danube AG (to be renamed DSM-Firmenich AG) for all the issued and outstanding ordinary shares in the capital of DSM (the Exchange Offer). This press release does not constitute an offer  or any solicitation of any offer  to buy or subscribe for any securities. This press release is not for general release  publication or distribution  in whole or in part  in or into  directly or indirectly  the United States or any other jurisdiction where such release  publication or distribution would violate applicable laws or regulations.HEERLEN  Netherlands  Jan. 16  2023 /PRNewswire/ -- Following the Offering Circular published on 22 November 2022  Royal DSM is required to announce transactions relating to the ordinary shares in its capital in accordance with the Dutch public offer rules. This includes the delivery of treasury shares to employees in view of settling the vesting of share units or the exercise of stock options.Pursuant to commitments entered into prior to issuing the Offering Circular  DSM has on 16 January 2023  delivered 420 ordinary shares to employees in view of settling the exercise of an equivalent number of stock options granted under the respective DSM Incentive Plan (average exercise price ‚Ç¨97.36). On the date hereof  the total number of issued and outstanding DSM ordinary shares is 173 080 990. As a consequence of the delivery included herein  the number of outstanding DSM ordinary shares increased by 0.0002%.DSMRoyal DSM is a global  purpose-led company in Health  Nutrition & Bioscience  applying science to improve the health of people  animals and the planet. DSM's purpose is to create brighter lives for all. DSM's products and solutions address some of the world's biggest challenges while simultaneously creating economic  environmental and societal value for all its stakeholders ‚Äì customers  employees  shareholders  and society at large. The company was founded in 1902 and is listed on Euronext Amsterdam. More information can be found at www.dsm.com.Or find us on:LinkedIn: http://www.linkedin.com/company/3108Twitter: http://www.twitter.com/DSMFacebook: http://www.facebook.com/DSMcompanyYouTube: http://www.youtube.com/user/dsmcompanyFor more informationDSM Media Relations Gareth Mead tel. +31 (0) 45 5782420 email media.contacts@dsm.com DSM Investor Relations Dave Huizing tel. +31 (0) 45 5782864 email investor.relations@dsm.comForward-looking statementsThis press release may contain forward-looking statements with respect to DSM's future (financial) performance and position. Such statements are based on current expectations  estimates and projections of DSM and information currently available to the company. DSM cautions readers that such statements involve certain risks and uncertainties that are difficult to predict and therefore it should be understood that many factors can cause actual performance and position to differ materially from these statements. DSM has no obligation to update the statements contained in this press release  unless required by law. The English language version of the press release is leading.Logo - https://mma.prnewswire.com/media/329419/dsm_logo.jpgSOURCE Royal DSM,neutral,0.02,0.98,0.0,mixed,0.26,0.14,0.6,True,English,"['DSM', 'delivery', 'shares', 'DSM Media Relations Gareth Mead', 'DSM Investor Relations Dave Huizing', 'Koninklijke DSM N.V.', 'respective DSM Incentive Plan', 'Dutch public offer rules', 'outstanding DSM ordinary shares', 'outstanding ordinary shares', 'Public Takeover Bids', 'English language version', 'future (financial) performance', 'average exercise price', 'global, purpose-led company', 'SOURCE Royal DSM', '420 ordinary shares', 'treasury shares', 'Dutch Decree', 'actual performance', 'Sections 13 paragraphs', 'biedingen Wft', 'Danube AG', 'Exchange Offer', 'United States', 'other jurisdiction', 'applicable laws', 'Offering Circular', 'share units', 'stock options', 'brighter lives', 'biggest challenges', 'economic, environmental', 'societal value', 'Euronext Amsterdam', 'current expectations', 'many factors', 'press release', 'general release', 'equivalent number', 'total number', 'Forward-looking statements', 'Such statements', 'More information', 'provisions', 'connection', 'capital', 'solicitation', 'securities', 'publication', 'distribution', 'part', 'regulations', 'HEERLEN', 'Netherlands', 'Jan.', '22 November', 'transactions', 'accordance', 'delivery', 'employees', 'view', 'vesting', 'commitments', '16 January', 'date', 'consequence', 'Health', 'Nutrition', 'Bioscience', 'people', 'animals', 'planet', 'products', 'solutions', 'world', 'stakeholders', 'customers', 'shareholders', 'society', 'LinkedIn', 'Twitter', 'Facebook', 'DSMcompany', 'YouTube', 'position', 'estimates', 'projections', 'readers', 'risks', 'uncertainties', 'obligation', 'Logo']",2023-01-16,2023-01-16,prnewswire.co.uk
16555,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/01/16/2589412/0/en/Guerbet-2023-Strategic-Priorities.html,Guerbet: 2023 Strategic Priorities,2023 Strategic Priorities        Diagnostic Imaging: increase EluciremTM sales and strengthen international positionsInterventional Imaging: prioritise......,English French2023 Strategic PrioritiesDiagnostic Imaging : increase Elucirem TM sales and strengthen international positions: increase Elucirem sales and strengthen international positions Interventional Imaging : prioritise Lipiodol sales with the development of innovative indications: prioritise Lipiodol sales with the development of innovative indications Artificial Intelligence: execution of the roadmap for the emergence of a major AI player dedicated to medical imaging in oncologyVillepinte  16 January 2023: Guerbet (FR0000032526 GBT)  a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.For several quarters  the Group has operated in an environment marked by a favorable trend in the contrast agent market  where structural volume growth seems to be accompanied by positive price effects over time  particularly in the face of difficult purchasing conditions (notably for iodine).In this demanding yet promising context  Guerbet intends to capitalise on its core target activities and established positions  allocate its resources to developing recognised products adapted to the immediate needs of professionals  and mobilising its teams around three main ambitions:Diagnostic Imaging: strategic reinforcementIn this market where Guerbet generates nearly 90% of its revenue  2023 will mark an important milestone with the market release in the United States of the first batches of the brand new EluciremTM  which is attracting strong interest from the scientific community and ordering parties. In Europe  the European Medicines Agency (EMA) review is expected in the second half of the year. In addition to ElucirmTM  the Group intends to strengthen its solid positions in diagnostic imaging (world‚Äôs number 2 in the MRI  number 4 in X-Rays) by supporting customer needs as close as possible with its comprehensive  interconnected offering  including contrast agents  injection systems  and digital solutions.Interventional Imaging: resources allocated to the growth of established productsCommercial development and expansion of applications of LipiodolEstablished for 40 years as a standard in the treatment of liver cancer  Lipiodol also has a strong foothold in other areas ‚Äì including vascular embolization  lymphography  and hysterosalpingography (HSG) ‚Äì which now account for a significant portion of sales volumes and future growth. The potential for development of new innovative indications appears to be significant  particularly in the treatment of musculoskeletal disorders  venous diseases  and post-surgery and cancer disorders. Research and development efforts will thus be accelerated in order to explore new applications for Lipiodol.Microcatheter activity divestment planIn connection with the evolution of its strategy aimed at leveraging key assets  Guerbet is planning the gradual divestment of its microcatheter activities historically housed within Accurate Medical Therapeutics. Since its acquisition in 2018  the microcatheters portfolio has been significantly expanded  now containing 38 references across the two SeQure¬Æ and DraKon‚Ñ¢ microcatheter ranges for peripheral embolization procedures. This activity has is not significant revenue contributor at the Group level and currently requires specialised  reinforced sales teams and significant investments to achieve its full commercial potential. These necessities are no longer in line with the Group‚Äôs development strategy.Guerbet also plans to divest the Occlugel technology acquired in 2018  including several ranges of microspheres for use in embolization.Artificial Intelligence: acceleration of the roadmapFollowing the termination of its collaboration with Merative (formerly IBM Watson Health) announced in October 2022  Guerbet has regained all the necessary latitude to roll out the commercial strategy while maintaining full ownership of the developed assets (application software source codes and algorithms) and their intellectual property. Very promising results were already obtained in 2022 in the detection of liver damage and prostate cancer. The commercial development of the solutions will benefit from the licensing agreement expected to be signed in the first half of 2023 with Intrasense following Guerbet‚Äôs acquisition of a stake in the company announced on 11 January. Guerbet ultimately aims to enable the development of a major player in artificial intelligence applied to medical imaging in oncology.Upcoming events:Publication of 2022 full-year revenueFebruary 9  2023  after tradingAbout GuerbetAt Guerbet  we build lasting relationships so that we enable people to live better. That is our purpose. We are a global leader in medical imaging  offering a comprehensive range of pharmaceutical products  medical devices  and digital and AI solutions for diagnostic and interventional imaging. As pioneers in contrast products for 95 years  with more than 2 600 employees worldwide  we continuously innovate and devote 8%-10% of our revenue to research and development in five centers in France  Israel  and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B ‚Äì mid caps) and generated ‚Ç¨732 million in revenue in 2021. For more information  please visit www.guerbet.com .About GadopiclenolGadopiclenol  initially invented by Guerbet with subsequent contribution of Bracco intellectual property  is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity. The efficacy and safety of Gadopiclenol have been evaluated in MRI of the Central Nervous System  head and neck  thorax  abdomen  pelvis and musculoskeletal system (refer to the approved USPI for full information).Details on Phase III clinical trials are available on www.ClinicalTrials.gov :‚Ä¢ Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) Full Text View - ClinicalTrials.gov‚Ä¢ Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) - Full Text View - ClinicalTrials.govGadopiclenol is currently in the process of examination by the European Medicines Agency.Forward-looking statementsThis press release may contain statements of a forward-looking nature  based on assumptions and predictions made by the management of the Guerbet group. Various known and unknown risks  uncertainties and other factors could lead to marked differences between the future results  financial situation  development and performances of the company  and the estimates made here. These factors include those mentioned in the public reports of Guerbet  available on its website www.guerbet.com .The company assumes no responsibility whatsoever in relation to the updating of these forward-looking statements  or how they correspond to future events or developments.Contacts:GuerbetJ√©r√¥me Estampes  Chief Financial Officer +33.1.45.91.50.00 / jerome.estampes@guerbet.comClaire Lauvernier  Communications Director +33.6.79.52.11.88 / claire.lauvernier@guerbet.comActifinMarianne Py  Financial Communications + 33.1.56.88.11.25 / mpy@actifin.frJennifer Jullia  Press +33.1.56.88.11.19 / jjullia@actifin.frAttachment,neutral,0.01,0.99,0.0,mixed,0.17,0.08,0.75,True,English,"['2023 Strategic Priorities', 'Guerbet', 'application software source codes', 'Microcatheter activity divestment plan', 'innovative indications Artificial Intelligence', '2023 Strategic Priorities Diagnostic Imaging', 'persistent inflationary pressures', 'positive price effects', 'difficult purchasing conditions', 'three main ambitions', 'European Medicines Agency', 'IBM Watson Health', 'new business opportunities', 'brand new EluciremTM', 'new innovative indications', 'core target activities', 'comprehensive, interconnected offering', 'DraKon‚Ñ¢ microcatheter ranges', 'Very promising results', 'Accurate Medical Therapeutics', 'structural volume growth', 'peripheral embolization procedures', 'Elucirem TM sales', 'major AI player', 'complex international environment', 'contrast agent market', 'significant revenue contributor', 'full commercial potential', 'microcatheter activities', 'gradual divestment', 'major player', 'Elucirem sales', 'strategic reinforcement', 'promising context', 'several ranges', 'full ownership', 'comprehensive range', 'medical imaging', 'contrast agents', 'significant portion', 'significant investments', 'new applications', 'Interventional Imaging', 'sales volumes', 'medical devices', 'international positions', 'English French', 'FR0000032526 GBT', 'global specialist', 'developing markets', 'several quarters', 'favorable trend', 'immediate needs', 'important milestone', 'market release', 'United States', 'first batches', 'strong interest', 'scientific community', 'ordering parties', 'EMA) review', 'second half', 'customer needs', 'injection systems', 'liver cancer', 'strong foothold', 'other areas', 'vascular embolization', 'future growth', 'musculoskeletal disorders', 'venous diseases', 'cancer disorders', 'microcatheters portfolio', 'two SeQure¬Æ', 'Occlugel technology', 'necessary latitude', 'intellectual property', 'liver damage', 'prostate cancer', 'licensing agreement', 'first half', 'Upcoming events', '2022 full-year revenue', 'lasting relationships', 'global leader', 'AI solutions', 'commercial strategy', 'solid positions', 'Commercial development', 'sales teams', 'Lipiodol sales', 'oncology Villepinte', 'recognised products', 'development efforts', 'key assets', 'pharmaceutical products', 'Group level', 'development strategy', 'digital solutions', 'execution', 'roadmap', 'emergence', 'Guerbet', 'revelation', 'time', 'face', 'iodine', 'demanding', 'resources', 'professionals', 'addition', 'ElucirmTM', 'world', 'MRI', 'X-Rays', 'expansion', '40 years', 'standard', 'treatment', 'lymphography', 'hysterosalpingography', 'HSG', 'post-surgery', 'Research', 'connection', 'evolution', 'acquisition', '38 references', 'necessities', 'line', 'microspheres', 'use', 'acceleration', 'termination', 'collaboration', 'Merative', 'October', 'algorithms', 'detection', 'Intrasense', 'stake', 'company', '11 January', 'Publication', 'February', 'people', 'purpose']",2023-01-16,2023-01-16,globenewswire.com
16556,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDI-36044/news/BGHL-EUR-NAV-s-42739160/?utm_medium=RSS&utm_content=20230116,BGHL (EUR): NAV(s),(marketscreener.com) ¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬† BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited would like...https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDI-36044/news/BGHL‚Ä¶,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 13 Jan 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 27.1859 ¬£ 23.9220 Estimated MTD return -2.09 % -2.05 % Estimated YTD return -2.09 % -2.05 % Estimated ITD return 171.86 % 139.22 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 22.00 N/A Premium/discount to estimated NAV -19.08 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 1 900.00 Premium/discount to estimated NAV N/A -20.58 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 302 469 126 294 Held in treasury 5 000 N/A Shares Issued 12 307 469 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 238.0429 Class GBP A Shares (estimated) ¬£ 127.6163The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.23,0.77,True,English,"['BGHL', 'EUR', 'NAV', 'A Liquidity Enhancement Agreement Euro Shares Sterling Shares Number', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'Class GBP A Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'N/A Sterling Shares Amsterdam', 'Guernsey Financial Services Commission', 'Dutch Financial Supervision Act', 'Sterling Shares Shares', 'Euro Shares Amsterdam', 'US Investment Company Act', 'A N/A Range', 'expert financial advice', 'GAVAUDAN HOLDING LIMITED', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'Gavaudan Investment Management', 'investment manager fees', 'BG Fund NAV', '5,000 N/A Shares', 'A Premium/discount', 'The Shares', 'Dutch Authority', 'Price N', 'N/A GBX', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'Emmanuel Gavaudan', 'The Company', 'investment performance', 'original investment', 'investment decision', 'NAV N/A', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'returns', 'AEX', 'LSE', 'Transactions', 'treasury', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-01-16,2023-01-16,marketscreener.com
16557,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDI-36044/news/BGHL-GBP-NAV-s-42739159/?utm_medium=RSS&utm_content=20230116,BGHL (GBP): NAV(s),(marketscreener.com)  ¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬†¬† BOUSSARD & GAVAUDAN HOLDING LIMITED Ordinary Shares The Directors of Boussard & Gavaudan Holding Limited...https://www.marketscreener.com/quote/stock/BOUSSARD-GAVAUDAN-HOLDI-36044/news/BGHL-GBP-NAV-‚Ä¶,"BOUSSARD & GAVAUDAN HOLDING LIMITEDOrdinary SharesThe Directors of Boussard & Gavaudan Holding Limited would like to announce the following information for the Company.Close of business 13 Jan 2023.Estimated NAVEuro Shares Sterling Shares Estimated NAV ‚Ç¨ 27.1859 ¬£ 23.9220 Estimated MTD return -2.09 % -2.05 % Estimated YTD return -2.09 % -2.05 % Estimated ITD return 171.86 % 139.22 %NAV and returns are calculated net of management and performance feesMarket informationEuro Shares Amsterdam (AEX) London (LSE) Market Close ‚Ç¨ 22.00 N/A Premium/discount to estimated NAV -19.08 % N/A Sterling Shares Amsterdam (AEX) London (LSE) Market Close N/A GBX 1 900.00 Premium/discount to estimated NAV N/A -20.58 %Transactions in own securities purchased into treasuryOrdinary Shares Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/A Range of Price N/A N/ALiquidity Enhancement Agreement Euro Shares Sterling Shares Number of shares N/A N/A Average Price N/A N/ABGHL CapitalBGHL Ordinary Shares Euro Shares Sterling Shares Shares Outstanding 12 302 469 126 294 Held in treasury 5 000 N/A Shares Issued 12 307 469 126 294Estimated BG Fund NAVClass B Euro Shares (estimated) ‚Ç¨ 238.0429 Class GBP A Shares (estimated) ¬£ 127.6163The Class B Euro Shares of BG Fund are not subject to investment manager fees  as the Investment Manager receives management fees and performance fees in respect of its role as Investment Manager of BGHL.For further information please contact:Boussard & Gavaudan Investment Management  LLP.Emmanuel Gavaudan +44 (0) 20 3751 5389 Email : info@bgam-uk.comThe Company is established as a closed-ended investment company domiciled in Guernsey. The Company has received the necessary approval of the Guernsey Financial Services Commission and the States of Guernsey Policy Council. The Company is registered with the Dutch Authority for the Financial Markets as a collective investment scheme pursuant to article 2:73 in conjunction with 2:66 of the Dutch Financial Supervision Act (Wet op het financieel toezicht). The shares of the Company (the ""Shares"") are listed on Euronext Amsterdam. The Shares are also listed on the Official List of the UK Listing Authority and admitted to trading on the London Stock Exchange plc's main market for listed securities.This is not an offer to sell or a solicitation of any offer to buy any securities in the United States or in any other jurisdiction. This announcement is not intended to and does not constitute  or form part of  any offer or invitation to purchase any securities or the solicitation of any vote or approval in any jurisdiction  nor shall there be any sale  issuance or transfer of the securities referred to in this announcement in any jurisdiction in contravention of applicable law.Neither the Company nor BG Fund ICAV has been  and neither will be  registered under the US Investment Company Act of 1940  as amended (the ""Investment Company Act""). In addition the securities referenced in this announcement have not been and will not be registered under the US Securities Act of 1933  as amended (the ""Securities Act""). Consequently any such securities may not be offered  sold or otherwise transferred within the United States or to  or for the account or benefit of  US persons except in accordance with the Securities Act or an exemption therefrom and under circumstances which will not require the issuer of such securities to register under the Investment Company Act. No public offering of any securities will be made in the United States.You should always bear in mind that:all investment is subject to risk;results in the past are no guarantee of future results;the investment performance of BGHL may go down as well as up. You may not get back all of your original investment; andif you are in any doubt about the contents of this communication or if you consider making an investment decision  you are advised to seek expert financial advice.This communication is for information purposes only and the information contained in this communication should not be relied upon as a substitute for financial or other professional advice.Attachment",neutral,0.0,1.0,0.0,negative,0.0,0.23,0.77,True,English,"['BGHL', 'GBP', 'NAV', 'A Liquidity Enhancement Agreement Euro Shares Sterling Shares Number', 'The Class B Euro Shares', 'BGHL Ordinary Shares Euro Shares', 'Class GBP A Shares', 'A N/A Average Price', 'London Stock Exchange plc', 'N/A Sterling Shares Amsterdam', 'Guernsey Financial Services Commission', 'Dutch Financial Supervision Act', 'Sterling Shares Shares', 'Euro Shares Amsterdam', 'US Investment Company Act', 'A N/A Range', 'expert financial advice', 'GAVAUDAN HOLDING LIMITED', 'Guernsey Policy Council', 'collective investment scheme', 'other professional advice', 'BG Fund ICAV', 'closed-ended investment company', 'UK Listing Authority', 'US Securities Act', 'Gavaudan Investment Management', 'investment manager fees', 'BG Fund NAV', '5,000 N/A Shares', 'A Premium/discount', 'The Shares', 'Dutch Authority', 'Price N', 'N/A GBX', 'Euronext Amsterdam', 'US persons', 'Financial Markets', 'The Directors', 'Emmanuel Gavaudan', 'The Company', 'investment performance', 'original investment', 'investment decision', 'NAV N/A', 'performance fees', 'BGHL Capital', 'management fees', 'MTD return', 'YTD return', 'ITD return', 'financieel toezicht', 'Official List', 'applicable law', 'public offering', 'other jurisdiction', 'United States', 'following information', 'information purposes', 'necessary approval', 'main market', 'future results', 'listed securities', 'Market information', 'BOUSSARD', 'business', 'returns', 'AEX', 'LSE', 'Transactions', 'treasury', 'respect', 'role', 'LLP.', 'Email', 'article', 'conjunction', 'solicitation', 'announcement', 'part', 'invitation', 'vote', 'sale', 'issuance', 'transfer', 'contravention', 'addition', 'account', 'benefit', 'accordance', 'exemption', 'circumstances', 'issuer', 'mind', 'risk', 'past', 'guarantee', 'doubt', 'contents', 'communication', 'substitute', 'Attachment']",2023-01-16,2023-01-16,marketscreener.com
16558,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/GUERBET-5011/news/Guerbet-2023-Strategic-Priorities-42743105/?utm_medium=RSS&utm_content=20230116,Guerbet: 2023 Strategic Priorities,(marketscreener.com) Full Text View - ClinicalTrials.gov Gadopiclenol is currently in the process of examination by the European Medicines Agency. ¬†Forward-looking statements This press release may contain statements of a forward-looking nature  based on assu‚Ä¶,2023 Strategic PrioritiesDiagnostic Imaging : increase Elucirem TM sales and strengthen international positions: increase Elucirem sales and strengthen international positions Interventional Imaging : prioritise Lipiodol sales with the development of innovative indications: prioritise Lipiodol sales with the development of innovative indications Artificial Intelligence: execution of the roadmap for the emergence of a major AI player dedicated to medical imaging in oncologyVillepinte  16 January 2023: Guerbet (FR0000032526 GBT)  a global specialist in contrast agents and solutions for medical imaging has announced its strategic priorities for 2023 in a complex international environment characterised by persistent inflationary pressures and the revelation of new business opportunities for products listed in developing markets.For several quarters  the Group has operated in an environment marked by a favorable trend in the contrast agent market  where structural volume growth seems to be accompanied by positive price effects over time  particularly in the face of difficult purchasing conditions (notably for iodine).In this demanding yet promising context  Guerbet intends to capitalise on its core target activities and established positions  allocate its resources to developing recognised products adapted to the immediate needs of professionals  and mobilising its teams around three main ambitions:Diagnostic Imaging: strategic reinforcementIn this market where Guerbet generates nearly 90% of its revenue  2023 will mark an important milestone with the market release in the United States of the first batches of the brand new EluciremTM  which is attracting strong interest from the scientific community and ordering parties. In Europe  the European Medicines Agency (EMA) review is expected in the second half of the year. In addition to ElucirmTM  the Group intends to strengthen its solid positions in diagnostic imaging (world‚Äôs number 2 in the MRI  number 4 in X-Rays) by supporting customer needs as close as possible with its comprehensive  interconnected offering  including contrast agents  injection systems  and digital solutions.Interventional Imaging: resources allocated to the growth of established productsCommercial development and expansion of applications of LipiodolEstablished for 40 years as a standard in the treatment of liver cancer  Lipiodol also has a strong foothold in other areas ‚Äì including vascular embolization  lymphography  and hysterosalpingography (HSG) ‚Äì which now account for a significant portion of sales volumes and future growth. The potential for development of new innovative indications appears to be significant  particularly in the treatment of musculoskeletal disorders  venous diseases  and post-surgery and cancer disorders. Research and development efforts will thus be accelerated in order to explore new applications for Lipiodol.Microcatheter activity divestment planIn connection with the evolution of its strategy aimed at leveraging key assets  Guerbet is planning the gradual divestment of its microcatheter activities historically housed within Accurate Medical Therapeutics. Since its acquisition in 2018  the microcatheters portfolio has been significantly expanded  now containing 38 references across the two SeQure¬Æ and DraKon‚Ñ¢ microcatheter ranges for peripheral embolization procedures. This activity has is not significant revenue contributor at the Group level and currently requires specialised  reinforced sales teams and significant investments to achieve its full commercial potential. These necessities are no longer in line with the Group‚Äôs development strategy.Guerbet also plans to divest the Occlugel technology acquired in 2018  including several ranges of microspheres for use in embolization.Artificial Intelligence: acceleration of the roadmapFollowing the termination of its collaboration with Merative (formerly IBM Watson Health) announced in October 2022  Guerbet has regained all the necessary latitude to roll out the commercial strategy while maintaining full ownership of the developed assets (application software source codes and algorithms) and their intellectual property. Very promising results were already obtained in 2022 in the detection of liver damage and prostate cancer. The commercial development of the solutions will benefit from the licensing agreement expected to be signed in the first half of 2023 with Intrasense following Guerbet‚Äôs acquisition of a stake in the company announced on 11 January. Guerbet ultimately aims to enable the development of a major player in artificial intelligence applied to medical imaging in oncology.Upcoming events:Publication of 2022 full-year revenueFebruary 9  2023  after tradingAbout GuerbetAt Guerbet  we build lasting relationships so that we enable people to live better. That is our purpose. We are a global leader in medical imaging  offering a comprehensive range of pharmaceutical products  medical devices  and digital and AI solutions for diagnostic and interventional imaging. As pioneers in contrast products for 95 years  with more than 2 600 employees worldwide  we continuously innovate and devote 8%-10% of our revenue to research and development in five centers in France  Israel  and the United States. Guerbet (GBT) is listed on Euronext Paris (segment B ‚Äì mid caps) and generated ‚Ç¨732 million in revenue in 2021. For more information  please visit www.guerbet.com .About GadopiclenolGadopiclenol  initially invented by Guerbet with subsequent contribution of Bracco intellectual property  is a new macrocyclic gadolinium-based contrast agent (GBCA) with high relaxivity. The efficacy and safety of Gadopiclenol have been evaluated in MRI of the Central Nervous System  head and neck  thorax  abdomen  pelvis and musculoskeletal system (refer to the approved USPI for full information).Details on Phase III clinical trials are available on www.ClinicalTrials.gov :‚Ä¢ Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI) Full Text View - ClinicalTrials.gov‚Ä¢ Efficacy and Safety of Gadopiclenol for Body Magnetic Resonance Imaging (MRI) - Full Text View - ClinicalTrials.govGadopiclenol is currently in the process of examination by the European Medicines Agency.Forward-looking statementsThis press release may contain statements of a forward-looking nature  based on assumptions and predictions made by the management of the Guerbet group. Various known and unknown risks  uncertainties and other factors could lead to marked differences between the future results  financial situation  development and performances of the company  and the estimates made here. These factors include those mentioned in the public reports of Guerbet  available on its website www.guerbet.com .The company assumes no responsibility whatsoever in relation to the updating of these forward-looking statements  or how they correspond to future events or developments.Contacts:GuerbetJ√©r√¥me Estampes  Chief Financial Officer +33.1.45.91.50.00 / jerome.estampes@guerbet.comClaire Lauvernier  Communications Director +33.6.79.52.11.88 / claire.lauvernier@guerbet.comActifinMarianne Py  Financial Communications + 33.1.56.88.11.25 / mpy@actifin.frJennifer Jullia  Press +33.1.56.88.11.19 / jjullia@actifin.frAttachment,neutral,0.01,0.99,0.0,negative,0.15,0.06,0.79,True,English,"['2023 Strategic Priorities', 'Guerbet', 'application software source codes', 'Microcatheter activity divestment plan', 'innovative indications Artificial Intelligence', 'persistent inflationary pressures', 'positive price effects', 'difficult purchasing conditions', 'three main ambitions', 'European Medicines Agency', 'IBM Watson Health', 'new business opportunities', 'brand new EluciremTM', 'new innovative indications', 'core target activities', 'comprehensive, interconnected offering', 'DraKon‚Ñ¢ microcatheter ranges', 'Very promising results', 'Accurate Medical Therapeutics', 'structural volume growth', 'peripheral embolization procedures', 'Elucirem TM sales', 'major AI player', 'complex international environment', 'contrast agent market', 'significant revenue contributor', 'full commercial potential', 'microcatheter activities', 'gradual divestment', 'major player', 'Elucirem sales', 'promising context', 'several ranges', 'full ownership', 'comprehensive range', 'contrast agents', 'significant portion', 'significant investments', 'new applications', 'medical imaging', 'sales volumes', 'medical devices', 'international positions', '2023 Strategic Priorities', 'Interventional Imaging', 'FR0000032526 GBT', 'global specialist', 'developing markets', 'several quarters', 'favorable trend', 'demanding yet', 'immediate needs', 'strategic reinforcement', 'important milestone', 'market release', 'United States', 'first batches', 'strong interest', 'scientific community', 'ordering parties', 'EMA) review', 'second half', 'customer needs', 'injection systems', 'liver cancer', 'strong foothold', 'other areas', 'vascular embolization', 'future growth', 'musculoskeletal disorders', 'venous diseases', 'cancer disorders', 'microcatheters portfolio', 'two SeQure¬Æ', 'Occlugel technology', 'necessary latitude', 'intellectual property', 'liver damage', 'prostate cancer', 'licensing agreement', 'first half', 'Upcoming events', '2022 full-year revenue', 'lasting relationships', 'global leader', 'AI solutions', 'commercial strategy', 'Diagnostic Imaging', 'solid positions', 'Commercial development', 'sales teams', 'Lipiodol sales', 'oncology Villepinte', 'recognised products', 'development efforts', 'key assets', 'pharmaceutical products', 'Group level', 'development strategy', 'digital solutions', 'execution', 'roadmap', 'emergence', 'Guerbet', 'revelation', 'time', 'face', 'iodine', 'resources', 'professionals', 'addition', 'ElucirmTM', 'world', 'MRI', 'X-Rays', 'expansion', '40 years', 'standard', 'treatment', 'lymphography', 'hysterosalpingography', 'HSG', 'post-surgery', 'Research', 'connection', 'evolution', 'acquisition', '38 references', 'necessities', 'line', 'microspheres', 'use', 'acceleration', 'termination', 'collaboration', 'Merative', 'October', 'algorithms', 'detection', 'Intrasense', 'stake', 'company', '11 January', 'Publication', 'February', 'people', 'purpose']",2023-01-16,2023-01-16,marketscreener.com
16559,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/PHARNEXT-SA-29750723/news/Pharnext-Presentation-corporate-de-Pharnext-42742728/?utm_medium=RSS&utm_content=20230116,Pharnext : Pr√©sentation corporate de Pharnext,(marketscreener.com)    1   New Therapies   for Neurodegenerative Diseases   CORPORATE PRESENTATION     January 2022         Disclaimer  ...https://www.marketscreener.com/quote/stock/PHARNEXT-SA-29750723/news/Pharnext-Presentation-‚Ä¶,"Disclaimer 2References herein to this presentation (the ""Presentation"") shall mean and include this document  any oral presentation accompanying this document provided by Pharnext SA (the ""Company"") and any further information that may be made available in connection with the subject matter contained herein.By viewing or receiving or reading this Presentation or attending any meeting where this Presentation is made  you agree to be bound by the limitations  qualifications and restrictions set out below:This Presentation is confidential  is intended for the recipient only and thus may not be forwarded  reproduced  redistributed or passed to any other person or published in whole or in part for any purpose. If this document has been received in error  it must be returned immediately to the Company. By receiving this Presentation  you become bound by the above-referred confidentiality obligation. Failure to comply with such confidentiality obligation may result in civil  administrative or criminal liabilities.Recipients of the Presentation should not deal or encourage any other person to deal in the securities of the Company.This Presentation is not directed to  or intended for distribution to or use by  any person or entity that is a citizen or resident or located in any locality  state  country or other jurisdiction where such distribution  transmission  publication  availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction.No securities of the Company have been registered under the U.S. Securities Act of 1933  as amended (the ""U.S. Securities Act"")  or under any state securities laws  and the securities of the Company may not be offered or sold in the United States (or to  or for the account or benefit of U.S. Persons) except pursuant to an exemption from  or a transaction not subject to  the registration requirements of the U.S. Securities Act. The Company has no current intention to register in the United States any portion of its securities or to conduct a public offering of any of its securities in the United States.No action has been undertaken or will be undertaken to make an offer to the public of securities requiring a publication of a prospectus in the United Kingdom or any member State of the European Economic Area (each a ""Relevant State""). As a result  the securities may not and will not be offered in any Member State  except pursuant to Article 1(4) or Article 3(2) of Regulation (EU) 2017/1129 of June 14  2017 (the ""Prospectus Regulation"") or under other circumstances not requiring the Company to publish a prospectus pursuant to the Prospectus Regulation and/or the applicable regulations in such Relevant States. For the purposes of this paragraph  ""securities offered to the public"" in a given Relevant State means a communication to any persons  in any form and by any means  presenting sufficient information on the terms of the offer and the securities to be offered  so as to enable an investor to decide to purchase or subscribe for those securities  as the same may be varied in that Relevant State.This Presentation has been prepared by the Company and is for information only. This document does not purport to contain comprehensive or complete information about the Company and is qualified in its entirety by the business  financial and other information that the Company is required to publish in accordance with the rules  regulations and practices applicable to companies listed on Euronext Growth Paris  including  in particular  the risk factors set out in the Company's annual management report to the shareholders  and in any other periodic report  which are available free of charge on the website of the Company (www.pharnext.fr). Information and other data appearing in such publications  and certain figures and numbers appearing in this document have been rounded. Consequently  the total amounts and percentages appearing in tables and elsewhere may not necessarily equal the sum of the individually rounded figures  amounts or percentages.No representation  warranty or undertaking  express or implied  is made as to the accuracy  completeness or appropriateness of the information and opinions contained in this Presentation  or its use for any purpose  and no reliance should be placed on any information or opinions contained herein. The Company  its subsidiaries  its advisors and representatives accept no responsibility for and shall not  under any circumstance  be held liable for any loss or damage that may arise from the use of this document or the information or opinions contained in it. In particular  this document contains information on the Company's markets and competitive position  and more specifically  on the size of its markets. This information has been drawn from various sources or from the Company's own estimates which may not be accurate and thus no reliance should be placed on such information. Any prospective investors must make their own investigation and assessments and consult with their own advisors concerning any evaluation of the Company and its prospects  and this document  or any part of it  may not form the basis of or be relied on in connection with any contact  commitment or investment decision.The information and opinions contained in this document are provided as of the date of this document only and may be updated  supplemented  revised or amended  and thus such information is subject to change at any time. Neither the Company  nor its advisors  nor any other person is under any obligation to update the information  statements or opinions contained in this document.All statements in the Presentation other than statements of historical fact are or may be deemed to be forward-looking statements. These forward-looking statements are not guarantees of future performance and involve a number of known and unknown risks and uncertainties. These risks and uncertainties  and other factors  could adversely affect the outcome of the forward- looking statements  and actual results could differ materially from those contemplated in the statements. As a result  you are cautioned not to rely on such forward-looking statements. Forward-looking statements speak only as of the date of this document and the Company expressly disclaims any obligation or undertaking to update or re-issue any forward-looking statements contained in this Presentation.Especially in the context of the current health crisis  these risks and uncertainties  include among other things  the uncertainties inherent in research and development of new products  including future clinical trial results and analysis of clinical data (including post marketing data)  decisions by regulatory authorities  such as the Food and Drug Admnistration or the European Medicines Agency  regarding whether and when to approve any drug  device or biological application that may be filed for any such product and candidates  as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates.",neutral,0.01,0.99,0.0,negative,0.0,0.2,0.8,True,English,"['Pr√©sentation', 'Pharnext', 'corporate', 'U.S. Securities Act', 'U.S. Persons', 'European Economic Area', 'Euronext Growth Paris', 'annual management report', 'other periodic report', 'state securities laws', 'other circumstances', 'other data', 'Pharnext SA', 'subject matter', 'confidentiality obligation', 'civil, administrative', 'criminal liabilities', 'United States', 'current intention', 'United Kingdom', 'member State', 'Relevant State', 'risk factors', 'competitive position', 'various sources', 'prospective investors', 'other person', 'other jurisdiction', 'registration requirements', 'applicable regulations', 'total amounts', 'other information', 'public offering', 'sufficient information', 'complete information', 'The Company', 'oral presentation', 'Prospectus Regulation', 'Disclaimer', 'References', 'document', 'connection', 'meeting', 'limitations', 'qualifications', 'restrictions', 'recipient', 'part', 'purpose', 'error', 'Failure', 'distribution', 'use', 'entity', 'citizen', 'resident', 'locality', 'country', 'transmission', 'publication', 'availability', 'licensing', 'account', 'benefit', 'exemption', 'transaction', 'portion', 'result', 'Article', 'June', 'paragraph', 'communication', 'means', 'terms', 'comprehensive', 'entirety', 'financial', 'accordance', 'rules', 'practices', 'companies', 'shareholders', 'charge', 'website', 'figures', 'numbers', 'percentages', 'tables', 'sum', 'representation', 'warranty', 'undertaking', 'accuracy', 'completeness', 'appropriateness', 'opinions', 'reliance', 'subsidiaries', 'advisors', 'representatives', 'responsibility', 'loss', 'damage', 'markets', 'size', 'estimates', 'investigation', 'assessments']",2023-01-16,2023-01-16,marketscreener.com
16560,EuroNext,NewsApi.org,https://www.marketscreener.com/quote/stock/KLEPIERRE-4665/news/Klepierre-SEMI-ANNUAL-STATEMENT-OF-LIQUIDITY-AGREEMENT-42742817/?utm_medium=RSS&utm_content=20230116,Kl√©pierre : SEMI-ANNUAL STATEMENT OF LIQUIDITY AGREEMENT,(marketscreener.com) REGULATED RELEASE SEMI-ANNUAL STATEMENTOF LIQUIDITY AGREEMENT Paris ‚Äì January 16  2023 In accordance with the provisions of the French Financial Markets Authority‚Äôs decision no.¬†2021-01 of June¬†22 ¬†2021  establishing liquidity contracts a‚Ä¶,REGULATED RELEASESEMI-ANNUAL STATEMENTOF LIQUIDITY AGREEMENTParis ‚Äì January 16  2023In accordance with the provisions of the French Financial Markets Authority‚Äôs decision no. 2021-01 of June 22  2021  establishing liquidity contracts as an accepted market practice  Kl√©pierre informs the public of the implementation of the liquidity contract for the second half of 2022:Available resources on December 31  2022: 0 Kl√©pierre share and 10 731 679.00 euros;Number of transactions on buy side over second half of 2022: 4 619 ;Number of transactions on sell side over second half of 2022: 5 363 ;Traded volume on buy side over second half of 2022: 1 217 464 shares for 24 881 044.46 euros ;Traded volume on sell side over second half of 2022: 1 247 464 shares for 25 461 380.60 euros.As a reminder At June 30  2022  available resources were 30 000 Kl√©pierre shares and 10 151 343.00 euros.At the date of signature of the liquidity contract with Rothschild Martin Maurel  February 1  2019  the available resources were 307 923 Kl√©pierre shares and 1 768 835.76 euros.TRANSACTIONS DETAILSDate Buy side Number of transactions Sell side Number of transactions Buy side Number of shares Sell side Number of shares Buy side Traded volume in EUR Sell side Traded volume in EUR 01-Jul-22 69 62 7 300 5 300 133 955.00 97 361.00 04-Jul-22 48 57 19 500 15 000 355 680.00 273 750.00 05-Jul-22 40 37 15 500 12 000 280 860.00 217 440.00 06-Jul-22 49 99 13 500 22 500 245 970.00 410 175.00 07-Jul-22 5 71 2 000 15 000 37 080.00 281 250.00 08-Jul-22 9 54 3 500 12 500 67 480.00 243 750.00 11-Jul-22 43 45 13 750 13 500 270 875.00 266 355.00 12-Jul-22 29 55 10 000 17 250 198 000.00 344 482.50 13-Jul-22 68 85 26 316 25 816 529 741.08 520 708.72 14-Jul-22 44 23 12 000 4 750 238 200.00 94 667.50 15-Jul-22 3 62 1 500 11 250 29 895.00 226 800.00 18-Jul-22 28 26 5 000 4 500 103 450.00 93 465.00 19-Jul-22 11 13 2 500 2 550 52 550.00 53 703.00 20-Jul-22 69 56 28 515 13 465 598 815.00 282 765.00 21-Jul-22 41 34 8 000 5 000 164 160.00 102 750.00 22-Jul-22 8 91 2 500 21 000 51 825.00 440 790.00 25-Jul-22 21 18 3 763 3 263 80 603.46 70 219.76 26-Jul-22 37 47 7 030 7 530 149 528.10 160 464.30 27-Jul-22 73 76 13 267 12 967 279 005.01 274 641.06 28-Jul-22 62 101 14 046 14 346 301 708.08 308 295.54 29-Jul-22 35 35 7 034 5 534 153 552.22 120 862.56 July 2022 792 1 147 216 521 245 021 4 322 932.95 4 884 695.94 01-Aug-22 46 7 13 500 1 500 291 330.00 32 685.00 02-Aug-22 34 106 10 500 19 500 224 070.00 418 470.00 03-Aug-22 36 51 10 500 12 000 227 220.00 260 400.00 04-Aug-22 27 29 7 750 9 750 168 717.50 212 745.00 05-Aug-22 40 22 6 750 4 750 146 070.00 103 122.50 08-Aug-22 32 38 9 000 11 700 197 910.00 257 400.00 09-Aug-22 23 16 6 750 6 050 148 837.50 133 705.00 10-Aug-22 35 36 4 966 5 666 111 288.06 127 088.38 11-Aug-22 24 16 5 950 3 750 135 422.00 85 500.00 12-Aug-22 22 32 6 000 8 200 137 040.00 187 780.00 15-Aug-22 34 13 8 200 7 000 188 846.00 161 350.00 16-Aug-22 31 8 6 950 1 950 159 085.50 45 025.50 17-Aug-22 40 0 8 500 0 190 995.00 0.00 18-Aug-22 42 20 11 250 3 750 249 187.50 83 550.00 19-Aug-22 37 41 10 500 10 500 226 905.00 227 640.00 22-Aug-22 34 25 9 500 12 000 201 495.00 255 840.00 23-Aug-22 26 22 7 500 6 500 161 250.00 140 335.00 24-Aug-22 27 23 8 000 6 000 167 600.00 126 420.00 25-Aug-22 29 49 6 956 7 456 146 006.44 156 874.24 26-Aug-22 63 53 16 750 6 750 349 405.00 142 155.00 29-Aug-22 23 33 6 500 8 000 132 990.00 163 920.00 30-Aug-22 25 29 7 000 5 500 144 620.00 114 235.00 31-Aug-22 24 13 6 750 2 250 139 252.50 46 710.00 August 2022 754 682 196 022 160 522 4 245 543.00 3 482 950.62Date Buy side Number of transactions Sell side Number of transactions Buy side Number of shares Sell side Number of shares Buy side Traded volume in EUR Sell side Traded volume in EUR 01-Sep-22 83 72 26 500 26 000 520 990.00 511 940.00 02-Sep-22 46 53 15 500 18 000 307 520.00 358 920.00 05-Sep-22 39 43 10 000 12 000 198 900.00 239 040.00 06-Sep-22 41 40 10 000 13 000 201 800.00 262 860.00 07-Sep-22 26 50 8 250 20 750 165 660.00 419 980.00 08-Sep-22 78 55 23 250 17 250 468 952.50 348 795.00 09-Sep-22 28 78 6 000 13 750 122 460.00 280 637.50 12-Sep-22 26 67 7 500 13 250 155 550.00 275 467.50 13-Sep-22 49 15 16 750 4 250 345 217.50 88 612.50 14-Sep-22 11 16 4 000 4 500 81 000.00 91 305.00 15-Sep-22 28 12 9 000 2 500 181 170.00 50 600.00 16-Sep-22 103 192 16 500 37 500 335 940.00 765 000.00 19-Sep-22 75 0 17 500 0 346 850.00 0.00 20-Sep-22 66 12 15 750 2 250 308 070.00 44 730.00 21-Sep-22 31 46 9 000 12 500 169 380.00 235 875.00 22-Sep-22 10 0 5 000 0 92 150.00 0.00 23-Sep-22 17 0 4 000 0 71 080.00 0.00 26-Sep-22 1 0 1 000 0 17 450.00 0.00 27-Sep-22 73 41 15 500 8 000 271 405.00 140 320.00 28-Sep-22 2 0 1 000 0 16 700.00 0.00 29-Sep-22 1 0 500 0 8 670.00 0.00 30-Sep-22 0 1 0 1 500 0.00 26 850.00 September 2022 834 793 222 500 207 000 4 386 915.00 4 140 932.50 03-Oct-22 0 3 0 1 000 0.00 18 270.00 04-Oct-22 92 121 19 750 15 750 366 165.00 294 052.50 05-Oct-22 39 10 6 500 2 000 118 040.00 37 140.00 07-Oct-22 30 41 6 500 9 000 115 375.00 159 840.00 10-Oct-22 1 0 1 250 0 21 762.50 0.00 11-Oct-22 0 1 0 1 750 0.00 31 115.00 12-Oct-22 2 0 3 000 0 52 890.00 0.00 13-Oct-22 82 83 20 000 17 500 357 800.00 314 300.00 14-Oct-22 16 35 4 750 7 250 86 355.00 132 530.00 17-Oct-22 59 150 12 500 30 000 229 250.00 554 100.00 18-Oct-22 128 231 25 000 43 669 468 250.00 820 540.51 19-Oct-22 20 72 3 500 12 331 66 080.00 235 152.17 20-Oct-22 38 76 15 500 18 000 292 175.00 340 920.00 21-Oct-22 76 23 15 000 7 500 277 950.00 138 975.00 24-Oct-22 140 222 28 000 40 500 526 680.00 763 425.00 25-Oct-22 97 131 24 750 31 950 470 992.50 610 245.00 26-Oct-22 143 113 35 250 35 050 693 720.00 690 835.50 27-Oct-22 59 57 15 950 16 050 318 840.50 321 642.00 28-Oct-22 32 28 9 000 9 400 181 530.00 190 068.00 31-Oct-22 41 29 10 000 6 500 203 300.00 132 340.00 October 2022 1 095 1 426 256 200 305 200 4 847 155.50 5 785 490.68Date Buy side Number of transactions Sell side Number of transactions Buy side Number of shares Sell side Number of shares Buy side Traded volume in EUR Sell side Traded volume in EUR 01-Nov-22 34 51 8 349 11 849 170 486.58 243 022.99 02-Nov-22 42 39 15 000 14 700 305 550.00 300 027.00 03-Nov-22 61 67 16 450 16 400 326 368.00 326 360.00 04-Nov-22 55 58 16 000 16 050 325 280.00 327 259.50 07-Nov-22 20 15 4 500 4 550 92 565.00 93 684.50 08-Nov-22 21 24 6 050 6 000 124 267.00 123 480.00 09-Nov-22 35 48 9 450 9 250 193 158.00 189 625.00 10-Nov-22 51 50 12 969 13 169 276 628.77 281 289.84 14-Nov-22 28 27 8 250 6 550 186 037.50 147 899.00 15-Nov-22 64 87 16 500 18 200 371 910.00 412 048.00 16-Nov-22 35 40 10 500 10 300 232 995.00 229 175.00 17-Nov-22 29 4 7 950 950 176 728.50 21 289.50 18-Nov-22 9 60 7 606 14 806 168 320.78 328 397.08 21-Nov-22 28 30 7 500 7 450 168 375.00 167 252.50 22-Nov-22 24 9 10 400 2 300 231 608.00 51 658.00 23-Nov-22 31 21 9 800 8 250 216 874.00 183 150.00 24-Nov-22 28 92 7 500 17 200 168 150.00 386 484.00 25-Nov-22 18 24 4 500 4 800 100 575.00 107 520.00 28-Nov-22 36 57 7 800 7 500 172 380.00 166 125.00 29-Nov-22 31 34 8 250 8 050 183 067.50 179 193.00 30-Nov-22 41 15 9 000 3 200 198 900.00 71 392.00 November 2022 721 852 204 324 201 524 4 390 224.63 4 336 331.91 01-Dec-22 42 71 13 700 19 800 303 592.00 439 164.00 02-Dec-22 14 14 4 100 4 300 90 200.00 94 858.00 05-Dec-22 36 40 8 550 8 250 190 066.50 183 892.50 06-Dec-22 12 10 4 947 4 747 110 268.63 106 095.45 07-Dec-22 17 18 6 800 7 000 150 144.00 154 910.00 08-Dec-22 34 39 9 475 9 450 208 923.75 208 750.50 09-Dec-22 25 26 8 000 8 325 178 160.00 185 980.50 12-Dec-22 52 3 14 000 10 000 305 900.00 218 000.00 13-Dec-22 42 62 10 500 14 200 233 940.00 314 814.00 14-Dec-22 24 26 6 750 6 550 151 200.00 147 244.00 15-Dec-22 11 18 3 500 3 700 79 100.00 83 768.00 16-Dec-22 24 4 5 350 3 650 118 074.50 79 752.50 19-Dec-22 5 7 1 500 3 000 32 670.00 65 430.00 20-Dec-22 17 9 4 500 4 000 94 905.00 84 720.00 21-Dec-22 0 2 0 700 0.00 14 924.00 22-Dec-22 10 13 2 250 2 050 48 870.00 44 649.00 23-Dec-22 6 9 1 975 2 475 42 936.50 54 054.00 27-Dec-22 11 0 5 000 0 109 400.00 0.00 28-Dec-22 21 63 5 250 9 450 114 765.00 207 522.00 29-Dec-22 9 8 2 000 2 500 43 520.00 54 525.00 30-Dec-22 11 21 3 750 4 050 81 637.50 87 925.50 December 2022 423 463 121 897 128 197 2 688 273.38 2 830 978.95 SECOND HALF 2022 4 619 5 363 1 217 464 1 247 464 24 881 044.46 25 461 380.60INVESTOR RELATIONS CONTACTS Paul Logerot  Group Head of IR and Financial Communication+33 (0)7 50 66 05 63 ‚Äî paul.logerot@klepierre.comTanguy Phelippeau  IR Officer+33 (0)7 72 09 29 57 ‚Äî tanguy.phelippeau@klepierre.comABOUT KL√âPIERREKl√©pierre is the European leader in shopping malls  combining property development and asset management skills. The Company‚Äôs portfolio is valued at ‚Ç¨20.6 billion at June 30  2022  and comprises large shopping centers in more than 10 countries in Continental Europe which together host hundreds of millions of visitors per year. Kl√©pierre holds a controlling stake in Steen & Str√∏m (56.1%)  Scandinavia‚Äôs number one shopping center owner and manager. Kl√©pierre is a French REIT (SIIC) listed on Euronext Paris and is included in the CAC Next 20 and EPRA Euro Zone Indexes. It is also included in ethical indexes  such as MSCI Europe ESG Leaders  FTSE4Good  Euronext Vigeo Europe 120  and features in CDP‚Äôs ‚ÄúA-list‚Äù. These distinctions underscore the Group‚Äôs commitment to a proactive sustainable development policy and its global leadership in the fight against climate change.For more information  please visit the newsroom on our website: www.klepierre.comAttachment,neutral,0.0,0.99,0.0,neutral,0.05,0.93,0.02,True,English,"['Kl√©pierre', 'SEMI-ANNUAL STATEMENT', 'LIQUIDITY AGREEMENT', 'French Financial Markets Authority', 'Rothschild Martin Maurel', '0 Kl√©pierre share', 'Buy side Number', 'Sell side Number', '307,923 Kl√©pierre shares', 'TRANSACTIONS DETAILS Date', 'REGULATED RELEASE', 'SEMI-ANNUAL STATEMENT', 'LIQUIDITY AGREEMENT', 'liquidity contracts', 'market practice', 'second half', 'available resources', '1,217,464 shares', '1,247,464 shares', 'Paris', 'January', 'accordance', 'provisions', 'decision', 'June', 'accepted', 'public', 'implementation', 'December', 'volume', '4.46 euros', '25,461,380.60 euros', 'reminder', 'signature', 'February', '5.76 euros', 'Jul-22', 'July', 'Aug', 'Sep', 'Oct-22', '679.00', '88', '10,151,343.00']",2023-01-16,2023-01-16,marketscreener.com
16561,EuroNext,NewsApi.org,https://www.globenewswire.com/news-release/2023/01/16/2589376/0/en/Kl%C3%A9pierre-SEMI-ANNUAL-STATEMENT-OF-LIQUIDITY-AGREEMENT.html,Kl√©pierre : SEMI-ANNUAL STATEMENT OF LIQUIDITY AGREEMENT,REGULATED RELEASE  SEMI-ANNUAL STATEMENTOF LIQUIDITY AGREEMENT  Paris ‚Äì January 16  2023  In accordance with the provisions of the French Financial...,English FrenchREGULATED RELEASESEMI-ANNUAL STATEMENTOF LIQUIDITY AGREEMENTParis ‚Äì January 16  2023In accordance with the provisions of the French Financial Markets Authority‚Äôs decision no. 2021-01 of June 22  2021  establishing liquidity contracts as an accepted market practice  Kl√©pierre informs the public of the implementation of the liquidity contract for the second half of 2022:Available resources on December 31  2022: 0 Kl√©pierre share and 10 731 679.00 euros;Number of transactions on buy side over second half of 2022: 4 619 ;Number of transactions on sell side over second half of 2022: 5 363 ;Traded volume on buy side over second half of 2022: 1 217 464 shares for 24 881 044.46 euros ;Traded volume on sell side over second half of 2022: 1 247 464 shares for 25 461 380.60 euros.As a reminder At June 30  2022  available resources were 30 000 Kl√©pierre shares and 10 151 343.00 euros.At the date of signature of the liquidity contract with Rothschild Martin Maurel  February 1  2019  the available resources were 307 923 Kl√©pierre shares and 1 768 835.76 euros.TRANSACTIONS DETAILSDate Buy side Number of transactions Sell side Number of transactions Buy side Number of shares Sell side Number of shares Buy side Traded volume in EUR Sell side Traded volume in EUR 01-Jul-22 69 62 7 300 5 300 133 955.00 97 361.00 04-Jul-22 48 57 19 500 15 000 355 680.00 273 750.00 05-Jul-22 40 37 15 500 12 000 280 860.00 217 440.00 06-Jul-22 49 99 13 500 22 500 245 970.00 410 175.00 07-Jul-22 5 71 2 000 15 000 37 080.00 281 250.00 08-Jul-22 9 54 3 500 12 500 67 480.00 243 750.00 11-Jul-22 43 45 13 750 13 500 270 875.00 266 355.00 12-Jul-22 29 55 10 000 17 250 198 000.00 344 482.50 13-Jul-22 68 85 26 316 25 816 529 741.08 520 708.72 14-Jul-22 44 23 12 000 4 750 238 200.00 94 667.50 15-Jul-22 3 62 1 500 11 250 29 895.00 226 800.00 18-Jul-22 28 26 5 000 4 500 103 450.00 93 465.00 19-Jul-22 11 13 2 500 2 550 52 550.00 53 703.00 20-Jul-22 69 56 28 515 13 465 598 815.00 282 765.00 21-Jul-22 41 34 8 000 5 000 164 160.00 102 750.00 22-Jul-22 8 91 2 500 21 000 51 825.00 440 790.00 25-Jul-22 21 18 3 763 3 263 80 603.46 70 219.76 26-Jul-22 37 47 7 030 7 530 149 528.10 160 464.30 27-Jul-22 73 76 13 267 12 967 279 005.01 274 641.06 28-Jul-22 62 101 14 046 14 346 301 708.08 308 295.54 29-Jul-22 35 35 7 034 5 534 153 552.22 120 862.56 July 2022 792 1 147 216 521 245 021 4 322 932.95 4 884 695.94 01-Aug-22 46 7 13 500 1 500 291 330.00 32 685.00 02-Aug-22 34 106 10 500 19 500 224 070.00 418 470.00 03-Aug-22 36 51 10 500 12 000 227 220.00 260 400.00 04-Aug-22 27 29 7 750 9 750 168 717.50 212 745.00 05-Aug-22 40 22 6 750 4 750 146 070.00 103 122.50 08-Aug-22 32 38 9 000 11 700 197 910.00 257 400.00 09-Aug-22 23 16 6 750 6 050 148 837.50 133 705.00 10-Aug-22 35 36 4 966 5 666 111 288.06 127 088.38 11-Aug-22 24 16 5 950 3 750 135 422.00 85 500.00 12-Aug-22 22 32 6 000 8 200 137 040.00 187 780.00 15-Aug-22 34 13 8 200 7 000 188 846.00 161 350.00 16-Aug-22 31 8 6 950 1 950 159 085.50 45 025.50 17-Aug-22 40 0 8 500 0 190 995.00 0.00 18-Aug-22 42 20 11 250 3 750 249 187.50 83 550.00 19-Aug-22 37 41 10 500 10 500 226 905.00 227 640.00 22-Aug-22 34 25 9 500 12 000 201 495.00 255 840.00 23-Aug-22 26 22 7 500 6 500 161 250.00 140 335.00 24-Aug-22 27 23 8 000 6 000 167 600.00 126 420.00 25-Aug-22 29 49 6 956 7 456 146 006.44 156 874.24 26-Aug-22 63 53 16 750 6 750 349 405.00 142 155.00 29-Aug-22 23 33 6 500 8 000 132 990.00 163 920.00 30-Aug-22 25 29 7 000 5 500 144 620.00 114 235.00 31-Aug-22 24 13 6 750 2 250 139 252.50 46 710.00 August 2022 754 682 196 022 160 522 4 245 543.00 3 482 950.62Date Buy side Number of transactions Sell side Number of transactions Buy side Number of shares Sell side Number of shares Buy side Traded volume in EUR Sell side Traded volume in EUR 01-Sep-22 83 72 26 500 26 000 520 990.00 511 940.00 02-Sep-22 46 53 15 500 18 000 307 520.00 358 920.00 05-Sep-22 39 43 10 000 12 000 198 900.00 239 040.00 06-Sep-22 41 40 10 000 13 000 201 800.00 262 860.00 07-Sep-22 26 50 8 250 20 750 165 660.00 419 980.00 08-Sep-22 78 55 23 250 17 250 468 952.50 348 795.00 09-Sep-22 28 78 6 000 13 750 122 460.00 280 637.50 12-Sep-22 26 67 7 500 13 250 155 550.00 275 467.50 13-Sep-22 49 15 16 750 4 250 345 217.50 88 612.50 14-Sep-22 11 16 4 000 4 500 81 000.00 91 305.00 15-Sep-22 28 12 9 000 2 500 181 170.00 50 600.00 16-Sep-22 103 192 16 500 37 500 335 940.00 765 000.00 19-Sep-22 75 0 17 500 0 346 850.00 0.00 20-Sep-22 66 12 15 750 2 250 308 070.00 44 730.00 21-Sep-22 31 46 9 000 12 500 169 380.00 235 875.00 22-Sep-22 10 0 5 000 0 92 150.00 0.00 23-Sep-22 17 0 4 000 0 71 080.00 0.00 26-Sep-22 1 0 1 000 0 17 450.00 0.00 27-Sep-22 73 41 15 500 8 000 271 405.00 140 320.00 28-Sep-22 2 0 1 000 0 16 700.00 0.00 29-Sep-22 1 0 500 0 8 670.00 0.00 30-Sep-22 0 1 0 1 500 0.00 26 850.00 September 2022 834 793 222 500 207 000 4 386 915.00 4 140 932.50 03-Oct-22 0 3 0 1 000 0.00 18 270.00 04-Oct-22 92 121 19 750 15 750 366 165.00 294 052.50 05-Oct-22 39 10 6 500 2 000 118 040.00 37 140.00 07-Oct-22 30 41 6 500 9 000 115 375.00 159 840.00 10-Oct-22 1 0 1 250 0 21 762.50 0.00 11-Oct-22 0 1 0 1 750 0.00 31 115.00 12-Oct-22 2 0 3 000 0 52 890.00 0.00 13-Oct-22 82 83 20 000 17 500 357 800.00 314 300.00 14-Oct-22 16 35 4 750 7 250 86 355.00 132 530.00 17-Oct-22 59 150 12 500 30 000 229 250.00 554 100.00 18-Oct-22 128 231 25 000 43 669 468 250.00 820 540.51 19-Oct-22 20 72 3 500 12 331 66 080.00 235 152.17 20-Oct-22 38 76 15 500 18 000 292 175.00 340 920.00 21-Oct-22 76 23 15 000 7 500 277 950.00 138 975.00 24-Oct-22 140 222 28 000 40 500 526 680.00 763 425.00 25-Oct-22 97 131 24 750 31 950 470 992.50 610 245.00 26-Oct-22 143 113 35 250 35 050 693 720.00 690 835.50 27-Oct-22 59 57 15 950 16 050 318 840.50 321 642.00 28-Oct-22 32 28 9 000 9 400 181 530.00 190 068.00 31-Oct-22 41 29 10 000 6 500 203 300.00 132 340.00 October 2022 1 095 1 426 256 200 305 200 4 847 155.50 5 785 490.68Date Buy side Number of transactions Sell side Number of transactions Buy side Number of shares Sell side Number of shares Buy side Traded volume in EUR Sell side Traded volume in EUR 01-Nov-22 34 51 8 349 11 849 170 486.58 243 022.99 02-Nov-22 42 39 15 000 14 700 305 550.00 300 027.00 03-Nov-22 61 67 16 450 16 400 326 368.00 326 360.00 04-Nov-22 55 58 16 000 16 050 325 280.00 327 259.50 07-Nov-22 20 15 4 500 4 550 92 565.00 93 684.50 08-Nov-22 21 24 6 050 6 000 124 267.00 123 480.00 09-Nov-22 35 48 9 450 9 250 193 158.00 189 625.00 10-Nov-22 51 50 12 969 13 169 276 628.77 281 289.84 14-Nov-22 28 27 8 250 6 550 186 037.50 147 899.00 15-Nov-22 64 87 16 500 18 200 371 910.00 412 048.00 16-Nov-22 35 40 10 500 10 300 232 995.00 229 175.00 17-Nov-22 29 4 7 950 950 176 728.50 21 289.50 18-Nov-22 9 60 7 606 14 806 168 320.78 328 397.08 21-Nov-22 28 30 7 500 7 450 168 375.00 167 252.50 22-Nov-22 24 9 10 400 2 300 231 608.00 51 658.00 23-Nov-22 31 21 9 800 8 250 216 874.00 183 150.00 24-Nov-22 28 92 7 500 17 200 168 150.00 386 484.00 25-Nov-22 18 24 4 500 4 800 100 575.00 107 520.00 28-Nov-22 36 57 7 800 7 500 172 380.00 166 125.00 29-Nov-22 31 34 8 250 8 050 183 067.50 179 193.00 30-Nov-22 41 15 9 000 3 200 198 900.00 71 392.00 November 2022 721 852 204 324 201 524 4 390 224.63 4 336 331.91 01-Dec-22 42 71 13 700 19 800 303 592.00 439 164.00 02-Dec-22 14 14 4 100 4 300 90 200.00 94 858.00 05-Dec-22 36 40 8 550 8 250 190 066.50 183 892.50 06-Dec-22 12 10 4 947 4 747 110 268.63 106 095.45 07-Dec-22 17 18 6 800 7 000 150 144.00 154 910.00 08-Dec-22 34 39 9 475 9 450 208 923.75 208 750.50 09-Dec-22 25 26 8 000 8 325 178 160.00 185 980.50 12-Dec-22 52 3 14 000 10 000 305 900.00 218 000.00 13-Dec-22 42 62 10 500 14 200 233 940.00 314 814.00 14-Dec-22 24 26 6 750 6 550 151 200.00 147 244.00 15-Dec-22 11 18 3 500 3 700 79 100.00 83 768.00 16-Dec-22 24 4 5 350 3 650 118 074.50 79 752.50 19-Dec-22 5 7 1 500 3 000 32 670.00 65 430.00 20-Dec-22 17 9 4 500 4 000 94 905.00 84 720.00 21-Dec-22 0 2 0 700 0.00 14 924.00 22-Dec-22 10 13 2 250 2 050 48 870.00 44 649.00 23-Dec-22 6 9 1 975 2 475 42 936.50 54 054.00 27-Dec-22 11 0 5 000 0 109 400.00 0.00 28-Dec-22 21 63 5 250 9 450 114 765.00 207 522.00 29-Dec-22 9 8 2 000 2 500 43 520.00 54 525.00 30-Dec-22 11 21 3 750 4 050 81 637.50 87 925.50 December 2022 423 463 121 897 128 197 2 688 273.38 2 830 978.95 SECOND HALF 2022 4 619 5 363 1 217 464 1 247 464 24 881 044.46 25 461 380.60INVESTOR RELATIONS CONTACTS Paul Logerot  Group Head of IR and Financial Communication+33 (0)7 50 66 05 63 ‚Äî paul.logerot@klepierre.comTanguy Phelippeau  IR Officer+33 (0)7 72 09 29 57 ‚Äî tanguy.phelippeau@klepierre.comABOUT KL√âPIERREKl√©pierre is the European leader in shopping malls  combining property development and asset management skills. The Company‚Äôs portfolio is valued at ‚Ç¨20.6 billion at June 30  2022  and comprises large shopping centers in more than 10 countries in Continental Europe which together host hundreds of millions of visitors per year. Kl√©pierre holds a controlling stake in Steen & Str√∏m (56.1%)  Scandinavia‚Äôs number one shopping center owner and manager. Kl√©pierre is a French REIT (SIIC) listed on Euronext Paris and is included in the CAC Next 20 and EPRA Euro Zone Indexes. It is also included in ethical indexes  such as MSCI Europe ESG Leaders  FTSE4Good  Euronext Vigeo Europe 120  and features in CDP‚Äôs ‚ÄúA-list‚Äù. These distinctions underscore the Group‚Äôs commitment to a proactive sustainable development policy and its global leadership in the fight against climate change.For more information  please visit the newsroom on our website: www.klepierre.comAttachment,neutral,0.0,0.99,0.0,neutral,0.03,0.96,0.01,True,English,"['Kl√©pierre', 'SEMI-ANNUAL STATEMENT', 'LIQUIDITY AGREEMENT', 'French Financial Markets Authority', 'accepted market practice', 'Rothschild Martin Maurel', '0 Kl√©pierre share', 'Buy side Number', 'Sell side Number', '307,923 Kl√©pierre shares', 'TRANSACTIONS DETAILS Date', 'English French', 'REGULATED RELEASE', 'SEMI-ANNUAL STATEMENT', 'LIQUIDITY AGREEMENT', 'liquidity contracts', 'second half', 'available resources', '17,464 shares', '1,247,464 shares', 'Paris', 'January', 'accordance', 'provisions', 'decision', 'June', 'public', 'implementation', 'December', 'volume', '25,461,380.60 euros', 'reminder', '10,151,343.00 euros', 'signature', 'February', '5.76 euros', 'Jul-22', 'July', 'Aug-22', 'August', 'Sep', 'Oct', '679.00', '88', '4.46']",2023-01-16,2023-01-16,globenewswire.com
16562,EuroNext,NewsApi.org,https://www.prnewswire.co.uk/news-releases/sic-power-semiconductor-market-to-experience-substantial-cagr-growth-of-26-0-by-2030--size-share-trends-industry-growth-key-drivers-and-opportunity-analysis-301721245.html,SiC Power Semiconductor Market to Experience Substantial CAGR Growth of 26.0% by 2030  Size  Share  Trends  Industry Growth  Key Drivers and Opportunity Analysis,"SEOUL  South Korea  Jan. 16  2023 /PRNewswire/ -- Recent study report released by Data Bridge Market research with titled ""SiC Power Semiconductor Market"" guarantees you will remain better informed than your competition. Highly in-depth data collection and re‚Ä¶","SEOUL  South Korea  Jan. 16  2023 /PRNewswire/ -- Recent study report released by Data Bridge Market research with titled ""SiC Power Semiconductor Market"" guarantees you will remain better informed than your competition. Highly in-depth data collection and results analysis has been conducted to generate the world class SiC Power Semiconductor market report. The report effectively communicates research findings such as consumer trends  market trends  and competitor behaviour that surround the target audience. This market research report contains a summary of research findings and insights uncovered during the data collection and analysis processes. It has information about a company's competition  industry trends/opportunities  and recommendations for next steps based on the research questions being addressed. SiC Power Semiconductor market research report helps guide decision-making and highlight market opportunities.SiC Power Semiconductor report is not only clear and concise but also detailed and comprehensive prepared by keeping in mind that stakeholders must be able to interpret the research findings with ease. As market research reports are presented to many stakeholders  not all of them will have a strong understanding of market research terms  so this report is written in clear and simple language. Moreover  all diagrams are clearly labelled and accurately described what they are displaying. While creating SiC Power Semiconductor report  it has been imagined that a reader has no prior knowledge on the topic to ensure and hence the findings are explained comprehensively.Data Bridge Market Research analyses that the global SiC power semiconductor market is expected to reach a value of USD 7 030 515.23 thousand by 2030  at a CAGR of 26.0% during the forecast period. The global SiC power semiconductor market report also comprehensively covers pricing analysis  patent analysis  and technological advancements.Download Sample Copy of SiC Power Semiconductor Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sic-power-semiconductor-marketMarket DefinitionSiC power semiconductor refers to the type of semiconductor that contains carbon and silicon and operates at very high voltage and temperature. SiC power semiconductors can be used in producing a strong as well as a very hard material. SiC power semiconductors can be implemented in various sectors such as telecommunication  energy and power  automotive  renewable power generation  and in different other areas. They are basically considered due to higher maximum thermal conductive properties that have widened the area of application. SiC power semiconductors are devices that are considered high-frequency power devices that are majorly applicable in wireless communications. SiC semiconductor offers ten times the dielectric breakdown field strength  three times the thermal conductivity  and three times the bandgap as compared to a silicon semiconductor. The SiC semiconductor has taken over the market because of its high performance and efficiency. The SiC power semiconductor offers to work at high voltage and current and offers low on-resistance in addition to being efficient at high temperatures. The combination of silicon carbide has thus proved to be a better and optimum choice of semiconductor.Market DriversAdvent Of SiC Power SemiconductorsThere are very useful properties of SiC as a semiconductor material. In applications such as inverters  motor drives  and battery chargers  silicon carbide (SiC) devices offer many advantages  such as improved power density  reduced cooling requirements  and reduced overall system cost. These advantages are enough to make SiC power semiconductors at the high efficient stage.The energy lost by SiC during the reverse recovery phase is only 1% of the energy lost by silicon which creates a huge difference in the efficiency of the material. The virtual absence of a tail current allows a faster turn‚Äìoff  and it makes lower losses. Since there is less energy to dissipate  a SiC device able to switch at higher frequencies and improve efficiency. The more efficient  small size  and lower weight of SiC as compared to other materials can create a higher-rated solution or a smaller design with reduced cooling requirements. Thus  the advent of SiC power semiconductors is a major factor expected to drive the growth of the Global SiC power semiconductor market.Rising Penetration of Electronic VehiclesThe world is changing so fast  and it is turning towards renewable energy. All sectors  market players  and government institutes are making more focus to build electric vehicle infrastructure and generate more demand for electric vehicles.As per the information from International Energy Agency (IEA)  16.5 million electric cars were on the road in 2021  a tripling in just three years  and this is a big number as compared to 2020. Electric car sales increased and doubled in China  continued to increase in Europe  and picked up in the U.S. in 2021. This data shows that there is a tremendous increase in the penetration of EVs in the market  which may positively affect the environment as well as the Global SiC power semiconductor market. SiC is highly efficient at high voltages  enabling fast battery charging times that are comparable to filling the tank of conventional vehicles. Silicon carbide power electronics are enabling a surge in 800-volt drive systems  paving the way for lighter EVs with greater range.Some of the major players operating in the SiC Power Semiconductor market are:WOLFSPEED  INC. STMicroelectronics ROHM CO.  LTD. Fuji Electric Co.  Ltd. Mitsubishi Electric Corporation Texas Instruments Incorporated Infineon Technologies AG Semikron Danfoss Xiamen Powerway Advanced Material Co.  Ltd. Renesas Electronics Corporation TOSHIBA ELECTRONIC DEVICES & STORAGE CORPORATION Microchip Technology Inc. Semiconductor Components Industries  LLC NXP Semiconductors UnitedSiC SemiQ Inc. Littlefuse  Inc. Allegro MicroSystems  Inc. Hitachi Power Semiconductor Device  Ltd. (A Subsidiary of Hitachi Group)  andGeneSiC SemiconductorGet Full PDF Research Report to Understand More @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-sic-power-semiconductor-marketRecent DevelopmentsIn December 2022   STMicroelectronics and Soitec (Euronext Paris)  in designing and manufacturing innovative semiconductor materials  announced the next stage of their cooperation on Silicon Carbide (SiC) substrates  with the qualification of Soitec's SiC substrate technology by ST planned over the next 18 months. The goal of this cooperation is the adoption by ST of Soitec's SmartSiC technology for its future 200mm substrate manufacturing  feeding its devices and modules manufacturing business  with volume production expected in the midterm. This collaboration will help the company to boost its financials as well as the growth of the Global SiC power semiconductor market.  in designing and manufacturing innovative semiconductor materials  announced the next stage of their cooperation on Silicon Carbide (SiC) substrates  with the qualification of Soitec's SiC substrate technology by ST planned over the next 18 months. The goal of this cooperation is the adoption by ST of Soitec's SmartSiC technology for its future 200mm substrate manufacturing  feeding its devices and modules manufacturing business  with volume production expected in the midterm. This collaboration will help the company to boost its financials as well as the growth of the Global SiC power semiconductor market. In July 2022   Semikron Danfoss and the Kyoto -based company ROHM Semiconductor have been collaborating for more than ten years with regard to the implementation of silicon carbide (SiC) inside power modules. Recently  ROHM's latest 4th generation of SiC MOSFETs has been fully qualified in SEMIKRON's eMPack modules for automotive use. Hence  both companies serve worldwide customers' needs. This collaboration enhanced the company's financials and made a positive impact on the growth of the Global SiC power semiconductor market.The report provides insights on the following pointers:Market Penetration: Comprehensive information on the product portfolios of the top players in the SiC Power Semiconductor marketProduct Development/Innovation: Detailed insights on upcoming technologies  R&D activities  and product launches in the marketCompetitive Assessment: In-depth assessment of the market strategies  and geographic and business segments of the leading players in the marketMarket Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographiesMarket Diversification: Exhaustive information about new products  untapped geographies  recent developments  and investments in the SiC Power Semiconductor MarketKey Industry Segmentation: SiC Power Semiconductor MarketBy TypeMOSFETSHybrid ModulesSchottky Barrier Diodes (SBDS)IGBTBipolar Junction Transistor (BJT)Pin DiodeJunction FET (JFET)By Voltage Range301-900 V901-1700 VAbove 1701 VBy Wafer Size6 Inch4 Inch2 InchAbove 6 InchBy Wafer TypeSiC epitaxial wafersBlank SiC wafersBy ApplicationElectric Vehicles (EV)(EV) PhotovoltaicsPower suppliesIndustrial motor drivesEV charging infrastructureRF DevicesBy VerticalAutomotiveUtilities and energyIndustrialTransportationIT and telecommunicationConsumer electronicsAerospace and defenseCommercialTo Gain More Insights about this Research  Visit @ https://www.databridgemarketresearch.com/reports/global-sic-power-semiconductor-marketA comprehensive analysis will be provided covering the following points in the report:Executive Market SummaryScope of the SiC Power Semiconductor ReportKey Finding and RecommendationsGrowth and Investment OpportunitiesSiC Power Semiconductor Market Value Chain/Supply Chain AnalysisSiC Power Semiconductor Market Attractive Investment PropositionCompetitive landscape and SWOT AnalysisSiC Power Semiconductor Market Segmentation OutlookRegional OutlookCompany Profiles of Key PlayersRegional Analysis/Insights: SiC Power Semiconductor MarketThe countries covered in the SiC power semiconductor market report are U.S.  Canada  Mexico  Germany  U.K.  Italy  France  Spain  Switzerland  Netherlands  Belgium  Russia  Turkey  Poland  Sweden  Denmark  Rest of Europe  Japan  China  South Korea  India  Australia and New Zealand  Hong Kong  Taiwan  Singapore  Thailand  Indonesia  Malaysia  Philippines  Vietnam  and Rest of Asia-Pacific  South Africa  UAE.  Israel  Egypt  Qatar  Saudi Arabia  Kuwait  Rest of the Middle East and Africa  Brazil  Argentina  and Rest of South America.In 2023  the Asia-Pacific region is expected to dominate the global SiC power semiconductor market due to the high demand for SiC power semiconductors. Additionally  the high demand for power modules and related devices is expected to act as a driving factor for the market's growth.Table of Contents:Introduction Market Segmentation Executive Summary Premium Insights Global SiC Power Semiconductor Market: Regulations Market Overview Global SiC Power Semiconductor Market  By Type Global SiC Power Semiconductor Market  By Voltage Range Global SiC Power Semiconductor Market  By Wafer Size Global SiC Power Semiconductor Market  By Wafer Type Global SiC Power Semiconductor Market  By Application Global SiC Power Semiconductor Market  By Vertical Global SiC Power Semiconductor Market  By Region Global SiC Power Semiconductor Market: Company Landscape SWOT Analyses Company Profile Questionnaires Related ReportsTo Check the Complete Table of contents  click here @ https://www.databridgemarketresearch.com/toc/?dbmr=global-sic-power-semiconductor-marketExplore More Reports:GaN and SiC Power Semiconductor Market  By Product (Sic Power Module  GaN Power Module  Discrete SiC  Dicrete GaN)  Application (Power Supplies  Industrial Motor Drives  H/EV  PV Inverters  Traction  Others)  Country (U.S.  Canada  Mexico  Brazil  Argentina  Rest of South America  Germany  Italy  U.K.  France  Spain  Netherlands  Belgium  Switzerland  Turkey  Russia  Rest of Europe  Japan  China  India  South Korea  Australia  Singapore  Malaysia  Thailand  Indonesia  Philippines  Rest of Asia-Pacific  Saudi Arabia  U.A.E  South Africa  Egypt  Israel  Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-gan-and-sic-power-semiconductor-marketAsia-Pacific SiC Power Semiconductor Market  By Type (MOSFETS  Hybrid Modules  Schottky Barrier Diodes (SBDS)  IGBT  Bipolar Junction Transistor (BJT)  Pin Diode  Junction FET (JFET)  and Others)  Voltage Range (301-900 V  901-1700 V  Above 1701 V)  Wafer size (6 Inch  4 Inch  2 Inch  Above 6 Inch)  Wafer type (SiC Epitaxial Wafers  Blank SiC Wafers)  Application (Electric Vehicles (EV)  Photovoltaics  Power Supplies  Industrial Motor Drives  EV Charging Infrastructure  RF Devices  and Others)  Vertical (Automotive  Utilities and Energy  Industrial  Transportation  IT and Telecommunication  Consumer Electronics  Aerospace and Defense  Commercial  and Others) https://www.databridgemarketresearch.com/reports/asia-pacific-sic-power-semiconductor-marketEurope SiC Power Semiconductor Market  By Type (MOSFETS  Hybrid Modules  Schottky Barrier Diodes (SBDS)  IGBT  Bipolar Junction Transistor (BJT)  Pin Diode  Junction FET (JFET)  and Others)  Voltage Range (301-900 V  901-1700 V  Above 1701 V)  Wafer size (6 Inch  4 Inch  2 Inch  Above 6 Inch)  Wafer type (SiC Epitaxial Wafers  Blank SiC Wafers)  Application (Electric Vehicles (EV)  Photovoltaics  Power Supplies  Industrial Motor Drives  EV Charging Infrastructure  RF Devices  and Others)  Vertical (Automotive  Utilities and Energy  Industrial  Transportation  IT and Telecommunication  Consumer Electronics  Aerospace and Defense  Commercial  and Others) https://www.databridgemarketresearch.com/reports/europe-sic-power-semiconductor-marketMiddle East and Africa SiC Power Semiconductor Market  By Type (MOSFETS  Hybrid Modules  Schottky Barrier Diodes (SBDS)  IGBT  Bipolar Junction Transistor (BJT)  Pin Diode  Junction FET (JFET)  and Others)  Voltage Range (301-900 V  901-1700 V  Above 1701 V)  Wafer size (6 Inch  4 Inch  2 Inch  Above 6 Inch)  Wafer type (SiC Epitaxial Wafers  Blank SiC Wafers)  Application (Electric Vehicles (EV)  Photovoltaics  Power Supplies  Industrial Motor Drives  EV Charging Infrastructure  RF Devices  and Others)  Vertical (Automotive  Utilities and Energy  Industrial  Transportation  IT and Telecommunication  Consumer Electronics  Aerospace and Defense  Commercial  and Others) https://www.databridgemarketresearch.com/reports/middle-east-and-africa-sic-power-semiconductor-marketNorth America SiC Power Semiconductor Market  By Type (MOSFETS  Hybrid Modules  Schottky Barrier Diodes (SBDS)  IGBT  Bipolar Junction Transistor (BJT)  Pin Diode  Junction FET (JFET)  and Others)  Voltage Range (301-900 V  901-1700 V  Above 1701 V)  Wafer size (6 Inch  4 Inch  2 Inch  Above 6 Inch)  Wafer type (SiC Epitaxial Wafers  Blank SiC Wafers)  Application (Electric Vehicles (EV)  Photovoltaics  Power Supplies  Industrial Motor Drives  EV Charging Infrastructure  RF Devices  and Others)  Vertical (Automotive  Utilities and Energy  Industrial  Transportation  IT and Telecommunication  Consumer Electronics  Aerospace and Defense  Commercial  and Others) https://www.databridgemarketresearch.com/reports/north-america-sic-power-semiconductor-marketPin Fin Heat Sink for Integrated Gate Bipolar Transistor (IGBT) Market  By Material Type (Copper  Aluminium)  Application (Consumer Electronics  Automotive Field  Others)  Country (U.S.  Canada  Mexico  Brazil  Argentina  Rest of South America  Germany  France  Italy  U.K.  Belgium  Spain  Russia  Turkey  Netherlands  Switzerland  Rest of Europe  Japan  China  India  South Korea  Australia  Singapore  Malaysia  Thailand  Indonesia  Philippines  Rest of Asia-Pacific  U.A.E  Saudi Arabia  Egypt  South Africa  Israel  Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-pin-fin-heat-sink-for-igbt-marketInsulated Gate Bipolar Transistor (IGBT) Discrete Semiconductor Market  By Type (Discrete IGBT  Modular IGBT)  Power Rating (High- Power  Medium- Power  Low- Power)  End- User (Automotive  Consumer Electronics  Communication  Industrial  Other End-Use Verticals) https://www.databridgemarketresearch.com/reports/global-igbt-discrete-semiconductor-marketInsulated Gate Bipolar Transistor (IGBT) Market  By Type (Discrete  Modular)  Power Rating (High-Power  Medium-Power  Low-Power)  End-user Industry (EV/HEV  Renewables  UPS  Rail  Motor Drives  Industrial  Commercial)  Country (U.S.  Canada  Mexico  Brazil  Argentina  Rest of South America  Germany  Italy  U.K.  France  Spain  Netherlands  Belgium  Switzerland  Turkey  Russia  Rest of Europe  Japan  China  India  South Korea  Australia  Singapore  Malaysia  Thailand  Indonesia  Philippines  Rest of Asia-Pacific  Saudi Arabia  U.A.E  South Africa  Egypt  Israel  Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-insulated-gate-bipolar-transistor-igbt-marketAbout Data Bridge Market Research:An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.Contact Us:-Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:- corporatesales@databridgemarketresearch.comLogo: https://mma.prnewswire.com/media/1011053/Data_Bridge_Market_Research_Logo.jpgSOURCE Data Bridge Market Research",neutral,0.0,1.0,0.0,mixed,0.51,0.13,0.36,True,English,"['SiC Power Semiconductor Market', 'Substantial CAGR Growth', 'Industry Growth', 'Key Drivers', 'Opportunity Analysis', 'Size', 'Share', 'Trends', 'world class SiC Power Semiconductor market report', 'global SiC power semiconductor market report', 'SiC Power Semiconductor market research report', 'higher maximum thermal conductive properties', 'dielectric breakdown field strength', 'SiC Power Semiconductor report', 'The SiC power semiconductor', 'Data Bridge Market research', 'SiC power semiconductors', 'Recent study report', 'The SiC semiconductor', 'market research reports', 'market research terms', 'renewable power generation', 'overall system cost', 'reverse recovery phase', 'faster turn‚Äìoff', 'frequency power devices', 'electric vehicle infrastructure', '16.5 million electric cars', 'Electric car sales', 'different other areas', 'depth data collection', 'high efficient stage', 'International Energy Agency', 'reduced cooling requirements', 'power density', 'market trends', 'market opportunities', 'Market Definition', 'Market Drivers', 'market players', 'thermal conductivity', 'useful properties', 'higher frequencies', 'SiC) devices', 'SiC device', 'semiconductor material', 'silicon semiconductor', 'research questions', 'research findings', 'electric vehicles', 'other materials', 'high voltage', 'high performance', 'high temperatures', 'renewable energy', 'South Korea', 'results analysis', 'consumer trends', 'competitor behaviour', 'target audience', 'analysis processes', 'industry trends/opportunities', 'next steps', 'simple language', 'prior knowledge', 'forecast period', 'pricing analysis', 'patent analysis', 'technological advancements', 'wireless communications', 'optimum choice', 'motor drives', 'battery chargers', 'huge difference', 'virtual absence', 'lower losses', 'lower weight', 'higher-rated solution', 'smaller design', 'major factor', 'Rising Penetration', 'Electronic Vehicles', 'government institutes', 'three years', 'big number', 'U.S.', 'tremendous increase', 'hard material', 'less energy', 'silicon carbide', 'many stakeholders', 'strong understanding', 'Sample Copy', 'various sectors', 'many advantages', 'tail current', 'SEOUL', 'Jan.', 'PRNewswire', 'competition', 'summary', 'insights', 'information', 'company', 'recommendations', 'decision-making', 'mind', 'clear', 'diagrams', 'reader', 'topic', 'value', 'CAGR', 'Download', 'databridgemarketresearch', 'global-sic-power-semiconductor-market', 'type', 'carbon', 'telecommunication', 'automotive', 'application', 'bandgap', 'efficiency', 'resistance', 'addition', 'combination', 'Advent', 'inverters', 'growth', 'focus', 'demand', 'IEA', 'road', 'tripling', 'China', 'Europe']",2023-01-16,2023-01-16,prnewswire.co.uk
16563,EuroNext,NewsApi.org,https://www.prnewswire.com/news-releases/nexans-launches-innovative-canadex-2-0-residential-cables-301721729.html,Nexans Launches Innovative CANADEX¬Æ 2.0 Residential Cables,Nexans offers CANADEX¬Æ 2.0 line of residential NMD90 cables that enables faster installation and lowers overall project costs In line with our strategy to be true partners with our customers  the cables are designed using feedback from electricians and incorp‚Ä¶,"Nexans offers CANADEX ¬Æ 2.0 line of residential NMD90 cables that enables faster installation and lowers overall project costs2.0 line of residential NMD90 cables that enables faster installation and lowers overall project costs In line with our strategy to be true partners with our customers  the cables are designed using feedback from electricians and incorporates three key features to streamline workflowThe cables are locally manufactured at Nexans' facilities in Fergus  ON and are constructed using partially recycled copper from our copper rod mill facility in MontrealTORONTO  Jan. 16  2023 /PRNewswire/ -- Nexans  a global organization and key driver for the world's transition to a more connected and sustainable future  today announced the launch of the CANADEX¬Æ 2.0 line of NMD90 cables  an upgrade to the existing line of CANADEX¬Æ cables. The line is designed to accelerate the installation process  allowing electricians to perform more work in less time  cut overall project costs  and reduce their carbon footprints.CANADEX¬Æ 2.0 cables are designed with the electricians' needs in mind with three key features intended to streamline the installation process. The ""INSTAGLIDE¬Æ"" technology allows for fast and efficient installation and the 'Easy-Lift' handle on Spools is more ergonomic  which improves safety on job sites. Nexans has also added metre markings to the cable to account for every metre of cable installed  reducing product waste.Jerome Leroy  Nexans' VP of Distribution and Usage Canada  said: "" In developing CANADEX¬Æ 2.0 cable  our team held focus groups with electricians to understand and gather qualitative insights and unmet needs to create a new line of cable with electricians in mind  democratizing the cable manufacturing process. This new line of residential cables is a revolutionary step in the electrification of Canadian households   using partially recycled copper from our copper rod mill facility in Montreal. Our cables are made by and for Canadians  and we are excited to embark on this new journey.""About NEXANSFor more than a century  Nexans has played a crucial role in electrifying the planet and is committed to electrifying the future. With 25 000 staff in 42 countries  the Group is driving the change towards the new world of electrification ‚Äî a safer  more sustainable  renewable  carbon-free world  accessible to all. In 2021  Nexans generated ‚Ç¨6.1 billion in standard sales. The Group is a leader in the design and manufacturing of cable systems and services in five main areas of activity: Energy Production & Transmission  Distribution  Usages  Industry & Solutions and Telecom & Data. Nexans was the first player in its industry to create a Corporate Foundation to support actions that promote access to energy for disadvantaged populations worldwide. The Group is committed to helping achieve carbon neutrality by 2030.Nexans. Electrify the future.Nexans is listed on the Euronext Paris stock market  compartment A.For more information  visit www.nexans.caFor more information about CANADEX¬Æ  visit nexanscanadex.caSOURCE Nexans",neutral,0.0,0.99,0.0,mixed,0.5,0.22,0.29,True,English,"['Innovative CANADEX¬Æ 2.0 Residential Cables', 'Nexans', 'Euronext Paris stock market', 'copper rod mill facility', 'sustainable, renewable, carbon-free world', 'overall project costs', 'five main areas', 'three key features', 'residential NMD90 cables', 'cable manufacturing process', 'key driver', 'residential cables', 'installation process', 'new world', 'sustainable future', 'faster installation', 'true partners', 'global organization', 'less time', 'carbon footprints', 'INSTAGLIDE¬Æ"" technology', 'efficient installation', ""Easy-Lift' handle"", 'job sites', 'product waste', 'Jerome Leroy', 'Usage Canada', 'focus groups', 'qualitative insights', 'unmet needs', 'revolutionary step', 'Canadian households', 'new journey', 'a century', 'crucial role', 'standard sales', 'first player', 'Corporate Foundation', 'disadvantaged populations', 'carbon neutrality', 'compartment A.', 'CANADEX¬Æ cables', 'CANADEX¬Æ 2.0 cables', 'The Group', 'cable systems', 'existing line', 'new line', 'metre markings', 'Energy Production', 'CANADEX ¬Æ 2.0 line', 'CANADEX¬Æ 2.0 line', ""Nexans' facilities"", ""Nexans' VP"", 'SOURCE Nexans', ""electricians' needs"", 'strategy', 'customers', 'feedback', 'workflow', 'Fergus', 'Montreal', 'TORONTO', 'Jan', 'PRNewswire', 'transition', 'connected', 'launch', 'upgrade', 'mind', 'Spools', 'safety', 'Distribution', 'team', 'electrification', 'Canadians', 'planet', '25,000 staff', '42 countries', 'change', 'leader', 'design', 'services', 'activity', 'Transmission', 'Usages', 'Industry', 'Solutions', 'Telecom', 'Data', 'actions', 'access', 'information', 'nexanscanadex']",2023-01-16,2023-01-16,prnewswire.com
16564,EuroNext,NewsApi.org,https://www.reuters.com/markets/commodities/euronext-switch-derivatives-clearing-italy-2024-2023-01-16/,Euronext to switch derivatives clearing to Italy in 2024,"Pan-European stock exchange Euronext <a href=""https://www.reuters.com/companies/ENX.PA"" target=""_blank"">(ENX.PA)</a> will shift clearing of derivatives trading to its new clearing arm in Italy by the third quarter of next year  it said on Monday  to compete d‚Ä¶","LONDON  Jan 16 (Reuters) - Pan-European stock exchange Euronext (ENX.PA) will shift clearing of derivatives trading to its new clearing arm in Italy by the third quarter of next year  it said on Monday  to compete directly with London Stock Exchange Group and Cboe.Euronext currently clears its derivatives transactions at LCH SA  owned by London Stock Exchange Group (LSEG) (LSEG.L)  but wants to build up its own in-house clearing operation  in tune with European Union efforts to deepen the bloc's capital market after Brexit.""Euronext confirms it expects to migrate the listed financial derivatives and commodities markets of Euronext Amsterdam  Euronext Brussels  Euronext Lisbon  Oslo Bors and Euronext Paris from LCH SA to Euronext Clearing by Q3 2024 "" the exchange said in a statement.It had already announced that Italy would become the default centre for clearing its stock transactions by the end of this year. Under EU 'open access' rules  customers can continue to clear their Euronext share trades at rivals such as LCH or Cboe if they want to.""We are very confident we will capture the bulk of our cash equities clearing "" Anthony Attia  Euronext global head of primary markets and post trade  told Reuters.Clearing equities and derivatives in one centre will build ""critical mass"" to allow customers to net across positions  Attia said.Euronext  which obtained its own clearing house as part of its acquisition of Borsa Italiana in Milan  owns just over 11% of LCH SA  a stake LSEG now has an option to buy.Attia said the stake was worth around 66.8 million euros ($72.2 million).LSEG had no comment on whether it would buy the stake.Separately  LSEG confirmed its agreement with Euronext on clearing financial and commodity derivatives would terminate next year but said LCH SA would remain ""strategically important"".LCH SA clears the majority of the Eurozone repo market and Euro credit derivatives market in addition to many European equity market venues  LSEG said.""We look forward to continuing to provide clearing services to our global customers  who benefit from access to our multi-asset offering "" LSEG added.($1 = 0.9249 euros)Reporting by Huw Jones Editing by David Goodman and Mark PotterOur Standards: The Thomson Reuters Trust Principles.",neutral,0.01,0.99,0.0,neutral,0.02,0.96,0.01,True,English,"['Euronext', 'derivatives', 'Italy', 'many European equity market venues', 'The Thomson Reuters Trust Principles', ""EU 'open access' rules"", 'London Stock Exchange Group', 'Euro credit derivatives market', 'Pan-European stock exchange Euronext', 'European Union efforts', 'Eurozone repo market', 'new clearing arm', 'Euronext share trades', 'house clearing operation', 'cash equities clearing', 'Euronext global head', 'capital market', 'stock transactions', 'Clearing equities', 'clearing house', 'clearing services', 'third quarter', 'derivatives transactions', 'commodities markets', 'Oslo Bors', 'default centre', 'primary markets', 'post trade', 'one centre', 'critical mass', 'Borsa Italiana', 'commodity derivatives', 'multi-asset offering', 'Huw Jones', 'David Goodman', 'Mark Potter', 'Euronext Amsterdam', 'Euronext Brussels', 'Euronext Lisbon', 'Euronext Paris', 'LCH SA', 'global customers', 'next year', 'financial derivatives', 'Anthony Attia', 'Jan', 'Italy', 'Monday', 'Cboe', 'LSEG', 'tune', 'bloc', 'Brexit', 'Q3', 'statement', 'end', 'rivals', 'bulk', 'positions', 'part', 'acquisition', 'Milan', 'stake', 'option', 'comment', 'agreement', 'majority', 'addition', '0.9249 euros', 'Reporting', 'Standards', '66.8']",2023-01-16,2023-01-16,reuters.com
16565,EuroNext,NewsApi.org,https://www.prnewswire.com/news-releases/sic-power-semiconductor-market-to-experience-substantial-cagr-growth-of-26-0-by-2030--size-share-trends-industry-growth-key-drivers-and-opportunity-analysis-301721242.html,SiC Power Semiconductor Market to Experience Substantial CAGR Growth of 26.0% by 2030  Size  Share  Trends  Industry Growth  Key Drivers and Opportunity Analysis,"SEOUL  South Korea  Jan. 16  2023 /PRNewswire/ -- Recent study report released by Data Bridge Market research with titled ""SiC Power Semiconductor Market"" guarantees you will remain better informed than your competition. Highly in-depth data collection and re‚Ä¶","SEOUL  South Korea  Jan. 16  2023 /PRNewswire/ -- Recent study report released by Data Bridge Market research with titled ""SiC Power Semiconductor Market"" guarantees you will remain better informed than your competition. Highly in-depth data collection and results analysis has been conducted to generate the world class SiC Power Semiconductor market report. The report effectively communicates research findings such as consumer trends  market trends  and competitor behaviour that surround the target audience. This market research report contains a summary of research findings and insights uncovered during the data collection and analysis processes. It has information about a company's competition  industry trends/opportunities  and recommendations for next steps based on the research questions being addressed. SiC Power Semiconductor market research report helps guide decision-making and highlight market opportunities.SiC Power Semiconductor report is not only clear and concise but also detailed and comprehensive prepared by keeping in mind that stakeholders must be able to interpret the research findings with ease. As market research reports are presented to many stakeholders  not all of them will have a strong understanding of market research terms  so this report is written in clear and simple language. Moreover  all diagrams are clearly labelled and accurately described what they are displaying. While creating SiC Power Semiconductor report  it has been imagined that a reader has no prior knowledge on the topic to ensure and hence the findings are explained comprehensively.Data Bridge Market Research analyses that the global SiC power semiconductor market is expected to reach a value of USD 7 030 515.23 thousand by 2030  at a CAGR of 26.0% during the forecast period. The global SiC power semiconductor market report also comprehensively covers pricing analysis  patent analysis  and technological advancements.Download Sample Copy of SiC Power Semiconductor Market @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-sic-power-semiconductor-marketMarket DefinitionSiC power semiconductor refers to the type of semiconductor that contains carbon and silicon and operates at very high voltage and temperature. SiC power semiconductors can be used in producing a strong as well as a very hard material. SiC power semiconductors can be implemented in various sectors such as telecommunication  energy and power  automotive  renewable power generation  and in different other areas. They are basically considered due to higher maximum thermal conductive properties that have widened the area of application. SiC power semiconductors are devices that are considered high-frequency power devices that are majorly applicable in wireless communications. SiC semiconductor offers ten times the dielectric breakdown field strength  three times the thermal conductivity  and three times the bandgap as compared to a silicon semiconductor. The SiC semiconductor has taken over the market because of its high performance and efficiency. The SiC power semiconductor offers to work at high voltage and current and offers low on-resistance in addition to being efficient at high temperatures. The combination of silicon carbide has thus proved to be a better and optimum choice of semiconductor.Market DriversAdvent Of SiC Power SemiconductorsThere are very useful properties of SiC as a semiconductor material. In applications such as inverters  motor drives  and battery chargers  silicon carbide (SiC) devices offer many advantages  such as improved power density  reduced cooling requirements  and reduced overall system cost. These advantages are enough to make SiC power semiconductors at the high efficient stage.The energy lost by SiC during the reverse recovery phase is only 1% of the energy lost by silicon which creates a huge difference in the efficiency of the material. The virtual absence of a tail current allows a faster turn‚Äìoff  and it makes lower losses. Since there is less energy to dissipate  a SiC device able to switch at higher frequencies and improve efficiency. The more efficient  small size  and lower weight of SiC as compared to other materials can create a higher-rated solution or a smaller design with reduced cooling requirements. Thus  the advent of SiC power semiconductors is a major factor expected to drive the growth of the Global SiC power semiconductor market.Rising Penetration of Electronic VehiclesThe world is changing so fast  and it is turning towards renewable energy. All sectors  market players  and government institutes are making more focus to build electric vehicle infrastructure and generate more demand for electric vehicles.As per the information from International Energy Agency (IEA)  16.5 million electric cars were on the road in 2021  a tripling in just three years  and this is a big number as compared to 2020. Electric car sales increased and doubled in China  continued to increase in Europe  and picked up in the U.S. in 2021. This data shows that there is a tremendous increase in the penetration of EVs in the market  which may positively affect the environment as well as the Global SiC power semiconductor market. SiC is highly efficient at high voltages  enabling fast battery charging times that are comparable to filling the tank of conventional vehicles. Silicon carbide power electronics are enabling a surge in 800-volt drive systems  paving the way for lighter EVs with greater range.Some of the major players operating in the SiC Power Semiconductor market are:WOLFSPEED  INC. STMicroelectronics ROHM CO.  LTD. Fuji Electric Co.  Ltd. Mitsubishi Electric Corporation Texas Instruments Incorporated Infineon Technologies AG Semikron Danfoss Xiamen Powerway Advanced Material Co.  Ltd. Renesas Electronics Corporation TOSHIBA ELECTRONIC DEVICES & STORAGE CORPORATION Microchip Technology Inc. Semiconductor Components Industries  LLC NXP Semiconductors UnitedSiC SemiQ Inc. Littlefuse  Inc. Allegro MicroSystems  Inc. Hitachi Power Semiconductor Device  Ltd. (A Subsidiary of Hitachi Group)  andGeneSiC SemiconductorGet Full PDF Research Report to Understand More @ https://www.databridgemarketresearch.com/checkout/buy/enterprise/global-sic-power-semiconductor-marketRecent DevelopmentsIn December 2022   STMicroelectronics and Soitec (Euronext Paris)  in designing and manufacturing innovative semiconductor materials  announced the next stage of their cooperation on Silicon Carbide (SiC) substrates  with the qualification of Soitec's SiC substrate technology by ST planned over the next 18 months. The goal of this cooperation is the adoption by ST of Soitec's SmartSiC technology for its future 200mm substrate manufacturing  feeding its devices and modules manufacturing business  with volume production expected in the midterm. This collaboration will help the company to boost its financials as well as the growth of the Global SiC power semiconductor market.  in designing and manufacturing innovative semiconductor materials  announced the next stage of their cooperation on Silicon Carbide (SiC) substrates  with the qualification of Soitec's SiC substrate technology by ST planned over the next 18 months. The goal of this cooperation is the adoption by ST of Soitec's SmartSiC technology for its future 200mm substrate manufacturing  feeding its devices and modules manufacturing business  with volume production expected in the midterm. This collaboration will help the company to boost its financials as well as the growth of the Global SiC power semiconductor market. In July 2022   Semikron Danfoss and the Kyoto -based company ROHM Semiconductor have been collaborating for more than ten years with regard to the implementation of silicon carbide (SiC) inside power modules. Recently  ROHM's latest 4th generation of SiC MOSFETs has been fully qualified in SEMIKRON's eMPack modules for automotive use. Hence  both companies serve worldwide customers' needs. This collaboration enhanced the company's financials and made a positive impact on the growth of the Global SiC power semiconductor market.The report provides insights on the following pointers:Market Penetration: Comprehensive information on the product portfolios of the top players in the SiC Power Semiconductor marketProduct Development/Innovation: Detailed insights on upcoming technologies  R&D activities  and product launches in the marketCompetitive Assessment: In-depth assessment of the market strategies  and geographic and business segments of the leading players in the marketMarket Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographiesMarket Diversification: Exhaustive information about new products  untapped geographies  recent developments  and investments in the SiC Power Semiconductor MarketKey Industry Segmentation: SiC Power Semiconductor MarketBy TypeMOSFETSHybrid ModulesSchottky Barrier Diodes (SBDS)IGBTBipolar Junction Transistor (BJT)Pin DiodeJunction FET (JFET)By Voltage Range301-900 V901-1700 VAbove 1701 VBy Wafer Size6 Inch4 Inch2 InchAbove 6 InchBy Wafer TypeSiC epitaxial wafersBlank SiC wafersBy ApplicationElectric Vehicles (EV)(EV) PhotovoltaicsPower suppliesIndustrial motor drivesEV charging infrastructureRF DevicesBy VerticalAutomotiveUtilities and energyIndustrialTransportationIT and telecommunicationConsumer electronicsAerospace and defenseCommercialTo Gain More Insights about this Research  Visit @ https://www.databridgemarketresearch.com/reports/global-sic-power-semiconductor-marketA comprehensive analysis will be provided covering the following points in the report:Executive Market SummaryScope of the SiC Power Semiconductor ReportKey Finding and RecommendationsGrowth and Investment OpportunitiesSiC Power Semiconductor Market Value Chain/Supply Chain AnalysisSiC Power Semiconductor Market Attractive Investment PropositionCompetitive landscape and SWOT AnalysisSiC Power Semiconductor Market Segmentation OutlookRegional OutlookCompany Profiles of Key PlayersRegional Analysis/Insights: SiC Power Semiconductor MarketThe countries covered in the SiC power semiconductor market report are U.S.  Canada  Mexico  Germany  U.K.  Italy  France  Spain  Switzerland  Netherlands  Belgium  Russia  Turkey  Poland  Sweden  Denmark  Rest of Europe  Japan  China  South Korea  India  Australia and New Zealand  Hong Kong  Taiwan  Singapore  Thailand  Indonesia  Malaysia  Philippines  Vietnam  and Rest of Asia-Pacific  South Africa  UAE.  Israel  Egypt  Qatar  Saudi Arabia  Kuwait  Rest of the Middle East and Africa  Brazil  Argentina  and Rest of South America.In 2023  the Asia-Pacific region is expected to dominate the global SiC power semiconductor market due to the high demand for SiC power semiconductors. Additionally  the high demand for power modules and related devices is expected to act as a driving factor for the market's growth.Table of Contents:Introduction Market Segmentation Executive Summary Premium Insights Global SiC Power Semiconductor Market: Regulations Market Overview Global SiC Power Semiconductor Market  By Type Global SiC Power Semiconductor Market  By Voltage Range Global SiC Power Semiconductor Market  By Wafer Size Global SiC Power Semiconductor Market  By Wafer Type Global SiC Power Semiconductor Market  By Application Global SiC Power Semiconductor Market  By Vertical Global SiC Power Semiconductor Market  By Region Global SiC Power Semiconductor Market: Company Landscape SWOT Analyses Company Profile Questionnaires Related ReportsTo Check the Complete Table of contents  click here @ https://www.databridgemarketresearch.com/toc/?dbmr=global-sic-power-semiconductor-marketExplore More Reports:GaN and SiC Power Semiconductor Market  By Product (Sic Power Module  GaN Power Module  Discrete SiC  Dicrete GaN)  Application (Power Supplies  Industrial Motor Drives  H/EV  PV Inverters  Traction  Others)  Country (U.S.  Canada  Mexico  Brazil  Argentina  Rest of South America  Germany  Italy  U.K.  France  Spain  Netherlands  Belgium  Switzerland  Turkey  Russia  Rest of Europe  Japan  China  India  South Korea  Australia  Singapore  Malaysia  Thailand  Indonesia  Philippines  Rest of Asia-Pacific  Saudi Arabia  U.A.E  South Africa  Egypt  Israel  Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-gan-and-sic-power-semiconductor-marketAsia-Pacific SiC Power Semiconductor Market  By Type (MOSFETS  Hybrid Modules  Schottky Barrier Diodes (SBDS)  IGBT  Bipolar Junction Transistor (BJT)  Pin Diode  Junction FET (JFET)  and Others)  Voltage Range (301-900 V  901-1700 V  Above 1701 V)  Wafer size (6 Inch  4 Inch  2 Inch  Above 6 Inch)  Wafer type (SiC Epitaxial Wafers  Blank SiC Wafers)  Application (Electric Vehicles (EV)  Photovoltaics  Power Supplies  Industrial Motor Drives  EV Charging Infrastructure  RF Devices  and Others)  Vertical (Automotive  Utilities and Energy  Industrial  Transportation  IT and Telecommunication  Consumer Electronics  Aerospace and Defense  Commercial  and Others) https://www.databridgemarketresearch.com/reports/asia-pacific-sic-power-semiconductor-marketEurope SiC Power Semiconductor Market  By Type (MOSFETS  Hybrid Modules  Schottky Barrier Diodes (SBDS)  IGBT  Bipolar Junction Transistor (BJT)  Pin Diode  Junction FET (JFET)  and Others)  Voltage Range (301-900 V  901-1700 V  Above 1701 V)  Wafer size (6 Inch  4 Inch  2 Inch  Above 6 Inch)  Wafer type (SiC Epitaxial Wafers  Blank SiC Wafers)  Application (Electric Vehicles (EV)  Photovoltaics  Power Supplies  Industrial Motor Drives  EV Charging Infrastructure  RF Devices  and Others)  Vertical (Automotive  Utilities and Energy  Industrial  Transportation  IT and Telecommunication  Consumer Electronics  Aerospace and Defense  Commercial  and Others) https://www.databridgemarketresearch.com/reports/europe-sic-power-semiconductor-marketMiddle East and Africa SiC Power Semiconductor Market  By Type (MOSFETS  Hybrid Modules  Schottky Barrier Diodes (SBDS)  IGBT  Bipolar Junction Transistor (BJT)  Pin Diode  Junction FET (JFET)  and Others)  Voltage Range (301-900 V  901-1700 V  Above 1701 V)  Wafer size (6 Inch  4 Inch  2 Inch  Above 6 Inch)  Wafer type (SiC Epitaxial Wafers  Blank SiC Wafers)  Application (Electric Vehicles (EV)  Photovoltaics  Power Supplies  Industrial Motor Drives  EV Charging Infrastructure  RF Devices  and Others)  Vertical (Automotive  Utilities and Energy  Industrial  Transportation  IT and Telecommunication  Consumer Electronics  Aerospace and Defense  Commercial  and Others) https://www.databridgemarketresearch.com/reports/middle-east-and-africa-sic-power-semiconductor-marketNorth America SiC Power Semiconductor Market  By Type (MOSFETS  Hybrid Modules  Schottky Barrier Diodes (SBDS)  IGBT  Bipolar Junction Transistor (BJT)  Pin Diode  Junction FET (JFET)  and Others)  Voltage Range (301-900 V  901-1700 V  Above 1701 V)  Wafer size (6 Inch  4 Inch  2 Inch  Above 6 Inch)  Wafer type (SiC Epitaxial Wafers  Blank SiC Wafers)  Application (Electric Vehicles (EV)  Photovoltaics  Power Supplies  Industrial Motor Drives  EV Charging Infrastructure  RF Devices  and Others)  Vertical (Automotive  Utilities and Energy  Industrial  Transportation  IT and Telecommunication  Consumer Electronics  Aerospace and Defense  Commercial  and Others) https://www.databridgemarketresearch.com/reports/north-america-sic-power-semiconductor-marketPin Fin Heat Sink for Integrated Gate Bipolar Transistor (IGBT) Market  By Material Type (Copper  Aluminium)  Application (Consumer Electronics  Automotive Field  Others)  Country (U.S.  Canada  Mexico  Brazil  Argentina  Rest of South America  Germany  France  Italy  U.K.  Belgium  Spain  Russia  Turkey  Netherlands  Switzerland  Rest of Europe  Japan  China  India  South Korea  Australia  Singapore  Malaysia  Thailand  Indonesia  Philippines  Rest of Asia-Pacific  U.A.E  Saudi Arabia  Egypt  South Africa  Israel  Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-pin-fin-heat-sink-for-igbt-marketInsulated Gate Bipolar Transistor (IGBT) Discrete Semiconductor Market  By Type (Discrete IGBT  Modular IGBT)  Power Rating (High- Power  Medium- Power  Low- Power)  End- User (Automotive  Consumer Electronics  Communication  Industrial  Other End-Use Verticals) https://www.databridgemarketresearch.com/reports/global-igbt-discrete-semiconductor-marketInsulated Gate Bipolar Transistor (IGBT) Market  By Type (Discrete  Modular)  Power Rating (High-Power  Medium-Power  Low-Power)  End-user Industry (EV/HEV  Renewables  UPS  Rail  Motor Drives  Industrial  Commercial)  Country (U.S.  Canada  Mexico  Brazil  Argentina  Rest of South America  Germany  Italy  U.K.  France  Spain  Netherlands  Belgium  Switzerland  Turkey  Russia  Rest of Europe  Japan  China  India  South Korea  Australia  Singapore  Malaysia  Thailand  Indonesia  Philippines  Rest of Asia-Pacific  Saudi Arabia  U.A.E  South Africa  Egypt  Israel  Rest of Middle East and Africa) https://www.databridgemarketresearch.com/reports/global-insulated-gate-bipolar-transistor-igbt-marketAbout Data Bridge Market Research:An absolute way to forecast what future holds is to comprehend the trend today!Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.Contact Us:-Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:- [email protected]Logo: https://mma.prnewswire.com/media/1011053/Data_Bridge_Market_Research_Logo.jpgSOURCE Data Bridge Market Research",neutral,0.0,1.0,0.0,mixed,0.51,0.13,0.36,True,English,"['SiC Power Semiconductor Market', 'Substantial CAGR Growth', 'Industry Growth', 'Key Drivers', 'Opportunity Analysis', 'Size', 'Share', 'Trends', 'world class SiC Power Semiconductor market report', 'global SiC power semiconductor market report', 'SiC Power Semiconductor market research report', 'higher maximum thermal conductive properties', 'dielectric breakdown field strength', 'SiC Power Semiconductor report', 'The SiC power semiconductor', 'Data Bridge Market research', 'SiC power semiconductors', 'Recent study report', 'The SiC semiconductor', 'market research reports', 'market research terms', 'renewable power generation', 'overall system cost', 'reverse recovery phase', 'faster turn‚Äìoff', 'frequency power devices', 'electric vehicle infrastructure', '16.5 million electric cars', 'Electric car sales', 'different other areas', 'depth data collection', 'high efficient stage', 'International Energy Agency', 'reduced cooling requirements', 'power density', 'market trends', 'market opportunities', 'Market Definition', 'Market Drivers', 'market players', 'thermal conductivity', 'useful properties', 'higher frequencies', 'SiC) devices', 'SiC device', 'semiconductor material', 'silicon semiconductor', 'research questions', 'research findings', 'electric vehicles', 'other materials', 'high voltage', 'high performance', 'high temperatures', 'renewable energy', 'South Korea', 'results analysis', 'consumer trends', 'competitor behaviour', 'target audience', 'analysis processes', 'industry trends/opportunities', 'next steps', 'simple language', 'prior knowledge', 'forecast period', 'pricing analysis', 'patent analysis', 'technological advancements', 'wireless communications', 'optimum choice', 'motor drives', 'battery chargers', 'huge difference', 'virtual absence', 'lower losses', 'lower weight', 'higher-rated solution', 'smaller design', 'major factor', 'Rising Penetration', 'Electronic Vehicles', 'government institutes', 'three years', 'big number', 'U.S.', 'tremendous increase', 'hard material', 'less energy', 'silicon carbide', 'many stakeholders', 'strong understanding', 'Sample Copy', 'various sectors', 'many advantages', 'tail current', 'SEOUL', 'Jan.', 'PRNewswire', 'competition', 'summary', 'insights', 'information', 'company', 'recommendations', 'decision-making', 'mind', 'clear', 'diagrams', 'reader', 'topic', 'value', 'CAGR', 'Download', 'databridgemarketresearch', 'global-sic-power-semiconductor-market', 'type', 'carbon', 'telecommunication', 'automotive', 'application', 'bandgap', 'efficiency', 'resistance', 'addition', 'combination', 'Advent', 'inverters', 'growth', 'focus', 'demand', 'IEA', 'road', 'tripling', 'China', 'Europe']",2023-01-16,2023-01-16,prnewswire.com
16566,EuroNext,NewsApi.org,https://www.uppermichiganssource.com/prnewswire/2023/01/16/nexans-launches-innovative-canadex-20-residential-cables/,Nexans Launches Innovative CANADEX¬Æ 2.0 Residential Cables,,"Nexans offers CANADEX ¬Æ 2.0 line of residential NMD90 cables that enables faster installation and lowers overall project costsIn line with our strategy to be true partners with our customers  the cables are designed using feedback from electricians and incorporates three key features to streamline workflowThe cables are locally manufactured at Nexans' facilities in Fergus  ON and are constructed using partially recycled copper from our copper rod mill facility in MontrealTORONTO  Jan. 16  2023 /PRNewswire/ -- Nexans  a global organization and key driver for the world's transition to a more connected and sustainable future  today announced the launch of the CANADEX¬Æ 2.0 line of NMD90 cables  an upgrade to the existing line of CANADEX¬Æ cables. The line is designed to accelerate the installation process  allowing electricians to perform more work in less time  cut overall project costs  and reduce their carbon footprints.Nexans Logo (PRNewswire)CANADEX¬Æ 2.0 cables are designed with the electricians' needs in mind with three key features intended to streamline the installation process. The ""INSTAGLIDE¬Æ"" technology allows for fast and efficient installation and the 'Easy-Lift' handle on Spools is more ergonomic  which improves safety on job sites. Nexans has also added metre markings to the cable to account for every metre of cable installed  reducing product waste.Jerome Leroy  Nexans' VP of Distribution and Usage Canada  said: "" In developing CANADEX¬Æ 2.0 cable  our team held focus groups with electricians to understand and gather qualitative insights and unmet needs to create a new line of cable with electricians in mind  democratizing the cable manufacturing process. This new line of residential cables is a revolutionary step in the electrification of Canadian households   using partially recycled copper from our copper rod mill facility in Montreal. Our cables are made by and for Canadians  and we are excited to embark on this new journey.""About NEXANSFor more than a century  Nexans has played a crucial role in electrifying the planet and is committed to electrifying the future. With 25 000 staff in 42 countries  the Group is driving the change towards the new world of electrification ‚Äî a safer  more sustainable  renewable  carbon-free world  accessible to all. In 2021  Nexans generated ‚Ç¨6.1 billion in standard sales. The Group is a leader in the design and manufacturing of cable systems and services in five main areas of activity: Energy Production & Transmission  Distribution  Usages  Industry & Solutions and Telecom & Data. Nexans was the first player in its industry to create a Corporate Foundation to support actions that promote access to energy for disadvantaged populations worldwide. The Group is committed to helping achieve carbon neutrality by 2030.Nexans. Electrify the future.Nexans is listed on the Euronext Paris stock market  compartment A.For more information  visit www.nexans.caFor more information about CANADEX¬Æ  visit nexanscanadex.caView original content to download multimedia:SOURCE Nexans",neutral,0.0,0.99,0.0,positive,0.99,0.01,0.0,True,English,"['Innovative CANADEX¬Æ 2.0 Residential Cables', 'Nexans', 'Euronext Paris stock market', 'copper rod mill facility', 'sustainable, renewable, carbon-free world', 'overall project costs', 'five main areas', 'three key features', 'residential NMD90 cables', 'cable manufacturing process', 'key driver', 'installation process', 'new world', 'sustainable future', 'residential cables', 'faster installation', 'true partners', 'global organization', 'less time', 'carbon footprints', 'INSTAGLIDE¬Æ"" technology', 'efficient installation', ""Easy-Lift' handle"", 'job sites', 'product waste', 'Jerome Leroy', 'Usage Canada', 'focus groups', 'qualitative insights', 'unmet needs', 'revolutionary step', 'Canadian households', 'new journey', 'a century', 'crucial role', 'standard sales', 'first player', 'Corporate Foundation', 'disadvantaged populations', 'carbon neutrality', 'compartment A.', 'original content', 'existing line', 'new line', 'The Group', 'cable systems', 'CANADEX¬Æ cables', 'CANADEX¬Æ 2.0 cables', 'CANADEX ¬Æ 2.0 line', 'CANADEX¬Æ 2.0 line', 'metre markings', 'Energy Production', ""Nexans' facilities"", 'Nexans Logo', ""Nexans' VP"", 'SOURCE Nexans', ""electricians' needs"", 'strategy', 'customers', 'feedback', 'workflow', 'Fergus', 'Montreal', 'TORONTO', 'PRNewswire', 'transition', 'connected', 'launch', 'upgrade', 'mind', 'Spools', 'safety', 'Distribution', 'team', 'electrification', 'Canadians', 'planet', '25,000 staff', '42 countries', 'change', 'leader', 'design', 'services', 'activity', 'Transmission', 'Usages', 'Industry', 'Solutions', 'Telecom', 'Data', 'actions', 'access', 'information', 'nexanscanadex', 'multimedia']",2023-01-16,2023-01-16,uppermichiganssource.com
16567,EuroNext,Bing API,https://www.ft.com/content/5cf637f6-52a4-4adf-bafe-fcaa9f0f20a6,Euronext to switch derivatives clearing to Italy in 2024,Euronext has agreed a deal to move part of its clearing business from a subsidiary of the London Stock Exchange Group  reducing its reliance on its British rival in a controversia,What is included in my trial?During your trial you will have complete digital access to FT.com with everything in both of our Standard Digital and Premium Digital packages.Standard Digital includes access to a wealth of global news  analysis and expert opinion. Premium Digital includes access to our premier business column  Lex  as well as 15 curated newsletters covering key business themes with original  in-depth reporting. For a full comparison of Standard and Premium Digital  click here.Change the plan you will roll onto at any time during your trial by visiting the ‚ÄúSettings & Account‚Äù section.What happens at the end of my trial?If you do nothing  you will be auto-enrolled in our premium digital monthly subscription plan and retain complete access for 65 ‚Ç¨ per month.For cost savings  you can change your plan at any time online in the ‚ÄúSettings & Account‚Äù section. If you‚Äôd like to retain your premium access and save 20%  you can opt to pay annually at the end of the trial.You may also opt to downgrade to Standard Digital  a robust journalistic offering that fulfils many user‚Äôs needs. Compare Standard and Premium Digital here.Any changes made can be done at any time and will become effective at the end of the trial period  allowing you to retain full access for 4 weeks  even if you downgrade or cancel.,neutral,0.01,0.99,0.0,positive,0.97,0.03,0.0,True,English,"['Euronext', 'derivatives', 'Italy', 'premium digital monthly subscription plan', 'premier business column', 'key business themes', 'original, in-depth reporting', 'robust journalistic offering', 'Premium Digital packages', 'premium access', 'digital access', 'Standard Digital', 'FT.com', 'global news', 'expert opinion', '15 curated newsletters', 'full comparison', 'cost savings', 'many user', 'full access', 'complete access', 'trial period', 'everything', 'wealth', 'analysis', 'Lex', 'time', 'Settings', 'Account', 'section', 'end', 'needs', 'changes', '4 weeks', '65']",2023-01-16,2023-01-16,ft.com
16568,EuroNext,Bing API,https://uk.style.yahoo.com/deinove-receivership-proceedings-180900709.html,DEINOVE - Update on the receivership proceedings,DEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent  global challenge of antibiotic resistance ,DeinoveDEINOVE (Euronext Growth Paris: ALDEI)  a French biotech company  pioneer in the exploration and exploitation of bacterial biodiversity to address the urgent  global challenge of antibiotic resistance  announces that  in the context of the receivership proceedings (‚Äúproc√©dure de redressement judiciaire‚Äù) opened on November 7  2022  the Montpellier Commercial Court met on January 13  2023 to examine the case and reserved its decision until January 23  2023.The listing of the Company's shares (ISIN: FR0010879056)  which has been suspended since January 11  2023  will remain suspended.ABOUT DEINOVEDEINOVE is a French biotechnology company pioneering the exploration of a new domain of life  unexplored at 99.9%: the ‚Äúmicrobial dark matter‚Äù. By revealing the metabolic potential of rare bacteria or still classified as uncultivable  it tackles a global health and economic challenge: antimicrobial resistance.The new therapies discovered and developed by DEINOVE target superbugs (microbes that have become resistant to one or more antimicrobials) that cause life-threatening infections which are now spreading at high speed.This breakthrough approach gave rise to one of the world‚Äôs first specialized micro-biotechnology platforms and a unique collection of nearly 10 000 rare strains and thousands of bacterial extracts. Today  DEINOVE is conducting several development programs  of which its first antibiotic candidate is currently evaluated in a Phase II clinical trial in severe Clostridioides difficile infection  one of the world‚Äôs first emergencies. The Company has also developed new bacterial micro-factories that address the other issue in the race against antimicrobial resistance: the industrial production of these rare and low concentrated compounds with often too complex chemical structures to be generated by chemical synthesis.Located at the heart of the Euromedecine park in Montpellier  DEINOVE has been listed on EURONEXT GROWTH¬Æ (ALDEI ‚Äì code ISIN FR0010879056) since 2010. The Company has 45 employees and relies on a network of world-class academic  technological  industrial and institutional partners.Story continuesCONTACTSInvestorsMario AlcarazChief Financial and Administrative Officer+33 (0)4 48 19 01 00ir@deinove.comMediaATCG Partners+33 (0)9 81 87 46 72communication@deinove.comAttachment,neutral,0.09,0.91,0.01,mixed,0.17,0.15,0.68,True,English,"['receivership proceedings', 'DEINOVE', 'Update', 'proc√©dure de redressement judiciaire', 'Phase II clinical trial', 'severe Clostridioides difficile infection', 'first specialized micro-biotechnology platforms', 'world-class academic, technological, industrial', 'microbial dark matter', 'several development programs', 'low concentrated compounds', 'first antibiotic candidate', 'complex chemical structures', 'French biotech company', 'French biotechnology company', 'Euronext Growth Paris', 'urgent, global challenge', 'Montpellier Commercial Court', 'new bacterial micro-factories', 'first emergencies', 'industrial production', 'EURONEXT GROWTH¬Æ', 'antibiotic resistance', 'global health', 'economic challenge', 'chemical synthesis', 'bacterial biodiversity', 'new domain', 'new therapies', 'bacterial extracts', 'The Company', 'receivership proceedings', 'metabolic potential', 'antimicrobial resistance', 'life-threatening infections', 'high speed', 'breakthrough approach', 'unique collection', 'other issue', 'Euromedecine park', 'institutional partners', 'Mario Alcaraz', 'Chief Financial', 'Administrative Officer', 'ATCG Partners', 'rare bacteria', '10,000 rare strains', 'Deinove', 'ALDEI', 'pioneer', 'exploration', 'exploitation', 'context', 'November', 'January', 'case', 'decision', 'listing', 'shares', 'superbugs', 'microbes', 'antimicrobials', 'rise', 'thousands', 'race', 'heart', 'code', 'ISIN', '45 employees', 'network', 'Story', 'CONTACTS', 'Investors', 'Media', 'communication', 'Attachment', '9']",2023-01-16,2023-01-16,uk.style.yahoo.com
16569,EuroNext,Bing API,https://au.finance.yahoo.com/news/euronext-confirms-expansion-euronext-clearing-170400575.html,Euronext confirms the expansion of Euronext Clearing to derivatives markets for Q3 2024,Contacts Media Contact Investor Relations Amsterdam +31 20 721 4133 Brussels +32 2 620 15 50 +33 1 70 48 24 27 Dublin +33 1 70 48 24 45 Lisbon +351 210 600 614 Milan +39 02 72 42 62 12 Oslo +47 41 69 59 10 Paris +33 1 70 48 24 45 Euronext confirms the expansion of Euronext Clearing to derivatives markets for Q3 2024 Amsterdam ,"EuronextContacts Media Contact Investor Relations Amsterdam +31 20 721 4133 Brussels +32 2 620 15 50 +33 1 70 48 24 27 Dublin +33 1 70 48 24 45 Lisbon +351 210 600 614 Milan +39 02 72 42 62 12 Oslo +47 41 69 59 10 Paris +33 1 70 48 24 45Euronext confirms the expansion of Euronext Clearing to derivatives markets for Q3 2024Amsterdam  Brussels  Dublin  Lisbon  Milan  Oslo and Paris ‚Äì 16 January 2023 ‚Äì Euronext  the leading pan-European market infrastructure  today announces that the European expansion of Euronext Clearing to Euronext derivatives markets is planned for Q3 2024.Since April 2021  Euronext has been the owner of a multi-asset clearing house  Euronext Clearing (formerly CC&G)  and is thus in a position to directly manage its clearing activities to complete its value chain. In November 2021  Euronext announced its ambition to internalise the clearing activity of its cash and derivatives flows  today operated by third-party providers. As a result Euronext Clearing will become Euronext‚Äôs clearing house (‚ÄúCCP‚Äù) of choice for cash equity1  listed derivatives and commodities markets.Combined with the successful migration of its Core Data Centre in June 2022 from Basildon (United Kingdom) to Bergamo (Italy) and the planned migration of the Borsa Italiana capital markets to Optiq¬Æ  Euronext‚Äôs proprietary trading platform  the expansion of Euronext Clearing will allow Euronext to manage the entire trading value chain of its markets by the end of 2024. Euronext will directly operate clearing activities for its cash  listed derivatives and commodities markets  and create value through a harmonised clearing framework across Euronext venues. It will provide one single platform for clients to access information on collateral  risk  and clearing. Euronext Clearing will bring margin efficiencies to clients with the implementation of a new Value-at-Risk methodology  offering the financial ecosystem with increasingly efficient and resilient solutions for risk capture and allocation within the system. This move will also bring efficiencies across all asset classes  with transparency on data  particularly on settlement  leveraging Euronext Securities to access the Target-2-Securities (T2S) settlement platform. Euronext Clearing will allow Euronext to significantly increase its footprint in the post-trade space and align strategic priorities between trading and clearing. Euronext will be in an ideal position to innovate and improve time-to-market  notably on derivatives products  to serve the evolving needs of its clients.Story continuesPositioning of Euronext Clearing as the CCP of choice across its cash equity markets1As announced on 3 November 2022  Euronext confirms the first phase of the expansion of Euronext Clearing with the expected positioning of Euronext Clearing as the Euronext CCP of choice for its cash equity markets1 by the end of Q4 2023. Euronext will continue to offer an open access CCP model for cash equity clearing.Migration2 of Euronext listed derivatives and commodities markets to Euronext Clearing expected in Q3 2024Euronext confirms it expects to migrate the listed financial derivatives and commodities markets of Euronext Amsterdam  Euronext Brussels  Euronext Lisbon  Oslo B√∏rs and Euronext Paris from LCH SA to Euronext Clearing by Q3 2024. As a reminder  Euronext Clearing already clears Euronext Milan listed derivatives.The migration of Euronext listed derivatives and commodities markets is the final step of the European expansion of Euronext Clearing set up as part of Euronext ‚ÄòGrowth for Impact 2024‚Äô strategic plan. It will unlock innovation capabilities  notably on derivatives products. Furthermore  the migration will maximise value extraction through a harmonised clearing framework across Euronext venues and deliver on the announced targeted run-rate annual synergies for 2024.Euronext and LCH SA are committed to working together to ensure an orderly migration of clearing flows from LCH SA to Euronext Clearing.Notification of early termination of the derivatives clearing agreement (the ‚ÄúAgreement‚Äù) with LCH SAAs Euronext Clearing undertakes derivatives clearing services in Europe  Euronext has decided to terminate the existing Agreement with LCH SA  under the terms of the Agreement. Therefore  on 16 January 2023  Euronext served LCH SA notice of termination for the purposes of the Agreement.As set up in the Agreement  Euronext will pay a termination fee of approximately ‚Ç¨36.03 million toLCH SA  to be provisioned in its income statement as non-underlying expenses in Q1 2023  and payable in 2024. It is reminded that this amount is included in the ‚Ç¨150 million of implementation costs related to the ‚ÄòGrowth for Impact 2024‚Äô strategic plan and already announced in November 2021.Following the notification of the early termination of the Agreement  LCH Group has the option to buy back Euronext's 11.1% stake in LCH SA. Further communications on the stake owned by Euronext in LCH SA will be made when appropriate.The termination of the Agreement does not impact the existing clearing agreement signed between MTS S.p.A and LCH SA nor the existing agreement related to the interoperability link on Italian Government Bonds between Euronext Clearing and LCH SA4.St√©phane Boujnah  Chief Executive Officer and Chairman of the Managing Board of Euronext  said:‚ÄúWe are pleased to announce that the migration of Euronext derivatives clearing activities to Euronext Clearing is planned for Q3 2024  a few months after the migration of Euronext cash clearing activities. Combined with the successful migration of the Core Data Centre to Bergamo in June 2022 and the planned migration of the Borsa Italiana capital markets to Optiq¬Æ in 2023  the expansion of our clearing activities is a major step towards the delivery our ‚ÄúGrowth for Impact 2024‚Äù strategic plan. This will significantly contribute to achieve the ‚Ç¨100 million 2024 targeted run-rate annual synergies related to the Borsa Italiana Group acquisition.Euronext has profoundly transformed itself over the past five years and is uniquely positioned to become the leading European market infrastructure. Euronext is now the leading listing venue and the largest liquidity pool in Europe  thanks to its single trading platform. The expansion of Euronext Clearing to Euronext markets is another significant transformational milestone  allowing Euronext to manage the entire trading value chain  and become a major player in the post-trade space.We look forward to completing these strategic milestones in the coming months. I would like to thank all the Euronext teams that have already been working on these key projects for more than a year and that will be critical to the delivery of these projects. I would like to thank LCH SA for the great collaboration during the past years.‚ÄùCONTACT ANALYSTS & INVESTORS ‚Äì ir@euronext.com Aur√©lie Cohen +33 1 70 48 24 27 ir@euronext.com Cl√©ment Kubiak +33 1 70 48 26 33 ir@euronext.comCONTACTS MEDIA ‚Äì mediateam@euronext.com Aur√©lie Cohen (Europe) +33 1 70 48 24 45 parispressoffice@euronext.com Marianne Aalders (Amsterdam) +31 20 721 41 33 maalders@euronext.com Pascal Brabant (Brussels) +32 2 620 15 50 pbrabant@euronext.com Sandra Machado (Lisbon) +351 210 600 614 smachado@euronext.com Andrea Monzani (Europe/Milan/Rome) +39 02 72 42 62 13 Italypressoffice@euronext.com Cathrine Lorvik Segerlund (Oslo) +47 41 69 59 10 clsegerlund@euronext.com Sarah Mound (Paris/Dublin) +33 1 70 48 24 45 parispressoffice@euronext.comAbout EuronextEuronext is the leading pan-European market infrastructure  connecting European economies to global capital markets  to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium  France  Ireland  Italy  the Netherlands  Norway and Portugal. With close to 1 930 listed equity issuers and around ‚Ç¨6.3 trillion in market capitalisation as of end December 2022  it has an unmatched blue chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets  one of Europe‚Äôs leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities  FX  Exchange Traded Funds  Warrants & Certificates  Bonds  Derivatives  Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing  and custody and settlement services through Euronext Securities central securities depositories in Denmark  Italy  Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market  it also operates a number of junior markets  simplifying access to listing for SMEs.For the latest news  go to euronext.com or follow us on Twitter ( twitter.com/ euronext ) and LinkedIn ( linkedin.com/ euronex t ).DisclaimerThis press release is for information purposes only: it is not a recommendation to engage in investment activities and is provided ‚Äúas is‚Äù  without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content  Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using  trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext‚Äôs subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext. This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is available at www.euronext.com/terms-use.¬© 2023  Euronext N.V. - All rights reserved.The Euronext Group processes your personal data in order to provide you with information about Euronext (the ""Purpose""). With regard to the processing of this personal data  Euronext will comply with its obligations under Regulation (EU) 2016/679 of the European Parliament and Council of 27 April 2016 (General Data Protection Regulation  ‚ÄúGDPR‚Äù)  and any applicable national laws  rules and regulations implementing the GDPR  as provided in its privacy statement available at: www.euronext.com/privacy-policy. In accordance with the applicable legislation you have rights with regard to the processing of your personal data: for more information on your rights  please refer to: www.euronext.com/data_subjects_rights_request_information. To make a request regarding the processing of your data or to unsubscribe from this press release service  please use our data subject request form at connect2.euronext.com/form/data-subjects-rights-request or email our Data Protection Officer at dpo@euronext.com.1 Excluding Oslo B√∏rs cash markets2 Migrations are subject to the declaration of non-objection of relevant regulators3 Of which ‚Ç¨6 million to be adjusted for inflation impact4 For more information  please refer to Euronext 2021 Universal Registration Document ‚Äì Section 7.2.1  Material ContractsAttachment",neutral,0.0,1.0,0.0,mixed,0.33,0.33,0.34,True,English,"['derivatives markets', 'Euronext Clearing', 'expansion', 'Q3', 'Contacts Media Contact Investor Relations', 'leading pan-European market infrastructure', 'Borsa Italiana capital markets', 'open access CCP model', 'entire trading value chain', 'one single platform', 'run-rate annual synergies', 'proprietary trading platform', 'Impact 2024‚Äô strategic plan', 'cash equity markets1', 'harmonised clearing framework', 'Core Data Centre', 'T2S) settlement platform', 'Oslo B√∏rs', 'multi-asset clearing house', 'cash equity clearing', 'LCH SA notice', 'derivatives clearing services', 'Euronext derivatives markets', 'derivatives clearing agreement', 'strategic priorities', 'commodities markets', 'new Value', 'value extraction', 'clearing activities', 'clearing activity', 'clearing flows', 'existing clearing', 'LCH Group', 'CC&G', 'third-party providers', 'United Kingdom', 'margin efficiencies', 'financial ecosystem', 'resilient solutions', 'asset classes', 'post-trade space', 'evolving needs', 'first phase', 'final step', 'innovation capabilities', 'income statement', 'underlying expenses', 'Further communications', 'derivatives flows', 'derivatives products', 'financial derivatives', 'Euronext Clearing', 'Risk methodology', 'risk capture', 'early termination', 'termination fee', 'Euronext venues', 'Euronext Securities', 'Euronext CCP', 'ideal position', 'expected positioning', 'implementation costs', 'listed derivatives', 'European expansion', 'successful migration', 'orderly migration', 'existing Agreement', 'Euronext ‚ÄòGrowth', 'Euronext Amsterdam', 'Euronext Brussels', 'Euronext Lisbon', 'Euronext Paris', 'Euronext Milan', 'Dublin', 'Q3', '16 January', 'April', 'owner', 'November', 'ambition', 'result', 'choice', 'June', 'Basildon', 'Bergamo', 'Italy', 'planned', 'Optiq¬Æ', 'end', 'clients', 'information', 'collateral', 'efficient', 'allocation', 'move', 'transparency', 'Target-2-Securities', 'footprint', 'time', 'Story', 'Q4', 'Migration2', 'reminder', 'targeted', 'Notification', 'terms', 'purposes', 'Q1', 'amount', 'option', '11.1% stake']",2023-01-16,2023-01-16,au.finance.yahoo.com
16570,EuroNext,Bing API,https://uk.news.yahoo.com/ferrari-n-v-periodic-report-155800075.html,Ferrari N.v.: Periodic Report on the Buyback Program,(NYSE/EXM: RACE) (‚ÄúFerrari‚Äù or the ‚ÄúCompany‚Äù) informs that the Company has purchased  under the Euro 200 million share buyback program announced on December 1  2022  as the second tranche of the multi-year share buyback program of approximately Euro 2 billion expected to be executed by 2026 in line with the disclosure made during the 2022 Capital Markets Day (the ‚ÄúSecond Tranche‚Äù) ,Ferrari N.V.Maranello (Italy)  January 16  2023 ‚Äì Ferrari N.V. (NYSE/EXM: RACE) (‚ÄúFerrari‚Äù or the ‚ÄúCompany‚Äù) informs that the Company has purchased  under the Euro 200 million share buyback program announced on December 1  2022  as the second tranche of the multi-year share buyback program of approximately Euro 2 billion expected to be executed by 2026 in line with the disclosure made during the 2022 Capital Markets Day (the ‚ÄúSecond Tranche‚Äù)  the additional common shares - reported in aggregate form  on a daily basis - on the Euronext Milan (EXM) as follows:TradingDate(dd/mm/yyyy)Stock ExchangeNumber of common shares purchasedAverage price per shareexcluding fees(‚Ç¨)Consideration excluding fees(‚Ç¨)09/01/2023 EXM 5 200 214.6976 1 116 427.52 10/01/2023 EXM 5 150 214.6407 1 105 399.61 11/01/2023 EXM 5 120 215.9513 1 105 670.66 12/01/2023 EXM 5 100 217.3482 1 108 475.82 13/01/2023 EXM 5 090 217.4830 1 106 988.47Total- 25 660 216.0157 5 542 962.07(*) translated at the European Central Bank EUR/USD exchange reference rate as of the date of each purchaseSince the announcement of such Second Tranche till January 13  2023  the total invested consideration has been:Euro 34 880 796.71 for No. 166 708 common shares purchased on the EXMUSD 8 757 853.08 (Euro 8 271 632.62*) for No. 40 049 common shares purchased on the NYSE.As of January 13  2023  the Company held in treasury No. 12 034 386 common shares equal to 4.68% of the total issued share capital including the common shares and the special voting shares  net of shares assigned under the Company‚Äôs equity incentive plan.Since July 1  2022 until January 13  2023  the Company has purchased a total of 980 494 own common shares on EXM and NYSE  including transactions for Sell to Cover  for a total consideration of Euro 193 878 109.04.A comprehensive overview of the transactions carried out under the buyback program  as well as the details of the above transactions  are available on Ferrari‚Äôs corporate website under the Buyback Programs section ( https://www.ferrari.com/en-EN/corporate/buyback-programs ).Story continuesAttachment,neutral,0.0,1.0,0.0,positive,0.43,0.4,0.16,True,English,"['Ferrari N.v.', 'Periodic Report', 'Buyback Program', 'EUR/USD exchange reference rate', '200 million share buyback program', 'multi-year share buyback program', 'Ferrari N.V. Maranello', 'Buyback Programs section', 'European Central Bank', 'equity incentive plan', '2022 Capital Markets Day', 'special voting shares', 'additional common shares', 'No. 166,708 common shares', 'No. 40,049 common shares', 'share capital', 'Stock Exchange', '12,034,386 common shares', 'treasury No.', 'second tranche', 'aggregate form', 'daily basis', 'Euronext Milan', 'Average price', 'comprehensive overview', 'corporate website', 'Trading Date', 'total consideration', 'Italy', 'NYSE/EXM', 'RACE', 'Company', 'December', 'line', 'disclosure', 'Number', 'fees', 'purchase', 'announcement', 'January', 'July', 'transactions', 'Sell', 'details', 'buyback-programs', 'Story', 'Attachment', '980,494']",2023-01-16,2023-01-16,uk.news.yahoo.com
16571,EuroNext,Bing API,https://www.nasdaq.com/articles/paris-wheat-eases-to-10-month-low-with-exports-in-focus,Paris wheat eases to 10-month low with exports in focus,Euronext wheat edged to a 10-month low on Monday as strength in the euro and cheaper Black Sea supplies kept a lid on prices despite talk of Moroccan demand. Volumes were light as a U.S. holiday deprived the market of usual direction.,"PARIS  Jan 16 (Reuters) - Euronext wheat edged to a 10-month low on Monday as strength in the euro and cheaper Black Sea supplies kept a lid on prices despite talk of Moroccan demand.Volumes were light as a U.S. holiday deprived the market of usual direction.Traders were also looking ahead to a wheat import tender by Algeria on Tuesday as a fresh gauge of Black Sea competition.March milling wheat BL2H3 on Paris-based Euronext was down 0.7% at 286.75 euros ($310.23) a tonne by 1640 GMT.The contract earlier fell to 286.25 euros for its lowest since March 8 and a weakest front-month price BL2c1 since Feb. 23.The filling of a chart gap to the downside added to selling impetus  dealers said.The euro EUR= earlier touched a nine-month peak against the dollar  making European grain more expensive for export.""The euro-dollar rate is playing an important role; you have to think of Euronext in dollar terms "" one futures dealer said.Competitive offers of Russian wheat in tenders by Turkey and Egypt last week have weighed on futures.‚ÄúShip insurance from Russian ports became considerably more expensive this year  but low Russian prices were able to overcome this in tenders last week from Turkey and Egypt ‚Äù one German trader said.Cheap prices were again being offered on Monday for shipments through Ukraine's wartime shipping corridor  traders said.However  fresh demand from Morocco for western European supplies was lending support.After chatter last week that several cargoes of French wheat had been sold for nearby shipment  there was talk that six to eight vessels may have been sold  including some German supplies.‚ÄúA bright spot is market talk that Morocco last week bought about 180 000 to 240 000 tonnes of milling wheat  mainly from France but possibly some to be sourced from Germany  for rapid arrival "" the German trader said.Brisk exports so far this season have underpinned physical premiums in France and Germany. GRAIN/SHP/FR  WHEAT/RTRIn Germany  standard 12% protein wheat for February delivery in Hamburg was offered for sale at a premium of about 13 to 14 euros over Euronext March  but with little purchase interest visible.($1 = 0.9243 euros)(Reporting by Gus Trompiz in Paris and Michael Hogan in Hamburg Editing by David Goodman )((gus.trompiz@thomsonreuters.com; +33 1 49 49 52 18; Reuters Messaging: gus.trompiz.thomsonreuters.com@reuters.net))The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq  Inc.",neutral,0.02,0.98,0.0,negative,0.0,0.05,0.95,True,English,"['Paris wheat', 'exports', 'focus', 'six to eight vessels', 'cheaper Black Sea supplies', 'March milling wheat BL2H3', 'Black Sea competition', 'U.S. holiday', 'weakest front-month price', 'wartime shipping corridor', 'little purchase interest', 'western European supplies', 'wheat import tender', 'one futures dealer', 'one German trader', 'low Russian prices', 'German supplies', 'Russian wheat', '180,000 to 240,000 tonnes', 'European grain', 'French wheat', '12% protein wheat', 'Russian ports', 'Euronext wheat', 'Euronext March', 'Moroccan demand', 'usual direction', 'fresh gauge', 'chart gap', 'nine-month peak', 'euro-dollar rate', 'important role', 'Competitive offers', 'Ship insurance', 'Cheap prices', 'fresh demand', 'several cargoes', 'nearby shipment', 'bright spot', 'rapid arrival', 'Brisk exports', 'physical premiums', 'February delivery', 'Gus Trompiz', 'Michael Hogan', 'David Goodman', '13 to 14 euros', 'Paris-based Euronext', 'dollar terms', 'Reuters Messaging', 'market talk', '286.75 euros', '286.25 euros', '0.9243 euros', 'Monday', 'strength', 'Volumes', 'Traders', 'Algeria', 'Tuesday', '1640 GMT', 'contract', 'Feb.', 'filling', 'downside', 'impetus', 'dealers', 'tenders', 'Turkey', 'Egypt', 'shipments', 'Ukraine', 'Morocco', 'support', 'chatter', 'France', 'Germany', 'GRAIN/SHP/FR', 'WHEAT/RTR', 'standard', 'Hamburg', 'sale', 'views', 'opinions', 'author', 'Nasdaq', 'Inc']",2023-01-16,2023-01-16,nasdaq.com
16572,EuroNext,Bing API,https://www.wvnews.com/business/innate-pharma-announces-publication-of-preclinical-data-with-a-trifunctional-nk-cell-engager-in-acute/article_029d36bf-279f-53d1-815d-1e503b12bc03.html,Innate Pharma Announces Publication of Preclinical Data with a Trifunctional NK Cell Engager in Acute Myeloid Leukemia in Nature Biotechnology,Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (‚Äú Innate ‚Äù or the ‚Äú Company ‚Äù) announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123.,Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (‚Äú Innate ‚Äù or the ‚Äú Company ‚Äù) announced today the publication in Nature Biotechnology of preclinical data showing the control of acute myeloid leukemia (AML) cells by a trifunctional NKp46-CD16a-NK cell engager (NKCE) targeting CD123.,neutral,0.0,0.99,0.01,neutral,0.0,0.99,0.01,True,English,"['Trifunctional NK Cell Engager', 'Acute Myeloid Leukemia', 'Innate Pharma', 'Preclinical Data', 'Nature Biotechnology', 'Publication', 'trifunctional NKp46-CD16a-NK cell engager', 'acute myeloid leukemia', 'Innate Pharma SA', 'Euronext Paris', 'Nature Biotechnology', 'preclinical data', 'AML) cells', 'IPH', 'Nasdaq', 'Company', 'publication', 'control', 'NKCE', 'CD123']",2023-01-16,2023-01-16,wvnews.com
16573,EuroNext,Bing API,https://technews.tmcnet.com/news/2023/01/16/9743346.htm,VEON CEO letter to 2023 Noteholders,VEON Ltd. (NASDAQ: VEON  Euronext Amsterdam: VEON)  a global digital operator that provides converged connectivity and online services  has today contacted holders (the ‚Äú2023 Noteholders‚Äù) of interests in the 5.,VEON Ltd. (NASDAQ: VEON  Euronext Amsterdam: VEON)  a global digital operator that provides converged connectivity and online services  has today contacted holders (the ‚Äú2023 Noteholders‚Äù) of interests in the 5.,neutral,0.01,0.99,0.0,neutral,0.0,1.0,0.0,True,English,"['VEON CEO letter', '2023 Noteholders', 'global digital operator', 'Euronext Amsterdam', 'converged connectivity', 'online services', 'VEON Ltd', 'NASDAQ', 'holders', 'interests']",2023-01-16,2023-01-16,technews.tmcnet.com
16574,EuroNext,Bing API,https://www.finanznachrichten.de/nachrichten-2023-01/58063593-onward-medical-onward-announces-participation-at-upcoming-events-399.htm,ONWARD Medical: ONWARD Announces Participation at Upcoming Events,EINDHOVEN  the Netherlands  LAUSANNE  Switzerland  and BOSTON  MA USA  Jan. 16  2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD)  the medical technology company creating innovative therap,"EINDHOVEN  the Netherlands  LAUSANNE  Switzerland  and BOSTON  MA USA  Jan. 16  2023 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD)  the medical technology company creating innovative therapies to restore movement  independence  and health in people with spinal cord injury  today announced that management will participate in the following events in the upcoming weeks:DegroofPetercam Healthcare ConferenceJanuary 26  2023Brussels  BelgiumDave Marver  CEO  will participate in 1:1 meetings.TechShare by Euronext (https://www.euronext.com/en/raise-capital/pre-ipo-programmes/techshare)(https://www.euronext.com/en/raise-capital/pre-ipo-programmes/techshare)January 27  2023Rotterdam  NetherlandsDave Marver will deliver the keynote address at the annual IPO educational program organized by Euronext.Sachs 4th Annual European HealthTech CEO Forum (https://www.sachsforum.com/4ehtf-about.html)(https://www.sachsforum.com/4ehtf-about.html)February 28  2023Zurich  SwitzerlandDave Marver will participate in the panel discussion  ""NextGen Medtech & Devices"".BioCapital Europe (https://www.biocapitaleurope.com/)(https://www.biocapitaleurope.com/)March 9  2023Amsterdam  NetherlandsDave Marver will give a company presentation.Oppenheimer 33rd Annual Healthcare ConferenceMarch 13-15  2023Virtual eventDave Marver or Lara Smith Weber  CFO  will give a company presentation.VFB Happening (Flemish Federation of Investors)March 25  2023Ghent  BelgiumDave Marver will give a company presentation.Information on upcoming conferences is available in the Investor section of the ONWARD website at https://ir.onwd.com/news-events.About ONWARD MedicalONWARD is a medical technology company creating innovative therapies to restore movement  independence  and health in people with spinal cord injuries. ONWARD's work builds on more than a decade of basic science and preclinical research conducted at the world's leading neuroscience laboratories. ONWARD's ARC Therapy  which can be delivered by implantable (ARC-IM) or external (ARC-EX) systems  is designed to deliver targeted  programmed spinal cord stimulation to restore movement and other functions in people with spinal cord injury  ultimately improving their quality of life.ONWARD has received five Breakthrough Device Designations from the U.S. FDA encompassing both ARC-IM and ARC-EX. ARC-EX is an external  non-invasive platform consisting of a wearable stimulator and wireless programmer. Positive top-line data were reported in September 2022 from the company's first pivotal study  called Up-LIFT  evaluating the ability of transcutaneous ARC Therapy to improve upper extremity strength and function. The company is now preparing marketing approval submissions for the U.S. and Europe. ARC-IM consists of an implantable pulse generator and lead placed near the spinal cord. The company completed its first-in-human use of the ARC-IM neurostimulator in May 2022.ONWARD is headquartered in Eindhoven  the Netherlands. It maintains a Science and Engineering Center in Lausanne  Switzerland  and has a growing U.S. presence in Boston  Massachusetts. The company has an academic partnership with .NeuroRestore  a collaboration between the Swiss Federal Institute of Technology. To access our 2023 Financial Calendar  please visit IR.ONWD.com.For Company Enquiries:info@onwd.comFor Media Enquiries:MC Services AGUS: Laurie Doyle  P: +1 339 832 0752Europe: Dr. Johanna Kobler  Katja Arnold  Kaja Skorka  P: +49 89 210 228 0media@onwd.comFor Investor Enquiries:investors@onwd.comDisclaimerCertain statements  beliefs and opinions in this press release are forward-looking  which reflect the Company or  as appropriate  the Company directors' current expectations and projections about future events. By their nature  forward-looking statements involve several risks  uncertainties  and assumptions that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks  uncertainties  and assumptions could adversely affect the outcome and financial effects of the plans and events described herein. A multitude of factors  including  but not limited to  changes in demand  competition  and technology  can cause actual events  performance  or results to differ significantly from any anticipated development. Forward-looking statements contained in this press release regarding past trends or activities should not be taken as a representation that such trends or activities will continue in the future. As a result  the Company expressly disclaims any obligation or undertaking to release any update or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events  conditions  assumptions  or circumstances on which these forward-looking statements are based. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements  which speak only as of the date of this press release.",neutral,0.01,0.99,0.0,negative,0.0,0.14,0.86,True,English,"['Upcoming Events', 'ONWARD Medical', 'Participation', '4th Annual European HealthTech CEO Forum', 'Oppenheimer 33rd Annual Healthcare Conference', 'targeted, programmed spinal cord stimulation', 'five Breakthrough Device Designations', 'annual IPO educational program', 'growing U.S. presence', 'ONWARD Medical N.V.', 'DegroofPetercam Healthcare Conference', 'spinal cord injury', 'spinal cord injuries', 'Lara Smith Weber', 'leading neuroscience laboratories', 'U.S. FDA', 'external, non-invasive platform', 'Positive top-line data', 'first pivotal study', 'upper extremity strength', 'marketing approval submissions', 'Swiss Federal Institute', 'MC Services AG', 'Dr. Johanna Kobler', 'implantable pulse generator', 'transcutaneous ARC Therapy', 'external (ARC-EX) systems', 'medical technology company', 'MA USA', 'GLOBE NEWSWIRE', 'innovative therapies', 'upcoming weeks', 'Dave Marver', 'keynote address', 'panel discussion', 'NextGen Medtech', 'Virtual event', 'VFB Happening', 'Flemish Federation', 'upcoming conferences', 'Investor section', 'a decade', 'preclinical research', 'implantable (ARC-IM', 'other functions', 'wearable stimulator', 'wireless programmer', 'human use', 'Engineering Center', 'academic partnership', '2023 Financial Calendar', 'Media Enquiries', 'Laurie Doyle', 'Katja Arnold', 'Kaja Skorka', 'Investor Enquiries', 'press release', 'financial effects', 'subsidiary undertakings', 'forward-looking statements', 'ONWARD website', 'company presentation', 'Company Enquiries', 'following events', 'basic science', 'ARC-IM neurostimulator', 'current expectations', 'several risks', 'actual results', 'actual events', 'past trends', 'BioCapital Europe', 'future events', 'ARC-EX.', 'EINDHOVEN', 'Netherlands', 'LAUSANNE', 'Switzerland', 'BOSTON', 'Jan', 'Euronext', 'ONWD', 'movement', 'independence', 'people', 'management', 'Brussels', 'Belgium', '1:1 meetings', 'TechShare', 'raise-capital', 'programmes', 'Rotterdam', 'Sachs', 'February', 'Zurich', 'Devices', 'March', 'Amsterdam', 'CFO', 'Investors', 'Ghent', 'Information', 'news-events', 'work', 'world', 'quality', 'life', 'September', 'ability', 'May', 'Massachusetts', 'NeuroRestore', 'collaboration', 'Disclaimer', 'beliefs', 'opinions', 'projections', 'nature', 'uncertainties', 'assumptions', 'outcome', 'plans', 'multitude', 'factors', 'changes', 'demand', 'competition', 'performance', 'development', 'activities', 'representation', 'obligation', 'update', 'revisions', 'conditions', 'circumstances', 'advisers', 'representatives', 'person', 'officers', 'employees']",2023-01-05,2023-01-16,finanznachrichten.de
16575,EuroNext,Twitter API,Twitter,FT : Euronext to switch derivatives clearing to Italy in 2024 https://t.co/gLILfTZSMa,nan,FT : Euronext to switch derivatives clearing to Italy in 2024 https://t.co/gLILfTZSMa,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['FT', 'Euronext', 'derivatives', 'Italy', 'FT', 'Euronext', 'derivatives', 'Italy']",2023-01-16,2023-01-16,Unknown
16576,EuroNext,Twitter API,Twitter,Euronext to switch derivatives clearing to Italy in 2024 via @FT https://t.co/SPRo7QXjzo,nan,Euronext to switch derivatives clearing to Italy in 2024 via @FT https://t.co/SPRo7QXjzo,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['Euronext', 'derivatives', 'Italy', 'FT', 'SPRo7QXjzo', 'Euronext', 'derivatives', 'Italy', 'FT', 'SPRo7QXjzo']",2023-01-16,2023-01-16,Unknown
16577,EuroNext,Twitter API,Twitter,Euronext to switch derivatives clearing to Italy in 2024 https://t.co/sYaH43M7dy,nan,Euronext to switch derivatives clearing to Italy in 2024 https://t.co/sYaH43M7dy,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['Euronext', 'derivatives', 'Italy', 'Euronext', 'derivatives', 'Italy']",2023-01-16,2023-01-16,Unknown
16578,EuroNext,Twitter API,Twitter,Euronext to switch derivatives clearing from London to Italy in 2024 https://t.co/HO7p4W1kO2 via @Reuters https://t.co/elDwqbNG8n,nan,Euronext to switch derivatives clearing from London to Italy in 2024 https://t.co/HO7p4W1kO2 via @Reuters https://t.co/elDwqbNG8n,neutral,0.01,0.99,0.0,neutral,0.01,0.99,0.0,True,English,"['Euronext', 'derivatives', 'London', 'Italy', 'Reuters', 'Euronext', 'derivatives', 'London', 'Italy', 'Reuters']",2023-01-16,2023-01-16,Unknown
16579,EuroNext,Twitter API,Twitter,Name me one important derivative traded on Euronext. See  you can‚Äôt.,nan,Name me one important derivative traded on Euronext. See  you can‚Äôt.,neutral,0.01,0.99,0.01,neutral,0.01,0.99,0.01,True,English,"['one important derivative', 'Euronext', 'one important derivative', 'Euronext']",2023-01-16,2023-01-16,Unknown
16580,EuroNext,Twitter API,Twitter,Lads  it‚Äôs Euronext https://t.co/vkovv6XAwa,nan,Lads  it‚Äôs Euronext https://t.co/vkovv6XAwa,neutral,0.09,0.9,0.01,neutral,0.09,0.9,0.01,True,English,"['Lads', 'Euronext', 'Lads', 'Euronext']",2023-01-16,2023-01-16,Unknown
16581,EuroNext,Twitter API,Twitter,Euronext to switch derivatives clearing to Italy in 2024https://t.co/ChzpSMVHky,nan,Euronext to switch derivatives clearing to Italy in 2024https://t.co/ChzpSMVHky,neutral,0.06,0.93,0.01,neutral,0.06,0.93,0.01,True,English,"['Euronext', 'derivatives', 'Italy', 'ChzpSMVHky', 'Euronext', 'derivatives', 'Italy', 'ChzpSMVHky']",2023-01-16,2023-01-16,Unknown
16582,EuroNext,Twitter API,Twitter,Euronext to switch derivatives clearing to Italy in 2024 https://t.co/XmO2KsI7T6 https://t.co/BtHI2Km6Ch‚Ä¶ https://t.co/TZeXO5DHnc,nan,Euronext to switch derivatives clearing to Italy in 2024 https://t.co/XmO2KsI7T6 https://t.co/BtHI2Km6Ch‚Ä¶ https://t.co/TZeXO5DHnc,neutral,0.1,0.89,0.01,neutral,0.1,0.89,0.01,True,English,"['Euronext', 'derivatives', 'Italy', 'XmO2KsI7T6', 'BtHI2Km6Ch', 'TZeXO5DHnc', 'Euronext', 'derivatives', 'Italy', 'XmO2KsI7T6', 'BtHI2Km6Ch', 'TZeXO5DHnc']",2023-01-16,2023-01-16,Unknown
16583,EuroNext,Twitter API,Twitter,[FinancialTimes] Euronext to switch derivatives clearing to Italy in 2024  https://t.co/GiHwLfpAeE,nan,[FinancialTimes] Euronext to switch derivatives clearing to Italy in 2024  https://t.co/GiHwLfpAeE,neutral,0.03,0.97,0.0,neutral,0.03,0.97,0.0,True,English,"['FinancialTimes', 'Euronext', 'derivatives', 'Italy', 'GiHwLfpAeE', 'FinancialTimes', 'Euronext', 'derivatives', 'Italy', 'GiHwLfpAeE']",2023-01-16,2023-01-16,Unknown
16584,EuroNext,Twitter API,Twitter,Euronext to switch derivatives clearing to Italy in 2024 https://t.co/HuHOVjJzi0,nan,Euronext to switch derivatives clearing to Italy in 2024 https://t.co/HuHOVjJzi0,neutral,0.02,0.98,0.0,neutral,0.02,0.98,0.0,True,English,"['Euronext', 'derivatives', 'Italy', 'HuHOVjJzi0', 'Euronext', 'derivatives', 'Italy', 'HuHOVjJzi0']",2023-01-16,2023-01-16,Unknown
16585,EuroNext,Twitter API,Twitter,Euronext to switch derivatives clearing to Italy in 2024 https://t.co/WK2gR5iz18,nan,Euronext to switch derivatives clearing to Italy in 2024 https://t.co/WK2gR5iz18,neutral,0.01,0.98,0.0,neutral,0.01,0.98,0.0,True,English,"['Euronext', 'derivatives', 'Italy', 'WK2gR5iz18', 'Euronext', 'derivatives', 'Italy', 'WK2gR5iz18']",2023-01-16,2023-01-16,Unknown
16586,EuroNext,Twitter API,Twitter,#TKWY #JUSTEAT UPDATE #EURONEXT SCENARIO + ADDED ONE GREEN SCENARIO AS FOR NOW THE HIGH IS LOWER THAN EXPECTED BUT‚Ä¶ https://t.co/Vqz3jld2X5,nan,#TKWY #JUSTEAT UPDATE #EURONEXT SCENARIO + ADDED ONE GREEN SCENARIO AS FOR NOW THE HIGH IS LOWER THAN EXPECTED BUT‚Ä¶ https://t.co/Vqz3jld2X5,neutral,0.12,0.86,0.02,neutral,0.12,0.86,0.02,True,English,"['ONE GREEN SCENARIO', 'EURONEXT SCENARIO', 'NOW', 'HIGH', 'Vqz3jld2X5', 'ONE GREEN SCENARIO', 'EURONEXT SCENARIO', 'NOW', 'HIGH', 'Vqz3jld2X5']",2023-01-16,2023-01-16,Unknown
16587,EuroNext,Twitter API,Twitter,üîµ Euronext to switch derivatives clearing to Italy in 2024 Euronext has agreed a deal to move part of its clearin‚Ä¶ https://t.co/XJF6oueYeN,nan,üîµ Euronext to switch derivatives clearing to Italy in 2024 Euronext has agreed a deal to move part of its clearin‚Ä¶ https://t.co/XJF6oueYeN,neutral,0.07,0.92,0.01,neutral,0.07,0.92,0.01,True,English,"['Euronext', 'derivatives', 'Italy', 'deal', 'part', 'clearin', 'XJF6oueYeN', 'Euronext', 'derivatives', 'Italy', 'deal', 'part', 'clearin', 'XJF6oueYeN']",2023-01-16,2023-01-16,Unknown
